

(12) STANDARD PATENT
(19) AUSTRALIAN PATENT OFFICE

(11) Application No. **AU 2015342990 B2**

(54) Title
Enzymatically polymerized gelling dextrans

(51) International Patent Classification(s)
C08B 37/02 (2006.01)

(21) Application No: **2015342990**

(22) Date of Filing: **2015.11.05**

(87) WIPO No: **WO16/073732**

(30) Priority Data

(31) Number
62/075,460

(32) Date
2014.11.05

(33) Country
US

(43) Publication Date: **2016.05.12**

(44) Accepted Journal Date: **2019.08.29**

(71) Applicant(s)
E. I. du Pont de Nemours and Company

(72) Inventor(s)
Nambiar, Rakesh;Guan, Rong;Cheng, Qiong;Dicosimo, Robert;Paullin, Jayme L.;Liang, Yuanfeng;Powley, Charles R.;Brun, Yefim

(74) Agent / Attorney
Houlihan² Pty Ltd, PO Box 611, BALWYN NORTH, VIC, 3104, AU

(56) Related Art
**ELINALVA M. PAULO ET AL, "Production, extraction and characterization of exopolysaccharides produced by the native Leuconostoc pseudomesenteroides R2 strain", ANAIS DA ACADEMIA BRASILEIRA DE CIENCIAS, (2012), vol. 84, no. 2, pp 495 - 508
CN 103992978 A**

(51) International Patent Classification:
C08B 37/02 (2006.01)(21) International Application Number:
PCT/US2015/059261(22) International Filing Date:
5 November 2015 (05.11.2015)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
62/075,460 5 November 2014 (05.11.2014) US(71) Applicant: **E. I. DU PONT DE NEMOURS AND COMPANY** [US/US]; Chestnut Run Plaza, 974 Centre Road, P.O. Box 2915, Wilmington, Delaware 19805 (US).(72) Inventors: **NAMBIAR, Rakesh**; 39 Doe Run Court, West Chester, Pennsylvania 19382 (US). **GUAN, Rong**; 1824 Faulkland Road, Wilmington, Delaware 19805 (US). **CHENG, Qiong**; 4 Collins Drive, Wilmington, Delaware 19803 (US). **DICOSIMO, Robert**; 1607 Masters Way, Chadds Ford, Delaware 19317-9720 (US). **PAULLIN, Jayme L.**; 2308 Wilson Avenue, Claymont, Delaware 19703 (US). **LIANG, Yuanfeng**; 9 Concord Crossing Lane, Chadds Ford, US 19317 (US). **POWLEY, Charles R.**; 172 Landis Way N, Wilmington, Delaware 19803 (US). **BRUN, Yefim**; 500 Rockwood Road, Wilmington, Delaware 19802 (US).(74) Agent: **CHESIRE, Dennis**; E. I. du Pont de Nemours and Company, Legal Patent Records Center, Chestnut Run Plaza 721/2340, 974 Centre Road, PO Box 2915, Wilmington, Delaware 19805 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))

[Continued on next page]

(54) Title: ENZYMATICALLY POLYMERIZED GELLING DEXTRANS




FIG. 1

(57) Abstract: Compositions are disclosed herein comprising dextran that comprises (i) 87-93 wt% glucose linked at positions 1 and 6; (ii) 0.1 -1.2 wt% glucose linked at positions 1 and 3; (iii) 0.1 -0.7 wt% glucose linked at positions 1 and 4; (iv) 7.7-8.6 wt% glucose linked at positions 1, 3 and 6; and (v) about 0.4-1.7 wt% glucose linked at (a) positions 1, 2 and 6, or (b) positions 1, 4 and 6. Aqueous forms of this composition have enhanced viscosity profiles. Further disclosed are methods of using compositions comprising dextran, such as increasing the viscosity of an aqueous composition. Enzymatic reactions for producing dextran are also disclosed.



-
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))* — *with sequence listing part of description (Rule 5.2(a))*

TITLE

ENZYMATICALLY POLYMERIZED GELLING DEXTRANS

This application claims the benefit of U.S. Provisional Application No. 62/075,460 (filed November 5, 2014), which is incorporated herein by reference
5 in its entirety.

FIELD OF INVENTION

The present disclosure is in the field of polysaccharides. For example, the disclosure pertains to certain dextran polymers, reactions comprising glucosyltransferase enzymes that synthesize these polymers, and use of the
10 polymers in various applications.

REFERENCE TO SEQUENCE LISTING SUBMITTED ELECTRONICALLY

The official copy of the sequence listing is submitted electronically via EFS-Web as an ASCII formatted sequence listing with a file named 20151105_CL6294USNP_SequenceListing.txt created on November 5, 2015,
15 and having a size of 164 kilobytes and is filed concurrently with the specification. The sequence listing contained in this ASCII-formatted document is part of the specification and is herein incorporated by reference in its entirety.

BACKGROUND

Driven by a desire to find new structural polysaccharides using enzymatic
20 syntheses or genetic engineering of microorganisms, researchers have discovered polysaccharides that are biodegradable and can be made economically from renewably sourced feedstocks. One such family of polysaccharides are alpha-glucans, which are polymers comprising glucose monomers linked by alpha-glycosidic bonds.

25 Dextrans represent a family of complex, branched alpha-glucans generally comprising chains of alpha-1,6-linked glucose monomers, with periodic side chains (branches) linked to the straight chains by alpha-1,3-linkage (Ioan et al., *Macromolecules* 33:5730-5739). Production of dextrans is typically done through fermentation of sucrose with bacteria (e.g., *Leuconostoc* or *Streptococcus*
30 species), where sucrose serves as the source of glucose for dextran polymerization (Naessens et al., *J. Chem. Technol. Biotechnol.* 80:845-860;

Sarwat et al., *Int. J. Biol. Sci.* 4:379-386; Onilude et al., *Int. Food Res. J.* 20:1645-1651). Although dextrans are used in several applications given their high solubility in water (e.g., adjuvants, stabilizers), this high solubility can negatively affect their general utility as thickening agents in hydrocolloid applications.

Thus, there is interest in developing new, higher viscosity dextran polymers that are more amenable to high viscosity applications. In turn, there is also interest in identifying glucosyltransferase enzymes that can synthesize such dextran polymers.

SUMMARY OF INVENTION

In one embodiment, the disclosure concerns a composition comprising dextran that comprises:

- (i) about 87-93 wt% glucose linked at positions 1 and 6;
- (ii) about 0.1-1.2 wt% glucose linked at positions 1 and 3;
- (iii) about 0.1-0.7 wt% glucose linked at positions 1 and 4;
- (iv) about 7.7-8.6 wt% glucose linked at positions 1, 3 and 6; and
- (v) about 0.4-1.7 wt% glucose linked at:
 - (a) positions 1, 2 and 6, or
 - (b) positions 1, 4 and 6;

wherein the weight-average molecular weight (Mw) of the dextran is about 50-200 million Daltons, the z-average radius of gyration of the dextran is about 200-280 nm, and the dextran optionally is not a product of a *Leuconostoc mesenteroides* glucosyltransferase enzyme.

In another embodiment, the dextran comprises: (i) about 89.5-90.5 wt% glucose linked at positions 1 and 6; (ii) about 0.4-0.9 wt% glucose linked at positions 1 and 3; (iii) about 0.3-0.5 wt% glucose linked at positions 1 and 4; (iv) about 8.0-8.3 wt% glucose linked at positions 1, 3 and 6; and (v) about 0.7-1.4 wt% glucose linked at: (a) positions 1, 2 and 6, or (b) positions 1, 4 and 6.

In another embodiment, the dextran comprises chains (long chains) linked together within a branching structure, wherein said chains are similar in length

and comprise substantially alpha-1,6-glucosidic linkages. The average length of the chains is about 10-50 monomeric units in another embodiment.

In another embodiment, the dextran is a product of a glucosyltransferase enzyme comprising an amino acid sequence that is at least 90% identical to SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:5, SEQ ID NO:9, SEQ ID NO:13, or SEQ ID NO:17.

In another embodiment, the composition is an aqueous composition having a viscosity of at least about 25 cPs.

In another embodiment, the Mw of the dextran is about 80-120 million Daltons.

In another embodiment, the z-average radius of gyration of the dextran is about 230-250 nm.

In another embodiment, the composition is in the form of a food product, personal care product, pharmaceutical product, household product, or industrial product. In another embodiment, the composition is in the form of a confectionery.

In another embodiment, the disclosure concerns a method for increasing the viscosity of an aqueous composition. This method comprises contacting at least one dextran compound as disclosed herein with an aqueous composition. The contacting step in this method results in increasing the viscosity of the aqueous composition, in comparison to the viscosity of the aqueous composition before the contacting step.

In another embodiment, the disclosure concerns a method of treating a material. This method comprises contacting a material with an aqueous composition comprising at least one dextran compound disclosed herein.

In another embodiment, the disclosure concerns an enzymatic reaction comprising water, sucrose and a glucosyltransferase enzyme comprising an amino acid sequence that is at least 90% identical to SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:5, SEQ ID NO:9, SEQ ID NO:13, or SEQ ID NO:17, wherein the glucosyltransferase enzyme synthesizes a dextran compound as disclosed herein.

In another embodiment, the disclosure concerns a method of producing dextran comprising the step of contacting at least water, sucrose, and a glucosyltransferase enzyme comprising an amino acid sequence that is at least 90% identical to SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:5, SEQ ID NO:9, SEQ ID NO:13, or SEQ ID NO:17, thereby producing dextran as disclosed herein..

This dextran can optionally be isolated.

In another embodiment, the viscosity of the dextran produced in the method is increased by decreasing the amount of sucrose in step (a).

BRIEF DESCRIPTION OF THE DRAWINGS AND SEQUENCES

- FIG. 1: HPLC analysis of sucrose consumption by a glucosyltransferase reaction comprising 100 g/L sucrose and a 0768 gtf (SEQ ID NO:1). Refer to Example 2.
- FIG. 2A: Map of plasmid pZZHB583 used to express 2919 gtf (SEQ ID NO:5) in *B. subtilis*. Refer to Example 3.
- FIG. 2B: Map of plasmid pZZHB582 used to express 2918 gtf (SEQ ID NO:9) in *B. subtilis*. Refer to Example 4.
- FIG. 2C: Map of plasmid pZZHB584 used to express 2920 gtf (SEQ ID NO:13) in *B. subtilis*. Refer to Example 5.
- FIG. 2D: Map of plasmid pZZHB585 used to express 2921 (SEQ ID NO:17) gtf in *B. subtilis*. Refer to Example 6.
- FIG. 3: HPLC analysis of sucrose consumption by a reaction comprising a commercially available dextran sucrase. Refer to Example 7.

Table 1. Summary of Nucleic Acid and Protein SEQ ID Numbers

Description	Nucleic acid SEQ ID NO.	Protein SEQ ID NO.
"0768 gtf", <i>Leuconostoc pseudomesenteroides</i> . Mature form of GENBANK Identification No. 497964659.		1 (1447 aa)
"0768 gtf", <i>Leuconostoc pseudomesenteroides</i> . Mature form of GENBANK Identification No. 497964659, but including a start methionine and additional N- and C-terminal amino acids.		2 (1457 aa)
WciGtf1, <i>Weissella cibaria</i> . Full length form	3 (4347 bases)	4 (1448 aa)

comprising signal sequence. GENBANK Accession No. ZP_08417432 (amino acid sequence).		
"2919 gtf", <i>Weissella cibaria</i> . Mature form of GENBANK Identification No. ZP_08417432.		5 (1422 aa)
"2919 gtf", <i>Weissella cibaria</i> . Sequence optimized for expression in <i>B. subtilis</i> . Encodes 2919 gtf with a heterologous signal sequence and additional N-terminal amino acids.	6 (4269 bases)	
LfeGtf1, <i>Lactobacillus fermentum</i> . Full length form comprising signal sequence. GENBANK Accession No. AAU08008 (amino acid sequence).	7 (4392 bases)	8 (1463 aa)
"2918 gtf", <i>Lactobacillus fermentum</i> . Mature form of GENBANK Identification No. AAU08008.		9 (1426 aa)
"2918 gtf", <i>Lactobacillus fermentum</i> . Sequence optimized for expression in <i>B. subtilis</i> . Encodes 2918 gtf with a heterologous signal sequence and additional N-terminal amino acids.	10 (4281 bases)	
SsoGtf4, <i>Streptococcus sobrinus</i> . Full length form comprising signal sequence. GENBANK Accession No. AAX76986 (amino acid sequence).	11 (4521 bases)	12 (1506 aa)
"2920 gtf", <i>Streptococcus sobrinus</i> . Mature form of GENBANK Identification No. AAX76986.		13 (1465 aa)
"2920 gtf", <i>Streptococcus sobrinus</i> . Sequence optimized for expression in <i>B. subtilis</i> . Encodes 2920 gtf with a heterologous signal sequence and additional N-terminal amino acids.	14 (4398 bases)	
SdoGtf7, <i>Streptococcus downei</i> . Full length form comprising signal sequence. GENBANK Accession No. ZP_08549987.1 (amino acid sequence).	15 (4360 bases)	16 (1453 aa)
"2921 gtf", <i>Streptococcus downei</i> . Mature form of GENBANK Identification No. ZP_08549987.1.		17 (1409 aa)
"2921 gtf", <i>Streptococcus downei</i> . Sequence optimized for expression in <i>B. subtilis</i> . Encodes 2921 gtf with a heterologous signal sequence and additional N-terminal amino acids.	18 (4230 bases)	

DETAILED DESCRIPTION

The disclosures of all cited patent and non-patent literature are incorporated herein by reference in their entirety.

- 5 Unless otherwise disclosed, the terms "a" and "an" as used herein are intended to encompass one or more (i.e., at least one) of a referenced feature.

The term “glucan” herein refers to a polysaccharide of D-glucose monomers that are linked by glucosidic linkages, which are a type of glycosidic linkage. An “alpha-glucan” herein refers to a glucan in which the constituent D-glucose monomers are alpha-D-glucose monomers.

5 The terms “dextran”, “dextran polymer”, “dextran compound” and the like are used interchangeably herein and refer to complex, branched alpha-glucans generally comprising chains of substantially (mostly) alpha-1,6-linked glucose monomers, with side chains (branches) linked mainly by alpha-1,3-linkage. The term “gelling dextran” herein refers to the ability of one or more dextrans
10 disclosed herein to form a viscous solution or gel-like composition (i) during enzymatic dextran synthesis and, optionally, (ii) when such synthesized dextran is isolated (e.g., >90% pure) and then placed in an aqueous composition.

 Dextran “long chains” herein can comprise “substantially [or mostly] alpha-1,6-glucosidic linkages”, meaning that they can have at least about 98.0% alpha-
15 1,6-glucosidic linkages in some aspects. Dextran herein can comprise a “branching structure” (branched structure) in some aspects. It is contemplated that in this structure, long chains branch from other long chains, likely in an iterative manner (e.g., a long chain can be a branch from another long chain, which in turn can itself be a branch from another long chain, and so on). It is
20 contemplated that long chains in this structure can be “similar in length”, meaning that the length (DP [degree of polymerization]) of at least 70% of all the long chains in a branching structure is within plus/minus 30% of the mean length of all the long chains of the branching structure.

 Dextran in some embodiments can also comprise “short chains” branching
25 from the long chains, typically being one to three glucose monomers in length, and comprising less than about 10% of all the glucose monomers of a dextran polymer. Such short chains typically comprise alpha-1,2-, alpha-1,3-, and/or alpha-1,4-glucosidic linkages (it is believed that there can also be a small percentage of such non-alpha-1,6 linkages in long chains in some aspects).


30 The terms “glycosidic linkage” and “glycosidic bond” are used interchangeably herein and refer to the covalent bond that joins a carbohydrate

molecule to another carbohydrate molecule. The terms “glucosidic linkage” and “glucosidic bond” are used interchangeably herein and refer to a glycosidic linkage between two glucose molecules. The term “alpha-1,6-glucosidic linkage” as used herein refers to the covalent bond that joins alpha-D-glucose molecules to each other through carbons 1 and 6 on adjacent alpha-D-glucose rings. The term “alpha-1,3-glucosidic linkage” as used herein refers to the covalent bond that joins alpha-D-glucose molecules to each other through carbons 1 and 3 on adjacent alpha-D-glucose rings. The term “alpha-1,2-glucosidic linkage” as used herein refers to the covalent bond that joins alpha-D-glucose molecules to each other through carbons 1 and 2 on adjacent alpha-D-glucose rings. The term “alpha-1,4-glucosidic linkage” as used herein refers to the covalent bond that joins alpha-D-glucose molecules to each other through carbons 1 and 4 on adjacent alpha-D-glucose rings. Herein, “alpha-D-glucose” will be referred to as “glucose.” All glucosidic linkages disclosed herein are alpha-glucosidic linkages, except where otherwise noted.

“Glucose (glucose monomers) linked at positions 1 and 6” herein refers to a glucose monomer of dextran in which only carbons 1 and 6 of the glucose monomer are involved in respective glucosidic linkages with two adjacent glucose monomers. This definition likewise applies to glucose (i) “linked at positions 1 and 3”, and (ii) “linked at positions 1 and 4”, taking into account, accordingly, the different carbon positions involved in each respective linkage.

“Glucose (glucose monomers) linked at positions 1, 3 and 6” herein refers to a glucose monomer of dextran in which carbons 1, 3 and 6 of the glucose monomer are involved in respective glucosidic linkages with three adjacent glucose monomers. A glucose linked only at positions 1, 3 and 6 is a branch point. This definition likewise applies to glucose linked at (i) positions 1, 2 and 6, and (ii) positions 1, 4 and 6, but taking into account, accordingly, the different carbon positions involved in each respective linkage.

Glucose positions (glucose carbon positions) 1, 2, 3, 4 and 6 herein are as known in the art (depicted in the following structure):



The glycosidic linkage profile of a dextran herein can be determined using any method known in the art. For example, a linkage profile can be determined using methods that use nuclear magnetic resonance (NMR) spectroscopy (e.g., ¹³C NMR or ¹H NMR). These and other methods that can be used are disclosed in Food Carbohydrates: Chemistry, Physical Properties, and Applications (S. W. Cui, Ed., Chapter 3, S. W. Cui, Structural Analysis of Polysaccharides, Taylor & Francis Group LLC, Boca Raton, FL, 2005), which is incorporated herein by reference.

The term “sucrose” herein refers to a non-reducing disaccharide composed of an alpha-D-glucose molecule and a beta-D-fructose molecule linked by an alpha-1,2-glycosidic bond. Sucrose is known commonly as table sugar.

The “molecular weight” of dextran herein can be represented as number-average molecular weight (M_n) or as weight-average molecular weight (M_w), the units of which are in Daltons or grams/mole. Alternatively, molecular weight can be represented as DP_w (weight average degree of polymerization) or DP_n (number average degree of polymerization). Various means are known in the art for calculating these molecular weight measurements such as with high-pressure liquid chromatography (HPLC), size exclusion chromatography (SEC), or gel permeation chromatography (GPC).

The term “radius of gyration” (R_g) herein refers to the mean radius of dextran, and is calculated as the root-mean-square distance of a dextran molecule’s components (atoms) from the molecule’s center of gravity. R_g can be provided in Angstrom or nanometer (nm) units, for example. The “z-average radius of gyration” of dextran herein refers to the R_g of dextran as measured using light scattering (e.g., MALS). Methods for measuring z-average R_g are known and can be used herein, accordingly. For example, z-average R_g can be

measured as disclosed in U.S. Patent No. 7531073, U.S. Patent Appl. Publ. Nos. 2010/0003515 and 2009/0046274, Wyatt (*Anal. Chim. Acta* 272:1-40), and Mori and Barth (Size Exclusion Chromatography, Springer-Verlag, Berlin, 1999), all of which are incorporated herein by reference.

5 The terms “glucosyltransferase enzyme”, “gtf enzyme”, “gtf enzyme catalyst”, “gtf”, “glucansucrase” and the like are used interchangeably herein. The activity of a gtf enzyme herein catalyzes the reaction of the substrate sucrose to make the products glucan and fructose. A gtf enzyme that produces a dextran (a type of glucan) can also be referred to as a dextransucrase. Other
10 products (byproducts) of a gtf reaction can include glucose (where glucose is hydrolyzed from the glucosyl-gtf enzyme intermediate complex), and various soluble oligosaccharides (e.g., DP2-DP7) such as leucrose. Wild type forms of glucosyltransferase enzymes generally contain (in the N-terminal to C-terminal direction) a signal peptide, a variable domain, a catalytic domain, and a glucan-
15 binding domain. A gtf herein is classified under the glycoside hydrolase family 70 (GH70) according to the CAZy (Carbohydrate-Active EnZymes) database (Cantarel et al., *Nucleic Acids Res.* 37:D233-238, 2009).

 The terms “glucosyltransferase catalytic domain” and “catalytic domain” are used interchangeably herein and refer to the domain of a glucosyltransferase
20 enzyme that provides glucan-producing activity to the glucosyltransferase enzyme.

 The terms “gtf reaction”, “gtf reaction solution”, “glucosyltransferase reaction”, “enzymatic reaction”, “dextran synthesis reaction”, “dextran reaction” and the like are used interchangeably herein and refer to a reaction that is
25 performed by a glucosyltransferase enzyme. A gtf reaction as used herein generally refers to a reaction initially comprising at least one active glucosyltransferase enzyme in a solution comprising sucrose and water, and optionally other components. Other components that can be in a gtf reaction after it has commenced include fructose, glucose, soluble oligosaccharides (e.g.,
30 DP2-DP7) such as leucrose, and dextran products. It is in a gtf reaction where the step of contacting water, sucrose and a glucosyltransferase enzyme is

performed. The term “under suitable gtf reaction conditions” as used herein, refers to gtf reaction conditions that support conversion of sucrose to dextran via glucosyltransferase enzyme activity. A gtf reaction herein is not naturally occurring.

5 A “control” gtf reaction as used herein can refer to a reaction using a glucosyltransferase not comprising an amino acid sequence that is at least 90% identical to SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:5, SEQ ID NO:9, SEQ ID NO:13, or SEQ ID NO:17. All the other features (e.g., sucrose concentration, temperature, pH, time) of a control reaction solution can be the same as the
10 reaction to which it is being compared.

 The “percent dry solids” of a gtf reaction refers to the wt% of all the sugars in a gtf reaction. The percent dry solids of a gtf reaction can be calculated, for example, based on the amount of sucrose used to prepare the reaction.

 The “yield” of dextran by a gtf reaction herein represents the weight of
15 dextran product expressed as a percentage of the weight of sucrose substrate that is converted in the reaction. For example, if 100 g of sucrose in a reaction solution is converted to products, and 10 g of the products is dextran, the yield of the dextran would be 10%. This yield calculation can be considered as a measure of selectivity of the reaction toward dextran.

20 The terms “percent by volume”, “volume percent”, “vol %”, “v/v %” and the like are used interchangeably herein. The percent by volume of a solute in a solution can be determined using the formula: $[(\text{volume of solute})/(\text{volume of solution})] \times 100\%$.

 The terms “percent by weight”, “weight percentage (wt%)”, “weight-weight
25 percentage (% w/w)” and the like are used interchangeably herein. Percent by weight refers to the percentage of a material on a mass basis as it is comprised in a composition, mixture, or solution.

 The term “increased” as used herein can refer to a quantity or activity that is at least about 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%,
30 14%, 15%, 16%, 17%, 18%, 19%, 20%, 50%, 100%, or 200% more than the quantity or activity for which the increased quantity or activity is being compared.

The terms “increased”, “elevated”, “enhanced”, “greater than”, “improved” and the like are used interchangeably herein.

The terms “polynucleotide”, “polynucleotide sequence”, and “nucleic acid sequence” are used interchangeably herein. These terms encompass nucleotide
5 sequences and the like. A polynucleotide may be a polymer of DNA or RNA that is single- or double-stranded, that optionally contains synthetic, non-natural or altered nucleotide bases. A polynucleotide may be comprised of one or more segments of cDNA, genomic DNA, synthetic DNA, or mixtures thereof.

The term “gene” as used herein refers to a DNA polynucleotide sequence
10 that expresses an RNA (RNA is transcribed from the DNA polynucleotide sequence) from a coding region (coding sequence), which RNA can be a messenger RNA (encoding a protein) or a non-protein-coding RNA. A gene may refer to the coding region alone, or may include regulatory sequences upstream and/or downstream to the coding region (e.g., promoters, 5'-untranslated regions,
15 3'-transcription terminator regions). A coding region encoding a protein can alternatively be referred to herein as an “open reading frame” (ORF). A gene that is “native” or “endogenous” refers to a gene as found in nature with its own regulatory sequences; such a gene is located in its natural location in the genome of a host cell. A “chimeric” gene refers to any gene that is not a native
20 gene, comprising regulatory and coding sequences that are not found together in nature (i.e., the regulatory and coding regions are heterologous with each other). Accordingly, a chimeric gene may comprise regulatory sequences and coding sequences that are derived from different sources, or regulatory sequences and coding sequences derived from the same source, but arranged in a manner
25 different than that found in nature. A “foreign” or “heterologous” gene refers to a gene that is introduced into a host organism by gene transfer. Foreign genes can comprise native genes inserted into a non-native organism, native genes introduced into a new location within the native host, or chimeric genes. Polynucleotide sequences in certain embodiments disclosed herein are
30 heterologous. A “transgene” is a gene that has been introduced into the genome by a transformation procedure. A “codon-optimized” open reading frame has its

frequency of codon usage designed to mimic the frequency of preferred codon usage of the host cell.

The term “recombinant” or “heterologous” as used herein refers to an artificial combination of two otherwise separated segments of sequence, e.g., by chemical synthesis or by the manipulation of isolated segments of nucleic acids by genetic engineering techniques. The terms “recombinant”, “transgenic”, “transformed”, “engineered” or “modified for exogenous gene expression” are used interchangeably herein.

A native amino acid sequence or polynucleotide sequence is naturally occurring, whereas a non-native amino acid sequence or polynucleotide sequence does not occur in nature.

“Regulatory sequences” as used herein refer to nucleotide sequences located upstream of a gene’s transcription start site (e.g., promoter), 5’ untranslated regions, and 3’ non-coding regions, and which may influence the transcription, processing or stability, or translation of an RNA transcribed from the gene. Regulatory sequences herein may include promoters, enhancers, silencers, 5’ untranslated leader sequences, introns, polyadenylation recognition sequences, RNA processing sites, effector binding sites, stem-loop structures, and other elements involved in regulation of gene expression. One or more regulatory elements herein may be heterologous to a coding region herein.

Methods for preparing recombinant constructs/vectors herein can follow standard recombinant DNA and molecular cloning techniques as described by J. Sambrook and D. Russell (Molecular Cloning: A Laboratory Manual, 3rd Edition, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 2001); T.J. Silhavy et al. (Experiments with Gene Fusions, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1984); and F.M. Ausubel et al. (Short Protocols in Molecular Biology, 5th Ed. Current Protocols, John Wiley and Sons, Inc., NY, 2002).

The terms “sequence identity” or “identity” as used herein with respect to polynucleotide or polypeptide sequences refer to the nucleic acid bases or amino acid residues in two sequences that are the same when aligned for maximum

correspondence over a specified comparison window. Thus, “percentage of sequence identity” or “percent identity” refers to the value determined by comparing two optimally aligned sequences over a comparison window, wherein the portion of the polynucleotide or polypeptide sequence in the comparison window may comprise additions or deletions (i.e., gaps) as compared to the reference sequence (which does not comprise additions or deletions) for optimal alignment of the two sequences. The percentage is calculated by determining the number of positions at which the identical nucleic acid base or amino acid residue occurs in both sequences to yield the number of matched positions, dividing the number of matched positions by the total number of positions in the window of comparison and multiplying the results by 100 to yield the percentage of sequence identity. It would be understood that, when calculating sequence identity between a DNA sequence and an RNA sequence, T residues of the DNA sequence align with, and can be considered “identical” with, U residues of the RNA sequence. For purposes of determining percent complementarity of first and second polynucleotides, one can obtain this by determining (i) the percent identity between the first polynucleotide and the complement sequence of the second polynucleotide (or vice versa), for example, and/or (ii) the percentage of bases between the first and second polynucleotides that would create canonical Watson and Crick base pairs.

The Basic Local Alignment Search Tool (BLAST) algorithm, which is available online at the National Center for Biotechnology Information (NCBI) website, may be used, for example, to measure percent identity between or among two or more of the polynucleotide sequences (BLASTN algorithm) or polypeptide sequences (BLASTP algorithm) disclosed herein. Alternatively, percent identity between sequences may be performed using a Clustal algorithm (e.g., ClustalW, ClustalV, or Clustal-Omega). For multiple alignments using a Clustal method of alignment, the default values may correspond to GAP PENALTY=10 and GAP LENGTH PENALTY=10. Default parameters for pairwise alignments and calculation of percent identity of protein sequences using a Clustal method may be KTUPLE=1, GAP PENALTY=3, WINDOW=5

and DIAGONALS SAVED=5. For nucleic acids, these parameters may be KTUPLE=2, GAP PENALTY=5, WINDOW=4 and DIAGONALS SAVED=4.

Alternatively still, percent identity between sequences may be performed using an EMBOSS algorithm (e.g., needle) with parameters such as GAP OPEN=10,
5 GAP EXTEND=0.5, END GAP PENALTY=false, END GAP OPEN=10, END GAP EXTEND=0.5 using a BLOSUM matrix (e.g., BLOSUM62).

Various polypeptide amino acid sequences and polynucleotide sequences are disclosed herein as features of certain embodiments. Variants of these sequences that are at least about 70-85%, 85-90%, or 90%-95% identical to the
10 sequences disclosed herein can be used. Alternatively, a variant amino acid sequence or polynucleotide sequence can have at least 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity with a sequence disclosed herein. The variant amino acid sequence or
15 polynucleotide sequence may have the same function/activity of the disclosed sequence, or at least about 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% of the function/activity of the disclosed sequence. Any polypeptide amino acid sequence disclosed herein not beginning with a methionine can typically further comprise at least a start-methionine at the
20 N-terminus of the amino acid sequence. Any polypeptide amino acid sequence disclosed herein beginning with a methionine can optionally be considered without this methionine residue (i.e., a polypeptide sequence can be referred to in reference to the position-2 residue to the C-terminal residue of the sequence).

The term "isolated" as used herein refers to any cellular component that
25 has been completely or partially purified from its native source (e.g., an isolated polynucleotide or polypeptide molecule). In some instances, an isolated polynucleotide or polypeptide molecule is part of a greater composition, buffer system or reagent mix. For example, an isolated polynucleotide or polypeptide molecule can be comprised within a cell or organism in a heterologous manner.
30 Another example is an isolated glucosyltransferase enzyme or reaction. "Isolated" herein can also characterize a dextran compound. As such, dextran

compounds of the present disclosure are synthetic, man-made compounds, and/or exhibit properties not believed to naturally occur.

An “aqueous composition” herein has a liquid component that comprises at least about 10 wt% water, for example. Examples of aqueous compositions include mixtures, solutions, dispersions (e.g., colloidal dispersions), suspensions and emulsions, for example. Aqueous compositions in certain embodiments comprise dextran that is dissolved in the aqueous composition (i.e., in solution, and typically has viscosity).

As used herein, the term “colloidal dispersion” refers to a heterogeneous system having a dispersed phase and a dispersion medium, i.e., microscopically dispersed insoluble particles are suspended throughout another substance (e.g., an aqueous composition such as water or aqueous solution). An example of a colloidal dispersion herein is a hydrocolloid. All, or a portion of, the particles of a colloidal dispersion such as a hydrocolloid can comprise certain dextran compounds of the present disclosure. The terms “dispersant” and “dispersion agent” are used interchangeably herein to refer to a material that promotes the formation and/or stabilization of a dispersion.

The terms “hydrocolloid” and “hydrogel” are used interchangeably herein. A hydrocolloid refers to a colloid system in which water is the dispersion medium.

The term “aqueous solution” herein refers to a solution in which the solvent comprises water. An aqueous solution can serve as a dispersant in certain aspects herein. Dextran compounds in certain embodiments can be dissolved, dispersed, or mixed within an aqueous solution.

The terms “dispersant”, “dispersion agent” and the like are used interchangeably herein to refer to a material that promotes the formation and stabilization of a dispersion of one substance in another. A “dispersion” herein refers to an aqueous composition comprising one or more particles (e.g., any ingredient of a personal care product, pharmaceutical product, food product, household product, or industrial product disclosed herein) that are scattered, or uniformly scattered, throughout the aqueous composition.

The term “viscosity” as used herein refers to the measure of the extent to which a fluid or an aqueous composition such as a hydrocolloid resists a force tending to cause it to flow. Various units of viscosity that can be used herein include centipoise (cPs) and Pascal-second (Pa·s). A centipoise is one one-hundredth of a poise; one poise is equal to $0.100 \text{ kg} \cdot \text{m}^{-1} \cdot \text{s}^{-1}$. Thus, the terms “viscosity modifier”, “viscosity-modifying agent” and the like as used herein refer to anything that can alter/modify the viscosity of a fluid or aqueous composition.

The term “shear thinning behavior” as used herein refers to a decrease in the viscosity of an aqueous composition as shear rate increases. The term “shear thickening behavior” as used herein refers to an increase in the viscosity of an aqueous composition as shear rate increases. “Shear rate” herein refers to the rate at which a progressive shearing deformation is applied to an aqueous composition. A shearing deformation can be applied rotationally.

The term “contacting” as used herein with respect to methods of increasing the viscosity of an aqueous composition refers to any action that results in bringing together an aqueous composition with a dextran. Contacting can be performed by any means known in the art, such as dissolving, mixing, shaking, or homogenization, for example.

The terms “confectionery”, “confection”, “sweets”, “sweetmeat”, “candy” and the like are used interchangeably herein. A confectionary refers to any flavored food product having a sweet taste, the consistency of which may be hard or soft, which is typically consumed by sucking and/or by chewing within the oral cavity. A confectionary can contain sugar or otherwise be sugar-free.

The terms “fabric”, “textile”, “cloth” and the like are used interchangeably herein to refer to a woven material having a network of natural and/or artificial fibers. Such fibers can be thread or yarn, for example.

A “fabric care composition” herein is any composition suitable for treating fabric in some manner. Examples of such a composition include laundry detergents and fabric softeners.

The terms “heavy duty detergent”, “all-purpose detergent” and the like are used interchangeably herein to refer to a detergent useful for regular washing of

white and colored textiles at any temperature. The terms “low duty detergent” or “fine fabric detergent” are used interchangeably herein to refer to a detergent useful for the care of delicate fabrics such as viscose, wool, silk, microfiber or other fabric requiring special care. “Special care” can include conditions of using excess water, low agitation, and/or no bleach, for example.

A “detergent composition” herein typically comprises at least one surfactant (detergent compound) and/or at least one builder. A “surfactant” herein refers to a substance that tends to reduce the surface tension of a liquid in which the substance is dissolved. A surfactant may act as a detergent, wetting agent, emulsifier, foaming agent, and/or dispersant, for example.

The terms “anti-redeposition agent”, “anti-soil redeposition agent”, “anti-greying agent” and the like herein refer to agents that help keep soils from redepositing onto clothing in laundry wash water after these soils have been removed, therefore preventing greying/discoloration of laundry. Anti-redeposition agents can function by helping keep soil dispersed in wash water and/or by blocking attachment of soil onto fabric surfaces.

An “oral care composition” herein is any composition suitable for treating an soft or hard surface in the oral cavity such as dental (teeth) and/or gum surfaces.

The term “adsorption” herein refers to the adhesion of a compound (e.g., dextran herein) to the surface of a material.

The terms “cellulase”, “cellulase enzyme” and the like are used interchangeably herein to refer to an enzyme that hydrolyzes beta-1,4-D-glucosidic linkages in cellulose, thereby partially or completely degrading cellulose. Cellulase can alternatively be referred to as “beta-1,4-glucanase”, for example, and can have endocellulase activity (EC 3.2.1.4), exocellulase activity (EC 3.2.1.91), or cellobiase activity (EC 3.2.1.21). “Cellulose” refers to an insoluble polysaccharide having a linear chain of beta-1,4-linked D-glucose monomeric units.

There is interest in developing new, high viscosity dextran polymers, which are more amenable to gelling applications. In turn, there is also interest in identifying glucosyltransferase enzymes that can synthesize such dextran polymers.

5 Embodiments of the present disclosure concern a composition comprising a dextran that comprises:

- (i) about 87-93 wt% glucose linked at positions 1 and 6;
- (ii) about 0.1-1.2 wt% glucose linked at positions 1 and 3;
- (iii) about 0.1-0.7 wt% glucose linked at positions 1 and 4;
- 10 (iv) about 7.7-8.6 wt% glucose linked at positions 1, 3 and 6; and
- (v) about 0.4-1.7 wt% glucose linked at: (a) positions 1, 2 and 6, or (b) positions 1, 4 and 6.

The weight-average molecular weight (Mw) and z-average radius of gyration of such dextran is about 50-200 million Daltons and about 200-280 nm,

15 respectively. Also, such dextran optionally is not a product of a *Leuconostoc mesenteroides* glucosyltransferase enzyme.

An example of this composition is a glucosyltransferase reaction in which a dextran with the above linkage, weight and size profile is synthesized.

Significantly, this dextran exhibits high viscosity in aqueous compositions, even
20 at relatively low concentrations of the dextran. It is believed that this high viscosity profile is unique in comparison to viscosity profiles of previously disclosed dextran polymers.

A dextran herein can comprise (i) about 87-93 wt% glucose linked only at
25 positions 1 and 6; (ii) about 0.1-1.2 wt% glucose linked only at positions 1 and 3; (iii) about 0.1-0.7 wt% glucose linked only at positions 1 and 4; (iv) about 7.7-8.6 wt% glucose linked only at positions 1, 3 and 6; and (v) about 0.4-1.7 wt% glucose linked only at: (a) positions 1, 2 and 6, or (b) positions 1, 4 and 6. In certain embodiments, a dextran can comprise (i) about 89.5-90.5 wt% glucose
30 linked only at positions 1 and 6; (ii) about 0.4-0.9 wt% glucose linked only at positions 1 and 3; (iii) about 0.3-0.5 wt% glucose linked only at positions 1 and 4;

(iv) about 8.0-8.3 wt% glucose linked only at positions 1, 3 and 6; and (v) about 0.7-1.4 wt% glucose linked only at: (a) positions 1, 2 and 6, or (b) positions 1, 4 and 6.

A dextran in some aspects of the present disclosure can comprise about
5 87, 87.5, 88, 88.5, 89, 89.5, 90, 90.5, 91, 91.5, 92, 92.5, or 93 wt% glucose
linked only at positions 1 and 6. There can be about 87-92.5, 87-92, 87-91.5, 87-
91, 87-90.5, 87-90, 87.5-92.5, 87.5-92, 87.5-91.5, 87.5-91, 87.5-90.5, 87.5-90,
88-92.5, 88-92, 88-91.5, 88-91, 88-90.5, 88-90, 88.5-92.5, 88.5-92, 88.5-91.5,
88.5-91, 88.5-90.5, 88.5-90, 89-92.5, 89-92, 89-91.5, 89-91, 89-90.5, 89-90,
10 89.5-92.5, 89.5-92, 89.5-91.5, 89.5-91, or 89.5-90.5 wt% glucose linked only at
positions 1 and 6, in some instances.

A dextran in some aspects can comprise about 0.1, 0.2, 0.3, 0.4, 0.5, 0.6,
0.7, 0.8, 0.9, 1.0, 1.1, or 1.2 wt% glucose linked only at positions 1 and 3. There
can be about 0.1-1.2, 0.1-1.0, 0.1-0.8, 0.3-1.2, 0.3-1.0, 0.3-0.8, 0.4-1.2, 0.4-1.0,
15 0.4-0.8, 0.5-1.2, 0.5-1.0, 0.5-0.8, 0.6-1.2, 0.6-1.0, or 0.6-0.8 wt% glucose linked
only at positions 1 and 3, in some instances.

A dextran in some aspects can comprise about 0.1, 0.2, 0.3, 0.4, 0.5, 0.6,
or 0.7 wt% glucose linked only at positions 1 and 4. There can be about 0.1-0.7,
0.1-0.6, 0.1-0.5, 0.1-0.4, 0.2-0.7, 0.2-0.6, 0.2-0.5, 0.2-0.4, 0.3-0.7, 0.3-0.6, 0.3-
20 0.5, or 0.3-0.4 wt% glucose linked only at positions 1 and 4, in some instances.

A dextran in some aspects can comprise about 7.7, 7.8, 7.9, 8.0, 8.1, 8.2,
8.3, 8.4, 8.5, or 8.6 wt% glucose linked only at positions 1, 3 and 6. There can
be about 7.7-8.6, 7.7-8.5, 7.7-8.4, 7.7-8.3, 7.7-8.2, 7.8-8.6, 7.8-8.5, 7.8-8.4, 7.8-
8.3, 7.8-8.2, 7.9-8.6, 7.9-8.5, 7.9-8.4, 7.9-8.3, 7.9-8.2, 8.0-8.6, 8.0-8.5, 8.0-8.4,
25 8.0-8.3, 8.0-8.2, 8.1-8.6, 8.1-8.5, 8.1-8.4, 8.1-8.3, or 8.1-8.2 wt% glucose linked
only at positions 1, 3 and 6, in some instances.

A dextran in some aspects can comprise about 0.4, 0.5, 0.6, 0.7, 0.8, 0.9,
1.0, 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, or 1.7 wt% glucose linked only at (a) positions 1, 2
and 6, or (b) positions 1, 4 and 6. There can be about 0.4-1.7, 0.4-1.6, 0.4-1.5,
30 0.4-1.4, 0.4-1.3, 0.5-1.7, 0.5-1.6, 0.5-1.5, 0.5-1.4, 0.5-1.3, 0.6-1.7, 0.6-1.6, 0.6-
1.5, 0.6-1.4, 0.6-1.3, 0.7-1.7, 0.7-1.6, 0.7-1.5, 0.7-1.4, 0.7-1.3, 0.8-1.7, 0.8-1.6,

0.8-1.5, 0.8-1.4, 0.8-1.3 wt% glucose linked only at (a) positions 1, 2 and 6, or (b) positions 1, 4 and 6, in some instances.

The glucosidic linkage profile of dextran can be determined using dextran produced following any protocol disclosed herein. An example of a suitable linkage determination protocol can be similar to, or the same as, the protocol disclosed in Example 9: For example, an 0768 gtf enzyme reaction that has been deactivated by heating the reaction at about 70-90 °C (e.g., 80 °C) for about 5-30 minutes (e.g., 10 minutes) is placed into dialysis tubing (e.g., made with regenerated cellulose) with an MWCO of 12-14 kDa (e.g., Spectra/Por® 4 Dialysis Tubing, Part No. 132706, Spectrum Laboratories, Inc.). The deactivated reaction is then dialyzed against a large volume of water (e.g., 3-5 L) at about 20-25 °C (room temp) over about 4-10 days (e.g., 7 days); this water can be exchanged every day during the dialysis. The dextran product is then (i) precipitated by mixing the dialyzed deactivated reaction with about 1-2x (1.5x) reaction volume of 100% methanol, (ii) washed at least two times with the same volume of 100% methanol, and (iii) dried at about 40-50 °C (e.g., 45 °C) (optionally under a vacuum). A dissolvable amount of dry dextran is dissolved in dimethyl sulfoxide (DMSO) or DMSO/5% LiCl, after which all free hydroxyl groups are methylated (e.g., by sequential addition of a NaOH/DMSO slurry followed with iodomethane). The methylated dextran is then extracted (e.g., into methylene chloride) and hydrolyzed to monomeric units using aqueous trifluoroacetic acid (TFA) at about 110-125 °C (e.g., 120 °C). The TFA is then evaporated and reductive ring opening is done using sodium borodeuteride. The hydroxyl groups created by hydrolyzing the glycosidic linkages are then acetylated by treating with acetyl chloride and TFA at a temperature of about 40-60 °C (e.g., 50 °C). Next, the derivatizing reagents are evaporated and the resulting methylated/acetylated monomers are reconstituted in acetonitrile; this preparation is then analyzed by GC/MS using an appropriate column (e.g., biscyanopropyl cyanopropylphenyl polysiloxane). The relative positioning of the methyl and acetyl functionalities render species with distinctive retention time indices and mass spectra that can be compared to published databases. In this

way, the derivatives of the monomeric units indicate how each monomer was originally linked in the dextran polymer.

It is believed that dextran herein may be a branched structure in which there are long chains (containing mostly or all alpha-1,6-linkages) that iteratively branch from each other (e.g., a long chain can be a branch from another long chain, which in turn can itself be a branch from another long chain, and so on). The branched structure may also comprise short branches from the long chains; these short chains are believed to mostly comprise alpha-1,3 and -1,4 linkages, for example. Branch points in the dextran, whether from a long chain branching from another long chain, or a short chain branching from a long chain, appear to comprise alpha-1,3, -1,4, or -1,2 linkages off of a glucose involved in alpha-1,6 linkage. On average, about 20%, 21%, 22%, 23%, 24%, 25%, 26%, 27%, 28%, 29%, 30%, 15-35%, 15-30%, 15-25%, 15-20%, 20-35%, 20-30%, 20-25%, 25-35%, or 25-30% of all branch points of dextran in some embodiments branch into long chains. Most (>98% or 99%) or all the other branch points branch into short chains.

The long chains of a dextran branching structure can be similar in length in some aspects. By being similar in length, it is meant that the length (DP) of at least 70%, 75%, 80%, 85%, or 90% of all the long chains in a branching structure is within plus/minus 15% (or 10%, 5%) of the mean length of all the long chains of the branching structure. In some aspects, the mean length (average length) of the long chains is about 10-50 DP (i.e., 10-50 glucose monomers). For example, the mean individual length of the long chains can be about 10, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 30, 35, 40, 45, 50, 10-50, 10-40, 10-30, 10-25, 10-20, 15-50, 15-40, 15-30, 15-25, 15-20, 20-50, 20-40, 20-30, or 20-25 DP.

Dextran long chains in certain embodiments can comprise substantially alpha-1,6-glucosidic linkages and a small amount (less than 2.0%) of alpha-1,3- and/or alpha-1,4-glucosidic linkages. For example, dextran long chains can comprise about, or at least about, 98%, 98.25%, 98.5%, 98.75%, 99%, 99.25%, 99.5%, 99.75%, or 99.9% alpha-1,6-glucosidic linkages. A dextran long chain in certain embodiments does not comprise alpha-1,4-glucosidic linkages (i.e., such

a long chain has mostly alpha-1,6 linkages and a small amount of alpha-1,3 linkages). Conversely, a dextran long chain in some embodiments does not comprise alpha-1,3-glucosidic linkages (i.e., such a long chain has mostly alpha-1,6 linkages and a small amount of alpha-1,4 linkages). Any dextran long chain of the above embodiments may further not comprise alpha-1,2-glucosidic linkages, for example. Still in some aspects, a dextran long chain can comprise 100% alpha-1,6-glucosidic linkages (excepting the linkage used by such long chain to branch from another chain).

Short chains of a dextran molecule in some aspects are one to three glucose monomers in length and comprise less than about 5-10% of all the glucose monomers of the dextran polymer. At least about 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or all of, short chains herein are 1-3 glucose monomers in length. The short chains of a dextran molecule can comprise less than about 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, or 1% of all the glucose monomers of the dextran molecule, for example.

Short chains of a dextran molecule in some aspects can comprise alpha-1,2-, alpha-1,3-, and/or alpha-1,4-glucosidic linkages. Short chains, when considered all together (not individually) may comprise (i) all three of these linkages, or (ii) alpha-1,3- and alpha-1,4-glucosidic linkages, for example. It is believed that short chains of a dextran molecule herein can be heterogeneous (i.e., showing some variation in linkage profile) or homogeneous (i.e., sharing similar or same linkage profile) with respect to the other short chains of the dextran.

Dextran in certain embodiments can have an Mw of about, or at least about, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 105, 110, 115, 120, 125, 130, 135, 140, 145, 150, 155, 160, 165, 170, 175, 180, 185, 190, 195, or 200 million (or any integer between 50 and 200 million) (or any range between two of these values).. The Mw of dextran can be about 50-200, 60-200, 70-200, 80-200, 90-200, 100-200, 110-200, 120-200, 50-180, 60-180, 70-180, 80-180, 90-180, 100-180, 110-180, 120-180, 50-160, 60-160, 70-160, 80-160, 90-160, 100-160, 110-

160, 120-160, 50-140, 60-140, 70-140, 80-140, 90-140, 100-140, 110-140, 120-140, 50-120, 60-120, 70-120, 80-120, 90-120, 100-120, 110-120, 50-110, 60-110, 70-110, 80-110, 90-110, 100-110, 50-100, 60-100, 70-100, 80-100, 90-100, or 95-105 million, for example. Any of these Mw's can be represented in DPw, if
5 desired, by dividing Mw by 162.14.

The z-average radius of gyration of a dextran herein can be about 200-280 nm. For example, the z-average Rg can be about 200, 205, 210, 215, 220, 225, 230, 235, 240, 245, 250, 255, 260, 265, 270, 275, or 280 nm (or any integer between 200-280 nm). As other examples, the z-average Rg can be about 200-
10 280, 200-270, 200-260, 200-250, 200-240, 200-230, 220-280, 220-270, 220-260, 220-250, 220-240, 220-230, 230-280, 230-270, 230-260, 230-250, 230-240, 240-280, 240-270, 240-260, 240-250, 250-280, 250-270, or 250-260 nm.

The Mw and/or z-average Rg of dextran in some aspects can be measured following a protocol similar to, or the same as, the protocol disclosed
15 in Example 9. For example, a Mw and/or z-average Rg herein can be measured by first dissolving dextran produced by an 0768 gtf at 0.4-0.6 mg/mL (e.g., ~0.5 mg/mL) in 0.05-1.0 M (e.g., ~0.075 M) Tris(hydroxymethyl)aminomethane buffer with 150-250 ppm (e.g., ~200 ppm) NaN₃. Solvation of dry dextran can be achieved by shaking for 12-18 hours at 45-55 °C (e.g., ~50 °C). The resulting
20 dextran solution can be entered into a suitable flow injection chromatographic apparatus comprising a separation module (e.g., Alliance™ 2695 separation module from Waters Corporation, Milford, MA) coupled with three online detectors: a differential refractometer (e.g., Waters 2414 refractive index detector), a multiangle light scattering (MALS) photometer (e.g., Heleos™-2 18-
25 angle multiangle MALS photometer) equipped with a quasielastic light scattering (QELS) detector (e.g., QELS detector from Wyatt Technologies, Santa Barbara, CA), and a differential capillary viscometer (e.g., ViscoStar™ differential capillary viscometer from Wyatt). Two suitable size-exclusion columns (e.g., AQUAGEL-OH GUARD columns from Agilent Technologies, Santa Clara, CA) can be used
30 to separate the dextran polymer peak from the injection peak, where the mobile phase can be the same as the sample solvent (above), the flow rate can be

about 0.2 mL/min, the injection volumes can be about 0.1 mL, and column temperature can be about 30°C. Suitable software can be used for data acquisition (e.g., Empower™ version 3 software from Waters) and for multidetector data reduction (Astra™ version 6 software from Wyatt). MALS data can provide weight-average molecular weight (Mw) and z-average radius of gyration (Rg), and QELS data can provide z-average hydrodynamic radius, for example.

A dextran herein can be a product of a glucosyltransferase enzyme comprising, or consisting of, an amino acid sequence that is 100% identical to, or at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to, SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:5, SEQ ID NO:9, SEQ ID NO:13, or SEQ ID NO:17 (and have gtf activity). Non-limiting examples of a glucosyltransferase enzyme comprising SEQ ID NO:1 (or a related sequence) include glucosyltransferase enzymes comprising, or consisting of, an amino acid sequence that is 100% identical to, or at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to, SEQ ID NO:2 (and have gtf activity). Production of dextran can be accomplished with a gtf reaction as disclosed herein, for example. Dextran as disclosed in the instant detailed description (e.g., molecular weight, linkage and branching profile) can optionally be characterized as a product of a glucosyltransferase enzyme comprising or consisting of SEQ ID NO:1 or 2 (or a related sequence thereof that is at least 90% identical [above]). In some other embodiments, a glucosyltransferase enzyme comprises or consists of an amino acid sequence that is 100% identical to, or at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to, the secreted portion (i.e., signal peptide removed) of the amino acid sequence encoded by SEQ ID NO:6, 10, 14, or 18.

A glucosyltransferase enzyme herein may be from various microbial sources, such as a bacteria or fungus. Examples of bacterial glucosyltransferase enzymes are those derived from a *Streptococcus* species, *Leuconostoc* species, *Lactobacillus* species, or *Weissella* species. Examples of *Streptococcus* species include *S. sobrinus*, *S. downei*, *S. salivarius*, *S. dentirosetti*, *S. mutans*, *S.*

oralis, *S. gallolyticus* and *S. sanguinis*. Examples of *Leuconostoc* species include *L. pseudomesenteroides*, *L. mesenteroides*, *L. amelibiosum*, *L. argentinum*, *L. carnosum*, *L. citreum*, *L. cremoris*, *L. dextranicum* and *L. fructosum*. Examples of *Lactobacillus* species include *L. fermentum*, *L. acidophilus*, *L. delbrueckii*, *L. helveticus*, *L. salivarius*, *L. casei*, *L. curvatus*, *L. plantarum*, *L. sakei*, *L. brevis*, *L. buchneri* and *L. reuteri*. Examples of *Weissella* species include *W. cibaria*, *W. confusa*, *W. halotolerans*, *W. hellenica*, *W. kandleri*, *W. kimchii*, *W. koreensis*, *W. minor*, *W. paramesenteroides*, *W. soli* and *W. thailandensis*. A glucosyltransferase in some aspects is not from *L. mesenteroides*.

Examples of glucosyltransferase enzymes herein can be any of the amino acid sequences disclosed herein and that further include 1-300 (or any integer there between [e.g., 10, 15, 20, 25, 30, 35, 40, 45, or 50]) residues on the N-terminus and/or C-terminus. Such additional residues may be from a corresponding wild type sequence from which the glucosyltransferase enzyme is derived, or may be a heterologous sequence such as an epitope tag (at either N- or C-terminus) or a heterologous signal peptide (at N-terminus), for example.

A glucosyltransferase enzyme used to produce dextran herein is typically in a mature form lacking an N-terminal signal peptide. An expression system for producing a mature glucosyltransferase enzyme herein may employ an enzyme-encoding polynucleotide that further comprises sequence encoding an N-terminal signal peptide to direct extra-cellular secretion. The signal peptide in such embodiments is cleaved from the enzyme during the secretion process. The signal peptide may either be native or heterologous to the glucosyltransferase. An example of a signal peptide useful herein is one from a bacterial (e.g., a *Bacillus* species such as *B. subtilis*) or fungal species. An example of a bacterial signal peptide is an aprE signal peptide, such as one from *Bacillus* (e.g., *B. subtilis*, see Vogtentanz et al., *Protein Expr. Purif.* 55:40-52, which is incorporated herein by reference).

SEQ ID NO:1, SEQ ID NO:5, SEQ ID NO:9, SEQ ID NO:13 and SEQ ID NO:17 are examples of mature glucosyltransferase enzymes that lack an N-

terminal signal peptide. Since these and related amino acid sequences do not begin with a methionine residue, it would be understood that an N-terminal start-methionine is preferably added to the sequence (directly or via an intervening heterologous amino acid sequence such as an epitope) if expressing any of these enzymes without using a signal peptide (such as with an expression system where the enzyme is expressed intracellularly and obtained from a cell lysate).

A glucosyltransferase enzyme in certain embodiments can be produced by any means known in the art. For example, a glucosyltransferase enzyme can be produced recombinantly in a heterologous expression system, such as a microbial heterologous expression system. Examples of heterologous expression systems include bacterial (e.g., *E. coli* such as TOP10, MG1655, or BL21 DE3; *Bacillus* sp. such as *B. subtilis*) and eukaryotic (e.g., yeasts such as *Pichia* sp. and *Saccharomyces* sp.) expression systems.

A glucosyltransferase enzyme disclosed herein may be used in any purification state (e.g., pure or non-pure). For example, the glucosyltransferase enzyme may be purified and/or isolated prior to its use. Examples of glucosyltransferase enzymes that are non-pure include those in the form of a cell lysate. A cell lysate or extract may be prepared from a bacteria (e.g., *E. coli*) used to heterologously express the enzyme. For example, the bacteria may be subjected to disruption using a French pressure cell. In alternative embodiments, bacteria may be homogenized with a homogenizer (e.g., APV, Rannie, Gaulin). A glucosyltransferase enzyme is typically soluble in these types of preparations. A bacterial cell lysate, extract, or homogenate herein may be used at about 0.15-0.3% (v/v) in a reaction for producing dextran from sucrose.

A heterologous gene expression system for expressing a glucosyltransferase enzyme herein can be designed for protein secretion, for example. A glucosyltransferase enzyme typically comprises a signal peptide in such embodiments. A glucosyltransferase enzyme in some embodiments does not occur in nature; for example, an enzyme herein is not believed to be one that

is naturally secreted (i.e., mature form) from a microbe (from which the glucosyltransferase enzyme herein could possibly have been derived).

The activity of a glucosyltransferase enzyme herein can be determined using any method known in the art. For example, glucosyltransferase enzyme activity can be determined by measuring the production of reducing sugars (fructose and glucose) in a reaction containing sucrose (~50 g/L), dextran T10 (~1 mg/mL) and potassium phosphate buffer (~pH 6.5, 50 mM), where the solution is held at ~22-25 °C for ~24-30 hours. The reducing sugars can be measured by adding 0.01 mL of the reaction to a mixture containing ~1 N NaOH and ~0.1% triphenyltetrazolium chloride and then monitoring the increase in absorbance at OD_{480nm} for ~five minutes. Also for instance, a unit of an enzyme such as gtf 0768 (comprising SEQ ID NO:1) herein can be defined as the amount of enzyme required to consume 1 g of sucrose in 1 hour at 26 °C, pH 6.5, and with 100 g/L of sucrose.

A dextran as presently disclosed can be a product of a glucosyltransferase as comprised in a glucosyltransferase reaction.

The temperature of a glucosyltransferase reaction herein can be controlled, if desired. In certain embodiments, the temperature is between about 5 °C to about 50 °C. The temperature in certain other embodiments is between about 20 °C to about 40 °C. Alternatively, the temperature may be about 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, or 40 °C. The temperature of a glucosyltransferase reaction herein may be maintained using various means known in the art. For example, the temperature can be maintained by placing the vessel containing the reaction in an air or water bath incubator set at the desired temperature.

The initial concentration of sucrose in a glucosyltransferase reaction herein can be about 20 g/L to 900 g/L, 20 g/L to 400 g/L, 75 g/L to 175 g/L, or 50 g/L to 150 g/L. The initial concentration of sucrose can be about 20, 30, 40, 50, 60, 70, 80, 90, 100, 110, 120, 130, 140, 150, 160, 200, 300, 400, 500, 600, 700, 800, 900, 50-150, 75-125, 90-110, 50-500, 100-500, 200-500, 300-500, 400-500, 50-400, 100-400, 200-400, 300-400, 50-300, 100-300, 200-300, 50-200, 100-

200, or 50-100 g/L (or any integer between 20 and 900 g/L), for example. "Initial concentration of sucrose" refers to the sucrose concentration in a gtf reaction just after all the reaction components have been added (at least water, sucrose, glucosyltransferase enzyme).

5 Sucrose used in a glucosyltransferase reaction herein can be highly pure ($\geq 99.5\%$) or be of any other purity or grade. For example, sucrose can have a purity of at least 99.0%, or can be reagent grade sucrose. As another example, incompletely refined sucrose can be used. Incompletely refined sucrose herein refers to sucrose that has not been processed to white refined sucrose. Thus,
10 incompletely refined sucrose can be completely unrefined or partially refined. Examples of unrefined sucrose are "raw sucrose" ("raw sugar") and solutions thereof. Examples of partially refined sucrose have not gone through one, two, three, or more crystallization steps. The ICUMSA (International Commission for Uniform Methods of Sugar Analysis) of incompletely refined sucrose herein can
15 be greater than 150, for example. Sucrose herein may be derived from any renewable sugar source such as sugar cane, sugar beets, cassava, sweet sorghum, or corn. Suitable forms of sucrose useful herein are crystalline form or non-crystalline form (e.g., syrup, cane juice, beet juice), for example. Additional suitable forms of incompletely refined sucrose are disclosed in U.S. Appl. Publ.
20 No. 2015/0275256, which is incorporated herein by reference.

 Methods of determining ICUMSA values for sucrose are well known in the art and disclosed by the International Commission for Uniform Methods of Sugar Analysis in ICUMSA Methods of Sugar Analysis: Official and Tentative Methods Recommended by the International Commission for Uniform Methods of Sugar
25 Analysis (ICUMSA) (Ed. H.C.S. de Whalley, Elsevier Pub. Co., 1964), for example, which is incorporated herein by reference. ICUMSA can be measured, for example, by ICUMSA Method GS1/3-7 as described by R.J. McCowage, R.M. Urquhart and M.L. Burge (Determination of the Solution Colour of Raw Sugars, Brown Sugars and Coloured Syrups at pH 7.0 – Official, Verlag Dr Albert
30 Bartens, 2011 revision), which is incorporated herein by reference.

The pH of a glucosyltransferase reaction in certain embodiments can be between about 4.0 to about 8.0. Alternatively, the pH can be about 4.0, 4.5, 5.0, 5.5, 6.0, 6.5, 7.0, 7.5, or 8.0. The pH can be adjusted or controlled by the addition or incorporation of a suitable buffer, including but not limited to:

5 phosphate, tris, citrate, or a combination thereof. Buffer concentration in a gtf reaction can be from 0 mM to about 100 mM, or about 10, 20, or 50 mM, for example.

A glucosyltransferase reaction can be contained within any vessel suitable for applying one or more of the reaction conditions disclosed herein. For
10 example, a glucosyltransferase reaction herein may be in a stainless steel, plastic, or glass vessel or container of a size suitable to contain a particular reaction. Such a vessel can optionally be equipped with a stirring device.

A glucosyltransferase reaction herein can optionally be agitated via stirring or orbital shaking, for example. Such agitation can be at about 50, 60, 70, 80,
15 90, 100, 110, 120, 130, 140, 150, 50-150, 60-140, 70-130, 80-120, or 90-110 rpm, for example.

The concentration of glucosyltransferase enzyme in a reaction can be at least about 15, 20, 25, 30, 35, or 40 U/L, for example. In some embodiments, 15-35, 15-30, 15-25, 20-35, 20-30, 20-25, 25-35, 25-30, or 30-35 U/L of
20 glucosyltransferase can be used.

A glucosyltransferase reaction herein can take about 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 18, 24, 30, 36, 48, 60, 72, 84, 96, 18-30, 20-28, or 22-26 hours to complete. Reaction time may depend, for example, on certain parameters such as the amount of sucrose and glucosyltransferase enzyme used in the reaction.

25 All the features herein defining a glucosyltransferase reaction can be combined, accordingly. Simply as an example, a reaction using an 0768 glucosyltransferase (comprising SEQ ID NO:1 or related sequence thereof) can initially contain 90-110 g/L (e.g., ~100 g/L) sucrose, 10-30 mM (e.g., ~20 mM) sodium phosphate buffer at pH 6.0-7.0 (e.g., ~pH 6.5), and 20-30 U/L (e.g., ~25
30 U/L) enzyme. Such a reaction can be held for about 20-28 hours (e.g., ~24 hours) with 50-150 rpm (e.g., ~100 rpm) shaking at 24-28 °C (e.g., ~26 °C).

In some embodiments, a glucosyltransferase reaction comprising a gtf 0768 enzyme (SEQ ID NO:1 or related sequences) and any amount of sucrose disclosed herein can be complete (e.g., 95% or more initially provided sucrose depleted) in less than about 24, 22, 20, 18, or 16 hours after initiating the reaction. Depletion of sucrose in such a reaction can be about, or at least about, 3, 4, 5, 6, 7, 8, 9, or 10 times faster than a same or similar reaction, but which comprises a *Leuconostoc mesenteroides* dextran sucrose instead of a gtf 0768 enzyme, for example.

A composition comprising a dextran herein can be non-aqueous (e.g., a dry composition). Examples of such embodiments include powders, granules, microcapsules, flakes, or any other form of particulate matter. Other examples include larger compositions such as pellets, bars, kernels, beads, tablets, sticks, or other agglomerates. A non-aqueous or dry composition herein typically has less than 3, 2, 1, 0.5, or 0.1 wt% water comprised therein. The amount of dextran herein in a non-aqueous or dry composition can be about, or at least about, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 99.5, or 99.9 wt%, for example. A non-aqueous composition herein can be in the form of a household product, personal care product, pharmaceutical product, industrial product, or food product, for example.

In certain embodiments of the present disclosure, a composition comprising a dextran can be an aqueous composition having a viscosity of about, or at least about, 25 cPs. Alternatively, an aqueous composition herein can have a viscosity of about, or at least about, 25, 50, 75, 100, 250, 500, 750, 1000, 2000, 3000, 4000, 5000, 6000, 7000, 8000, 9000, 10000, 11000, 12000, 13000, 14000, 15000, 16000, 17000, 18000, 19000, 20000, 25000, 30000, 35000, 40000, 45000, or 50000 cPs (or any integer between 25 and 50000 cPs), for example. Examples of aqueous compositions include hydrocolloids and aqueous solutions.

Viscosity can be measured with an aqueous composition herein at any temperature between about 3 °C to about 110 °C (or any integer between 3 and 110 °C). Alternatively, viscosity can be measured at a temperature between about 4 °C to 30 °C, or about 20 °C to 25 °C, for example. Viscosity can be measured at atmospheric pressure (about 760 torr) or any other higher or lower pressure.

The viscosity of an aqueous composition disclosed herein can be measured using a viscometer or rheometer, or using any other means known in the art. It would be understood by those skilled in the art that a viscometer or rheometer can be used to measure the viscosity of aqueous compositions herein that exhibits rheological behavior (i.e., having viscosities that vary with flow conditions). The viscosity of such embodiments can be measured at a rotational shear rate of about 0.1 to 1000 rpm (revolutions per minute), for example. Alternatively, viscosity can be measured at a rotational shear rate of about 10, 60, 150, 250, or 600 rpm.

In certain embodiments, viscosity can be measured with an aqueous composition in which the constituent dextran was synthesized. For example, viscosity can be measured for a gtf reaction herein that is at or near completion. Viscosity can thus be measured with an aqueous composition in which the constituent dextran is not purified (e.g., other components in the composition, aside from water, are present at greater than 1, 5, or 10 wt%); such a composition can contain one or more salts, buffers, proteins (e.g., gtf enzymes), sugars (e.g., fructose, glucose, leucrose, oligosaccharides).

The pH of an aqueous composition disclosed herein can be between about 2.0 to about 12.0, for example. Alternatively, pH can be about 2.0, 3.0, 4.0, 5.0, 6.0, 7.0, 8.0, 9.0, 10.0, 11.0, 12.0; or between 5.0 to about 12.0; or between about 4.0 and 8.0; or between about 5.0 and 8.0, for example.

An aqueous composition herein such as a hydrocolloid or aqueous solution can comprise a solvent having about, or at least about, 10 wt% water. In other embodiments, a solvent is about, or at least about, 20, 30, 40, 50, 60, 70,

80, 90, or 100 wt% water (or any integer value between 10 and 100 wt%), for example.

A dextran herein can be present in an aqueous composition at a wt% of about, or at least about, 0.01, 0.05, 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1.0, 1.2, 1.4, 1.6, 1.8, 2.0, 2.5, 3.0, 3.5, 4.0, 4.5, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, or 90 wt%, for example. Example 8 below demonstrates that dextran in certain aspects provides high viscosity to aqueous solutions at relatively low concentrations of the dextran. Thus, certain embodiments of the present disclosure are drawn to aqueous compositions with less than about 30, 29, 28, 27, 26, 25, 24, 23, 22, 21, 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2, 1, or 0.5 wt% dextran herein.

An aqueous composition herein can comprise other components in addition to dextran. For example, an aqueous composition can comprise one or more salts such as a sodium salt (e.g., NaCl, Na₂SO₄). Other non-limiting examples of salts include those having (i) an aluminum, ammonium, barium, calcium, chromium (II or III), copper (I or II), iron (II or III), hydrogen, lead (II), lithium, magnesium, manganese (II or III), mercury (I or II), potassium, silver, sodium strontium, tin (II or IV), or zinc cation, and (ii) an acetate, borate, bromate, bromide, carbonate, chlorate, chloride, chlorite, chromate, cyanamide, cyanide, dichromate, dihydrogen phosphate, ferricyanide, ferrocyanide, fluoride, hydrogen carbonate, hydrogen phosphate, hydrogen sulfate, hydrogen sulfide, hydrogen sulfite, hydride, hydroxide, hypochlorite, iodate, iodide, nitrate, nitride, nitrite, oxalate, oxide, perchlorate, permanganate, peroxide, phosphate, phosphide, phosphite, silicate, stannate, stannite, sulfate, sulfide, sulfite, tartrate, or thiocyanate anion. Thus, any salt having a cation from (i) above and an anion from (ii) above can be in an aqueous composition, for example. A salt can be present in an aqueous composition herein at a wt% of about .01 to about 10.00 (or any hundredth increment between .01 and 10.00), for example.

A composition herein may optionally contain one or more active enzymes. Non-limiting examples of suitable enzymes include proteases, cellulases, hemicellulases, peroxidases, lipolytic enzymes (e.g., metallolipolytic enzymes),
5 xylanases, lipases, phospholipases, esterases (e.g., arylesterase, polyesterase),
perhydrolases, cutinases, pectinases, pectate lyases, mannanases, keratinases, reductases, oxidases (e.g., choline oxidase), phenoloxidases, lipoxygenases, ligninases, pullulanases, tannases, pentosanases, malanases, beta-glucanases, arabinosidases, hyaluronidases, chondroitinases, laccases, metalloproteinases,
10 amadoriases, glucoamylases, arabinofuranosidases, phytases, isomerases, transferases and amylases. If an enzyme(s) is included, it may be comprised in a composition herein at about 0.0001-0.1 wt% (e.g., 0.01-0.03 wt%) active enzyme (e.g., calculated as pure enzyme protein), for example.

A cellulase herein can have endocellulase activity (EC 3.2.1.4),
15 exocellulase activity (EC 3.2.1.91), or cellobiase activity (EC 3.2.1.21). A cellulase herein is an "active cellulase" having activity under suitable conditions for maintaining cellulase activity; it is within the skill of the art to determine such suitable conditions.

A cellulase herein may be derived from any microbial source, such as a
20 bacteria or fungus. Chemically-modified cellulases or protein-engineered mutant cellulases are included. Suitable cellulases include, but are not limited to, cellulases from the genera *Bacillus*, *Pseudomonas*, *Streptomyces*, *Trichoderma*, *Humicola*, *Fusarium*, *Thielavia* and *Acremonium*. As other examples, a cellulase may be derived from *Humicola insolens*, *Myceliophthora thermophila* or *Fusarium oxysporum*; these and other cellulases are disclosed in U.S. Patent Nos.
25 4435307, 5648263, 5691178, 5776757 and 7604974, which are all incorporated herein by reference. Exemplary *Trichoderma reesei* cellulases are disclosed in U.S. Patent Nos. 4689297, 5814501, 5324649, and International Patent Appl. Publ. Nos. WO92/06221 and WO92/06165, all of which are incorporated herein
30 by reference. Exemplary *Bacillus* cellulases are disclosed in U.S. Patent No. 6562612, which is incorporated herein by reference. A cellulase, such as any of

the foregoing, preferably is in a mature form lacking an N-terminal signal peptide. Commercially available cellulases useful herein include CELLUZYME[®] and CAREZYME[®] (Novozymes A/S); CLAZINASE[®] and PURADAX[®] HA (DuPont Industrial Biosciences), and KAC-500(B)[®] (Kao Corporation).

5 Alternatively, a cellulase herein may be produced by any means known in the art, such as described in U.S. Patent Nos. 4435307, 5776757 and 7604974, which are incorporated herein by reference. For example, a cellulase may be produced recombinantly in a heterologous expression system, such as a microbial or fungal heterologous expression system. Examples of heterologous
10 expression systems include bacterial (e.g., *E. coli*, *Bacillus* sp.) and eukaryotic systems. Eukaryotic systems can employ yeast (e.g., *Pichia* sp., *Saccharomyces* sp.) or fungal (e.g., *Trichoderma* sp. such as *T. reesei*, *Aspergillus* species such as *A. niger*) expression systems, for example.

 One or more cellulases can be directly added as an ingredient when
15 preparing a composition disclosed herein. Alternatively, one or more cellulases can be indirectly (inadvertently) provided in the disclosed composition. For example, cellulase can be provided in a composition herein by virtue of being present in a non-cellulase enzyme preparation used for preparing a composition. Cellulase in compositions in which cellulase is indirectly provided thereto can be
20 present at about 0.1-10 ppb (e.g., less than 1 ppm), for example. A contemplated benefit of a composition herein, by virtue of employing a dextran compound, is that non-cellulase enzyme preparations that might have background cellulase activity can be used without concern that the desired effects of the dextran will be negated by the background cellulase activity.

25 A cellulase in certain embodiments can be thermostable. Cellulase thermostability refers to the ability of the enzyme to retain activity after exposure to an elevated temperature (e.g. about 60-70 °C) for a period of time (e.g., about 30-60 minutes). The thermostability of a cellulase can be measured by its half-life ($t_{1/2}$) given in minutes, hours, or days, during which time period half the
30 cellulase activity is lost under defined conditions.

A cellulase in certain embodiments can be stable to a wide range of pH values (e.g. neutral or alkaline pH such as pH of ~7.0 to ~11.0). Such enzymes can remain stable for a predetermined period of time (e.g., at least about 15 min., 30 min., or 1 hour) under such pH conditions.

5 At least one, two, or more cellulases may be included in the composition. The total amount of cellulase in a composition herein typically is an amount that is suitable for the purpose of using cellulase in the composition (an “effective amount”). For example, an effective amount of cellulase in a composition intended for improving the feel and/or appearance of a cellulose-containing fabric
10 is an amount that produces measurable improvements in the feel of the fabric (e.g., improving fabric smoothness and/or appearance, removing pills and fibrils which tend to reduce fabric appearance sharpness). As another example, an effective amount of cellulase in a fabric stonewashing composition herein is that amount which will provide the desired effect (e.g., to produce a worn and faded
15 look in seams and on fabric panels). The amount of cellulase in a composition herein can also depend on the process parameters in which the composition is employed (e.g., equipment, temperature, time, and the like) and cellulase activity, for example. The effective concentration of cellulase in an aqueous composition in which a fabric is treated can be readily determined by a skilled artisan. In
20 fabric care processes, cellulase can be present in an aqueous composition (e.g., wash liquor) in which a fabric is treated in a concentration that is minimally about 0.01-0.1 ppm total cellulase protein, or about 0.1-10 ppb total cellulase protein (e.g., less than 1 ppm), to maximally about 100, 200, 500, 1000, 2000, 3000, 4000, or 5000 ppm total cellulase protein, for example.

25 Dextran polymers provided herein are believed to be mostly or completely stable (resistant) to being degraded by cellulase. For example, the percent degradation of a dextran herein by one or more cellulases is believed to be less than 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, or 1%, or is 0%. Such percent degradation can be determined, for example, by comparing the molecular weight
30 of dextran polymer before and after treatment with a cellulase for a period of time (e.g., ~24 hours).

Aqueous compositions in certain embodiments are believed to have shear thinning behavior or shear thickening behavior. Shear thinning behavior is observed as a decrease in viscosity of the aqueous composition as shear rate increases, whereas shear thickening behavior is observed as an increase in viscosity of the aqueous composition as shear rate increases. Modification of the shear thinning behavior or shear thickening behavior of an aqueous composition herein can be due to the admixture of a dextran to the aqueous composition. Thus, one or more dextran compounds of the present disclosure can be added to an aqueous composition to modify its rheological profile (i.e., the flow properties of an aqueous liquid, solution, or mixture are modified). Also, one or more dextran compounds can be added to an aqueous composition to modify its viscosity.

The rheological properties of aqueous compositions herein can be observed by measuring viscosity over an increasing rotational shear rate (e.g., from about 0.1 rpm to about 1000 rpm). For example, shear thinning behavior of an aqueous composition disclosed herein can be observed as a decrease in viscosity (cPs) by about, or at least about, 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, or 95% (or any integer between 5% and 95%) as the rotational shear rate increases from about 10 rpm to 60 rpm, 10 rpm to 150 rpm, 10 rpm to 250 rpm, 60 rpm to 150 rpm, 60 rpm to 250 rpm, or 150 rpm to 250 rpm. As another example, shear thickening behavior of an aqueous composition disclosed herein can be observed as an increase in viscosity (cPs) by about, or at least about, 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 100%, 125%, 150%, 175%, or 200% (or any integer between 5% and 200%) as the rotational shear rate increases from about 10 rpm to 60 rpm, 10 rpm to 150 rpm, 10 rpm to 250 rpm, 60 rpm to 150 rpm, 60 rpm to 250 rpm, or 150 rpm to 250 rpm.

An aqueous composition disclosed herein can be in the form of, and/or comprised in, a food product, personal care product, pharmaceutical product, household product, or industrial product, such as any of those products described below. Dextran compounds herein can be used as thickening agents in each of these products. Such a thickening agent may be used in conjunction with one or more other types of thickening agents if desired, such as those disclosed in U.S. Patent No. 8541041, the disclosure of which is incorporated herein by reference in its entirety.

Dextran compounds disclosed herein are believed to be useful for providing one or more of the following physical properties to a personal care product, pharmaceutical product, household product, industrial product, or food product: thickening, freeze/thaw stability, lubricity, moisture retention and release, texture, consistency, shape retention, emulsification, binding, suspension, dispersion, gelation, reduced mineral hardness, for example.

Examples of a concentration or amount of a dextran in a product can be any of the weight percentages provided herein, for example.

Personal care products herein are not particularly limited and include, for example, skin care compositions, cosmetic compositions, antifungal compositions, and antibacterial compositions. Personal care products herein may be in the form of, for example, lotions, creams, pastes, balms, ointments, pomades, gels, liquids, combinations of these and the like. The personal care products disclosed herein can include at least one active ingredient, if desired. An active ingredient is generally recognized as an ingredient that causes an intended pharmacological effect.

In certain embodiments, a skin care product can be applied to skin for addressing skin damage related to a lack of moisture. A skin care product may also be used to address the visual appearance of skin (e.g., reduce the appearance of flaky, cracked, and/or red skin) and/or the tactile feel of the skin (e.g., reduce roughness and/or dryness of the skin while improved the softness and subtleness of the skin). A skin care product typically may include at least one active ingredient for the treatment or prevention of skin ailments, providing a

cosmetic effect, or for providing a moisturizing benefit to skin, such as zinc oxide, petrolatum, white petrolatum, mineral oil, cod liver oil, lanolin, dimethicone, hard fat, vitamin A, allantoin, calamine, kaolin, glycerin, or colloidal oatmeal, and combinations of these. A skin care product may include one or more natural

5 moisturizing factors such as ceramides, hyaluronic acid, glycerin, squalane, amino acids, cholesterol, fatty acids, triglycerides, phospholipids, glycosphingolipids, urea, linoleic acid, glycosaminoglycans, mucopolysaccharide, sodium lactate, or sodium pyrrolidone carboxylate, for example. Other

10 ingredients that may be included in a skin care product include, without limitation, glycerides, apricot kernel oil, canola oil, squalane, squalene, coconut oil, corn oil, jojoba oil, jojoba wax, lecithin, olive oil, safflower oil, sesame oil, shea butter, soybean oil, sweet almond oil, sunflower oil, tea tree oil, shea butter, palm oil, cholesterol, cholesterol esters, wax esters, fatty acids, and orange oil.

A personal care product herein can also be in the form of makeup, lipstick,

15 mascara, rouge, foundation, blush, eyeliner, lip liner, lip gloss, other cosmetics, sunscreen, sun block, nail polish, nail conditioner, bath gel, shower gel, body wash, face wash, lip balm, skin conditioner, cold cream, moisturizer, body spray, soap, body scrub, exfoliant, astringent, scruffing lotion, depilatory, permanent waving solution, antidandruff formulation, antiperspirant composition, deodorant,

20 shaving product, pre-shaving product, after-shaving product, cleanser, skin gel, rinse, dentifrice composition, toothpaste, or mouthwash, for example. An example of a personal care product (e.g., a cleanser, soap, scrub, cosmetic) comprises a carrier or exfoliation agent (e.g., jojoba beads [jojoba ester beads]) (e.g., about 1-10, 3-7, 4-6, or 5 wt%); such an agent may optionally be dispersed

25 within the product.

A personal care product in some aspects can be a hair care product. Examples of hair care products herein include shampoo, hair conditioner (leave-in or rinse-out), cream rinse, hair dye, hair coloring product, hair shine product, hair serum, hair anti-frizz product, hair split-end repair product, mousse, hair

30 spray, and styling gel. A hair care product can be in the form of a liquid, paste, gel, solid, or powder in some embodiments. A hair care product as presently

disclosed typically comprises one or more of the following ingredients, which are generally used to formulate hair care products: anionic surfactants such as polyoxyethylenelauryl ether sodium sulfate; cationic surfactants such as stearyltrimethylammonium chloride and/or distearyltrimethylammonium chloride; 5 nonionic surfactants such as glyceryl monostearate, sorbitan monopalmitate and/or polyoxyethylenecetyl ether; wetting agents such as propylene glycol, 1,3-butylene glycol, glycerin, sorbitol, pyroglutamic acid salts, amino acids and/or trimethylglycine; hydrocarbons such as liquid paraffins, petrolatum, solid paraffins, squalane and/or olefin oligomers; higher alcohols such as stearyl 10 alcohol and/or cetyl alcohol; superfatting agents; antidandruff agents; disinfectants; anti-inflammatory agents; crude drugs; water-soluble polymers such as methyl cellulose, hydroxycellulose and/or partially deacetylated chitin (in addition to one or more dextrans as disclosed herein); antiseptics such as paraben; ultra-violet light absorbers; pearling agents; pH adjustors; perfumes; 15 and pigments.

A pharmaceutical product herein can be in the form of an emulsion, liquid, elixir, gel, suspension, solution, cream, or ointment, for example. Also, a pharmaceutical product herein can be in the form of any of the personal care products disclosed herein, such as an antibacterial or antifungal composition. A 20 pharmaceutical product can further comprise one or more pharmaceutically acceptable carriers, diluents, and/or pharmaceutically acceptable salts. A dextran compound disclosed herein can also be used in capsules, encapsulants, tablet coatings, and as an excipients for medicaments and drugs.

Non-limiting examples of food products herein include vegetable, meat, 25 and soy patties; reformed seafood; reformed cheese sticks; cream soups; gravies and sauces; salad dressing; mayonnaise; onion rings; jams, jellies, and syrups; pie filling; potato products such as French fries and extruded fries; batters for fried foods, pancakes/waffles and cakes; pet foods; confectioneries (candy); beverages; frozen desserts; ice cream; cultured dairy products such as 30 cottage cheese, yogurt, cheeses, and sour creams; cake icing and glazes; whipped topping; leavened and unleavened baked goods; and the like.

In certain embodiments, dextran herein can be comprised in a foodstuff or any other ingestible material (e.g., enteral pharmaceutical preparation) in an amount that provides the desired degree of thickening and/or dispersion. For example, the concentration or amount of dextran in a product can be about 0.1-3 wt%, 0.1-4 wt%, 0.1-5 wt%, or 0.1-10 wt%.

A household and/or industrial product herein can be in the form of drywall tape-joint compounds; mortars; grouts; cement plasters; spray plasters; cement stucco; adhesives; pastes; wall/ceiling texturizers; binders and processing aids for tape casting, extrusion forming, injection molding and ceramics; spray adherents and suspending/dispersing aids for pesticides, herbicides, and fertilizers; fabric care products such as fabric softeners and laundry detergents; hard surface cleaners; air fresheners; polymer emulsions; gels such as water-based gels; surfactant solutions; paints such as water-based paints; protective coatings; adhesives; sealants and caulks; inks such as water-based ink; metal-working fluids; or emulsion-based metal cleaning fluids used in electroplating, phosphatizing, galvanizing and/or general metal cleaning operations, for example.

A dextran compound disclosed herein can be comprised in a personal care product, pharmaceutical product, household product, or industrial product in an amount that provides a desired degree of thickening and/or dispersion, for example. Examples of a concentration or amount of a dextran compound in a product can be any of the weight percentages provided above, for example.

An aqueous composition in some aspects can comprise about 0.5-2.0 wt% dextran herein (e.g., ~1.0 wt%), about 15-25 wt% (e.g., ~20 wt%) of moisturizer such as oil (e.g., mineral oil), about 4-6 wt% (~5 wt%) surfactant/emulsifier (e.g., one or both of sorbitan monooleate or polysorbate 80, such as ~2.6 wt% sorbitan monooleate and ~2.4 wt% polysorbate 80), optionally 0.25-1.0 wt% (e.g., 0.5 wt%) preservative (e.g., preservative comprising one or more of propylene glycol, diazolidinyl urea, methylparaben, or propylparaben [e.g., Germaben[®] II]), and optionally one or more other ingredients. Such compositions can be in the form of an emulsion, for example. In these and some

other related aspects, dextran as presently disclosed can be used as a substitute for compounds (e.g., xanthan gum, crosslinked polyacrylic acid polymers such as Carbopol® Ultrez 10) typically used to provide viscosity to certain consumer products such as personal care (e.g., lotion), food, and/or pharmaceutical products. Still in some aspects the sensory experience rating of an aqueous composition (e.g., personal care item such as lotion), as measured by ASTM E1490-3 ("Standard Practice for Descriptive Skinfeel Analysis of Creams and Lotions", ASTM International, West Conshohocken, PA, 2003, DOI: 10.1520/E1490-03, incorporated herein by reference), can be less than about 8, 7, or 6, where each of rub-out sliminess, afterfeel stickiness, pick-up stringiness and pick-up stickiness are measured in the evaluation.

A food product herein can be in the form of a confectionery, for example. A confectionary herein can contain one or more sugars (e.g., sucrose, fructose, dextrose) for sweetening, or otherwise be sugar-free.

Examples of confectioneries herein include boiled sugars (hard boiled candies [i.e., hard candy]), dragees, jelly candies, gums, licorice, chews, caramels, toffee, fudge, chewing gums, bubble gums, nougat, chewy pastes, halawa, tablets, lozenges, icing, frosting, pudding, and gels (e.g., fruit gels, gelatin dessert). Other examples of confectioneries include aerated confectioneries such as marshmallows, and baked confectioneries.

A confectionery herein can optionally be prepared with chocolate, in any form (e.g., bars, candies, bonbons, truffles, lentils). A confectionary can be coated with chocolate, sugar-coated, candied, glazed, and/or film-coated, for example. Film-coating processes typically comprise applying to the surface of a confectionery a film-forming liquid composition which becomes, after drying, a protective film. This film-coating serves, for example, to protect the active principles contained in the confectionery; to protect the confectionery itself from moisture, shocks, and/or friability; and/or to confer the confectionery attractive visual properties (e.g., shine, uniform color, smooth surface).

In certain embodiments, a confectionery can be filled with a filling that is liquid, pasty, solid, or powdered. Dextran herein can be comprised in such a

filling, in which case dextran is optionally also included in the confectionery component being filled.

A confectionery herein is optionally sugar-free, comprising no sugar and typically instead having one or more artificial and/or non-sugar sweeteners (optionally non-caloric) (e.g., aspartame, saccharin, STEVIA, SUCRALOSE). A sugar-free confectionery in certain embodiments can comprise one or more polyols (e.g., erythritol, glycerol, lactitol, mannitol, maltitol, xylitol), soluble fibers, and/or proteins in place of sugar.

A food product herein can be in the form of a pet food, for example. A pet food herein can be a food for a domesticated animal such as a dog or cat (or any other companion animal), for example. A pet food in certain embodiments provides to a domestic animal one or more of the following: necessary dietary requirements, treats (e.g., dog biscuits), food supplements. Examples of pet food include dry pet food (e.g., kernels, kibbles), semi-moist compositions, wet pet food (e.g., canned pet food), or any combination thereof. Wet pet food typically has a moisture content over 65%. Semi-moist pet food typically has a moisture content of 20-65% and can include humectants such as propylene glycol, potassium sorbate, and ingredients that prevent microbial growth (bacteria and mold). Dry pet food typically has a moisture content less than 20% and its processing usually includes extruding, drying and/or baking. A pet food can optionally be in the form of a gravy, yogurt, powder, suspension, chew, or treat (e.g., biscuits); all these compositions can also be used as pet food supplements, if desired. Pet treats can be semi-moist chewable treats; dry treats; chewable bones; baked, extruded or stamped treats; or confection treats, for example. Examples of pet food compositions/formulations in which a dextran herein can be added include those disclosed in U.S. Patent Appl. Publ. Nos. 2013/0280352 and 2010/0159103, and U.S. Patent No. 6977084, which are all incorporated herein by reference.

Compositions disclosed herein can be in the form of a fabric care composition. A fabric care composition herein can be used for hand wash,

machine wash and/or other purposes such as soaking and/or pretreatment of fabrics, for example. A fabric care composition may take the form of, for example, a laundry detergent; fabric conditioner; any wash-, rinse-, or dryer-added product; unit dose or spray. Fabric care compositions in a liquid form may be in the form of an aqueous composition as disclosed herein. In other aspects, a fabric care composition can be in a dry form such as a granular detergent or dryer-added fabric softener sheet. Other non-limiting examples of fabric care compositions herein include: granular or powder-form all-purpose or heavy-duty washing agents; liquid, gel or paste-form all-purpose or heavy-duty washing agents; liquid or dry fine-fabric (e.g. delicates) detergents; cleaning auxiliaries such as bleach additives, "stain-stick", or pre-treatments; substrate-laden products such as dry and wetted wipes, pads, or sponges; sprays and mists.

A detergent composition herein may be in any useful form, e.g., as powders, granules, pastes, bars, unit dose, or liquid. A liquid detergent may be aqueous, typically containing up to about 70 wt% of water and 0 wt% to about 30 wt% of organic solvent. It may also be in the form of a compact gel type containing only about 30 wt% water.

A detergent composition herein typically comprises one or more surfactants, wherein the surfactant is selected from nonionic surfactants, anionic surfactants, cationic surfactants, ampholytic surfactants, zwitterionic surfactants, semi-polar nonionic surfactants and mixtures thereof. In some embodiments, the surfactant is present at a level of from about 0.1% to about 60%, while in alternative embodiments the level is from about 1% to about 50%, while in still further embodiments the level is from about 5% to about 40%, by weight of the detergent composition. A detergent will usually contain 0 wt% to about 50 wt% of an anionic surfactant such as linear alkylbenzenesulfonate (LAS), alpha-olefinsulfonate (AOS), alkyl sulfate (fatty alcohol sulfate) (AS), alcohol ethoxysulfate (AEOS or AES), secondary alkanesulfonates (SAS), alpha-sulfo fatty acid methyl esters, alkyl- or alkenylsuccinic acid, or soap. In addition, a detergent composition may optionally contain 0 wt% to about 40 wt% of a nonionic surfactant such as alcohol ethoxylate (AEO or AE), carboxylated alcohol

ethoxylates, nonylphenol ethoxylate, alkylpolyglycoside, alkyltrimethylamineoxide, ethoxylated fatty acid monoethanolamide, fatty acid monoethanolamide, or polyhydroxy alkyl fatty acid amide (as described for example in WO92/06154, which is incorporated herein by reference).

- 5 A detergent composition herein typically comprises one or more detergent builders or builder systems. One or more oxidized poly alpha-1,3-glucan compounds can be included as a builder, for example. In some aspects, oxidized poly alpha-1,3-glucan can be included as a co-builder, in which it is used together with one or more additional builders such as any disclosed herein.
- 10 Oxidized poly alpha-1,3-glucan compounds for use herein are disclosed in U.S. Patent Appl. Publ. No. 2015/0259439. In some embodiments incorporating at least one builder, the cleaning compositions comprise at least about 1%, from about 3% to about 60%, or even from about 5% to about 40%, builder by weight of the composition. Builders (in addition to oxidized poly alpha-1,3-glucan)
- 15 include, but are not limited to, alkali metal, ammonium and alkanolammonium salts of polyphosphates, alkali metal silicates, alkaline earth and alkali metal carbonates, aluminosilicates, polycarboxylate compounds, ether hydroxypolycarboxylates, copolymers of maleic anhydride with ethylene or vinyl methyl ether, 1, 3, 5-trihydroxy benzene-2, 4, 6-trisulphonic acid, and
- 20 carboxymethyloxysuccinic acid, various alkali metal, ammonium and substituted ammonium salts of polyacetic acids such as ethylenediamine tetraacetic acid and nitrilotriacetic acid, as well as polycarboxylates such as mellitic acid, succinic acid, citric acid, oxydisuccinic acid, polymaleic acid, benzene 1,3,5-tricarboxylic acid, carboxymethyloxysuccinic acid, and soluble salts thereof. Indeed, it is
- 25 contemplated that any suitable builder will find use in various embodiments of the present disclosure. Additional examples of a detergent builder or complexing agent include zeolite, diphosphate, triphosphate, phosphonate, citrate, nitrilotriacetic acid (NTA), ethylenediaminetetraacetic acid (EDTA), diethylenetriaminepentaacetic acid (DTMPA), alkyl- or alkenylsuccinic acid,
- 30 soluble silicates or layered silicates (e.g., SKS-6 from Hoechst).

In some embodiments, builders form water-soluble hardness ion complexes (e.g., sequestering builders), such as citrates and polyphosphates (e.g., sodium tripolyphosphate and sodium tripolyphosphate hexahydrate, potassium tripolyphosphate, and mixed sodium and potassium tripolyphosphate, etc.). It is contemplated that any suitable builder will find use in the present disclosure, including those known in the art (See, e.g., EP2100949).

In some embodiments, suitable builders can include phosphate builders and non-phosphate builders. In some embodiments, a builder is a phosphate builder. In some embodiments, a builder is a non-phosphate builder. A builder can be used in a level of from 0.1% to 80%, or from 5% to 60%, or from 10% to 50%, by weight of the composition. In some embodiments, the product comprises a mixture of phosphate and non-phosphate builders. Suitable phosphate builders include mono-phosphates, di-phosphates, tri-polyphosphates or oligomeric-polyphosphates, including the alkali metal salts of these compounds, including the sodium salts. In some embodiments, a builder can be sodium tripolyphosphate (STPP). Additionally, the composition can comprise carbonate and/or citrate, preferably citrate that helps to achieve a neutral pH composition. Other suitable non-phosphate builders include homopolymers and copolymers of polycarboxylic acids and their partially or completely neutralized salts, monomeric polycarboxylic acids and hydroxycarboxylic acids and their salts. In some embodiments, salts of the above mentioned compounds include ammonium and/or alkali metal salts, i.e., lithium, sodium, and potassium salts, including sodium salts. Suitable polycarboxylic acids include acyclic, alicyclic, hetero-cyclic and aromatic carboxylic acids, wherein in some embodiments, they can contain at least two carboxyl groups which are in each case separated from one another by, in some instances, no more than two carbon atoms.

A detergent composition herein can comprise at least one chelating agent. Suitable chelating agents include, but are not limited to copper, iron and/or manganese chelating agents and mixtures thereof. In embodiments in which at least one chelating agent is used, the composition comprises from about 0.1% to

about 15%, or even from about 3.0% to about 10%, chelating agent by weight of the composition.

A detergent composition herein can comprise at least one deposition aid. Suitable deposition aids include, but are not limited to, polyethylene glycol, polypropylene glycol, polycarboxylate, soil release polymers such as polytelephthalic acid, clays such as kaolinite, montmorillonite, atapulgite, illite, bentonite, halloysite, and mixtures thereof.

A detergent composition herein can comprise one or more dye transfer inhibiting agents. Suitable polymeric dye transfer inhibiting agents include, but are not limited to, polyvinylpyrrolidone polymers, polyamine N-oxide polymers, copolymers of N-vinylpyrrolidone and N-vinylimidazole, polyvinylloxazolidones and polyvinylimidazoles or mixtures thereof. Additional dye transfer inhibiting agents include manganese phthalocyanine, peroxidases, polyvinylpyrrolidone polymers, polyamine N-oxide polymers, copolymers of N-vinylpyrrolidone and N-vinylimidazole, polyvinylloxazolidones and polyvinylimidazoles and/or mixtures thereof; chelating agents examples of which include ethylene-diamine-tetraacetic acid (EDTA); diethylene triamine penta methylene phosphonic acid (DTPMP); hydroxy-ethane diphosphonic acid (HEDP); ethylenediamine N,N'-disuccinic acid (EDDS); methyl glycine diacetic acid (MGDA); diethylene triamine penta acetic acid (DTPA); propylene diamine tetracetic acid (PDT A); 2-hydroxypyridine-N-oxide (HPNO); or methyl glycine diacetic acid (MGDA); glutamic acid N,N-diacetic acid (N,N-dicarboxymethyl glutamic acid tetrasodium salt (GLDA); nitrilotriacetic acid (NTA); 4,5-dihydroxy-m-benzenedisulfonic acid; citric acid and any salts thereof; N-hydroxyethyl ethylenediaminetri-acetic acid (HEDTA), triethylenetetraaminehexaacetic acid (TTHA), N-hydroxyethyliminodiacetic acid (HEIDA), dihydroxyethylglycine (DHEG), ethylenediaminetetrapropionic acid (EDTP) and derivatives thereof, which can be used alone or in combination with any of the above. In embodiments in which at least one dye transfer inhibiting agent is used, a composition herein may comprise from about 0.0001% to about 10%, from about 0.01% to about 5%, or even from about 0.1% to about 3%, by weight of the composition.

A detergent composition herein can comprise silicates. In some of these embodiments, sodium silicates (e.g., sodium disilicate, sodium metasilicate, and/or crystalline phyllosilicates) find use. In some embodiments, silicates are present at a level of from about 1% to about 20% by weight of the composition.

5 In some embodiments, silicates are present at a level of from about 5% to about 15% by weight of the composition.

A detergent composition herein can comprise dispersants. Suitable water-soluble organic materials include, but are not limited to the homo- or co-polymeric acids or their salts, in which the polycarboxylic acid comprises at least
10 two carboxyl radicals separated from each other by not more than two carbon atoms.

A detergent composition herein may additionally comprise one or more enzymes. Examples of enzymes include proteases, cellulases, hemicellulases, peroxidases, lipolytic enzymes (e.g., metallolipolytic enzymes), xylanases,
15 lipases, phospholipases, esterases (e.g., arylesterase, polyesterase), perhydrolases, cutinases, pectinases, pectate lyases, mannanases, keratinases, reductases, oxidases (e.g., choline oxidase, phenoloxidase), phenoloxidases, lipoxygenases, ligninases, pullulanases, tannases, pentosanases, malanases, beta-glucanases, arabinosidases, hyaluronidases, chondroitinases, laccases,
20 metalloproteinases, amadoriases, glucoamylases, alpha-amylases, beta-amylases, galactosidases, galactanases, catalases, carageenases, hyaluronidases, keratinases, lactases, ligninases, peroxidases, phosphatases, polygalacturonases, pullulanases, rhamnogalactouronases, tannases, transglutaminases, xyloglucanases, xylosidases, metalloproteases,
25 arabinofuranosidases, phytases, isomerases, transferases and/or amylases in any combination.

Any cellulase disclosed above is contemplated for use in the disclosed detergent compositions. Suitable cellulases include, but are not limited to Humicola insolens cellulases (See e.g., U.S. Pat. No. 4435307). Exemplary
30 cellulases contemplated for use herein are those having color care benefit for a textile. Examples of cellulases that provide a color care benefit are disclosed in

EP0495257, EP0531372, EP531315, WO96/11262, WO96/29397, WO94/07998; WO98/12307; WO95/24471, WO98/08940, and U.S. Patent Nos. 5457046, 5686593 and 5763254, all of which are incorporated herein by reference.

Examples of commercially available cellulases useful in a detergent include

- 5 CELLUSOFT[®], CELLUCLEAN[®], CELLUZYME[®], and CAREZYME[®] (Novo Nordisk A/S and Novozymes A/S); CLAZINASE[®], PURADAX HA[®], and REVITALENZ[™] (DuPont Industrial Biosciences); BIOTOUCH[®] (AB Enzymes); and KAC-500(B)[™] (Kao Corporation). Additional cellulases are disclosed in, e.g., US7595182, US8569033, US7138263, US3844890, US4435307,
10 US4435307, and GB2095275.

In some embodiments, a detergent composition can comprise one or more enzymes (e.g., any disclosed herein), each at a level from about 0.00001% to about 10% by weight of the composition and the balance of cleaning adjunct materials by weight of composition. In some other embodiments, a detergent
15 composition can also comprise each enzyme at a level of about 0.0001% to about 10%, about 0.001% to about 5%, about 0.001% to about 2%, or about 0.005% to about 0.5%, by weight of the composition.

Suitable proteases include those of animal, vegetable or microbial origin.

- In some embodiments, microbial proteases are used. In some embodiments,
20 chemically or genetically modified mutants are included. In some embodiments, the protease is a serine protease, preferably an alkaline microbial protease or a trypsin-like protease. Examples of alkaline proteases include subtilisins, especially those derived from *Bacillus* (e.g., subtilisin, lentus, amyloliquefaciens, subtilisin Carlsberg, subtilisin 309, subtilisin 147 and subtilisin 168). Additional
25 examples include those mutant proteases described in U.S. Pat. Nos. RE34606, 5955340, 5700676, 6312936 and 6482628, all of which are incorporated herein by reference. Additional protease examples include, but are not limited to, trypsin (e.g., of porcine or bovine origin), and the *Fusarium* protease described in WO89/06270. In some embodiments, commercially available protease enzymes
30 include, but are not limited to, MAXATASE[®], MAXACAL[™], MAXAPEM[™], OPTICLEAN[®], OPTIMASE[®], PROPERASE[®], PURAFECT[®], PURAFECT[®] OXP,

PURAMAX™, EXCELLASE™, PREFERENZ™ proteases (e.g. P100, P110, P280), EFFECTENZ™ proteases (e.g. P1000, P1050, P2000), EXCELLENZ™ proteases (e.g. P1000), ULTIMASE®, and PURAFAST™ (Genencor); ALCALASE®, SAVINASE®, PRIMASE®, DURAZYM™, POLARZYME®,

5 OVOZYME®, KANNASE®, LIQUANASE®, NEUTRASE®, RELEASE® and ESPERASE® (Novozymes); BLAP™ and BLAP™ variants (Henkel Kommanditgesellschaft auf Aktien, Duesseldorf, Germany), and KAP (B. alkalophilus subtilisin; Kao Corp., Tokyo, Japan). Various proteases are described in WO95/23221, WO92/21760, WO09/149200, WO09/149144,

10 WO09/149145, WO11/072099, WO10/056640, WO10/056653, WO11/140364, WO12/151534, U.S. Pat. Publ. No. 2008/0090747, and U.S. Pat. Nos. 5801039, 5340735, 5500364, 5855625, RE34606, 5955340, 5700676, 6312936, 6482628, 8530219, and various other patents. In some further embodiments, neutral metalloproteases find use in the present disclosure, including but not limited to,

15 the neutral metalloproteases described in WO1999014341, WO1999033960, WO1999014342, WO1999034003, WO2007044993, WO2009058303 and WO2009058661, all of which are incorporated herein by reference. Exemplary metalloproteases include nprE, the recombinant form of neutral metalloprotease expressed in *Bacillus subtilis* (See e.g., WO07/044993), and PMN, the purified

20 neutral metalloprotease from *Bacillus amyloliquefaciens*.

Suitable mannanases include, but are not limited to, those of bacterial or fungal origin. Chemically or genetically modified mutants are included in some embodiments. Various mannanases are known which find use in the present disclosure (See, e.g., U.S. Pat. Nos. 6566114, 6602842, and 6440991, all of

25 which are incorporated herein by reference). Commercially available mannanases that find use in the present disclosure include, but are not limited to MANNASTAR®, PURABRITE™, and MANNAWAY®.

Suitable lipases include those of bacterial or fungal origin. Chemically modified, proteolytically modified, or protein engineered mutants are included.

30 Examples of useful lipases include those from the genera *Humicola* (e.g., *H. lanuginosa*, EP258068 and EP305216; *H. insolens*, WO96/13580),

Pseudomonas (e.g., *P. alcaligenes* or *P. pseudoalcaligenes*, EP218272; *P. cepacia*, EP331376; *P. stutzeri*, GB1372034; *P. fluorescens* and *Pseudomonas* sp. strain SD 705, WO95/06720 and WO96/27002; *P. wisconsinensis*, WO96/12012); and *Bacillus* (e.g., *B. subtilis*, Dartois et al., *Biochemica et Biophysica Acta* 1131:253-360; *B. stearothermophilus*, JP64/744992; *B. pumilus*, WO91/16422). Furthermore, a number of cloned lipases find use in some embodiments of the present disclosure, including but not limited to, *Penicillium camembertii* lipase (See, Yamaguchi et al., Gene 103:61-67 [1991]), *Geotricum candidum* lipase (See, Schimada et al., J. Biochem., 106:383-388 [1989]), and various *Rhizopus* lipases such as *R. delemar* lipase (See, Hass et al., Gene 109:117-113 [1991]), a *R. niveus* lipase (Kugimiya et al., Biosci. Biotech. Biochem. 56:716-719 [1992]) and *R. oryzae* lipase. Additional lipases useful herein include, for example, those disclosed in WO92/05249, WO94/01541, WO95/35381, WO96/00292, WO95/30744, WO94/25578, WO95/14783, WO95/22615, WO97/04079, WO97/07202, EP407225 and EP260105. Other types of lipase polypeptide enzymes such as cutinases also find use in some embodiments of the present disclosure, including but not limited to, cutinase derived from *Pseudomonas mendocina* (See, WO88/09367), and cutinase derived from *Fusarium solani* pisi (See, WO90/09446). Examples of certain commercially available lipase enzymes useful herein include M1 LIPASE™, LUMA FAST™, and LIPOMAX™ (Genencor); LIPEX®, LIPOLASE® and LIPOLASE® ULTRA (Novozymes); and LIPASE P™ "Amano" (Amano Pharmaceutical Co. Ltd., Japan).

Suitable polyesterases include, for example, those disclosed in WO01/34899, WO01/14629 and U.S. Patent No. 6933140.

A detergent composition herein can also comprise 2,6-beta-D-fructan hydrolase, which is effective for removal/cleaning of certain biofilms present on household and/or industrial textiles/laundry.

Suitable amylases include, but are not limited to those of bacterial or fungal origin. Chemically or genetically modified mutants are included in some embodiments. Amylases that find use in the present disclosure, include, but are

not limited to, alpha-amylases obtained from *B. licheniformis* (See e.g., GB1296839). Additional suitable amylases include those disclosed in WO9510603, WO9526397, WO9623874, WO9623873, WO9741213, WO9919467, WO0060060, WO0029560, WO9923211, WO9946399, 5 WO0060058, WO0060059, WO9942567, WO0114532, WO02092797, WO0166712, WO0188107, WO0196537, WO0210355, WO9402597, WO0231124, WO9943793, WO9943794, WO2004113551, WO2005001064, WO2005003311, WO0164852, WO2006063594, WO2006066594, WO2006066596, WO2006012899, WO2008092919, WO2008000825, 10 WO2005018336, WO2005066338, WO2009140504, WO2005019443, WO2010091221, WO2010088447, WO0134784, WO2006012902, WO2006031554, WO2006136161, WO2008101894, WO2010059413, WO2011098531, WO2011080352, WO2011080353, WO2011080354, WO2011082425, WO2011082429, WO2011076123, WO2011087836, 15 WO2011076897, WO94183314, WO9535382, WO9909183, WO9826078, WO9902702, WO9743424, WO9929876, WO9100353, WO9605295, WO9630481, WO9710342, WO2008088493, WO2009149419, WO2009061381, WO2009100102, WO2010104675, WO2010117511, and WO2010115021, all of which are incorporated herein by reference.

20 Suitable amylases include, for example, commercially available amylases such as STAINZYME[®], STAINZYME PLUS[®], NATALASE[®], DURAMYL[®], TERMAMYL[®], TERMAMYL ULTRA[®], FUNGAMYL[®] and BAN[™] (Novo Nordisk A/S and Novozymes A/S); RAPIDASE[®], POWERASE[®], PURASTAR[®] and PREFERENZ[™] (DuPont Industrial Biosciences).

25 Suitable peroxidases/oxidases contemplated for use in the compositions include those of plant, bacterial or fungal origin. Chemically modified or protein engineered mutants are included. Examples of peroxidases useful herein include those from the genus *Coprinus* (e.g., *C. cinereus*, WO93/24618, WO95/10602, and WO98/15257), as well as those referenced in 30 WO2005056782, WO2007106293, WO2008063400, WO2008106214, and

WO2008106215. Commercially available peroxidases useful herein include, for example, GUARDZYME™ (Novo Nordisk A/S and Novozymes A/S).

In some embodiments, peroxidases are used in combination with hydrogen peroxide or a source thereof (e.g., a percarbonate, perborate or persulfate) in the compositions of the present disclosure. In some alternative
5 embodiments, oxidases are used in combination with oxygen. Both types of enzymes are used for “solution bleaching” (i.e., to prevent transfer of a textile dye from a dyed fabric to another fabric when the fabrics are washed together in a wash liquor), preferably together with an enhancing agent (See e.g.,
10 WO94/12621 and WO95/01426). Suitable peroxidases/oxidases include, but are not limited to, those of plant, bacterial or fungal origin. Chemically or genetically modified mutants are included in some embodiments.

Enzymes that may be comprised in a detergent composition herein may be stabilized using conventional stabilizing agents, e.g., a polyol such as
15 propylene glycol or glycerol; a sugar or sugar alcohol; lactic acid; boric acid or a boric acid derivative (e.g., an aromatic borate ester).

A detergent composition in certain embodiments may comprise one or more other types of polymers in addition to a dextran as disclosed herein. Examples of other types of polymers useful herein include carboxymethyl
20 cellulose (CMC), poly(vinylpyrrolidone) (PVP), polyethylene glycol (PEG), poly(vinyl alcohol) (PVA), polycarboxylates such as polyacrylates, maleic/acrylic acid copolymers and lauryl methacrylate/acrylic acid copolymers.

A detergent composition herein may contain a bleaching system. For example, a bleaching system can comprise an H₂O₂ source such as perborate or
25 percarbonate, which may be combined with a peracid-forming bleach activator such as tetraacetythylenediamine (TAED) or nonanoyloxybenzenesulfonate (NOBS). Alternatively, a bleaching system may comprise peroxyacids (e.g., amide, imide, or sulfone type peroxyacids). Alternatively still, a bleaching system can be an enzymatic bleaching system comprising perhydrolase, for example,
30 such as the system described in WO2005/056783.

A detergent composition herein may also contain conventional detergent ingredients such as fabric conditioners, clays, foam boosters, suds suppressors, anti-corrosion agents, soil-suspending agents, anti-soil redeposition agents, dyes, bactericides, tarnish inhibitors, optical brighteners, or perfumes. The pH of a detergent composition herein (measured in aqueous solution at use concentration) is usually neutral or alkaline (e.g., pH of about 7.0 to about 11.0).

It is believed that a dextran herein can be included as an anti-redeposition agent and/or clay soil removal agent in a detergent composition such as a fabric care composition, if desired (such agents can optionally be characterized as whiteness maintenance agents in certain aspects). Examples of other suitable anti-redeposition and/or clay soil removal agents herein include polyethoxy zwitterionic surfactants, water-soluble copolymers of acrylic or methacrylic acid with acrylic or methacrylic acid-ethylene oxide condensates (e.g., U.S. Pat. No. 3719647), cellulose derivatives such as carboxymethylcellulose and hydroxypropylcellulose (e.g., U.S. Pat. Nos. 3597416 and 3523088), and mixtures comprising nonionic alkyl polyethoxy surfactant, polyethoxy alkyl quaternary cationic surfactant and fatty amide surfactant (e.g., U.S. Pat. No. 4228044). Non-limiting examples of other suitable anti-redeposition and clay soil removal agents are disclosed in U.S. Pat. Nos. 4597898 and 4891160, and Int. Pat. Appl. Publ. No. WO95/32272, all of which are incorporated herein by reference.

Particular forms of detergent compositions that can be adapted for purposes disclosed herein are disclosed in, for example, US20090209445A1, US20100081598A1, US7001878B2, EP1504994B1, WO2001085888A2, WO2003089562A1, WO2009098659A1, WO2009098660A1, WO2009112992A1, WO2009124160A1, WO2009152031A1, WO2010059483A1, WO2010088112A1, WO2010090915A1, WO2010135238A1, WO2011094687A1, WO2011094690A1, WO2011127102A1, WO2011163428A1, WO2008000567A1, WO2006045391A1, WO2006007911A1, WO2012027404A1, EP1740690B1, WO2012059336A1, US6730646B1, WO2008087426A1, WO2010116139A1, and WO2012104613A1, all of which are incorporated herein by reference.

Laundry detergent compositions herein can optionally be heavy duty (all purpose) laundry detergent compositions. Exemplary heavy duty laundry detergent compositions comprise a deterative surfactant (10%-40% wt/wt), including an anionic deterative surfactant (selected from a group of linear or
5 branched or random chain, substituted or unsubstituted alkyl sulphates, alkyl sulphonates, alkyl alkoxyated sulphate, alkyl phosphates, alkyl phosphonates, alkyl carboxylates, and/or mixtures thereof), and optionally non-ionic surfactant (selected from a group of linear or branched or random chain, substituted or
10 unsubstituted alkyl alkoxyated alcohol, e.g., C8-C18 alkyl ethoxyated alcohols and/or C6-C12 alkyl phenol alkoxyates), where the weight ratio of anionic deterative surfactant (with a hydrophilic index (Hlc) of from 6.0 to 9) to non-ionic deterative surfactant is greater than 1:1. Suitable deterative surfactants also include cationic deterative surfactants (selected from a group of alkyl pyridinium
15 compounds, alkyl quaternary ammonium compounds, alkyl quaternary phosphonium compounds, alkyl ternary sulphonium compounds, and/or mixtures thereof); zwitterionic and/or amphoteric deterative surfactants (selected from a group of alkanolamine sulfo-betaines); ampholytic surfactants; semi-polar non-ionic surfactants and mixtures thereof.

A detergent herein such as a heavy duty laundry detergent composition
20 may optionally include, a surfactancy boosting polymer consisting of amphiphilic alkoxyated grease cleaning polymers (selected from a group of alkoxyated polymers having branched hydrophilic and hydrophobic properties, such as alkoxyated polyalkylenimines in the range of 0.05 wt% - 10 wt%) and/or random graft polymers (typically comprising of hydrophilic backbone comprising
25 monomers selected from the group consisting of: unsaturated C1-C6 carboxylic acids, ethers, alcohols, aldehydes, ketones, esters, sugar units, alkoxy units, maleic anhydride, saturated polyalcohols such as glycerol, and mixtures thereof; and hydrophobic side chain(s) selected from the group consisting of: C4-C25
30 alkyl group, polypropylene, polybutylene, vinyl ester of a saturated C1-C6 mono-carboxylic acid, C1-C6 alkyl ester of acrylic or methacrylic acid, and mixtures thereof.

A detergent herein such as a heavy duty laundry detergent composition may optionally include additional polymers such as soil release polymers (include anionically end-capped polyesters, for example SRP1, polymers comprising at least one monomer unit selected from saccharide, dicarboxylic acid, polyol and combinations thereof, in random or block configuration, ethylene terephthalate-based polymers and co-polymers thereof in random or block configuration, for example REPEL-O-TEX SF, SF-2 AND SRP6, EXCARE SRA100, SRA300, SRN100, SRN170, SRN240, SRN300 AND SRN325, MARLOQUEST SL), anti-redeposition agent(s) herein (0.1 wt% to 10 wt%), include carboxylate polymers, such as polymers comprising at least one monomer selected from acrylic acid, maleic acid (or maleic anhydride), fumaric acid, itaconic acid, aconitic acid, mesaconic acid, citraconic acid, methylenemalononic acid, and any mixture thereof, vinylpyrrolidone homopolymer, and/or polyethylene glycol, molecular weight in the range of from 500 to 100,000 Da); and polymeric carboxylate (such as maleate/acrylate random copolymer or polyacrylate homopolymer).

A detergent herein such as a heavy duty laundry detergent composition may optionally further include saturated or unsaturated fatty acids, preferably saturated or unsaturated C12-C24 fatty acids (0 wt% to 10 wt%); deposition aids in addition to a dextran compound disclosed herein (examples for which include polysaccharides, cellulosic polymers, poly diallyl dimethyl ammonium halides (DADMAC), and co-polymers of DAD MAC with vinyl pyrrolidone, acrylamides, imidazoles, imidazolinium halides, and mixtures thereof, in random or block configuration, cationic guar gum, cationic starch, cationic polyacrylamides, and mixtures thereof.

A detergent herein such as a heavy duty laundry detergent composition may optionally further include dye transfer inhibiting agents, examples of which include manganese phthalocyanine, peroxidases, polyvinylpyrrolidone polymers, polyamine N-oxide polymers, copolymers of N-vinylpyrrolidone and N-vinylimidazole, polyvinylloxazolidones and polyvinylimidazoles and/or mixtures thereof; chelating agents, examples of which include ethylene-diamine-tetraacetic acid (EDTA), diethylene triamine penta methylene phosphonic acid

(DTPMP), hydroxy-ethane diphosphonic acid (HEDP), ethylenediamine N,N'-disuccinic acid (EDDS), methyl glycine diacetic acid (MGDA), diethylene triamine penta acetic acid (DTPA), propylene diamine tetracetic acid (PDTA), 2-hydroxypyridine-N-oxide (HPNO), or methyl glycine diacetic acid (MGDA),
 5 glutamic acid N,N-diacetic acid (N,N-dicarboxymethyl glutamic acid tetrasodium salt (GLDA), nitrilotriacetic acid (NTA), 4,5-dihydroxy-m-benzenedisulfonic acid, citric acid and any salts thereof, N-hydroxyethylethylenediaminetriacetic acid (HEDTA), triethylenetetraaminehexaacetic acid (TTHA), N-hydroxyethyliminodiacetic acid (HEIDA), dihydroxyethylglycine (DHEG),
 10 ethylenediaminetetrapropionic acid (EDTP), and derivatives thereof.

A detergent herein such as a heavy duty laundry detergent composition may optionally include silicone or fatty-acid based suds suppressors; hueing dyes, calcium and magnesium cations, visual signaling ingredients, anti-foam (0.001 wt% to about 4.0 wt%), and/or a structurant/thickener (0.01 wt% to 5 wt%)
 15 selected from the group consisting of diglycerides and triglycerides, ethylene glycol distearate, microcrystalline cellulose, microfiber cellulose, biopolymers, xanthan gum, gellan gum, and mixtures thereof). Such structurant/thickener would be, in certain embodiments, in addition to the one or more dextran compounds comprised in the detergent. A structurant can also be referred to as
 20 a structural agent.

A detergent herein can be in the form of a heavy duty dry/solid laundry detergent composition, for example. Such a detergent may include: (i) a deterative surfactant, such as any anionic deterative surfactant disclosed herein, any non-ionic deterative surfactant disclosed herein, any cationic deterative
 25 surfactant disclosed herein, any zwitterionic and/or amphoteric deterative surfactant disclosed herein, any ampholytic surfactant, any semi-polar non-ionic surfactant, and mixtures thereof; (ii) a builder, such as any phosphate-free builder (e.g., zeolite builders in the range of 0 wt% to less than 10 wt%), any phosphate builder (e.g., sodium tri-polyphosphate in the range of 0 wt% to less
 30 than 10 wt%), citric acid, citrate salts and nitrilotriacetic acid, any silicate salt (e.g., sodium or potassium silicate or sodium meta-silicate in the range of 0 wt%

to less than 10 wt%); any carbonate salt (e.g., sodium carbonate and/or sodium bicarbonate in the range of 0 wt% to less than 80 wt%), and mixtures thereof; (iii) a bleaching agent, such as any photobleach (e.g., sulfonated zinc phthalocyanines, sulfonated aluminum phthalocyanines, xanthenes dyes, and mixtures thereof), any hydrophobic or hydrophilic bleach activator (e.g., dodecanoyl oxybenzene sulfonate, decanoyl oxybenzene sulfonate, decanoyl oxybenzoic acid or salts thereof, 3,5,5-trimethyl hexanoyl oxybenzene sulfonate, tetraacetyl ethylene diamine-TAED, nonanoyloxybenzene sulfonate-NOBS, nitrile quats, and mixtures thereof), any source of hydrogen peroxide (e.g., inorganic perhydrate salts, examples of which include mono or tetra hydrate sodium salt of perborate, percarbonate, persulfate, perphosphate, or persilicate), any preformed hydrophilic and/or hydrophobic peracids (e.g., percarboxylic acids and salts, percarbonic acids and salts, perimidic acids and salts, peroxymonosulfuric acids and salts, and mixtures thereof); and/or (iv) any other components such as a bleach catalyst (e.g., imine bleach boosters examples of which include iminium cations and polyions, iminium zwitterions, modified amines, modified amine oxides, N-sulphonyl imines, N-phosphonyl imines, N-acyl imines, thiadiazole dioxides, perfluoroimines, cyclic sugar ketones, and mixtures thereof), and a metal-containing bleach catalyst (e.g., copper, iron, titanium, ruthenium, tungsten, molybdenum, or manganese cations along with an auxiliary metal cations such as zinc or aluminum and a sequester such as EDTA, ethylenediaminetetra(methylenephosphonic acid).

Compositions disclosed herein can be in the form of a dishwashing detergent composition, for example. Examples of dishwashing detergents include automatic dishwashing detergents (typically used in dishwasher machines) and hand-washing dish detergents. A dishwashing detergent composition can be in any dry or liquid/aqueous form as disclosed herein, for example. Components that may be included in certain embodiments of a dishwashing detergent composition include, for example, one or more of a phosphate; oxygen- or chlorine-based bleaching agent; non-ionic surfactant;

alkaline salt (e.g., metasilicates, alkali metal hydroxides, sodium carbonate); any active enzyme disclosed herein; anti-corrosion agent (e.g., sodium silicate); anti-foaming agent; additives to slow down the removal of glaze and patterns from ceramics; perfume; anti-caking agent (in granular detergent); starch (in tablet-based detergents); gelling agent (in liquid/gel based detergents); and/or sand (powdered detergents).

Dishwashing detergents such as an automatic dishwasher detergent or liquid dishwashing detergent can comprise (i) a non-ionic surfactant, including any ethoxylated non-ionic surfactant, alcohol alkoxylated surfactant, epoxy-capped poly(oxyalkylated) alcohol, or amine oxide surfactant present in an amount from 0 to 10 wt%; (ii) a builder, in the range of about 5-60 wt%, including any phosphate builder (e.g., mono-phosphates, di-phosphates, tri-polyphosphates, other oligomeric-polyphosphates, sodium tripolyphosphate-STPP), any phosphate-free builder (e.g., amino acid-based compounds including methyl-glycine-diacetic acid [MGDA] and salts or derivatives thereof, glutamic-N,N-diacetic acid [GLDA] and salts or derivatives thereof, iminodisuccinic acid (IDS) and salts or derivatives thereof, carboxy methyl inulin and salts or derivatives thereof, nitrilotriacetic acid [NTA], diethylene triamine penta acetic acid [DTPA], B-alaninediacetic acid [B-ADA] and salts thereof), homopolymers and copolymers of poly-carboxylic acids and partially or completely neutralized salts thereof, monomeric polycarboxylic acids and hydroxycarboxylic acids and salts thereof in the range of 0.5 wt% to 50 wt%, or sulfonated/carboxylated polymers in the range of about 0.1 wt% to about 50 wt%; (iii) a drying aid in the range of about 0.1 wt% to about 10 wt% (e.g., polyesters, especially anionic polyesters, optionally together with further monomers with 3 to 6 functionalities – typically acid, alcohol or ester functionalities which are conducive to polycondensation, polycarbonate-, polyurethane- and/or polyurea-polyorganosiloxane compounds or precursor compounds thereof, particularly of the reactive cyclic carbonate and urea type); (iv) a silicate in the range from about 1 wt% to about 20 wt% (e.g., sodium or potassium silicates such as sodium disilicate, sodium meta-silicate and crystalline phyllosilicates); (v) an

inorganic bleach (e.g., perhydrate salts such as perborate, percarbonate, perphosphate, persulfate and persilicate salts) and/or an organic bleach (e.g., organic peroxyacids such as diacyl- and tetraacylperoxides, especially diperoxydodecanedioic acid, diperoxytetradecanedioic acid, and

- 5 diperoxyhexadecanedioic acid); (vi) a bleach activator (e.g., organic peracid precursors in the range from about 0.1 wt% to about 10 wt%) and/or bleach catalyst (e.g., manganese triazacyclononane and related complexes; Co, Cu, Mn, and Fe bispyridylamine and related complexes; and pentamine acetate cobalt(III) and related complexes); (vii) a metal care agent in the range from
10 about 0.1 wt% to 5 wt% (e.g., benzotriazoles, metal salts and complexes, and/or silicates); and/or (viii) any active enzyme disclosed herein in the range from about 0.01 to 5.0 mg of active enzyme per gram of automatic dishwashing detergent composition, and an enzyme stabilizer component (e.g., oligosaccharides, polysaccharides, and inorganic divalent metal salts).

15

Various examples of detergent formulations comprising at least one dextran herein are disclosed below (1-19):

- 1) A detergent composition formulated as a granulate having a bulk density of at least 600 g/L comprising: linear alkylbenzenesulfonate (calculated
20 as acid) at about 7-12 wt%; alcohol ethoxysulfate (e.g., C12-18 alcohol, 1-2 ethylene oxide [EO]) or alkyl sulfate (e.g., C16-18) at about 1-4 wt%; alcohol ethoxylate (e.g., C14-15 alcohol) at about 5-9 wt%; sodium carbonate at about 14-20 wt%; soluble silicate (e.g., $\text{Na}_2\text{O} \cdot 2\text{SiO}_2$) at about 2-6 wt%; zeolite (e.g., NaAlSiO_4) at about 15-22 wt%; sodium sulfate at about 0-6 wt%; sodium
25 citrate/citric acid at about 0-15 wt%; sodium perborate at about 11-18 wt%; TAED at about 2-6 wt%; dextran herein up to about 2 wt%; other polymers (e.g., maleic/acrylic acid copolymer, PVP, PEG) at about 0-3 wt%; optionally an enzyme(s) (calculated as pure enzyme protein) at about 0.0001-0.1 wt%; and minor ingredients (e.g., suds suppressors, perfumes, optical brightener,
30 photobleach) at about 0-5 wt%.

2) A detergent composition formulated as a granulate having a bulk density of at least 600 g/L comprising: linear alkylbenzenesulfonate (calculated as acid) at about 6-11 wt%; alcohol ethoxysulfate (e.g., C12-18 alcohol, 1-2 EO) or alkyl sulfate (e.g., C16-18) at about 1-3 wt%; alcohol ethoxylate (e.g., C14-15 alcohol) at about 5-9 wt%; sodium carbonate at about 15-21 wt%; soluble silicate (e.g., $\text{Na}_2\text{O} \cdot 2\text{SiO}_2$) at about 1-4 wt%; zeolite (e.g., NaAlSiO_4) at about 24-34 wt%; sodium sulfate at about 4-10 wt%; sodium citrate/citric acid at about 0-15 wt%; sodium perborate at about 11-18 wt%; TAED at about 2-6 wt%; dextran herein up to about 2 wt%; other polymers (e.g., maleic/acrylic acid copolymer, PVP, PEG) at about 1-6 wt%; optionally an enzyme(s) (calculated as pure enzyme protein) at about 0.0001-0.1 wt%; and minor ingredients (e.g., suds suppressors, perfumes, optical brightener, photobleach) at about 0-5 wt%.

3) A detergent composition formulated as a granulate having a bulk density of at least 600 g/L comprising: linear alkylbenzenesulfonate (calculated as acid) at about 5-9 wt%; alcohol ethoxysulfate (e.g., C12-18 alcohol, 7 EO) at about 7-14 wt%; soap as fatty acid (e.g., C16-22 fatty acid) at about 1-3 wt%; sodium carbonate at about 10-17 wt%; soluble silicate (e.g., $\text{Na}_2\text{O} \cdot 2\text{SiO}_2$) at about 3-9 wt%; zeolite (e.g., NaAlSiO_4) at about 23-33 wt%; sodium sulfate at about 0-4 wt%; sodium perborate at about 8-16 wt%; TAED at about 2-8 wt%; phosphonate (e.g., EDTMPA) at about 0-1 wt%; dextran herein up to about 2 wt%; other polymers (e.g., maleic/acrylic acid copolymer, PVP, PEG) at about 0-3 wt%; optionally an enzyme(s) (calculated as pure enzyme protein) at about 0.0001-0.1 wt%; and minor ingredients (e.g., suds suppressors, perfumes, optical brightener) at about 0-5 wt%.

4) A detergent composition formulated as a granulate having a bulk density of at least 600 g/L comprising: linear alkylbenzenesulfonate (calculated as acid) at about 8-12 wt%; alcohol ethoxylate (e.g., C12-18 alcohol, 7 EO) at about 10-25 wt%; sodium carbonate at about 14-22 wt%; soluble silicate (e.g., $\text{Na}_2\text{O} \cdot 2\text{SiO}_2$) at about 1-5 wt%; zeolite (e.g., NaAlSiO_4) at about 25-35 wt%; sodium sulfate at about 0-10 wt%; sodium perborate at about 8-16 wt%; TAED at about 2-8 wt%; phosphonate (e.g., EDTMPA) at about 0-1 wt%; dextran herein

up to about 2 wt%; other polymers (e.g., maleic/acrylic acid copolymer, PVP, PEG) at about 1-3 wt%; optionally an enzyme(s) (calculated as pure enzyme protein) at about 0.0001-0.1 wt%; and minor ingredients (e.g., suds suppressors, perfumes) at about 0-5 wt%.

5 5) An aqueous liquid detergent composition comprising: linear alkylbenzenesulfonate (calculated as acid) at about 15-21 wt%; alcohol ethoxylate (e.g., C12-18 alcohol, 7 EO; or C12-15 alcohol, 5 EO) at about 12-18 wt%; soap as fatty acid (e.g., oleic acid) at about 3-13 wt%; alkenylsuccinic acid (C12-14) at about 0-13 wt%; aminoethanol at about 8-18 wt%; citric acid at about
10 2-8 wt%; phosphonate at about 0-3 wt%; dextran herein up to about 2 wt%; other polymers (e.g., PVP, PEG) at about 0-3 wt%; borate at about 0-2 wt%; ethanol at about 0-3 wt%; propylene glycol at about 8-14 wt%; optionally an enzyme(s) (calculated as pure enzyme protein) at about 0.0001-0.1 wt%; and minor ingredients (e.g., dispersants, suds suppressors, perfume, optical brightener) at
15 about 0-5 wt%.

 6) An aqueous structured liquid detergent composition comprising: linear alkylbenzenesulfonate (calculated as acid) at about 15-21 wt%; alcohol ethoxylate (e.g., C12-18 alcohol, 7 EO; or C12-15 alcohol, 5 EO) at about 3-9 wt%; soap as fatty acid (e.g., oleic acid) at about 3-10 wt%; zeolite (e.g.,
20 NaAlSiO₄) at about 14-22 wt%; potassium citrate about 9-18 wt%; borate at about 0-2 wt%; dextran herein up to about 2 wt%; other polymers (e.g., PVP, PEG) at about 0-3 wt%; ethanol at about 0-3 wt%; anchoring polymers (e.g., lauryl methacrylate/acrylic acid copolymer, molar ratio 25:1, MW 3800) at about 0-3 wt%; glycerol at about 0-5 wt%; optionally an enzyme(s) (calculated as pure
25 enzyme protein) at about 0.0001-0.1 wt%; and minor ingredients (e.g., dispersants, suds suppressors, perfume, optical brightener) at about 0-5 wt%.

 7) A detergent composition formulated as a granulate having a bulk density of at least 600 g/L comprising: fatty alcohol sulfate at about 5-10 wt%, ethoxylated fatty acid monoethanolamide at about 3-9 wt%; soap as fatty acid at
30 about 0-3 wt%; sodium carbonate at about 5-10 wt%; soluble silicate (e.g., Na₂O 2SiO₂) at about 1-4 wt%; zeolite (e.g., NaAlSiO₄) at about 20-40 wt%; sodium

sulfate at about 2-8 wt%; sodium perborate at about 12-18 wt%; TAED at about 2-7 wt%; dextran herein up to about 2 wt%; other polymers (e.g., maleic/acrylic acid copolymer, PEG) at about 1-5 wt%; optionally an enzyme(s) (calculated as pure enzyme protein) at about 0.0001-0.1 wt%; and minor ingredients (e.g.,
5 optical brightener, suds suppressors, perfumes) at about 0-5 wt%.

8) A detergent composition formulated as a granulate comprising: linear alkylbenzenesulfonate (calculated as acid) at about 8-14 wt%; ethoxylated fatty acid monoethanolamide at about 5-11 wt%; soap as fatty acid at about 0-3 wt%; sodium carbonate at about 4-10 wt%; soluble silicate (e.g., $\text{Na}_2\text{O} \cdot 2\text{SiO}_2$) at about
10 1-4 wt%; zeolite (e.g., NaAlSiO_4) at about 30-50 wt%; sodium sulfate at about 3-11 wt%; sodium citrate at about 5-12 wt%; dextran herein up to about 2 wt%; other polymers (e.g., PVP, maleic/acrylic acid copolymer, PEG) at about 1-5 wt%; optionally an enzyme(s) (calculated as pure enzyme protein) at about 0.0001-0.1 wt%; and minor ingredients (e.g., suds suppressors, perfumes) at
15 about 0-5 wt%.

9) A detergent composition formulated as a granulate comprising: linear alkylbenzenesulfonate (calculated as acid) at about 6-12 wt%; nonionic surfactant at about 1-4 wt%; soap as fatty acid at about 2-6 wt%; sodium carbonate at about 14-22 wt%; zeolite (e.g., NaAlSiO_4) at about 18-32 wt%;
20 sodium sulfate at about 5-20 wt%; sodium citrate at about 3-8 wt%; sodium perborate at about 4-9 wt%; bleach activator (e.g., NOBS or TAED) at about 1-5 wt%; dextran herein up to about 2 wt%; other polymers (e.g., polycarboxylate or PEG) at about 1-5 wt%; optionally an enzyme(s) (calculated as pure enzyme protein) at about 0.0001-0.1 wt%; and minor ingredients (e.g., optical brightener,
25 perfume) at about 0-5 wt%.

10) An aqueous liquid detergent composition comprising: linear alkylbenzenesulfonate (calculated as acid) at about 15-23 wt%; alcohol ethoxysulfate (e.g., C12-15 alcohol, 2-3 EO) at about 8-15 wt%; alcohol ethoxylate (e.g., C12-15 alcohol, 7 EO; or C12-15 alcohol, 5 EO) at about 3-9
30 wt%; soap as fatty acid (e.g., lauric acid) at about 0-3 wt%; aminoethanol at about 1-5 wt%; sodium citrate at about 5-10 wt%; hydrotrope (e.g., sodium

toluenesulfonate) at about 2-6 wt%; borate at about 0-2 wt%; dextran herein up to about 1 wt%; ethanol at about 1-3 wt%; propylene glycol at about 2-5 wt%; optionally an enzyme(s) (calculated as pure enzyme protein) at about 0.0001-0.1 wt%; and minor ingredients (e.g., dispersants, perfume, optical brighteners) at about 0-5 wt%.

11) An aqueous liquid detergent composition comprising: linear alkylbenzenesulfonate (calculated as acid) at about 20-32 wt%; alcohol ethoxylate (e.g., C12-15 alcohol, 7 EO; or C12-15 alcohol, 5 EO) at about 6-12 wt%; aminoethanol at about 2-6 wt%; citric acid at about 8-14 wt%; borate at about 1-3 wt%; dextran herein up to about 2 wt%; ethanol at about 1-3 wt%; propylene glycol at about 2-5 wt%; other polymers (e.g., maleic/acrylic acid copolymer, anchoring polymer such as lauryl methacrylate/acrylic acid copolymer) at about 0-3 wt%; glycerol at about 3-8 wt%; optionally an enzyme(s) (calculated as pure enzyme protein) at about 0.0001-0.1 wt%; and minor ingredients (e.g., hydrotropes, dispersants, perfume, optical brighteners) at about 0-5 wt%.

12) A detergent composition formulated as a granulate having a bulk density of at least 600 g/L comprising: anionic surfactant (e.g., linear alkylbenzenesulfonate, alkyl sulfate, alpha-olefinsulfonate, alpha-sulfo fatty acid methyl esters, alkanesulfonates, soap) at about 25-40 wt%; nonionic surfactant (e.g., alcohol ethoxylate) at about 1-10 wt%; sodium carbonate at about 8-25 wt%; soluble silicate (e.g., $\text{Na}_2\text{O} \cdot 2\text{SiO}_2$) at about 5-15 wt%; sodium sulfate at about 0-5 wt%; zeolite (NaAlSiO_4) at about 15-28 wt%; sodium perborate at about 0-20 wt%; bleach activator (e.g., TAED or NOBS) at about 0-5 wt%; dextran herein up to about 2 wt%; optionally an enzyme(s) (calculated as pure enzyme protein) at about 0.0001-0.1 wt%; and minor ingredients (e.g., perfume, optical brighteners) at about 0-3 wt%.

13) Detergent compositions as described in (1)-(12) above, but in which all or part of the linear alkylbenzenesulfonate is replaced by C12-C18 alkyl sulfate.

14) A detergent composition formulated as a granulate having a bulk density of at least 600 g/L comprising: C12-C18 alkyl sulfate at about 9-15 wt%; alcohol ethoxylate at about 3-6 wt%; polyhydroxy alkyl fatty acid amide at about 1-5 wt%; zeolite (e.g., NaAlSiO₄) at about 10-20 wt%; layered disilicate (e.g., SK56 from Hoechst) at about 10-20 wt%; sodium carbonate at about 3-12 wt%; soluble silicate (e.g., Na₂O 2SiO₂) at 0-6 wt%; sodium citrate at about 4-8 wt%; sodium percarbonate at about 13-22 wt%; TAED at about 3-8 wt%; dextran herein up to about 2 wt%; other polymers (e.g., polycarboxylates and PVP) at about 0-5 wt%; optionally an enzyme(s) (calculated as pure enzyme protein) at about 0.0001-0.1 wt%; and minor ingredients (e.g., optical brightener, photobleach, perfume, suds suppressors) at about 0-5 wt%.

15) A detergent composition formulated as a granulate having a bulk density of at least 600 g/L comprising: C12-C18 alkyl sulfate at about 4-8 wt%; alcohol ethoxylate at about 11-15 wt%; soap at about 1-4 wt%; zeolite MAP or zeolite A at about 35-45 wt%; sodium carbonate at about 2-8 wt%; soluble silicate (e.g., Na₂O 2SiO₂) at 0-4 wt%; sodium percarbonate at about 13-22 wt%; TAED at about 1-8 wt%; dextran herein up to about 3 wt%; other polymers (e.g., polycarboxylates and PVP) at about 0-3 wt%; optionally an enzyme(s) (calculated as pure enzyme protein) at about 0.0001-0.1 wt%; and minor ingredients (e.g., optical brightener, phosphonate, perfume) at about 0-3 wt%.

16) Detergent formulations as described in (1)-(15) above, but that contain a stabilized or encapsulated peracid, either as an additional component or as a substitute for an already specified bleach system(s).

17) Detergent compositions as described in (1), (3), (7), (9) and (12) above, but in which perborate is replaced by percarbonate.

18) Detergent compositions as described in (1), (3), (7), (9), (12), (14) and (15) above, but that additionally contain a manganese catalyst. A manganese catalyst, for example, is one of the compounds described by Hage et al. (1994, *Nature* 369:637-639), which is incorporated herein by reference.

19) Detergent compositions formulated as a non-aqueous detergent liquid comprising a liquid non-ionic surfactant (e.g., a linear alkoxylated primary

alcohol), a builder system (e.g., phosphate), dextran herein, optionally an enzyme(s), and alkali. The detergent may also comprise an anionic surfactant and/or bleach system.

It is believed that numerous commercially available detergent formulations can be adapted to include a dextran compound disclosed herein. Examples include PUREX[®] ULTRAPACKS (Henkel), FINISH[®] QUANTUM (Reckitt Benckiser), CLOROX[™] 2 PACKS (Clorox), OXICLEAN MAX FORCE POWER PAKS (Church & Dwight), TIDE[®] STAIN RELEASE, CASCADE[®] ACTIONPACS, and TIDE[®] PODS[™] (Procter & Gamble).

Compositions disclosed herein can be in the form of an oral care composition, for example. Examples of oral care compositions include dentifrices, toothpaste, mouth wash, mouth rinse, chewing gum, and edible strips that provide some form of oral care (e.g., treatment or prevention of cavities [dental caries], gingivitis, plaque, tartar, and/or periodontal disease). An oral care composition can also be for treating an "oral surface", which encompasses any soft or hard surface within the oral cavity including surfaces of the tongue, hard and soft palate, buccal mucosa, gums and dental surfaces. A "dental surface" herein is a surface of a natural tooth or a hard surface of artificial dentition including a crown, cap, filling, bridge, denture, or dental implant, for example.

An oral care composition herein can comprise about 0.01-15.0 wt% (e.g., ~0.1-10 wt% or ~0.1-5.0 wt%, ~0.1-2.0 wt%) of one or more dextran ether compounds as disclosed herein, for example. One or more dextran ether compounds comprised in an oral care composition can sometimes be provided therein as a thickening agent and/or dispersion agent, which may be useful to impart a desired consistency and/or mouth feel to the composition. One or more other thickening or dispersion agents can also be provided in an oral care composition herein, such as a carboxyvinyl polymer, carrageenan (e.g., L-carrageenan), natural gum (e.g., karaya, xanthan, gum arabic, tragacanth), colloidal magnesium aluminum silicate, or colloidal silica, for example.

An oral care composition herein may be a toothpaste or other dentifrice, for example. Such compositions, as well as any other oral care composition herein, can additionally comprise, without limitation, one or more of an anticaries agent, antimicrobial or antibacterial agent, anticalculus or tartar control agent, surfactant, abrasive, pH-modifying agent, foam modulator, humectant, flavorant, sweetener, pigment/colorant, whitening agent, and/or other suitable components. Examples of oral care compositions to which one or more dextran compounds can be added are disclosed in U.S. Patent Appl. Publ. Nos. 2006/0134025, 2002/0022006 and 2008/0057007, which are incorporated herein by reference.

An anticaries agent herein can be an orally acceptable source of fluoride ions. Suitable sources of fluoride ions include fluoride, monofluorophosphate and fluorosilicate salts as well as amine fluorides, including olaflur (N'-octadecyltrimethylendiamine-N,N,N'-tris(2-ethanol)-dihydrofluoride), for example. An anticaries agent can be present in an amount providing a total of about 100-20000 ppm, about 200-5000 ppm, or about 500-2500 ppm, fluoride ions to the composition, for example. In oral care compositions in which sodium fluoride is the sole source of fluoride ions, an amount of about 0.01-5.0 wt%, about 0.05-1.0 wt%, or about 0.1-0.5 wt%, sodium fluoride can be present in the composition, for example.

An antimicrobial or antibacterial agent suitable for use in an oral care composition herein includes, for example, phenolic compounds (e.g., 4-allylcatechol; p-hydroxybenzoic acid esters such as benzylparaben, butylparaben, ethylparaben, methylparaben and propylparaben; 2-benzylphenol; butylated hydroxyanisole; butylated hydroxytoluene; capsaicin; carvacrol; creosol; eugenol; guaiacol; halogenated bisphenolics such as hexachlorophene and bromochlorophene; 4-hexylresorcinol; 8-hydroxyquinoline and salts thereof; salicylic acid esters such as menthyl salicylate, methyl salicylate and phenyl salicylate; phenol; pyrocatechol; salicylanilide; thymol; halogenated diphenylether compounds such as triclosan and triclosan monophosphate), copper (II) compounds (e.g., copper (II) chloride, fluoride, sulfate and hydroxide), zinc ion sources (e.g., zinc acetate, citrate, gluconate, glycinate, oxide, and sulfate),

phthalic acid and salts thereof (e.g., magnesium monopotassium phthalate), hexetidine, octenidine, sanguinarine, benzalkonium chloride, domiphen bromide, alkylpyridinium chlorides (e.g. cetylpyridinium chloride, tetradecylpyridinium chloride, N-tetradecyl-4-ethylpyridinium chloride), iodine, sulfonamides, 5 bisbiguanides (e.g., alexidine, chlorhexidine, chlorhexidine digluconate), piperidino derivatives (e.g., delmopinol, octapinol), magnolia extract, grapeseed extract, rosemary extract, menthol, geraniol, citral, eucalyptol, antibiotics (e.g., augmentin, amoxicillin, tetracycline, doxycycline, minocycline, metronidazole, neomycin, kanamycin, clindamycin), and/or any antibacterial agents disclosed in 10 U.S. Patent No. 5776435, which is incorporated herein by reference. One or more antimicrobial agents can optionally be present at about 0.01-10 wt% (e.g., 0.1-3 wt%), for example, in the disclosed oral care composition.

An anticalculus or tartar control agent suitable for use in an oral care composition herein includes, for example, phosphates and polyphosphates (e.g., 15 pyrophosphates), polyaminopropanesulfonic acid (AMPS), zinc citrate trihydrate, polypeptides (e.g., polyaspartic and polyglutamic acids), polyolefin sulfonates, polyolefin phosphates, diphosphonates (e.g., azacycloalkane-2,2-diphosphonates such as azacycloheptane-2,2-diphosphonic acid), N-methyl azacyclopentane-2,3-diphosphonic acid, ethane-1-hydroxy-1,1-diphosphonic acid (EHDP), ethane- 20 1-amino-1,1-diphosphonate, and/or phosphonoalkane carboxylic acids and salts thereof (e.g., their alkali metal and ammonium salts). Useful inorganic phosphate and polyphosphate salts include, for example, monobasic, dibasic and tribasic sodium phosphates, sodium tripolyphosphate, tetrapolyphosphate, mono-, di-, tri- and tetra-sodium pyrophosphates, disodium dihydrogen pyrophosphate, sodium 25 trimetaphosphate, sodium hexametaphosphate, or any of these in which sodium is replaced by potassium or ammonium. Other useful anticalculus agents in certain embodiments include anionic polycarboxylate polymers (e.g., polymers or copolymers of acrylic acid, methacrylic, and maleic anhydride such as polyvinyl methyl ether/maleic anhydride copolymers). Still other useful anticalculus agents 30 include sequestering agents such as hydroxycarboxylic acids (e.g., citric, fumaric, malic, glutaric and oxalic acids and salts thereof) and

aminopolycarboxylic acids (e.g., EDTA). One or more anticalculus or tartar control agents can optionally be present at about 0.01-50 wt% (e.g., about 0.05-25 wt% or about 0.1-15 wt%), for example, in the disclosed oral care composition.

5 A surfactant suitable for use in an oral care composition herein may be anionic, non-ionic, or amphoteric, for example. Suitable anionic surfactants include, without limitation, water-soluble salts of C₈₋₂₀ alkyl sulfates, sulfonated monoglycerides of C₈₋₂₀ fatty acids, sarcosinates, and taurates. Examples of anionic surfactants include sodium lauryl sulfate, sodium coconut monoglyceride
10 sulfonate, sodium lauryl sarcosinate, sodium lauryl isoethionate, sodium laureth carboxylate and sodium dodecyl benzenesulfonate. Suitable non-ionic surfactants include, without limitation, poloxamers, polyoxyethylene sorbitan esters, fatty alcohol ethoxylates, alkylphenol ethoxylates, tertiary amine oxides, tertiary phosphine oxides, and dialkyl sulfoxides. Suitable amphoteric surfactants
15 include, without limitation, derivatives of C₈₋₂₀ aliphatic secondary and tertiary amines having an anionic group such as a carboxylate, sulfate, sulfonate, phosphate or phosphonate. An example of a suitable amphoteric surfactant is cocoamidopropyl betaine. One or more surfactants are optionally present in a total amount of about 0.01-10 wt% (e.g., about 0.05-5.0 wt% or about 0.1-2.0
20 wt%), for example, in the disclosed oral care composition.

 An abrasive suitable for use in an oral care composition herein may include, for example, silica (e.g., silica gel, hydrated silica, precipitated silica), alumina, insoluble phosphates, calcium carbonate, and resinous abrasives (e.g., a urea-formaldehyde condensation product). Examples of insoluble phosphates
25 useful as abrasives herein are orthophosphates, polymetaphosphates and pyrophosphates, and include dicalcium orthophosphate dihydrate, calcium pyrophosphate, beta-calcium pyrophosphate, tricalcium phosphate, calcium polymetaphosphate and insoluble sodium polymetaphosphate. One or more abrasives are optionally present in a total amount of about 5-70 wt% (e.g., about
30 10-56 wt% or about 15-30 wt%), for example, in the disclosed oral care

composition. The average particle size of an abrasive in certain embodiments is about 0.1-30 microns (e.g., about 1-20 microns or about 5-15 microns).

An oral care composition in certain embodiments may comprise at least one pH-modifying agent. Such agents may be selected to acidify, make more basic, or buffer the pH of a composition to a pH range of about 2-10 (e.g., pH ranging from about 2-8, 3-9, 4-8, 5-7, 6-10, or 7-9). Examples of pH-modifying agents useful herein include, without limitation, carboxylic, phosphoric and sulfonic acids; acid salts (e.g., monosodium citrate, disodium citrate, monosodium malate); alkali metal hydroxides (e.g. sodium hydroxide, carbonates such as sodium carbonate, bicarbonates, sesquicarbonates); borates; silicates; phosphates (e.g., monosodium phosphate, trisodium phosphate, pyrophosphate salts); and imidazole.

A foam modulator suitable for use in an oral care composition herein may be a polyethylene glycol (PEG), for example. High molecular weight PEGs are suitable, including those having an average molecular weight of about 200000-7000000 (e.g., about 500000-5000000 or about 1000000-2500000), for example. One or more PEGs are optionally present in a total amount of about 0.1-10 wt% (e.g. about 0.2-5.0 wt% or about 0.25-2.0 wt%), for example, in the disclosed oral care composition.

An oral care composition in certain embodiments may comprise at least one humectant. A humectant in certain embodiments may be a polyhydric alcohol such as glycerin, sorbitol, xylitol, or a low molecular weight PEG. Most suitable humectants also may function as a sweetener herein. One or more humectants are optionally present in a total amount of about 1.0-70 wt% (e.g., about 1.0-50 wt%, about 2-25 wt%, or about 5-15 wt%), for example, in the disclosed oral care composition.

A natural or artificial sweetener may optionally be comprised in an oral care composition herein. Examples of suitable sweeteners include dextrose, sucrose, maltose, dextrin, invert sugar, mannose, xylose, ribose, fructose, levulose, galactose, corn syrup (e.g., high fructose corn syrup or corn syrup solids), partially hydrolyzed starch, hydrogenated starch hydrolysate, sorbitol,

mannitol, xylitol, maltitol, isomalt, aspartame, neotame, saccharin and salts thereof, dipeptide-based intense sweeteners, and cyclamates. One or more sweeteners are optionally present in a total amount of about 0.005-5.0 wt%, for example, in the disclosed oral care composition.

5 A natural or artificial flavorant may optionally be comprised in an oral care composition herein. Examples of suitable flavorants include vanillin; sage; marjoram; parsley oil; spearmint oil; cinnamon oil; oil of wintergreen (methylsalicylate); peppermint oil; clove oil; bay oil; anise oil; eucalyptus oil; citrus oils; fruit oils; essences such as those derived from lemon, orange, lime,
10 grapefruit, apricot, banana, grape, apple, strawberry, cherry, or pineapple; bean- and nut-derived flavors such as coffee, cocoa, cola, peanut, or almond; and adsorbed and encapsulated flavorants. Also encompassed within flavorants herein are ingredients that provide fragrance and/or other sensory effect in the mouth, including cooling or warming effects. Such ingredients include, without
15 limitation, menthol, menthyl acetate, menthyl lactate, camphor, eucalyptus oil, eucalyptol, anethole, eugenol, cassia, oxanone, Irisone[®], propenyl guaithol, thymol, linalool, benzaldehyde, cinnamaldehyde, N-ethyl-p-menthan-3-carboxamine, N,2,3-trimethyl-2-isopropylbutanamide, 3-(1-menthoxy)-propane-1,2-diol, cinnamaldehyde glycerol acetal (CGA), and menthone glycerol acetal
20 (MGA). One or more flavorants are optionally present in a total amount of about 0.01-5.0 wt% (e.g., about 0.1-2.5 wt%), for example, in the disclosed oral care composition.

 An oral care composition in certain embodiments may comprise at least one bicarbonate salt. Any orally acceptable bicarbonate can be used, including
25 alkali metal bicarbonates such as sodium or potassium bicarbonate, and ammonium bicarbonate, for example. One or more bicarbonate salts are optionally present in a total amount of about 0.1-50 wt% (e.g., about 1-20 wt%), for example, in the disclosed oral care composition.

 An oral care composition in certain embodiments may comprise at least
30 one whitening agent and/or colorant. A suitable whitening agent is a peroxide compound such as any of those disclosed in U.S. Patent No. 8540971, which is

incorporated herein by reference. Suitable colorants herein include pigments, dyes, lakes and agents imparting a particular luster or reflectivity such as pearling agents, for example. Specific examples of colorants useful herein include talc; mica; magnesium carbonate; calcium carbonate; magnesium
5 silicate; magnesium aluminum silicate; silica; titanium dioxide; zinc oxide; red, yellow, brown and black iron oxides; ferric ammonium ferrocyanide; manganese violet; ultramarine; titanated mica; and bismuth oxychloride. One or more colorants are optionally present in a total amount of about 0.001-20 wt% (e.g., about 0.01-10 wt% or about 0.1-5.0 wt%), for example, in the disclosed oral care
10 composition.

Additional components that can optionally be included in an oral composition herein include one or more enzymes (above), vitamins, and anti-adhesion agents, for example. Examples of vitamins useful herein include vitamin C, vitamin E, vitamin B5, and folic acid. Examples of suitable anti-
15 adhesion agents include solbrol, ficin, and quorum-sensing inhibitors.

The present disclosure also concerns a method for increasing the viscosity of an aqueous composition. This method comprises contacting at least one dextran compound as presently disclosed with the aqueous composition.
20 The contacting step in this method results in increasing the viscosity of the aqueous composition, in comparison to the viscosity of the aqueous composition before the contacting step.

An aqueous composition herein can be water (e.g., de-ionized water), an aqueous solution, or a hydrocolloid, for example. The viscosity of an aqueous composition before the contacting step, measured at about 20-25 °C, can be
25 about 0-10000 cPs (or any integer between 0-10000 cPs), for example. Since the aqueous composition can be a hydrocolloid or the like in certain embodiments, it should be apparent that the method can be used to increase the viscosity of aqueous compositions that are already viscous.

30 Contacting dextran herein with an aqueous composition increases the viscosity of the aqueous composition in certain embodiments. This increase in

viscosity can be an increase of at least about 1%, 10%, 100%, 1000%, 100000%, or 1000000% (or any integer between 1% and 1000000%), for example, compared to the viscosity of the aqueous composition before the contacting step. It should be apparent that very large percent increases in viscosity can be obtained with the disclosed method when the aqueous composition has little to no viscosity before the contacting step. An increase in viscosity can be determined, for example, by comparing the viscosity of the aqueous composition obtained by the method (i.e., after the contacting step) with the viscosity of the aqueous composition as it had existed before the method (i.e., before the contacting step).

Contacting dextran herein with an aqueous composition increases the shear thinning behavior or shear thickening behavior of the aqueous composition in certain embodiments. Thus, dextran rheologically modifies the aqueous composition in these embodiments. The increase in shear thinning behavior or shear thickening behavior can be an increase of at least about 1%, 10%, 100%, 1000%, 100000%, or 1000000% (or any integer between 1% and 1000000%), for example, compared to the shear thinning behavior or shear thickening behavior of the aqueous composition before the contacting step. It should be apparent that very large percent increases in rheologic modification can be obtained with the disclosed method when the aqueous composition has little to no rheologic behavior before the contacting step.

The contacting step in a method for increasing the viscosity of an aqueous composition can be performed by mixing or dissolving any dextran as presently disclosed in the aqueous composition by any means known in the art. For example, mixing or dissolving can be performed manually or with a machine (e.g., industrial mixer or blender, orbital shaker, stir plate, homogenizer, sonicator, bead mill). Mixing or dissolving can comprise a homogenization step in certain embodiments. Homogenization (as well as any other type of mixing) can be performed for about 5 to 60, 5 to 30, 10 to 60, 10 to 30, 5 to 15, or 10 to 15 seconds (or any integer between 5 and 60 seconds), or longer periods of time as necessary to mix dextran with the aqueous composition. A homogenizer can

be used at about 5000 to 30000 rpm, 10000 to 30000 rpm, 15000 to 30000 rpm, 15000 to 25000 rpm, or 20000 rpm (or any integer between 5000 and 30000 rpm), for example.

After a dextran herein is mixed with or dissolved into an aqueous composition, the resulting aqueous composition may be filtered, or may not be filtered. For example, an aqueous composition prepared with a homogenization step may or may not be filtered.

Certain embodiments of the above method can be used to prepare an aqueous composition disclosed herein, such as a food product (e.g., a confectionery such as a candy filling), pharmaceutical product (e.g., excipient), household product (e.g., laundry detergent, fabric softener, dishwasher detergent), personal care product (e.g., a water-containing dentifrice such as toothpaste), or industrial product.

The present disclosure also concerns a method of treating a material. This method comprises contacting a material with an aqueous composition comprising at least one dextran compound as disclosed herein.

A material contacted with an aqueous composition in a contacting method herein can comprise a fabric in certain embodiments. A fabric herein can comprise natural fibers, synthetic fibers, semi-synthetic fibers, or any combination thereof. A semi-synthetic fiber herein is produced using naturally occurring material that has been chemically derivatized, an example of which is rayon. Non-limiting examples of fabric types herein include fabrics made of (i) cellulosic fibers such as cotton (e.g., broadcloth, canvas, chambray, chenille, chintz, corduroy, cretonne, damask, denim, flannel, gingham, jacquard, knit, matelassé, oxford, percale, poplin, plissé, sateen, seersucker, sheers, terry cloth, twill, velvet), rayon (e.g., viscose, modal, lyocell), linen, and Tencel®; (ii) proteinaceous fibers such as silk, wool and related mammalian fibers; (iii) synthetic fibers such as polyester, acrylic, nylon, and the like; (iv) long vegetable fibers from jute, flax, ramie, coir, kapok, sisal, henequen, abaca, hemp and sunn; and (v) any combination of a fabric of (i)-(iv). Fabric comprising a combination of

fiber types (e.g., natural and synthetic) include those with both a cotton fiber and polyester, for example. Materials/articles containing one or more fabrics herein include, for example, clothing, curtains, drapes, upholstery, carpeting, bed linens, bath linens, tablecloths, sleeping bags, tents, car interiors, etc. Other materials comprising natural and/or synthetic fibers include, for example, non-woven fabrics, paddings, paper, and foams.

An aqueous composition that is contacted with a fabric can be, for example, a fabric care composition (e.g., laundry detergent, fabric softener).

Thus, a treatment method in certain embodiments can be considered a fabric care method or laundry method if employing a fabric care composition therein. A fabric care composition herein is contemplated to effect one or more of the following fabric care benefits (i.e., surface substantive effects): wrinkle removal, wrinkle reduction, wrinkle resistance, fabric wear reduction, fabric wear resistance, fabric pilling reduction, extended fabric life, fabric color maintenance, fabric color fading reduction, reduced dye transfer, fabric color restoration, fabric soiling reduction, fabric soil release, fabric shape retention, fabric smoothness enhancement, anti-redeposition of soil on fabric, anti-greying of laundry, improved fabric hand/handle, and/or fabric shrinkage reduction.

Examples of conditions (e.g., time, temperature, wash/rinse volumes) for conducting a fabric care method or laundry method herein are disclosed in WO1997/003161 and U.S. Patent Nos. 4794661, 4580421 and 5945394, which are incorporated herein by reference. In other examples, a material comprising fabric can be contacted with an aqueous composition herein: (i) for at least about 5, 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 110, or 120 minutes; (ii) at a temperature of at least about 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, or 95 °C (e.g., for laundry wash or rinse: a “cold” temperature of about 15-30 °C, a “warm” temperature of about 30-50 °C, a “hot” temperature of about 50-95 °C); (iii) at a pH of about 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12 (e.g., pH range of about 2-12, or about 3-11); (iv) at a salt (e.g., NaCl) concentration of at least about 0.5, 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, or 4.0 wt%; or any combination of (i)-(iv).

The contacting step in a fabric care method or laundry method can comprise any of washing, soaking, and/or rinsing steps, for example. Contacting a material or fabric in still further embodiments can be performed by any means known in the art, such as dissolving, mixing, shaking, spraying, treating, 5 immersing, flushing, pouring on or in, combining, painting, coating, applying, affixing to, and/or communicating an effective amount of a dextran compound herein with the fabric or material. In still further embodiments, contacting may be used to treat a fabric to provide a surface substantive effect. As used herein, the term "fabric hand" or "handle" refers to a person's tactile sensory response 10 towards fabric which may be physical, physiological, psychological, social or any combination thereof. In one embodiment, the fabric hand may be measured using a PhabrOmeter[®] System for measuring relative hand value (available from Nu Cybertek, Inc. Davis, CA) (American Association of Textile Chemists and Colorists (AATCC test method "202-2012, Relative Hand Value of Textiles: 15 Instrumental Method"))).

In certain embodiments of treating a material comprising fabric, a dextran compound component(s) of the aqueous composition adsorbs to the fabric. This feature is believed to render dextran compounds herein useful as anti-redeposition agents and/or anti-greying agents in fabric care compositions 20 disclosed (in addition to their viscosity-modifying effect). An anti-redeposition agent or anti-greying agent herein helps keep soil from redepositing onto clothing in wash water after the soil has been removed. It is further contemplated that adsorption of one or more dextran compounds herein to a fabric enhances mechanical properties of the fabric.

25 Adsorption of a dextran compound to a fabric herein can be measured using a colorimetric technique (e.g., Dubois et al., 1956, *Anal. Chem.* 28:350-356; Zemljič et al., 2006, *Lenzinger Berichte* 85:68-76; both incorporated herein by reference), for example, or any other method known in the art.

Other materials that can be contacted in the above treatment method 30 include surfaces that can be treated with a dish detergent (e.g., automatic dishwashing detergent or hand dish detergent). Examples of such materials

include surfaces of dishes, glasses, pots, pans, baking dishes, utensils and flatware made from ceramic material, china, metal, glass, plastic (e.g., polyethylene, polypropylene, polystyrene, etc.) and wood (collectively referred to herein as "tableware"). Thus, the treatment method in certain embodiments can be considered a dishwashing method or tableware washing method, for example. Examples of conditions (e.g., time, temperature, wash volume) for conducting a dishwashing or tableware washing method herein are disclosed in U.S. Patent No. 8575083, which is incorporated herein by reference. In other examples, a tableware article can be contacted with an aqueous composition herein under a suitable set of conditions such as any of those disclosed above with regard to contacting a fabric-comprising material.

Other materials that can be contacted in the above treatment method include oral surfaces such as any soft or hard surface within the oral cavity including surfaces of the tongue, hard and soft palate, buccal mucosa, gums and dental surfaces (e.g., natural tooth or a hard surface of artificial dentition such as a crown, cap, filling, bridge, denture, or dental implant). Thus, a treatment method in certain embodiments can be considered an oral care method or dental care method, for example. Conditions (e.g., time, temperature) for contacting an oral surface with an aqueous composition herein should be suitable for the intended purpose of making such contact. Other surfaces that can be contacted in a treatment method also include a surface of the integumentary system such as skin, hair or nails.

Thus, certain embodiments of the present disclosure concern material (e.g., fabric) that comprises a dextran compound herein. Such material can be produced following a material treatment method as disclosed herein, for example. A material may comprise a dextran compound in certain embodiments if the compound is adsorbed to, or otherwise in contact with, the surface of the material.

Certain embodiments of a method of treating a material herein further comprise a drying step, in which a material is dried after being contacted with the aqueous composition. A drying step can be performed directly after the

contacting step, or following one or more additional steps that might follow the contacting step (e.g., drying of a fabric after being rinsed, in water for example, following a wash in an aqueous composition herein). Drying can be performed by any of several means known in the art, such as air drying (e.g., ~20-25 °C), or
5 at a temperature of at least about 30, 40, 50, 60, 70, 80, 90, 100, 120, 140, 160, 170, 175, 180, or 200 °C, for example. A material that has been dried herein typically has less than 3, 2, 1, 0.5, or 0.1 wt% water comprised therein. Fabric is a preferred material for conducting an optional drying step.

An aqueous composition used in a treatment method herein can be any
10 aqueous composition disclosed herein, such as in the above embodiments or in the below Examples. Thus, the dextran component(s) of an aqueous composition can be any as disclosed herein. Examples of aqueous compositions include detergents (e.g., laundry detergent or dish detergent) and water-containing dentifrices such as toothpaste.

15 The present disclosure also concerns an enzymatic reaction comprising water, sucrose and a glucosyltransferase enzyme comprising, or consisting of, an amino acid sequence that is at least 90% identical to SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:5, SEQ ID NO:9, SEQ ID NO:13, or SEQ ID NO:17. The
20 glucosyltransferase enzyme synthesizes dextran as presently disclosed. Significantly, dextran synthesized in this gtf reaction exhibits high viscosity in aqueous compositions, even at relatively low concentrations of the dextran. It is believed that this high viscosity profile is unique in comparison to viscosity profiles of previously disclosed dextran polymers.

25 Dextran synthesized in an enzymatic reaction herein can be as characterized (e.g., molecular weight, linkage and branching profile) in the above disclosure regarding dextran as produced by a glucosyltransferase enzyme. A glucosyltransferase enzyme in an enzymatic reaction herein can be as characterized in the above disclosure regarding dextran as produced by a
30 glucosyltransferase enzyme.

One or more different glucosyltransferase enzymes may be used in an enzymatic reaction herein. A single glucosyltransferase enzyme (e.g., gtf 0768) is used in some cases, as opposed to situations in which multiple enzymes may be present (e.g., a bacterial or yeast fermentation). An enzymatic reaction can be as characterized (e.g., initial sucrose concentration and sucrose type, pH, temperature, time) in the above disclosure regarding dextran as produced by a glucosyltransferase enzyme. Also, any features presently disclosed of a method of producing dextran can apply to a glucosyltransferase reaction.

The present disclosure also concerns a method for producing dextran comprising the step of contacting at least water, sucrose, and a glucosyltransferase enzyme comprising an amino acid sequence that is at least 90% identical to SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:5, SEQ ID NO:9, SEQ ID NO:13, or SEQ ID NO:17. This contacting step results in production of dextran as presently disclosed. Dextran produced in the contacting step can optionally be isolated.

Dextran synthesized in a synthesis method herein can be as characterized (e.g., molecular weight, linkage and branching profile) in the above disclosure regarding dextran as produced by a glucosyltransferase enzyme. A glucosyltransferase enzyme in a synthesis method herein can be as characterized in the above disclosure regarding dextran as produced by a glucosyltransferase enzyme. Any features of an enzymatic reaction as disclosed above can apply to the instant synthesis method.

The contacting step in a method herein of producing dextran comprises providing an enzymatic reaction comprising water, sucrose and any glucosyltransferase enzyme disclosed herein. The contacting step of the disclosed method can be performed in any number of ways. For example, the desired amount of sucrose can first be dissolved in water (optionally, other components may also be added at this stage of preparation, such as buffer components), followed by addition of one or more glucosyltransferase enzymes. The solution may be kept still, or agitated via stirring or orbital shaking, for example.

The reaction can be, and typically is, cell-free. Thus, a dextran herein is not isolated from a cell, such as a bacteria (e.g., *L. mesenteroides*), in some aspects.

Completion of a glucosyltransferase reaction in certain embodiments can be gauged, for example, by determining whether reaction viscosity is no longer increasing and/or by measuring the amount of sucrose left in the reaction (residual sucrose), where a percent sucrose consumption of over about 90% can indicate reaction completion. Typically, a reaction of the disclosed process can take about 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 18, 24, 30, 36, 48, 60, 72, 84, or 96 hours to complete. Reaction time may depend, for example, on certain parameters such as the amount of sucrose and glucosyltransferase enzyme used in the reaction.

The yield of dextran produced in a glucosyltransferase reaction in certain embodiments can be about, or at least about, 10%, 15%, 20%, 25%, 30%, 35%, 40%, or 45%, based on the weight of the sucrose used in the reaction.

Dextran produced in the disclosed method may optionally be isolated. For example, dextran may be precipitated with alcohol (e.g., 90-100% methanol, ethanol, or isopropanol) and then separated from the supernatant, which may comprise water, fructose, and optionally one or more of residual sucrose and byproduct (e.g., glucose; leucrose and other soluble oligosaccharides). Such separation can be by centrifugation or filtration, for example. Precipitated dextran can optionally be washed one or more times (e.g., 2-4 times; 2, 3, 4 or more times) with alcohol (e.g., 70-100%, or at least 70%, 80%, 90%, 95%, or 100% methanol, ethanol, or isopropanol). In other examples, dextran isolation can comprise using an ultrafiltration and/or dialysis technique (i.e., a molecular weight cut-off technique), such as disclosed in U.S. Patent Appl. Publ. No. 2014/0142294 and U.S. Patent No. 6977249, which are incorporated herein by reference. Measurements of certain dextran features herein (e.g., linkage profile, molecular weight) can be made with dextran isolated as above, if desired.

A dextran synthesis method herein is believed to be useful for producing dextran with increased or decreased viscosity, depending on the amount of

sucrose used in the method. In general, the lower the sucrose concentration used in a glucosyltransferase reaction, the higher the viscosity of the dextran product, and vice versa. Any sucrose concentration disclosed herein can be used in a glucosyltransferase reaction, where the dextran product of the reaction

5 has a viscosity that is greater than that of a dextran product produced in a reaction comprising a higher sucrose concentration, and vice versa. In certain aspects, any viscosity disclosed herein can be used to characterize embodiments of this method, and an increase in viscosity can be at least about 2-, 3-, 4-, 5-, 6-, 7-, 8-, 9-, 10-, 20-, 50-, 100-, 150-, 200-, or 250-fold higher. A

10 glucosyltransferase enzyme in certain embodiments of this method can be gtf 0768 (comprising SEQ ID NO:1 or related sequences).

Non-limiting examples of compositions and methods disclosed herein include:

1. A composition comprising dextran, wherein the dextran comprises:

- 15 (i) about 87-93 wt% glucose linked at positions 1 and 6;
(ii) about 0.1-1.2 wt% glucose linked at positions 1 and 3;
(iii) about 0.1-0.7 wt% glucose linked at positions 1 and 4;
(iv) about 7.7-8.6 wt% glucose linked at positions 1, 3 and 6; and
(v) about 0.4-1.7 wt% glucose linked at:
- 20 (a) positions 1, 2 and 6, or
(b) positions 1, 4 and 6;

wherein the weight-average molecular weight (Mw) of the dextran is about 50-200 million Daltons, the z-average radius of gyration of the dextran is about 200-280 nm, and the dextran optionally is not a product of a *Leuconostoc*

25 *mesenteroides* glucosyltransferase enzyme.

2. The composition of embodiment 1, wherein the dextran comprises:

- (i) about 89.5-90.5 wt% glucose linked at positions 1 and 6;
(ii) about 0.4-0.9 wt% glucose linked at positions 1 and 3;
(iii) about 0.3-0.5 wt% glucose linked at positions 1 and 4;
30 (iv) about 8.0-8.3 wt% glucose linked at positions 1, 3 and 6; and
(v) about 0.7-1.4 wt% glucose linked at:

(a) positions 1, 2 and 6, or

(b) positions 1, 4 and 6.

3. The composition of embodiment 1 or 2, wherein the dextran comprises chains linked together within a branching structure, wherein the chains are similar in length and comprise substantially alpha-1,6-glucosidic linkages.

4. The composition of embodiment 1, 2, or 3, wherein the average length of the chains is about 10-50 monomeric units.

5. The composition of embodiment 1, 2, 3, or 4, wherein the dextran is a product of a glucosyltransferase enzyme comprising an amino acid sequence that is at least 90% identical to SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:5, SEQ ID NO:9, SEQ ID NO:13, or SEQ ID NO:17.

6. The composition of embodiment 1, 2, 3, 4, or 5, wherein the composition is an aqueous composition having a viscosity of at least about 25 cPs.

7. The composition of embodiment 1, 2, 3, 4, 5, or 6, wherein the Mw of the dextran is about 80-120 million Daltons.

8. The composition of embodiment 1, 2, 3, 4, 5, 6, or 7, wherein the z-average radius of gyration of the dextran is about 230-250 nm.

9. The composition of embodiment 1, 2, 3, 4, 5, 6, 7, or 8, wherein the composition is in the form of a food product, personal care product, pharmaceutical product, household product, or industrial product.

10. The composition of embodiment 9, wherein the composition is in the form of a confectionery.

11. A method for increasing the viscosity of an aqueous composition, the method comprising: contacting dextran according to any of embodiments 1-8 with the aqueous composition, wherein the viscosity of the aqueous composition is increased by the dextran compared to the viscosity of the aqueous composition before the contacting step.

12. A method of treating a material, the method comprising: contacting a material with an aqueous composition comprising dextran according to any of embodiments 1-8.

13. An enzymatic reaction comprising water, sucrose and a glucosyltransferase enzyme comprising an amino acid sequence that is at least 90% identical to SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:5, SEQ ID NO:9, SEQ ID NO:13, or SEQ ID NO:17, wherein the glucosyltransferase enzyme

5 synthesizes dextran according to any of embodiments 1-8.

14. A method for producing dextran, the method comprising:

a) contacting at least water, sucrose, and a glucosyltransferase enzyme comprising an amino acid sequence that is at least 90% identical to SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:5, SEQ ID NO:9, SEQ ID NO:13, or SEQ ID

10 NO:17, whereby dextran according to any of embodiments 1-8 is produced; and

b) optionally, isolating the dextran produced in step (a).

15. The method of embodiment 14, wherein the viscosity of the dextran produced in the method is increased by decreasing the amount of sucrose in step (a).

EXAMPLES

The present disclosure is further defined in Examples 1-6 and 8-11. It should be understood that these Examples, while indicating certain preferred aspects of the disclosure, are given by way of illustration only. From the above discussion and these Examples, one skilled in the art can ascertain the essential characteristics of this disclosure, and without departing from the spirit and scope thereof, can make various changes and modifications to adapt the disclosure to various uses and conditions.

GENERAL METHODS

Cloning and Expression of Glucosyltransferase Enzymes in *Bacillus subtilis*

Each glucosyltransferase used in Examples 3-6 was prepared as follows.

A plasmid encoding the gtf enzyme (pZZHB582, pZZHB583, pZZHB584, or pZZHB585, which allow for gtf expression and secretion from *B. subtilis*; see FIGs. 2A-D) was amplified using Illustra TempliPhi® 100 Amplification Kit (GE Healthcare Life Sciences, NJ). Competent *B. subtilis* cells (Δ spoIIIE, Δ aprE, Δ nprE, degUHy32, Δ scoC, Δ nprB, Δ vpr, Δ epr, Δ wprA, Δ mpr, Δ ispA, Δ bpr) were

transformed with the amplification product. Cells were plated on Luria Agar plates supplemented with 5 ppm chloramphenicol. Colonies from the transformation plate were inoculated into 5 mL LB medium and incubated at 37 °C overnight. Aliquots (25-50 µL) from each culture were then transferred to 250-
5 mL shake flasks containing 30 mL of Grant's II Medium supplemented with 5 ppm chloramphenicol and incubated at 30 °C with shaking (280 rpm) for 24 hours. Cells were harvested by centrifugation at 14000 rpm for 1 hour.

Supernatants were analyzed by SDS-PAGE for secreted gtf product and further dialyzed three times against a solution containing 20 mM Tris, pH 7.5 for a total
10 of 20 hours. Dialyzed samples were aliquoted at 25 mL per 50-mL conical centrifuge tube, and the tubes were placed at an angle at -80 °C for about 1 hour. Once the samples were frozen, the tube lid was removed and replaced with PARAFILM that was pierced 5-10 times with a high-gauge needle. The PARAFILM-covered frozen samples were lyophilized in a FreeZone® Freeze Dry
15 System (Labconco Corp., Kansas City, MO) according to the manufacturer's instruction.

Stock Solutions of Glucosyltransferase Enzymes

An enzyme stock solution was made for each gtf by adding 10 mL of molecular grade H₂O into each 50-mL conical centrifuge tube containing
20 lyophilized enzyme powder.

EXAMPLE 1

Expression of a Glucosyltransferase (0768) in *E. coli* and Production of Active Crude Enzyme Lysate

This Example describes expression of a mature glucosyltransferase (gtf)
25 enzyme in *E. coli*. Crude cell lysate of an *E. coli* expression strain was produced and showed gel product-forming activity in the presence of sucrose.

A putative YG repeat-containing hydrolase (categorized in GENBANK under GI number 339480768, but now having GI number 497964659) with 1484 amino acids was identified from *Leuconostoc pseudomesenteroides* strain
30 KCTC3652 by whole genome shotgun sequencing. This putative glucosyltransferase (designated herein as gtf 0768) belongs to the GH70 family

of glycosyl hydrolases containing a glucan-binding domain. The N-terminal 37 amino acid segment of gtf 0768 was deduced as the signal peptide of the enzyme by the SIGNALP 4.0 program (Petersen et al., *Nature Methods* 8:785-786). The mature form of gtf 0768 is represented by SEQ ID NO:1.

5 To construct a plasmid for bacterial expression of gtf 0768, a DNA sequence encoding a mature form of the gtf without the signal peptide was synthesized by GenScript USA Inc. (Piscataway, NJ). The synthesized sequence was subcloned into the NheI and HindIII sites of the pET23D+ vector (NOVAGEN[®]; Merck KGaA, Darmstadt, Germany). The 0768 gtf (SEQ ID NO:2)
10 encoded by this construct included a start methionine and 3 additional amino acids (Ala-Ser-Ala) at the N-terminus, and 6 histidine residues at the C-terminus, compared to the wild type mature (predicted) form of gtf 0768 (SEQ ID NO:1) (i.e., SEQ ID NO:1 is comprised in SEQ ID NO:2). The plasmid construct was sequence-confirmed and transformed into *E. coli* BL21 DE3 host cells with
15 ampicillin selection, resulting in expression strain EC0052.

 Cells of EC0052 and a control strain containing only empty pET23D+ vector were grown in LB medium with 100 µg/mL ampicillin to OD₆₀₀ ~0.5, and then induced with 1 mM IPTG at 37 °C for 3 hours or alternatively induced at 23 °C overnight. Following this induction period, cells were collected by
20 centrifugation at 4000xg for 10 min and resuspended in PBS buffer pH 6.8. The cells were then lysed by passing through a French Press at 14,000 psi (~96.53 MPa) twice, afterwhich cell debris was pelleted by centrifugation at 15,000xg for 20 min. The supernatants of each crude cell lysate were aliquoted and frozen at -80 °C.

25 The activity of crude cell lysate from EC0052 cells was checked by reaction with sucrose. A control reaction was set up similarly using cell lysate prepared from cells containing the empty vector. Each sucrose reaction was set up using 10% (v/v) of cell lysate with 100 g/L sucrose, 10 mM sodium citrate pH 5, and 1 mM CaCl₂. After incubation of the reactions at 37 °C for a few hours, a
30 gel-like product, believed to be a dextran, was formed in the tube in which EC0052 cell lysate had been added. No gel-like product was formed in the

control reaction. HPLC analysis confirmed that sucrose was consumed in the reaction containing EC0052 cell lysate, and not in the control reaction. This result suggested that the EC0052 crude cell lysate expressed active gtf 0768 enzyme, and that this gtf produced a dextran product having high viscosity.

5 Thus, reactions comprising water, sucrose and an enzyme comprising SEQ ID NO:1 synthesized a gelling product, believed to be a dextran. This result demonstrated that gtf 0768 likely has glucosyltransferase activity.

EXAMPLE 2

Reaction of Sucrose with Gtf 0768 and Analysis of a Gelling Dextran Reaction

Product

10 This Example describes additional reactions comprising water, sucrose and gtf 0768, supplementing the results provided in Example 1. Also, this Example provides glycosidic linkage analysis of the gelling product synthesized by gtf 0768, showing that this product is a type of dextran.

15 Reagents for preparing gtf reactions:

- Sucrose (Sigma Prod. No. S-9378).

- Sodium phosphate buffer stock (200 mM) (pH 5.5): prepare 250 mL in water using sodium phosphate monobasic monohydrate (Sigma Prod. No. S9638) and sodium phosphate dibasic heptahydrate (Sigma Prod. No. S9390),
20 accordingly.

- Gtf 0768 enzyme solution (cell lysate as prepared in Example 1).

Conditions of three gtf reactions:

A 1000-mL reaction was prepared containing 2.72 g of sodium phosphate buffer stock (pH 5.5), 100 g/L sucrose, and 2 mL of gtf 0768 enzyme solution.

25 The reaction was stirred at 26 °C for 20 hours, and became viscous. The gtf enzyme was deactivated by heating the reaction at 80 °C for 10 minutes. The deactivated viscous reaction was then mixed with 3 liters of 100% methanol to precipitate the viscous product. A white precipitate was formed, which was then filtered, followed by four washes with 120 ml of 100% methanol. The solid
30 product was dried at room temperature under vacuum in an oven for 72 hours.

A 725-mL reaction was prepared containing 1.97 g of sodium phosphate buffer, 300 g/L sucrose, and 1.45 mL of gtf 0768 enzyme solution. The reaction was stirred at 26 °C for 20 hours, and became viscous. The gtf enzyme was deactivated by adding methanol to the reaction mixture. The deactivated
5 reaction was then mixed with 3 liters of 100% methanol to precipitate the viscous product. A white precipitate was formed, which was then filtered, followed by four washes with 120 mL of 100% methanol. The solid product was dried at room temperature under vacuum in an oven for 72 hours.

A 200-mL reaction was prepared containing 0.544 g of sodium phosphate
10 buffer, 400 g/L sucrose, and 0.4 mL of gtf 0768 enzyme solution. The reaction was stirred at 26 °C for 20 hours, and became viscous. The gtf enzyme was deactivated by adding methanol to the reaction mixture. The deactivated reaction was then mixed with 3 liters of 100% methanol to precipitate the viscous product. A white precipitate was formed, which was then filtered, followed by
15 four washes with 120 mL of 100% methanol. The solid product was dried at room temperature under vacuum in an oven for 72 hours.

A 200-mL reaction was prepared containing 0.544 g of sodium phosphate buffer, 800 g/L sucrose, and 0.4 mL of gtf 0768 enzyme solution. The reaction was stirred at 26 °C for 20 hours, and became viscous. The gtf enzyme was
20 deactivated by adding methanol to the reaction mixture. The deactivated reaction was then mixed with 3 liters of 100% methanol to precipitate the viscous product. A white precipitate was formed, which was then filtered, followed by four washes with 120 ml of 100% methanol. The solid product was dried at room temperature under vacuum in an oven for 72 hours.

25 Samples (100 µL) of each reaction were taken at 0, 2, 4, and 18 hours, respectively. The gtf enzyme was deactivated in each sample by heating at 80 °C for 10 minutes. Each sample was then diluted 10-fold with water and centrifuged at 14,000 rpm for 5 minutes, after which 200 µL of supernatant was used for HPLC analysis to measure sucrose consumption during the reaction.
30 The following HPLC conditions were applied for analyzing each sample: column (AMINEX HPX-87C carbohydrate column, 300 x 7.8 mm, Bio-Rad, No. 125-

0095), eluent (water), flow rate (0.6 mL/min), temperature (85 °C), refractive index detector. HPLC analysis of the samples indicated substantial sucrose consumption during the 0768 gtf reaction (FIG. 1, reaction comprising 100 g/L sucrose) (this sucrose consumption occurred significantly faster than the sucrose consumption observed in a reaction using a dextran sucrase obtained from a commercial source – refer to Example 7).

HPLC was also used to analyze other products of the reaction comprising 100 g/L sucrose. Polymer yield was back-calculated by subtracting the amount of all other saccharides left in the reaction from the amount of the starting sucrose. The back-calculated number was consistent with the viscous product dry weight analysis. Sucrose, leucrose, glucose and fructose were quantified by HPLC with an HPX-87C column (HPLC conditions as described above). DP2-7 disaccharides were quantified by HPLC with the following conditions: column (AMINEX HPX-42A carbohydrate column, 300 x 7.8 mm, Bio-Rad, No. 125-0097), eluent (water), flow rate (0.6 mL/min), temperature (85 °C), refractive index detector. These HPLC analyses indicated that the glucosyl-containing saccharide products of the 0768 gtf reaction consisted of 91% polymer product, 1% glucose, 6.5% leucrose, and 1.5% DP2-7 oligosaccharides.

The glycosidic linkage profile of the gelling polymer product of the reaction comprising 100 g/L sucrose was determined by ^{13}C NMR. Dry polymer (25-30 mg) as prepared above was dissolved in 1 mL of deuterated DMSO containing 3 wt% LiCl with stirring at 50 °C. Using a glass pipet, 0.8 mL of the preparation was transferred into a 5-mm NMR tube. A quantitative ^{13}C NMR spectrum was acquired using a Bruker Avance (Billerica, MA) 500 MHz NMR spectrometer equipped with a CPDul cryoprobe, at a spectral frequency of 125.76 MHz, using a spectral window of 26041.7 Hz. An inverse-gated decoupling pulse sequence using waltz decoupling was used with an acquisition time of 0.629 second, an inter-pulse delay of 5 seconds, and 6000 pulses. The time domain data were transformed using an exponential multiplication of 2.0 Hz.

The NMR results indicated that the gelling polymer product comprised about 90% alpha-1,6-glucosidic linkages, about 4-5% alpha-1,3-glucosidic

linkages, and about 5-6% alpha-1,4 and -1,2 glucosidic linkages. The main chain(s) of the polymer product appeared to mostly comprise alpha-1,6-glucosidic linkages, but also a very small amount of alpha-1,3 and -1,4 glucosidic linkages. Other alpha-1,3 and -1,4 glucosidic linkages, and all of the alpha-1,2-glucosidic linkages, appeared to be in branches off the main chain(s). The gelling product thus appears to be a gelling dextran.

A different protocol (not the above ^{13}C NMR procedure) is presently recommended herein for determining the linkage profile of dextran produced by gtf 0768. This protocol is disclosed below in Example 9, indicating a linkage profile similar to that disclosed in this Example.

The number-average molecular weight (M_n) and weight-average molecular weight (M_w) of the gelling dextran product of the reaction comprising 100 g/L sucrose was determined by size-exclusion chromatography (SEC). Dry polymer as prepared above was dissolved in DMAc and 5% LiCl (0.5 mg/mL) with shaking overnight at 100 °C. The chromatographic system used was an Alliance™ 2695 separation module from Waters Corporation (Milford, MA) coupled with three on-line detectors: a differential refractometer 2410 from Waters, a Heleos™ 8+ multiangle light scattering photometer from Wyatt Technologies (Santa Barbara, CA), and a ViscoStar™ differential capillary viscometer from Wyatt. Columns used for SEC were four styrene-divinyl benzene columns from Shodex (Japan) and two linear KD-806M, KD-802 and KD-801 columns to improve resolution at the low molecular weight region of a polymer distribution. The mobile phase was DMAc with 0.11% LiCl. The chromatographic conditions used were 50 °C in the column and detector compartments, 40 °C in the sample and injector compartment, a flow rate of 0.5 mL/min, and an injection volume of 100 μL . The software packages used for data reduction were Empower™ version 3 from Waters (calibration with broad glucan polymer standard) and Astra® version 6 from Wyatt (triple detection method with column calibration). It was determined from this procedure that the gelling dextran product had an M_n of 2229400 and an M_w of 5365700.

A different protocol (not the above SEC procedure) is presently recommended herein for determining the molecular weight of dextran produced by gtf 0768. This protocol is disclosed below in Example 9, indicating a molecular weight more than one order of magnitude greater than the molecular weight disclosed in this Example.

Thus, reactions comprising water, sucrose and an enzyme comprising SEQ ID NO:1 synthesized a gelling dextran product, as determined by the product's predominant alpha-1,6 glucosidic linkage profile. Example 8 below discloses comparing the viscosity of this product versus the viscosities of certain commercially available dextrans. Example 9 discloses further production of dextran with a gtf enzyme comprising SEQ ID NO:1, along with yield, molecular weight, and linkage analysis of the dextran.

EXAMPLE 3

Expression of a Glucosyltransferase (2919) and Use Thereof to Produce a Gelling Dextran Product

This Example describes expression of a mature *Weissella cibaria* glucosyltransferase (gtf) enzyme in *B. subtilis*. Also, this Example shows that this enzyme produces a gelling product, likely a dextran, when used in a reaction containing water and sucrose.

A glucosyltransferase gene, WciGtf1, was identified from *Weissella cibaria* KACC 11862. The nucleic acid sequence of this gene (positions 23315 to 27661 of GENBANK Accession No. NZ_AEKT01000035.1) is set forth in SEQ ID NO:3 and encodes the protein sequence of SEQ ID NO:4 (GENBANK Accession No. ZP_08417432). At the N-terminus of the WciGtf1 protein (SEQ ID NO:4) is a signal peptide of 26 amino acids, as predicted by the SIGNALP 4.0 program (Petersen et al., *Nature Methods* 8:785-786). This indicates that WciGtf1 (SEQ ID NO:4) is a secreted protein. The mature, secreted form of the WciGtf1 protein is herein referred to as 2919 gtf, and is set forth in SEQ ID NO:5.

The nucleotide sequence encoding 2919 gtf was optimized for expression in *B. subtilis*. The optimized sequence (SEQ ID NO:6) was synthesized by Generay (Shanghai, China), and inserted into plasmid p2JM103BBI (Vogtentanz

et al., *Protein Expr. Purif.* 55:40-52), resulting in plasmid pZZHB583 (FIG. 2A). Plasmid pZZHB583 contains an aprE promoter operably linked to a sequence encoding (i) an aprE signal sequence used to direct heterologous protein (2919 gtf in this case) secretion in *B. subtilis*, (ii) Ala-Gly-Lys to facilitate the secretion, and (iii) 2919 gtf (SEQ ID NO:5) (i-iii are fused together in the amino-to-carboxy direction).

Plasmid pZZHB583 was transformed into *B. subtilis* cells for 2919 gtf expression and purification (see General Methods).

The activity of 2919 gtf (SEQ ID NO:5) was determined in a 250-mL reaction at room temperature comprising 100 g/L sucrose, 20 mM sodium phosphate buffer (pH 5.5), and 6.25 mL of enzyme stock. The reaction was carried out at room temperature with shaking (150 rpm) for 48 hours.

Samples (100 μ L) were taken from the reaction at 0, 1, 3, 5, 24, and 48 hour time points, respectively. Enzyme was deactivated by heating each sample at 80 °C for 10 minutes. Samples were diluted 10-fold with water and centrifuged at 14000 rpm for 5 minutes. Supernatant (200 μ L) was used for HPLC analysis.

The concentrations of leucrose, glucose, and fructose in the gtf reaction were determined using HPLC, which was performed with an Agilent 1260 chromatography system equipped with an AMINEX HPX-87C column (300 x 7.8 mm) placed in a thermostatted column compartment at 85 °C, and a refractive index detector. HPLC elution was carried out with Milli-Q® water at 0.6 mL/min. Sucrose, leucrose, glucose, and fructose were identified by comparison with corresponding standards. Their concentrations were calculated based on a peak area standard curves. Sucrose was consumed almost completely by the end of the reaction. Aside from a viscous dextran product, 2919 gtf (SEQ ID NO:5) produced mostly fructose (~50%), and small amounts of leucrose (~5%) and glucose (~1%).

The concentration of oligosaccharides (DP2-DP7) in the gtf reaction was determined by HPLC analysis, which was performed with an Agilent 1260 chromatography system equipped with an AMINEX HPX-42A column (300 x 7.8 mm) placed in a thermostatted column compartment at 85 °C, and a refractive

index detector. HPLC elution was carried out with Milli-Q[®] water at 0.6 mL/min. Formation of oligosaccharides was identified by comparison with corresponding standards. The concentration of the oligosaccharides was calculated based on standard curves from peak area. 2919 gtf (SEQ ID NO:5) produced a small
5 amount of DP2-DP7 oligosaccharides (~3%) by the end of the reaction.

Thus, reactions comprising water, sucrose and an enzyme comprising SEQ ID NO:5 synthesized a gelling product, which is believed to be a dextran polymer. Experimental results demonstrated that gtf 2919 likely has glucosyltransferase activity.

10 EXAMPLE 4

Expression of a Glucosyltransferase (2918) and Use Thereof to Produce a Gelling Dextran Product

This Example describes expression of a mature *Lactobacillus fermentum* glucosyltransferase (gtf) enzyme in *B. subtilis*. Also, this Example shows that
15 this enzyme produces a gelling product, likely a dextran, when used in a reaction containing water and sucrose.

A glucosyltransferase gene, LfeGtf1, was identified from *Lactobacillus fermentum*. The nucleic acid sequence of this gene (positions 618 to 5009 of GENBANK Accession No. AY697433.1) is set forth in SEQ ID NO:7 and encodes
20 the protein sequence of SEQ ID NO:8 (GENBANK Accession No. AAU08008). At the N-terminus of the LfeGtf1 protein (SEQ ID NO:8) is a signal peptide of 37 amino acids, as predicted by the SIGNALP 4.0 program. This indicates that LfeGtf1 (SEQ ID NO:8) is a secreted protein. The mature, secreted form of the LfeGtf1 protein is herein referred to as 2918 gtf, and is set forth in SEQ ID NO:9.

25 The nucleotide sequence encoding 2918 gtf was optimized for expression in *B. subtilis*. The optimized sequence (SEQ ID NO:10) was synthesized by Generay (Shanghai, China), and inserted into plasmid p2JM103BBI, resulting in plasmid pZZHB582 (FIG. 2B). Plasmid pZZHB582 contains an aprE promoter operably linked to a sequence encoding (i) an aprE signal sequence used to
30 direct heterologous protein (2918 gtf in this case) secretion in *B. subtilis*, (ii) Ala-

Gly-Lys to facilitate the secretion, and (iii) 2918 gtf (SEQ ID NO:9) (i-iii are fused together in the amino-to-carboxy direction).

Plasmid pZZHB582 was transformed into *B. subtilis* cells for 2918 gtf expression and purification (see General Methods).

5 The activity of 2918 gtf (SEQ ID NO:9) was determined in a 250-mL reaction at room temperature comprising 100 g/L sucrose, 20 mM sodium phosphate buffer (pH 5.5), and 6.25 mL of enzyme stock. The reaction was carried out at room temperature with shaking (150 rpm) for 6 days.

10 Samples (100 μ L) were taken from the reaction at 0, 1, 3, 5, 24, 48 and 144 hour time points, respectively. Enzyme was deactivated by heating each sample at 80 °C for 10 minutes. Samples were diluted 10-fold with water and centrifuged at 14000 rpm for 5 minutes. Supernatant (200 μ L) was used for HPLC analysis.

15 The concentrations of sucrose, leucrose, glucose, fructose and oligosaccharides (DP2-DP7) in the gtf reaction were determined using HPLC procedures as described in Example 3. Sucrose was consumed almost completely by the end of the reaction. Aside from a viscous dextran product, 2918 gtf (SEQ ID NO:9) produced mostly fructose (~50%), and small amounts of leucrose (~5%) and glucose (~1%). 2918 gtf (SEQ ID NO:9) produced a small
20 amount of DP2-DP7 oligosaccharides (~1%).

Thus, reactions comprising water, sucrose and an enzyme comprising SEQ ID NO:9 synthesized a gelling product, which is believed to be a dextran polymer. Experimental results demonstrated that gtf 2920 likely has glucosyltransferase activity.

25

EXAMPLE 5

Expression of a Glucosyltransferase (2920) and Use Thereof to Produce a Gelling Dextran Product

30 This Example describes expression of a mature *Streptococcus sobrinus* glucosyltransferase (gtf) enzyme in *B. subtilis*. Also, this Example shows that this enzyme produces a gelling product, likely a dextran, when used in a reaction containing water and sucrose.

A glucosyltransferase gene, SsoGtf4, was identified from *Streptococcus sobrinus* B13N. The nucleic acid sequence of this gene (positions 198 to 4718 of GENBANK Accession No. AY966490) is set forth in SEQ ID NO:11 and encodes the protein sequence of SEQ ID NO:12 (GENBANK Accession No. AAX76986).

5 At the N-terminus of the SsoGtf4 protein (SEQ ID NO:12) is a signal peptide of 41 amino acids, as predicted by the SIGNALP 4.0 program. This indicates that SsoGtf4 (SEQ ID NO:12) is a secreted protein. The mature, secreted form of the SsoGtf4 protein is herein referred to as 2920 gtf, and is set forth in SEQ ID NO:13.

10 The nucleotide sequence encoding 2920 gtf was optimized for expression in *B. subtilis*. The optimized sequence (SEQ ID NO:14) was synthesized by Generay (Shanghai, China), and inserted into plasmid p2JM103BBI, resulting in plasmid pZZHB584 (FIG. 2C). Plasmid pZZHB584 contains an aprE promoter operably linked to a sequence encoding (i) an aprE signal sequence used to
15 direct heterologous protein (2920 gtf in this case) secretion in *B. subtilis*, (ii) Ala-Gly-Lys to facilitate the secretion, and (iii) 2920 gtf (SEQ ID NO:13) (i-iii are fused together in the amino-to-carboxy direction).

Plasmid pZZHB584 was transformed into *B. subtilis* cells for 2920 gtf expression and purification (see General Methods).

20 The activity of 2920 gtf (SEQ ID NO:13) was determined in a 250-mL reaction at room temperature comprising 100 g/L sucrose, 20 mM sodium phosphate buffer (pH 5.5), and 6.25 mL of enzyme stock. The reaction was carried out at room temperature with shaking (150 rpm) for 6 days.

Samples (100 μ L) were taken from the reaction at 0, 1, 3, 5, 24, 48, 72
25 and 144 hour time points, respectively. Enzyme was deactivated by heating each sample at 80 °C for 10 minutes. Samples were diluted 10-fold with water and centrifuged at 14000 rpm for 5 minutes. Supernatant (200 μ L) was used for HPLC analysis.

The concentrations of sucrose, leucrose, glucose, fructose and
30 oligosaccharides (DP2-DP7) in the gtf reaction were determined using HPLC procedures as described in Example 3. Sucrose was consumed almost

completely by the end of the reaction. Aside from a viscous dextran product, 2920 gtf (SEQ ID NO:13) produced mostly fructose (~50%), leucrose (~20%), and a small amount of glucose (~3%). 2920 gtf (SEQ ID NO:13) produced a small amount of DP2-DP7 oligosaccharides (~1%).

5 Thus, reactions comprising water, sucrose and an enzyme comprising SEQ ID NO:13 synthesized a gelling product, which is believed to be a dextran polymer. Experimental results demonstrated that gtf 2920 likely has glucosyltransferase activity.

EXAMPLE 6

Expression of a Glucosyltransferase (2921) and Use Thereof to Produce a Gelling Dextran Product

10 This Example describes expression of a mature *Streptococcus downei* glucosyltransferase (gtf) enzyme in *B. subtilis*. Also, this Example shows that this enzyme produces a gelling product, likely a dextran, when used in a reaction
15 containing water and sucrose.

 A glucosyltransferase gene, SdoGtf7, was identified from *Streptococcus downei* MFe28. The nucleic acid sequence of this gene (positions 16 to 2375 of GENBANK Accession No. AB476746) is set forth in SEQ ID NO:15 and encodes the protein sequence of SEQ ID NO:16 (GENBANK Accession No.
20 ZP_08549987.1). At the N-terminus of the SdoGtf7 protein (SEQ ID NO:16) is a signal peptide of 44 amino acids, as predicted by the SIGNALP 4.0 program. This indicates that SdoGtf7 protein (SEQ ID NO:16) is a secreted protein. The mature, secreted form of the SdoGtf7 protein is herein referred to as 2921 gtf, and is set forth in SEQ ID NO:17.

25 The nucleotide sequence encoding 2921 gtf was optimized for expression in *B. subtilis*. The optimized sequence (SEQ ID NO:18) was synthesized by Generay (Shanghai, China), and inserted into plasmid p2JM103BBI, resulting in plasmid pZZHB585 (FIG. 2D). Plasmid pZZHB585 contains an aprE promoter operably linked to a sequence encoding (i) an aprE signal sequence used to
30 direct heterologous protein (2921 gtf in this case) secretion in *B. subtilis*, (ii) Ala-

Gly-Lys to facilitate the secretion, and (iii) 2921 gtf (SEQ ID NO:17) (i-iii are fused together in the amino-to-carboxy direction).

Plasmid pZZHB585 was transformed into *B. subtilis* cells for 2921 gtf expression and purification (see General Methods).

5 The activity of 2921 gtf (SEQ ID NO:17) was determined in a 250-mL reaction at room temperature comprising 100 g/L sucrose, 20 mM sodium phosphate buffer (pH 5.5), and 6.25 mL of enzyme stock. The reaction was carried out at room temperature with shaking (150 rpm) for 8 days.

10 Samples (100 μ L) were taken from the reaction at the reaction start and on 1, 2, 3, 6, 7 and 8 day time points, respectively. Enzyme was deactivated by heating each sample at 80 °C for 10 minutes. Samples were diluted 10-fold with water and centrifuged at 14000 rpm for 5 minutes. Supernatant (200 μ L) was used for HPLC analysis.

15 The concentrations of sucrose, leucrose, glucose, fructose and oligosaccharides (DP2-DP7) in the gtf reaction were determined using HPLC procedures as described in Example 3. About 43% sucrose remained in the reaction on day 8. Aside from a viscous dextran product, 2921 gtf (SEQ ID NO:17) produced mostly fructose (~31%), leucrose (~6%), and glucose (~3%). No obvious production of DP2-DP7 oligosaccharides was observed.

20 Thus, reactions comprising water, sucrose and an enzyme comprising SEQ ID NO:17 synthesized a gelling product, which is believed to be a dextran polymer. Experimental results demonstrated that gtf 2921 likely has glucosyltransferase activity.

EXAMPLE 7 (Comparative)

25 Production of Dextran Using Commercially Available Dextran Sucrase

This Example describes synthesizing dextran using a commercially available dextran sucrase in reactions comprising water and sucrose. The dextran produced in this was analyzed in Example 8 in comparison to the gelling dextran products synthesized in Examples 1-6.

30 Reagents for preparing dextran sucrase reaction:

- Sucrose (Sigma Prod. No. S-9378). 400 g/L stock solution was prepared.

- Sodium phosphate buffer stock (200 mM) (pH 5.5): prepare 250 mL in water using sodium phosphate monobasic monohydrate (Sigma Prod. No. S9638) and sodium phosphate dibasic heptahydrate (Sigma Prod. No. S9390), accordingly.

- Dextran sucrose, lyophilized powder, ≥ 100 units/mg protein, from *Leuconostoc mesenteroides* (Sigma Prod. No. D9909).

A 50-mL reaction was prepared containing 20 mM sodium phosphate (pH 5.5), 110 g/L sucrose, and 10 units of dextran sucrose from Sigma-Aldrich. The dextran sucrose was added last when preparing the reaction. The reaction was carried out in a 125-mL capped shake flask at 26 °C with shaking (100 rpm) for 7 days. Samples (100 μ L) of the reaction were taken at 0, 3, 6, 24, 48 and 168 hours, respectively. The dextran sucrose was deactivated in each sample by heating at 80 °C for 10 minutes. Each sample was then diluted 10-fold with water and centrifuged at 14,000 rpm for 5 minutes, after which 200 μ L of supernatant was used for HPLC analysis to measure sucrose consumption during the reaction.

The following HPLC conditions were applied for analyzing each sample: column (AMINEX HPX-87C carbohydrate column, 300 x 7.8 mm, Bio-Rad, No. 125-0095), eluent (water), flow rate (0.6 mL/min), temperature (85 °C), refractive index detector. HPLC analysis of the samples indicated sucrose consumption during the dextran sucrose reaction (FIG. 3). It is notable that the sucrose consumption rate by the commercial dextran sucrose was much slower compared to the sucrose consumption rate of gtf 0768 (Example 2). Specifically, while gtf 0768 depleted most sucrose after about 17-18 hours of reaction time (FIG. 1), commercial dextran sucrose depleted only about 20% of sucrose within this same time period, and required about 168 hours to deplete all or most sucrose.

HPLC was also used to analyze other products of the reaction. Dextran yield was back-calculated by subtracting the amount of all other saccharides left

in the reaction from the amount of the starting sucrose. The back-calculated number was consistent with dextran dry weight analysis. Sucrose, leucrose, glucose, fructose, and DP2-7 disaccharides were quantified by HPLC as described in Example 2. These HPLC analyses indicated that the saccharide products of the commercial dextran sucrase reaction consisted of 49% dextran, 0.3% sucrose, 44% fructose, 1% glucose, 5% leucrose, and 1% DP2-7 oligosaccharides.

The dextran produced in this Example was analyzed in Example 8 in comparison to the gelling dextran products synthesized in Examples 1-6.

EXAMPLE 8

Viscosity of Dextran Samples

This Example describes measuring the viscosities of the dextran polymers produced in Examples 1-7, as well as the viscosity of dextran obtained from a commercial source. Viscosity measurements were made at various shear rates.

Dextran polymer samples were prepared as described in Examples 1-7. Specifically, enzymatic reactions were conducted, after which polymer was methanol-precipitated and washed with methanol (100%) four times, and then dried. Solutions (2 wt% and/or 3 wt%) of each sample were prepared by adding the appropriate amount of polymer to de-ionized (DI) water. Each preparation was then mixed using a bench top vortexer until polymer was fully in solution. Each of these samples is referred to in Tables 2 and 3 (below) as "After PPT" (after precipitation). A 2 wt% solution of dextran (Mw = 956978) obtained from TCI America (Portland, OR; catalogue No. D0061) was similarly prepared; this dextran is referred to below as "commercial dextran".

To determine the viscosity of each polymer solution at various shear rates, each solution was subjected to various shear rates using a viscometer while the temperature was held constant at 20 °C. Also, polymer samples obtained directly, without precipitation, from each of the enzymatic reactions described in Examples 1-7 were subjected to various shear rates (referred to in Tables 2 and 3 as "Before PPT"). The shear rate was increased using a gradient program

which increased from 0-10 rpm and the shear rate was increased by 0.17 (1/s) every 30 seconds. The results of this experiment are listed in Table 2.

Table 2
Viscosity of Certain Dextran Solutions at Various Shear Rates

Dextran Sample ^a	Viscosity (cPs) @ 0.17 rpm	Viscosity (cPs) @ 1.03 rpm	Viscosity (cPs) @ 2.62 rpm	Viscosity (cPs) @ 4.22 rpm
Gtf 0768 (SEQ ID NO:1) Before PPT (Example 2, 100 g/L sucrose reaction)	47976.13	11376.70	12956.11	14390.76
Gtf 0768 (SEQ ID NO:1) After PPT – 3 wt% (Example 2, 100 g/L sucrose reaction)		15778.40	6245.31 ^b	4119.58 ^b
Gtf 0768 (SEQ ID NO:1) After PPT – 2 wt% (Example 2, 100 g/L sucrose reaction)		4091.84	3417.10	2874.10
Gtf 2918 (SEQ ID NO:9) Before PPT (Example 4)		n/a ^b	n/a ^b	n/a ^b
Gtf 2919 (SEQ ID NO:5) Before PPT (Example 3)		98864	38671	25580
Gtf 2920 (SEQ ID NO:13) Before PPT (Example 5)		3874.85	4205.66	4119.58 ^b
Gtf 2920 (SEQ ID NO:13) After PPT – 3 wt% (Example 5)		6168.76	3294.43	2288.24
Gtf 2921 (SEQ ID NO:17) Before PPT (Example 6)		3533.86	2143.72	1748.95
Gtf 2921 (SEQ ID NO:17) After PPT – 3 wt% (Example 6)		4634.32	2780.4	1984.89
Commercial dextran sucrose Before PPT (Example 7)	16759.42			

5

^a Polymer samples are listed according to the respective enzyme used to synthesize the sample.

^b Measurement was outside the specification limits of the viscometer.

Polymer samples were also subjected to various higher shear rates using a viscometer while the temperature was held constant at 20 °C.. The shear rate was increased using a gradient program which increased from 10-250 rpm and the shear rate was increased by 7.36 (1/s) every 20 seconds. The results of this experiment are listed in Table 3.

Table 3

Viscosity of Certain Dextran Solutions at Various Shear Rates

Dextran Sample ^a	Viscosity (cPs) @ 14.72 rpm	Viscosity (cPs) @ 102.9 rpm	Viscosity (cPs) @ 250 rpm
Gtf 2918 (SEQ ID NO:9) After PPT – 3 wt% (Example 4)	149.95	69.68	48.97
Gtf 2919 (SEQ ID NO:5) After PPT – 3 wt% (Example 3)	80.82	41.23	29.49
2 wt% Commercial dextran	241.41	105.28	68.88
Commercial dextran sucrose After PPT – 2 wt% (Example 7)	11.09 ^b	10.31 ^b	8.27
	Viscosity (cPs) @ 14.11 rpm	Viscosity (cPs) @ 98.69 rpm	Viscosity (cPs) @ 162.1 rpm
Gtf 0768 (SEQ ID NO:1) After PPT – 2 wt% (Example 2, 400 g/L sucrose reaction)	49.89	23.61	18.32
Gtf 0768 (SEQ ID NO:1) After PPT – 2 wt% (Example 2, 800 g/L sucrose reaction)	5.44	2.72	1.58

^a Polymer samples are listed according to the respective enzyme used to synthesize the sample. Alternatively, dextran obtained from a commercial source was analyzed ("Commercial dextran").

^b Measurement was outside the specification limits of the viscometer.

These data demonstrate that solutions of the dextran product of a glucosyltransferase comprising SEQ ID NO:1 can in most cases exhibit increased viscosity even after precipitation and resolution, as compared to the viscosities of commercially obtained dextran and the dextran product of a commercially obtained dextran sucrase. This observation also appears to apply to the respective polymer products of glucosyltransferases comprising SEQ ID NO:5, 9, 13, or 17.

It is also noteworthy that, based on Tables 2-3, as the amount of sucrose in a gtf 0768 reaction is decreased from 800 g/L to 100 g/L, the viscosity of the dextran product appears to increase. Specifically, Table 3 indicates (at 14.11 rpm/2 wt% loading) viscosities of 5.44 cPs and 49.89 cPs for dextran products of reactions comprising 800 and 400 g/L sucrose, respectively, and Table 2 (gtf 0768, 2 wt% loading) may indicate a viscosity of about 957 cPs (exponential extrapolated at a rotation of 14.11 rpm) for dextran product of a reaction comprising 100 g/L sucrose. This result suggests that the viscosity of a dextran product can be controlled by modifying the level of sucrose initially provided to reaction.

EXAMPLE 9

Further Production and Analysis of Dextran Synthesized by Gtf 0768

This Example is in addition to Example 2, describing another reaction comprising water, sucrose and gtf 0768. Also, this Example provides additional linkage and molecular weight analyses of the gelling product synthesized by gtf 0768, showing that this product is a type of dextran.

Reagents for preparing gtf reaction:

- Sucrose (Sigma Prod. No. S-9378).
- Sodium phosphate buffer stock (1 M, pH 6.5, Teknova Cat No: S0276).
- Gtf 0768 enzyme solution (cell lysate as prepared in Example 1).

Gtf reaction conditions:

A 50-mL reaction was prepared containing 20 mM sodium phosphate buffer (buffer was diluted 50-fold with ddH₂O from 1 M stock, pH 6.5), 100 g/L sucrose, and 0.1 mL of gtf 0768 enzyme solution. The reaction was shaken at

100 rpm in an incubator shaker (Innova, Model 4000) at 26 °C for 43 hours; the reaction became viscous after about 24 hours.

The gtf enzyme was deactivated by heating the reaction at 80 °C for 10 minutes. The deactivated viscous reaction was then mixed with 75 mL of 100% methanol to precipitate the viscous product. A white precipitate was formed. After carefully decanting the supernatant, the white precipitate was washed twice with 75 mL of 100% methanol. The solid product was dried at 45 °C under vacuum in an oven for 48 hours.

Samples (1 mL) of the reaction were taken at 0, 0.5, 1, 2, and 24 hours, respectively. The gtf enzyme was deactivated in each sample by heating at 80 °C for 10 minutes. Each sample was then diluted 10-fold with sterile water. 500 µL of diluted sample was transferred into a centrifuge tube filter (SPIN-X, 0.45-µm Nylon, 2.0 mL Polypropylene Tube, Costar # 8170) and centrifuged at 12,000 rpm in a table centrifuge for 60 minutes, after which 200 µL of flowthrough was used for HPLC analysis to measure sucrose consumption during the reaction. The following HPLC conditions were applied for analyzing each sample: column (AMINEX HPX-87C carbohydrate column, 300 x 7.8 mm, Bio-Rad, No. 125-0095), eluent (water), flow rate (0.6 mL/min), temperature (85 °C), refractive index detector. HPLC analysis of the samples indicated substantial sucrose consumption during the 0768 gtf reaction.

HPLC was also used to analyze other products of the reaction. Polymer yield was back-calculated by subtracting the amount of all other saccharides left in the reaction from the amount of the starting sucrose. The back-calculated number was consistent with the viscous product dry weight analysis. Sucrose, leucrose, glucose and fructose were quantified by HPLC with an HPX-87C column (HPLC conditions as described above). DP2-7 oligosaccharides were quantified by HPLC with the following conditions: column (AMINEX HPX-42A carbohydrate column, 300 x 7.8 mm, Bio-Rad, No. 125-0097), eluent (water), flow rate (0.6 mL/min), temperature (85 °C), refractive index detector. These HPLC analyses indicated that the glucosyl-containing saccharide products of the

0768 gtf reaction consisted of 92.3% polymer product, 1.3% glucose, 5.0% leucrose, and 1.4% DP2-7 oligosaccharides.

A sample of dry dextran powder product (~0.2 g) of the above reaction was used for molecular weight analysis. Molecular weight was determined by a flow injection chromatographic method using an Alliance™ 2695 separation module from Waters Corporation (Milford, MA) coupled with three online detectors: a differential refractometer 2414 from Waters, a Heleos™-2 18-angle multiangle light scattering (MALS) photometer with quasielastic light scattering (QELS) detector from Wyatt Technologies (Santa Barbara, CA), and a ViscoStar™ differential capillary viscometer from Wyatt. The dry dextran powder was dissolved at 0.5 mg/mL in aqueous Tris (Tris[hydroxymethyl]aminomethane) buffer (0.075 M) containing 200 ppm NaN₃. The dissolution of dextran was achieved by shaking overnight at 50 °C. Two AQUAGEL-OH GUARD columns from Agilent Technologies (Santa Clara, CA) were used to separate the dextran polymer peak from the injection peak. The mobile base for this procedure was the same as the dextran solvent, the flow rate was 0.2 mL/min, the injection volume was 0.1 mL, and the column temperature was 30 °C. Empower™ version 3 software from Waters was used for data acquisition, and Astra™ version 6 software from Wyatt was used for multidetector data reduction. It was determined from this work that the dextran polymer product had a weight-average molecular weight (M_w) of 1.022 (+/- 0.025) x 10⁸ g/mol (i.e., roughly 100 million Daltons) (from MALS analysis), a z-average radius of gyration of 243.33 (+/-0.42) nm (from MALS analysis), and a z-average hydrodynamic radius of 215 nm (from QELS analysis). It was also determined from QELS analysis that the dextran has a standard deviation of particle size distribution (PSD) of about 0.259, indicating that the dextran likely is polydisperse in terms of hydrodynamic size.

For glycosidic linkage analysis purposes, a 50-mL gtf reaction was prepared as described above in this Example, except that the reaction time was 24 hours (reaction had become viscous). The gtf enzyme was deactivated by heating the reaction at 80 °C for 10 minutes. The deactivated viscous reaction

was then placed into a regenerated cellulose sturdy dialysis tubing with a molecular weight cut-off (MWCO) of 12-14 kDa (Spectra/Por[®] 4 Dialysis Tubing, Part No. 132706, Spectrum Laboratories, Inc.) and dialyzed against 4 L of filter water at room temperature over one week. Water was exchanged every day during this dialysis. The dialyzed viscous reaction was then precipitated and dried as described above in this Example. About 0.2 g of dry powder was submitted for GC/MS linkage analysis.

Linkage analysis was performed according to methods described by Pettolino et al. (*Nature Protocols* 7:1590-1607), which is incorporated herein by reference. Briefly, a dry dextran sample was dissolved in dimethyl sulfoxide (DMSO) or 5% lithium chloride in DMSO, then all free hydroxyl groups were methylated by sequential addition of a sodium hydroxide/DMSO slurry followed by iodomethane. The methylated polymer was then extracted into methylene chloride and hydrolyzed to monomeric units using aqueous trifluoroacetic acid (TFA) at 120 °C. The TFA was then evaporated from the sample and reductive ring opening was done using sodium borodeuteride, which also labeled the reducing end with a deuterium atom. The hydroxyl groups created by hydrolyzing the glycosidic linkages were then acetylated by treating with acetyl chloride and TFA at a temperature of 50 °C. Finally, the derivatizing reagents were evaporated and the resulting methylated/acetylated monomers were reconstituted in acetonitrile and analyzed by gas chromatography with mass spectrometry (GC/MS) using a biscyanopropyl cyanopropylphenyl polysiloxane column. The relative positioning of the methyl and acetyl functionalities, along with the deuterium label, yielded species that have distinctive retention time indices and mass spectra that can be compared to published databases. In this way, the derivatives of the monomeric units indicated how each monomer was originally linked in the dextran polymer and whether the monomer was a branch point. The results of analyzing these samples (dextran initially dissolved in DMSO or DMSO/5% LiCl) are provided in Table 4.

Table 4
Linkage Profile of Gtf 0768 Dextran Product

Sample	Wt%/Mol% of Glucose Monomers in Dextran				
	3-glc ^a	6-glc ^b	4-glc ^c	3,6-glc ^d	2,6- + 4,6-glc ^e
DMSO	0.4	90.2	0.4	8.3	0.7
DMSO/5% LiCl	0.9	89.3	0.4	8.0	1.4

^a Glucose monomer linked at carbon positions 1 and 3.

^b Glucose monomer linked at carbon positions 1 and 6.

^c Glucose monomer linked at carbon positions 1 and 4.

^d Glucose monomer linked at carbon positions 1, 3 and 6.

^e Glucose monomer linked at carbon positions 1, 2 and 6, or 1, 4 and 6.

In general, the results in Table 4 indicate that the dextran product

analyzed above comprises:

- (i) about 87-93 wt% glucose linked only at positions 1 and 6;
- (ii) about 0.1-1.2 wt% glucose linked only at positions 1 and 3;
- (iii) about 0.1-0.7 wt% glucose linked only at positions 1 and 4;
- (iv) about 7.7-8.6 wt% glucose linked only at positions 1, 3 and 6; and
- (v) about 0.4-1.7 wt% glucose linked only at (a) positions 1, 2 and 6, or (b) positions 1, 4 and 6.

Based on this information and some other studies (data not shown), it is contemplated that this product is a branched structure in which there are long chains (containing mostly or all alpha-1,6-linkages) of about 20 DP in length (average) that iteratively branch from each other (e.g., a long chain can be a branch from another long chain, which in turn can itself be a branch from another long chain, and so on). The branched structure also appears to comprise short branches from the long chains; these short chains are believed to be 1-3 DP in length and mostly comprise alpha-1,3 and -1,4 linkages, for example. Branch points in the dextran, whether from a long chain branching from another long chain, or a short chain branching from a long chain, appear to comprise alpha-1,3, -1,4, or -1,2 linkages off of a glucose involved in alpha-1,6 linkage. Roughly 25% of all the branch points of the dextran branched into a long chain.

Thus, reactions comprising water, sucrose and an enzyme comprising SEQ ID NO:1 synthesized a very large gelling dextran product, as determined by the product's high Mw and predominant alpha-1,6 glucosidic linkage profile.

EXAMPLE 10

5 Formulation Comprising Dextran Synthesized by Gtf 0768

This Example discloses a formulation comprising the dextran product of gtf 0768. This formulation was shown to have better sensory characteristics (or “feel”) compared to formulations comprising certain compounds (xanthan gum, Carbopol®) commonly used for providing viscosity to certain consumer products
10 (e.g., personal care compositions such as lotion).

Three different emulsions were prepared and compared against each other in a skinfeel study, as follows.

Dextran-Based Emulsion: Dextran was produced using gtf 0768 (comprising SEQ ID NO:1) in a reaction similar to the reaction disclosed in
15 Example 9. At room temperature, polysorbate 80, sorbitan monooleate and mineral oil (Phase B, Table 5) were combined in a small vessel, and mixed by hand until homogeneous. Phase B was slowly added to water (Phase A, Table 5) under moderate propeller mixing. The mixture was homogenized at 5000-9000 rpm for approximately 5-10 minutes. Dextran (Phase C, Table 5) was then
20 added under moderate propeller mixing. Germaben® II (Phase D, Table 5) was then added as a preservative under moderate propeller mixing. The dextran could optionally have been pre-hydrated using a portion of the water from phase A.

Table 5
Dextran-Based Emulsion

Ingredients	% Activity	wt % (Desired)	wt % (Neat)	Grams
Phase A				
Water (deionized)			73.50	73.50
Phase B				
Polysorbate 80	100.00	2.43	2.43	2.43
Sorbitan Monooleate	100.00	2.57	2.57	2.57
Mineral Oil	100.00	20.00	20.00	20.00
Phase C				
Dextran	100.00	1.00	1.00	1.00
Phase D				
Germaben® II	100.00	0.50	0.50	0.50
			100.00	100.00

- 5 **Xanthan Gum-Based Emulsion (Control 1):** At room temperature, xanthan gum and water (Phase A, Table 6) were combined under moderate propeller mixing until homogeneous. Polysorbate 80, sorbitan monooleate and mineral oil (Phase B, Table 6) were combined in a small vessel, and mixed by hand until homogeneous. Phase B was slowly added to Phase A under
- 10 moderate propeller mixing. The mixture was homogenized at 5000-9000 rpm for approximately 5-10 minutes. Germaben® II (Phase C, Table 6) was then added as a preservative under moderate propeller mixing.

Table 6
Xanthan Gum-Based Emulsion

Ingredients	% Activity	wt % (Desired)	wt % (Neat)	Grams
Phase A				
Water (deionized)			74.00	74.00
Xanthan Gum	100.00	0.50	0.50	0.50
Phase B				
Polysorbate 80	100.00	2.43	2.43	2.43
Sorbitan Monooleate	100.00	2.57	2.57	2.57
Mineral Oil	100.00	20.00	20.00	20.00
Phase C				
Germaben [®] II	100.00	0.50	0.50	0.50
			100.00	100.00

- 5 **Carbopol[®] Ultrez 10-Based Emulsion (Control 2):** At room temperature, Carbopol[®] Ultrez 10 and water (Phase A, Table 7) were combined under moderate propeller mixing until homogeneous. Polysorbate 80, sorbitan monooleate and mineral oil (Phase B, Table 7) were combined in a small vessel, and mixed by hand until homogeneous. Phase B was slowly added to Phase A
- 10 under moderate propeller mixing. The mixture was homogenized at 5000-9000 rpm for approximately 5-10 minutes. Germaben[®] II (Phase C, Table 7) was then added as a preservative under moderate propeller mixing. A 20-wt% solution of sodium hydroxide was used to neutralize the emulsion to pH 5.5.

Table 7
Carbopol® Ultrez 10-Based Emulsion

Ingredients	% Activity	wt % (Desired)	wt % (Neat)	Grams
Phase A				
Water (deionized)			74.00	74.00
Carbopol® Ultrez 10	100.00	0.50	0.50	0.50
Phase B				
Polysorbate 80	100.00	2.43	2.43	2.43
Sorbitan Monooleate	100.00	2.57	2.57	2.57
Mineral Oil	100.00	20.00	20.00	20.00
Phase C				
Germaben® II	100.00	0.50	0.50	0.50
			100.00	100.00

- 5 **Skinfeel Analysis and Results:** A double-blind, skinfeel analysis was performed according to ASTM E1490-3 (“Standard Practice for Descriptive Skinfeel Analysis of Creams and Lotions”, ASTM International, West Conshohocken, PA, 2003, DOI: 10.1520/E1490-03, incorporated herein by reference) to compare each of the above emulsions. The primary attributes
- 10 evaluated in this study were rub-out sliminess, afterfeel stickiness, pick-up stringiness and pick-up stickiness. Panelists assessed attributes on a scale from 1-5, where 1 exhibits the least of the attribute and 5 exhibits the most of the attribute. The results are reported in Table 8 below as an average value of the panelists’ ratings for each attribute. The sum average of these values (Σ , Table
- 15 8) indicates that the overall sensory experience for emulsions (e.g., lotions) produced with dextran as presently disclosed exceeds the results of similar emulsions produced with either xanthan gum or Carbopol® Ultrez 10.

Table 8
Carbopol® Ultrez 10-Based Emulsion

Skinfeel Attribute	Average Rating		
	Dextran	Xanthan Gum	Carbopol® Ultrez 10
Rub-Out Sliminess	2	3	2
Afterfeel Stickiness	2	2	3
Pick-Up Stringiness	1	3	3
Pick-Up Stickiness	2	3	2
Σ	7	11	10

It is noteworthy that the dextran-containing emulsion scored better than the control emulsions in the skinfeel analysis, especially since there was two-times the amount of dextran (1 wt%) in the emulsion compared to the amount of xanthan gum (0.5 wt%) or Carbopol® Ultrez 10 (0.5 wt%) in the control emulsions.

Thus, dextran produced by gtf 0768 (comprising SEQ ID NO:1) can be suitable for use in compositions where enhanced sensory characteristics are desirable, such as in personal care and food products, for example.

EXAMPLE 11

Dextran-Comprising Cleanser with Suspended Particles

This Example discloses a cleanser comprising the dextran product of gtf 0768. Jojoba ester beads could be suspended in this composition, indicating that the dextran can function as a dispersant.

Dextran was produced using gtf 0768 (comprising SEQ ID NO:1) in a reaction similar to the reaction disclosed in Example 9. At room temperature water, dextran, glycerin, polysorbate 20, cocamidopropyl betaine, PPG-2 hydroxyethyl cocamide and disodium EDTA were combined according to the formulation in Table 9, and mixed by hand until homogeneous. Jojoba beads were then added and mixing was continued until the beads were homogeneously dispersed. The dextran could optionally have been pre-hydrated using a portion of the water component.

Table 9
Dextran-Based Jojoba Bead Suspension

Ingredient	% Activity	wt% (Desired)	wt% (Neat)	Grams
Water (deionized)			22.95	22.95
Dextran	100	5	5	5
Glycerin	100	10	10	10
Polysorbate 20	100	5.25	5.25	5.25
Cocamidopropyl Betaine	35.97	20	55.6	55.6
PPG-2 Hydroxyethyl Cocamide	100	1	1	1
Disodium EDTA	100	0.1	0.1	0.1
Jojoba Ester Beads	100	0.1	0.1	0.1
			100	100

Thus, dextran produced by gtf 0768 (comprising SEQ ID NO:1) can be
5 used as a dispersant in aqueous compositions such as certain personal care
products.

The claims defining the invention are as follows:

1. A composition comprising dextran, wherein said dextran comprises:

- (i) about 87-93 wt% glucose linked at positions 1 and 6;
- (ii) about 0.1-1.2 wt% glucose linked at positions 1 and 3;
- (iii) about 0.1-0.7 wt% glucose linked at positions 1 and 4;
- (iv) about 7.7-8.6 wt% glucose linked at positions 1, 3 and 6; and
- (v) about 0.4-1.7 wt% glucose linked at:
 - (a) positions 1, 2 and 6, or
 - (b) positions 1, 4 and 6;

wherein the weight-average molecular weight (Mw) of said dextran is about 50-200 million Daltons, and the z-average radius of gyration of said dextran is about 200-280 nm.

2. The composition of claim 1, wherein the dextran comprises:


- (i) about 89.5-90.5 wt% glucose linked at positions 1 and 6;
- (ii) about 0.4-0.9 wt% glucose linked at positions 1 and 3;
- (iii) about 0.3-0.5 wt% glucose linked at positions 1 and 4;
- (iv) about 8.0-8.3 wt% glucose linked at positions 1, 3 and 6; and
- (v) about 0.7-1.4 wt% glucose linked at:
 - (a) positions 1, 2 and 6, or
 - (b) positions 1, 4 and 6.

3. The composition of claim 1 or claim 2, wherein the dextran comprises chains linked together within a branching structure, wherein said chains are similar in length and comprise substantially alpha-1,6-glucosidic linkages.

4. The composition of claim 3, wherein the average length of the chains is about 10-50 monomeric units.

5. The composition of any one of claims 1 to 4, wherein the dextran is a product of a glucosyltransferase enzyme comprising an amino acid sequence that is at least 90% identical to SEQ ID NO:1 or SEQ ID NO:2.
6. The composition of any one of claims 1 to 5, wherein the composition is an aqueous composition.
7. The composition of any one of claims 1 to 6, wherein the Mw of the dextran is about 80-120 million Daltons.
8. The composition of any one of claims 1 to 7, wherein the z-average radius of gyration of said dextran is about 230-250 nm.
9. The composition of any one of claims 1 to 8, wherein the composition is in the form of a food product, personal care product, pharmaceutical product, household product, or industrial product.
10. The composition of claim 9, wherein the composition is in the form of a confectionery.
11. An isolated enzymatic reaction comprising water, sucrose and a glucosyltransferase enzyme comprising an amino acid sequence that is at least 90% identical to SEQ ID NO:1 or SEQ ID NO:2, wherein the glucosyltransferase enzyme synthesizes dextran.
12. The isolated enzymatic reaction of claim 11, wherein the reaction is (i) cell-free and/or (ii) comprises only one glucosyltransferase.
13. The isolated enzymatic reaction of claim 11 or claim 12, wherein the glucosyltransferase enzyme comprises an amino acid sequence that is at least 95% identical to SEQ ID NO:1 or SEQ ID NO:2

- 5
14. A method for producing dextran, said method comprising:
contacting at least water, sucrose, and a glucosyltransferase enzyme in an
isolated reaction, wherein the glucosyltransferase enzyme comprises an
amino acid sequence that is at least 90% identical to SEQ ID NO:1 or SEQ
ID NO:2, whereby dextran is produced.
15. The method of claim 14 further comprising the step of isolating the dextran
produced.
- 0
16. The method of claim 14 or claim 15, wherein the reaction is (i) cell-free
and/or (ii) comprises only one glucosyltransferase.
- 5
17. The method of any one of claims 14 to 16, wherein the glucosyltransferase
enzyme comprises an amino acid sequence that is at least 95% identical to
SEQ ID NO:1 or SEQ ID NO:2.
- 0
18. The method of any one of claims 14 to 17, wherein the viscosity of the
dextran produced in the method is increased by decreasing the amount of
sucrose.
19. Dextran as produced in the isolated enzymatic reaction of any one of claims
11 to 13, or as produced by the method of any one of claims 14 to 18.
- 25
20. A method for increasing the viscosity of an aqueous composition, the
method comprising:
contacting dextran according to any one of claims 1 to 5, 7, 8, or 19 with
the aqueous composition, wherein the viscosity of the aqueous composition
is increased by said dextran compared to the viscosity of the aqueous
composition before the contacting step.
- 30
21. A method of treating a material, said method comprising:
contacting a material with an aqueous composition comprising dextran
according to any one of claims 1 to 5, 7, 8, or 19.

**FIG. 1**




FIG. 2A




FIG. 2B




FIG. 2C




FIG. 2D




FIG. 3

20151105_CL6294WOPCT_SequenceListing
SEQUENCE LISTING

<110> E. I. du Pont de Nemours and Company
Nambiar, Rakesh

<120> ENZYMATICALLY POLYMERIZED GELLING DEXTRANS

<130> CL6294

<150> US 62/075,460
<151> 2014-11-05

<160> 18

<170> PatentIn version 3.5

<210> 1
<211> 1447
<212> PRT
<213> Leuconostoc pseudomesenteroides

<220>
<221> MISC_FEATURE
<222> (1)..(1447)
<223> mature 0768 gtf

<400> 1

Asp	Gln	Asn	Val	Asn	Asp	Pro	Ser	Val	Ala	Thr	Thr	Thr	Gln	Asn	Val
1				5					10					15	
Val	Thr	Asp	Gln	Asp	Thr	Ser	Ile	Asp	Ala	Ser	Val	Ala	Thr	Thr	Val
			20					25					30		
Asn	Pro	Asn	Leu	Asp	Asp	Thr	Gln	Ala	Asp	Asn	Thr	Asn	Ile	Gln	Thr
		35					40					45			
Pro	Thr	Asp	Gln	Asn	Asp	Glu	Ser	Lys	Asp	Thr	Thr	Pro	Lys	Val	Glu
	50					55					60				
Thr	Gly	Asp	Thr	Thr	Asn	Ser	Gln	Ser	Thr	Glu	Ala	Gln	Glu	Thr	Thr
65					70					75					80
Ala	Gln	Thr	Asn	Asn	Asp	Val	Glu	Thr	Pro	Gln	Asn	Ser	Asp	Ala	Ala
			85						90					95	
Ile	Glu	Thr	Gly	Leu	Leu	Thr	Thr	Asn	Gln	Ile	Arg	Tyr	Val	Asn	
			100					105					110		
Pro	Asp	Gly	Thr	Val	Leu	Thr	Gly	Ala	Tyr	Lys	Thr	Ile	Asn	Gly	Asn
		115					120					125			
Thr	Tyr	Tyr	Phe	Asp	Asp	Asp	Ser	Gly	Val	Ala	Leu	Val	Gly	Leu	His
	130					135					140				
Lys	Ile	Gly	Asp	Thr	Leu	Lys	Gly	Phe	Ser	Leu	Asn	Gly	Val	Gln	Val
145					150					155					160
Lys	Gly	Asp	Tyr	Leu	Thr	Ala	Ala	Asn	Gly	Asp	Lys	Tyr	Tyr	Phe	Asp
			165						170					175	
Ser	Asn	Gly	Asn	Ala	Val	Ser	Gly	Val	Gln	Gln	Ile	Asn	Gly	Lys	Thr
			180					185					190		
Tyr	Tyr	Phe	Asp	Ser	Thr	Gly	Lys	Leu	Met	Lys	Gly	Tyr	Thr	Ala	Val
		195					200					205			
Leu	Asn	Gly	Val	Val	Thr	Phe	Phe	Asn	Ser	Thr	Thr	Gly	Glu	Ala	Asp
	210					215					220				
Asn	Thr	Asp	Ala	Ser	Thr	Ile	Lys	Thr	Gly	Val	Thr	Ile	Asp	Asn	Ser
225					230					235					240
Asp	Tyr	Thr	Val	His	Asn	Ala	Ala	Tyr	Asp	Asn	Thr	Ala	Ala	Ser	Phe
			245						250					255	
Asp	Asn	Ile	Asn	Gly	Tyr	Leu	Thr	Ala	Glu	Ser	Trp	Tyr	Arg	Pro	Lys
			260					265					270		
Glu	Ile	Leu	Glu	Asn	Gly	Glu	Ser	Trp	Arg	Pro	Ser	Thr	Ala	Glu	Asp
	275						280					285			
Lys	Arg	Pro	Ile	Leu	Ile	Thr	Trp	Gln	Pro	Asp	Ile	Val	Thr	Glu	Val
	290					295					300				
Asn	Tyr	Leu	Asn	Met	Met	Ala	Ala	Asn	Gly	Leu	Leu	Ser	Ile	Asn	Ala

20151105_CL6294WOPCT_SequenceListing

305	Pro	Phe	Thr	Thr	Ala	310	Ser	Asp	Leu	Ala	Ile	315	Met	Asn	Asp	Ala	Val	320	Arg
					325							330						335	
Ala	Val	Gln	Lys	Asn	Ile	Glu	Met	Arg	Ile	Ser	Gln	Glu	Lys	Ser	Thr				
			340																
Asp	Trp	Leu	Lys	Ala	Leu	Met	Thr	Gln	Phe	Ile	Asn	Thr	Gln	Pro	Gln				
		355																	
Trp	Asn	Glu	Val	Ser	Glu	Ser	Pro	Ser	Asn	Asp	His	Leu	Gln	Gly	Gly				
		370																	
Ala	Leu	Thr	Tyr	Val	Asn	Ser	Pro	Leu	Thr	Pro	Asp	Ala	Asn	Ser	Asn				
					390														
Phe	Arg	Leu	Leu	Asn	Arg	Thr	Pro	Thr	Asn	Gln	Ser	Gly	Thr	Thr	Arg				
				405															
Tyr	Asp	Thr	Asp	Lys	Ser	Lys	Gly	Gly	Phe	Glu	Leu	Leu	Leu	Ala	Asn				
			420																
Asp	Val	Asp	Asn	Ser	Asn	Pro	Val	Val	Gln	Ala	Glu	Gln	Leu	Asn	Trp				
		435																	
Leu	Tyr	Tyr	Leu	Met	Asn	Phe	Gly	Ser	Ile	Thr	Ala	Asn	Asp	Pro	Thr				
		450																	
Ala	Asn	Phe	Asp	Gly	Ile	Arg	Val	Asp	Ala	Val	Asp	Asn	Val	Asp	Ala				
					470														
Asp	Leu	Leu	Gln	Ile	Ala	Ser	Asp	Tyr	Phe	Lys	Leu	Ala	Tyr	Gly	Thr				
				485															
Ser	Leu	Ser	Asp	Thr	Asn	Ala	Asn	Gln	His	Leu	Ser	Ile	Leu	Glu	Asp				
			500																
Trp	Ser	Ala	Asn	Asp	Ala	Glu	Tyr	Met	Ser	Lys	Thr	Gly	Ser	Asn	Gln				
		515																	
Leu	Thr	Met	Asp	Thr	Tyr	Thr	Gln	Gln	Gln	Leu	Leu	Phe	Ser	Leu	Thr				
		530																	
Lys	Gln	Val	Gly	Asn	Arg	Ala	Asp	Met	Arg	Arg	Phe	Leu	Glu	Tyr	Phe				
					550														
Met	Ile	Asn	Arg	Ala	Asn	Asp	Ser	Thr	Glu	Asn	Val	Ala	Thr	Pro	Asn				
				565															
Tyr	Ser	Phe	Val	Arg	Ala	His	Asp	Ser	Glu	Val	Gln	Thr	Val	Ile	Ala				
			580																
Thr	Ile	Ile	Lys	Asp	Leu	His	Pro	Asp	Val	Val	Asn	Ser	Leu	Ala	Pro				
		595																	
Thr	Gln	Ala	Gln	Leu	Glu	Glu	Ala	Phe	Ala	Val	Tyr	Asn	Ala	Asp	Met				
		610																	
Asn	Arg	Val	Asp	Lys	Gln	Tyr	Thr	Gln	Tyr	Asn	Met	Pro	Ser	Ala	Tyr				
					630														
Ala	Met	Leu	Leu	Thr	Asn	Lys	Asp	Thr	Ile	Pro	Arg	Val	Tyr	Tyr	Gly				
				645															
Asp	Leu	Tyr	Thr	Asp	Asp	Gly	Glu	Tyr	Met	Gly	Thr	Gln	Thr	Pro	Tyr				
			660																
Tyr	Asp	Ala	Ile	Val	Asn	Leu	Leu	Gln	Ser	Arg	Val	Lys	Tyr	Val	Ala				
		675																	
Gly	Gly	Gln	Ser	Met	Ala	Val	Asp	Gln	His	Asp	Ile	Leu	Thr	Ser	Val				
		690																	
Arg	Tyr	Gly	Lys	Asn	Leu	Ala	Asp	Ala	Asn	Ala	Thr	Ser	Asp	Asp	Leu				
					710														
Thr	Ser	Ile	Asn	Ser	Gly	Ile	Gly	Val	Ile	Val	Ser	Asn	Asn	Pro	Asn				
				725															
Leu	Ser	Leu	Ala	Ser	Gly	Glu	Thr	Val	Val	Leu	His	Met	Gly	Ile	Ala				
			740																
His	Ala	Asn	Gln	Val	Tyr	Arg	Glu	Ile	Leu	Glu	Thr	Thr	Asp	Asn	Gly				
			755																
Ile	Ala	Asn	Asn	Thr	Asp	Ile	Phe	Lys	Thr	Thr	Asp	Ser	Asn	Gly	Asp				
					775														
Leu	Ile	Phe	Thr	Ala	Ser	Glu	Ile	His	Gly	Tyr	Ser	Asn	Val	Gln	Val				
					790														
Ser	Gly	Phe	Leu	Ser	Val	Trp	Ala	Pro	Lys	Asp	Ala	Thr	Asp	Asp	Gln				
				805															
Asp	Val	Arg	Thr	Ala	Ala	Ser	Glu	Ser	Thr	Ser	Asn	Asp	Gly	Asn	Thr				
			820																
Leu	His	Ser	Asn	Ala	Ala	Leu	Asp	Ser	Asn	Leu	Ile	Tyr	Glu	Gly	Phe				
			835																
Ser	Asn	Phe	Gln	Ser	Thr	Pro	Gln	Ser	Glu	Ser	Glu	Phe	Ala	Asn	Val				

	850					855					860					
Lys 865	Ile	Ala	Ala	Asn	Val 870	Asn	Leu	Phe	Lys	Ser 875	Trp	Gly	Val	Thr	Ser 880	
Phe	Gln	Met	Ala	Pro 885	Gln	Tyr	Arg	Ser	Ser 890	Thr	Asp	Thr	Ser	Phe 895	Leu	
Asp	Ser	Ile	Ile 900	Gln	Asn	Gly	Tyr	Ala 905	Phe	Thr	Asp	Arg	Tyr 910	Asp	Leu	
Gly	Phe 915	Glu	Thr	Pro	Thr	Lys	Tyr 920	Gly	Thr	Asp	Gln	Gln 925	Leu	Arg	Asp	
Ala	Ile 930	Lys	Ala	Leu	His	Ala 935	Asn	Gly	Ile	Gln	Ala 940	Met	Ala	Asp	Phe	
Val 945	Pro	Asp	Gln	Ile	Tyr 950	Asn	Leu	Pro	Gln	Thr	Glu	Leu	Val	Ser	Val 960	
Ser	Arg	Thr	Asp	Ser 965	Leu	Gly	Asn	Gln	Ser 970	Ala	Asn	Ser	Asn	Ala 975	Ala	
Asn	Val	Leu	Tyr 980	Val	Ser	His	Thr	Val 985	Gly	Gly	Gly	Glu	Tyr 990	Gln	Ser	
Lys	Tyr	Gly 995	Gly	Glu	Phe	Leu	Ala 1000	Ile	Ile	Lys	Ser	Lys 1005	Tyr	Pro	Ser	
Leu	Phe 1010	Lys	Thr	Ile	Gln	Val 1015	Ser	Thr	Gly	Leu	Pro 1020	Ile	Asp	Asp		
Ser	Thr 1025	Lys	Ile	Lys	Glu	Trp 1030	Ser	Ala	Lys	Tyr	Phe 1035	Asn	Gly	Ser		
Asn	Ile 1040	Gln	Gly	Arg	Gly	Phe 1045	Gly	Tyr	Val	Leu	Ser 1050	Asp	Gly	Gly		
Thr	Gln 1055	Asn	Tyr	Phe	Lys	Val 1060	Ile	Ser	Asn	Ser	Thr 1065	Asp	Asp	Asp		
Phe	Leu 1070	Pro	Asn	Gln	Leu	Thr 1075	Gly	Lys	Pro	Thr	Met 1080	Thr	Gly	Phe		
Glu	Gln 1085	Thr	Ser	Lys	Gly	Ile 1090	Val	Tyr	Tyr	Ser	Lys 1095	Ser	Gly	Ile		
Gln	Ala 1100	Lys	Asn	Gln	Phe	Val 1105	Lys	Asp	Asp	Val	Ser 1110	Gly	Asn	Tyr		
Tyr	Tyr 1115	Phe	Asn	Lys	Asn	Gly 1120	Leu	Met	Thr	Val	Gly 1125	Ser	Lys	Thr		
Ile	Asn 1130	Gly	Lys	Asn	Tyr	Met 1135	Phe	Leu	Pro	Asn	Gly 1140	Val	Glu	Leu		
Arg	Gly 1145	Ser	Phe	Leu	Gln	Thr 1150	Ala	Asp	Gly	Thr	Val 1155	Asn	Tyr	Tyr		
Ala	Thr 1160	Asn	Gly	Ala	Gln	Val 1165	Gln	Asp	Ser	Tyr	Val 1170	Thr	Asp	Thr		
Glu	Gly 1175	Asn	Ser	Tyr	Tyr	Phe 1180	Asp	Gly	Asp	Gly	Glu 1185	Met	Val	Thr		
Gly	Thr 1190	Tyr	Thr	Val	Asp	Gly 1195	His	Ala	Gln	Tyr	Phe 1200	Asp	Val	Asn		
Gly	Val 1205	Gln	Thr	Lys	Gly	Ala 1210	Ile	Ile	Thr	Leu	Gly 1215	Gly	Val	Gln		
Arg	Tyr 1220	Tyr	Gln	Ala	Gly	Asn 1225	Gly	Asn	Leu	Ala	Thr 1230	Asn	Gln	Tyr		
Val	Ser 1235	Tyr	Asn	Asn	Ser	Trp 1240	Tyr	Tyr	Ala	Asn	Thr 1245	Lys	Gly	Glu		
Leu	Val 1250	Thr	Gly	Val	Gln	Ser 1255	Ile	Asn	Gly	Asn	Val 1260	Gln	Tyr	Phe		
Ala	Ser 1265	Asn	Gly	Gln	Gln	Ile 1270	Lys	Gly	Gln	Ile	Val 1275	Val	Thr	Gly		
Asn	Gln 1280	Lys	Ser	Tyr	Tyr	Asp 1285	Ala	Asn	Thr	Gly	Asn 1290	Leu	Ile	Lys		
Asn	Asp 1295	Phe	Leu	Thr	Pro	Asp 1300	Gln	Gly	Lys	Thr	Trp 1305	Tyr	Tyr	Ala		
Asp	Gln 1310	Asp	Gly	Asn	Leu	Val 1315	Val	Gly	Ala	Gln	Glu 1320	Val	Asn	Gly		
His	Lys 1325	Leu	Tyr	Phe	Asp	Asp 1330	Asn	Gly	Ile	Gln	Ile 1335	Lys	Asp	Gln		
Ile	Ile 1340	Ser	Asn	Asp	Gly	Gln 1345	Gln	Tyr	Tyr	Tyr	Gln 1350	Gly	Gly	Asn		
Gly	Asp 1355	Leu	Val	Thr	Asn	Arg 1360	Tyr	Ile	Ser	Tyr	Asn 1365	Asp	Ser	Trp		
Tyr	Tyr															

20151105_CL6294WOPCT_SequenceListing

1370	Ile Asn Gly Glu Thr Gln Tyr Phe Arg Thr Asp Gly Arg Gln Val	1375	1380
1385	Lys Gly Gln Ile Ile Ala Asp Gly Asp Lys Gln His Tyr Tyr Asp	1390	1395
1400	Ala Asp Ser Gly Asn Leu Val Lys Asn Asn Phe Val Thr Val Asp	1405	1410
1415	Gln Gly Lys Thr Trp Tyr Tyr Ala Asp Gln Asp Gly Asn Leu Ser	1420	1425
1430	Leu Val Asp Arg	1435	1440
1445			

<210> 2
 <211> 1457
 <212> PRT
 <213> Artificial sequence

<220>
 <223> 0768 gtf mature protein with start codon and other added sequences

<400> 2

Met Ala Ser Ala Asp Gln Asn Val Asn Asp Pro Ser Val Ala Thr Thr	1	5	10	15
Thr Gln Asn Val Val Thr Asp Gln Asp Thr Ser Ile Asp Ala Ser Val	20	25	30	
Ala Thr Thr Val Asn Pro Asn Leu Asp Asp Thr Gln Ala Asp Asn Thr	35	40	45	
Asn Ile Gln Thr Pro Thr Asp Gln Asn Asp Glu Ser Lys Asp Thr Thr	50	55	60	
Pro Lys Val Glu Thr Gly Asp Thr Thr Asn Ser Ser Thr Glu Ala	65	70	75	80
Gln Glu Thr Thr Ala Gln Thr Asn Asn Asp Val Glu Thr Pro Gln Asn	85	90	95	
Ser Asp Ala Ala Ile Glu Thr Gly Leu Leu Thr Thr Asn Asn Gln Ile	100	105	110	
Arg Tyr Val Asn Pro Asp Gly Thr Val Leu Thr Gly Ala Tyr Lys Thr	115	120	125	
Ile Asn Gly Asn Thr Tyr Tyr Phe Asp Asp Asp Ser Gly Val Ala Leu	130	135	140	
Val Gly Leu His Lys Ile Gly Asp Thr Leu Lys Gly Phe Ser Leu Asn	145	150	155	160
Gly Val Gln Val Lys Gly Asp Tyr Leu Thr Ala Ala Asn Gly Asp Lys	165	170	175	
Tyr Tyr Phe Asp Ser Asn Gly Asn Ala Val Ser Gly Val Gln Gln Ile	180	185	190	
Asn Gly Lys Thr Tyr Tyr Phe Asp Ser Thr Gly Lys Leu Met Lys Gly	195	200	205	
Tyr Thr Ala Val Leu Asn Gly Val Val Thr Phe Phe Asn Ser Thr Thr	210	215	220	
Gly Glu Ala Asp Asn Thr Asp Ala Ser Thr Ile Lys Thr Gly Val Thr	225	230	235	240
Ile Asp Asn Ser Asp Tyr Thr Val His Asn Ala Ala Tyr Asp Asn Thr	245	250	255	
Ala Ala Ser Phe Asp Asn Ile Asn Gly Tyr Leu Thr Ala Glu Ser Trp	260	265	270	
Tyr Arg Pro Lys Glu Ile Leu Glu Asn Gly Glu Ser Trp Arg Pro Ser	275	280	285	
Thr Ala Glu Asp Lys Arg Pro Ile Leu Ile Thr Trp Gln Pro Asp Ile	290	295	300	
Val Thr Glu Val Asn Tyr Leu Asn Met Met Ala Ala Asn Gly Leu Leu	305	310	315	320
Ser Ile Asn Ala Pro Phe Thr Thr Ala Ser Asp Leu Ala Ile Met Asn	325	330	335	
Asp Ala Val Arg Ala Val Gln Lys Asn Ile Glu Met Arg Ile Ser Gln	340	345	350	
Glu Lys Ser Thr Asp Trp Leu Lys Ala Leu Met Thr Gln Phe Ile Asn	355	360	365	

20151105_CL6294WOPCT_SequenceListing

Thr	Gln	Pro	Gln	Trp	Asn	Glu	Val	Ser	Glu	Ser	Pro	Ser	Asn	Asp	His
370						375					380				
Leu	Gln	Gly	Gly	Ala	Leu	Thr	Tyr	Val	Asn	Ser	Pro	Leu	Thr	Pro	Asp
385					390					395					400
Ala	Asn	Ser	Asn	Phe	Arg	Leu	Leu	Asn	Arg	Thr	Pro	Thr	Asn	Gln	Ser
				405					410					415	
Gly	Thr	Thr	Arg	Tyr	Asp	Thr	Asp	Lys	Ser	Lys	Gly	Gly	Phe	Glu	Leu
			420					425					430		
Leu	Leu	Ala	Asn	Asp	Val	Asp	Asn	Ser	Asn	Pro	Val	Val	Gln	Ala	Glu
		435					440					445			
Gln	Leu	Asn	Trp	Leu	Tyr	Tyr	Leu	Met	Asn	Phe	Gly	Ser	Ile	Thr	Ala
450					455					460					
Asn	Asp	Pro	Thr	Ala	Asn	Phe	Asp	Gly	Ile	Arg	Val	Asp	Ala	Val	Asp
465					470					475					480
Asn	Val	Asp	Ala	Asp	Leu	Leu	Gln	Ile	Ala	Ser	Asp	Tyr	Phe	Lys	Leu
				485					490					495	
Ala	Tyr	Gly	Thr	Ser	Leu	Ser	Asp	Thr	Asn	Ala	Asn	Gln	His	Leu	Ser
			500					505					510		
Ile	Leu	Glu	Asp	Trp	Ser	Ala	Asn	Asp	Ala	Glu	Tyr	Met	Ser	Lys	Thr
		515					520					525			
Gly	Ser	Asn	Gln	Leu	Thr	Met	Asp	Thr	Tyr	Thr	Gln	Gln	Gln	Leu	Leu
530					535						540				
Phe	Ser	Leu	Thr	Lys	Gln	Val	Gly	Asn	Arg	Ala	Asp	Met	Arg	Arg	Phe
545				550						555					560
Leu	Glu	Tyr	Phe	Met	Ile	Asn	Arg	Ala	Asn	Asp	Ser	Thr	Glu	Asn	Val
				565					570					575	
Ala	Thr	Pro	Asn	Tyr	Ser	Phe	Val	Arg	Ala	His	Asp	Ser	Glu	Val	Gln
			580					585					590		
Thr	Val	Ile	Ala	Thr	Ile	Ile	Lys	Asp	Leu	His	Pro	Asp	Val	Val	Asn
		595					600					605			
Ser	Leu	Ala	Pro	Thr	Gln	Ala	Gln	Leu	Glu	Glu	Ala	Phe	Ala	Val	Tyr
610					615						620				
Asn	Ala	Asp	Met	Asn	Arg	Val	Asp	Lys	Gln	Tyr	Thr	Gln	Tyr	Asn	Met
625				630						635					640
Pro	Ser	Ala	Tyr	Ala	Met	Leu	Leu	Thr	Asn	Lys	Asp	Thr	Ile	Pro	Arg
				645					650					655	
Val	Tyr	Tyr	Gly	Asp	Leu	Tyr	Thr	Asp	Gly	Glu	Tyr	Met	Gly	Thr	
			660					665				670			
Gln	Thr	Pro	Tyr	Tyr	Asp	Ala	Ile	Val	Asn	Leu	Leu	Gln	Ser	Arg	Val
		675					680					685			
Lys	Tyr	Val	Ala	Gly	Gly	Gln	Ser	Met	Ala	Val	Asp	Gln	His	Asp	Ile
690					695						700				
Leu	Thr	Ser	Val	Arg	Tyr	Gly	Lys	Asn	Leu	Ala	Asp	Ala	Asn	Ala	Thr
705					710					715					720
Ser	Asp	Asp	Leu	Thr	Ser	Ile	Asn	Ser	Gly	Ile	Gly	Val	Ile	Val	Ser
				725					730					735	
Asn	Asn	Pro	Asn	Leu	Ser	Leu	Ala	Ser	Gly	Glu	Thr	Val	Val	Leu	His
			740					745					750		
Met	Gly	Ile	Ala	His	Ala	Asn	Gln	Val	Tyr	Arg	Glu	Ile	Leu	Glu	Thr
		755					760					765			
Thr	Asp	Asn	Gly	Ile	Ala	Asn	Asn	Thr	Asp	Ile	Phe	Lys	Thr	Thr	Asp
					775					780					
Ser	Asn	Gly	Asp	Leu	Ile	Phe	Thr	Ala	Ser	Glu	Ile	His	Gly	Tyr	Ser
785				790						795					800
Asn	Val	Gln	Val	Ser	Gly	Phe	Leu	Ser	Val	Trp	Ala	Pro	Lys	Asp	Ala
				805					810					815	
Thr	Asp	Asp	Gln	Asp	Val	Arg	Thr	Ala	Ala	Ser	Glu	Ser	Thr	Ser	Asn
			820					825					830		
Asp	Gly	Asn	Thr	Leu	His	Ser	Asn	Ala	Ala	Leu	Asp	Ser	Asn	Leu	Ile
		835					840					845			
Tyr	Glu	Gly	Phe	Ser	Asn	Phe	Gln	Ser	Thr	Pro	Gln	Ser	Glu	Ser	Glu
850					855						860				
Phe	Ala	Asn	Val	Lys	Ile	Ala	Ala	Asn	Val	Asn	Leu	Phe	Lys	Ser	Trp
865					870					875					880
Gly	Val	Thr	Ser	Phe	Gln	Met	Ala	Pro	Gln	Tyr	Arg	Ser	Ser	Thr	Asp
				885					890					895	
Thr	Ser	Phe	Leu	Asp	Ser	Ile	Ile	Gln	Asn	Gly	Tyr	Ala	Phe	Thr	Asp
			900					905					910		

20151105_CL6294WOPCT_SequenceListing

Arg	Tyr	Asp	Leu	Gly	Phe	Glu	Thr	Pro	Thr	Lys	Tyr	Gly	Thr	Asp	Gln
		915					920					925			
Gln	Leu	Arg	Asp	Ala	Ile	Lys	Ala	Leu	His	Ala	Asn	Gly	Ile	Gln	Ala
	930					935					940				
Met	Ala	Asp	Phe	Val	Pro	Asp	Gln	Ile	Tyr	Asn	Leu	Pro	Gln	Thr	Glu
945					950					955					960
Leu	Val	Ser	Val	Ser	Arg	Thr	Asp	Ser	Leu	Gly	Asn	Gln	Ser	Ala	Asn
				965					970					975	
Ser	Asn	Ala	Ala	Asn	Val	Leu	Tyr	Val	Ser	His	Thr	Val	Gly	Gly	Gly
			980					985					990		
Glu	Tyr	Gln	Ser	Lys	Tyr	Gly	Gly	Glu	Phe	Leu	Ala	Ile	Ile	Lys	Ser
		995					1000						1005		
Lys	Tyr	Pro	Ser	Leu	Phe	Lys	Thr	Ile	Gln	Val	Ser	Thr	Gly	Leu	
	1010					1015						1020			
Pro	Ile	Asp	Asp	Ser	Thr	Lys	Ile	Lys	Glu	Trp	Ser	Ala	Lys	Tyr	
	1025					1030						1035			
Phe	Asn	Gly	Ser	Asn	Ile	Gln	Gly	Arg	Gly	Phe	Gly	Tyr	Val	Leu	
	1040					1045						1050			
Ser	Asp	Gly	Gly	Thr	Gln	Asn	Tyr	Phe	Lys	Val	Ile	Ser	Asn	Ser	
	1055					1060						1065			
Thr	Asp	Asp	Asp	Phe	Leu	Pro	Asn	Gln	Leu	Thr	Gly	Lys	Pro	Thr	
	1070					1075						1080			
Met	Thr	Gly	Phe	Glu	Gln	Thr	Ser	Lys	Gly	Ile	Val	Tyr	Tyr	Ser	
	1085					1090						1095			
Lys	Ser	Gly	Ile	Gln	Ala	Lys	Asn	Gln	Phe	Val	Lys	Asp	Asp	Val	
	1100					1105						1110			
Ser	Gly	Asn	Tyr	Tyr	Tyr	Phe	Asn	Lys	Asn	Gly	Leu	Met	Thr	Val	
	1115					1120						1125			
Gly	Ser	Lys	Thr	Ile	Asn	Gly	Lys	Asn	Tyr	Met	Phe	Leu	Pro	Asn	
	1130					1135						1140			
Gly	Val	Glu	Leu	Arg	Gly	Ser	Phe	Leu	Gln	Thr	Ala	Asp	Gly	Thr	
	1145					1150						1155			
Val	Asn	Tyr	Tyr	Ala	Thr	Asn	Gly	Ala	Gln	Val	Gln	Asp	Ser	Tyr	
	1160					1165						1170			
Val	Thr	Asp	Thr	Glu	Gly	Asn	Ser	Tyr	Tyr	Phe	Asp	Gly	Asp	Gly	
	1175					1180						1185			
Glu	Met	Val	Thr	Gly	Thr	Tyr	Thr	Val	Asp	Gly	His	Ala	Gln	Tyr	
	1190					1195						1200			
Phe	Asp	Val	Asn	Gly	Val	Gln	Thr	Lys	Gly	Ala	Ile	Ile	Thr	Leu	
	1205					1210						1215			
Gly	Gly	Val	Gln	Arg	Tyr	Tyr	Gln	Ala	Gly	Asn	Gly	Asn	Leu	Ala	
	1220					1225						1230			
Thr	Asn	Gln	Tyr	Val	Ser	Tyr	Asn	Asn	Ser	Trp	Tyr	Tyr	Ala	Asn	
	1235					1240						1245			
Thr	Lys	Gly	Glu	Leu	Val	Thr	Gly	Val	Gln	Ser	Ile	Asn	Gly	Asn	
	1250					1255						1260			
Val	Gln	Tyr	Phe	Ala	Ser	Asn	Gly	Gln	Gln	Ile	Lys	Gly	Gln	Ile	
	1265					1270						1275			
Val	Val	Thr	Gly	Asn	Gln	Lys	Ser	Tyr	Tyr	Asp	Ala	Asn	Thr	Gly	
	1280					1285						1290			
Asn	Leu	Ile	Lys	Asn	Asp	Phe	Leu	Thr	Pro	Asp	Gln	Gly	Lys	Thr	
	1295					1300						1305			
Trp	Tyr	Tyr	Ala	Asp	Gln	Asp	Gly	Asn	Leu	Val	Val	Gly	Ala	Gln	
	1310					1315						1320			
Glu	Val	Asn	Gly	His	Lys	Leu	Tyr	Phe	Asp	Asp	Asn	Gly	Ile	Gln	
	1325					1330						1335			
Ile	Lys	Asp	Gln	Ile	Ile	Ser	Asn	Asp	Gly	Gln	Gln	Tyr	Tyr	Tyr	
	1340					1345						1350			
Gln	Gly	Gly	Asn	Gly	Asp	Leu	Val	Thr	Asn	Arg	Tyr	Ile	Ser	Tyr	
	1355					1360						1365			
Asn	Asp	Ser	Trp	Tyr	Tyr	Ala	Asp	Ala	Thr	Gly	Val	Leu	Val	Thr	
	1370					1375						1380			
Gly	Gln	Gln	Ile	Ile	Asn	Gly	Glu	Thr	Gln	Tyr	Phe	Arg	Thr	Asp	
	1385					1390						1395			
Gly	Arg	Gln	Val	Lys	Gly	Gln	Ile	Ile	Ala	Asp	Gly	Asp	Lys	Gln	
	1400					1405						1410			
His	Tyr	Tyr	Asp	Ala	Asp	Ser	Gly	Asn	Leu	Val	Lys	Asn	Asn	Phe	
	1415					1420						1425			

20151105_CL6294WOPCT_SequenceListing

Val Thr Val Asp Gln Gly Lys Thr Trp Tyr Tyr Ala Asp Gln Asp
 1430 1435 1440
 Gly Asn Leu Ser Leu Val Asp Arg His His His His His His
 1445 1450 1455

<210> 3
 <211> 4347
 <212> DNA
 <213> Weissella cibaria

<400> 3
 atgtacaagt ccggaagatt ttgggtagct gccggtgctt tgtttgttg gctggcattc 60
 gctggtaaca cgcaggctga tactgtatta ccaagtgaac aacgtgcaac ggagacgaca 120
 cagacgacac agaccagtga agacacgtcc gccactaaga cgcggcatc ggcgctcgact 180
 tcaagctcag tcaatgttga cacgagtgc ctgcctgaca gttcaagtac ggtagttgat 240
 agtacaagtg caagtgcaag cgtagttagt gatagcgtcg ctgtgccaga tactggatca 300
 caatttacga gttcgtcagg gtcaatgtca tcatcatttg ttaagtcac actagcggca 360
 acaactagtg atgcttctgg cagtcagtcg gcggcgggta ctagcgcaac cgtttagttcg 420
 gtggccacga gtagttcagc atcttcagtg acaacagcca caagcgaatc agcagtgata 480
 agcagcgccg tgtcagatgg ttacatgat gaagtggtg attgggtcta ttatcgagct 540
 ggaaaaaagt tagtcggtcg acaaacgatt gatacgtttg cggtttactt tgacgccgat 600
 ggcaacaag tcaagggtga ttggcgtgaa agtgatggt accgtgcgta ttatgatgga 660
 caagaaggac gagcattaac gcaaacgcaa gcagtcaat gcgttatcta cggttttaat 720
 caaagcggct atcaaatcaa gaatgatttc ggccaaacag cgaatcgaga tacgtattat 780
 ttcgacgcac aaggtcatgt tgtcacggga atccaaacaa ttgcaaacaa ggtttatgat 840
 ttgatgagc aaggtcgaat ctgaaaaggc attgccagc cagttgatga caagatgatg 900
 tattttgatg atcaaacagg tgttgacaa ccggctgata atcctgaatt caaccctgaa 960
 acggaaccgg ttcctgacga caatatcaaa cataatgcag cacatggtac gacaccagca 1020
 gattttgatt cgatggctgg ctacctgacg gctgatactt ggtatcgccc aaccgatatt 1080
 ttggaaaatg gtgagacgtg gcgcgaatcg caaccaactg aatttcgacc actgtttagca 1140
 acttggtggc caacaaaaca aactcaggcc gattacgtga actacatgaa tcacgcatta 1200
 gatattgtcaa atgcaagtgt gtcagctgcc gattcagaag ccacgctaac tgcggcaacc 1260
 gatgctattc aagcggccgt tgagcaccaa attacggtgc gccaatcaac ggcttggtta 1320
 cgtgaattaa tggccgcgtt tgttgtaga cagccacagt ggaataaaac cagtgaagat 1380
 gttaatgatg atcatttgca aggtggggcg ctaacatttg agaataacgg cgacacagac 1440
 gctaattcgg attatgcct catgaatcgc acgccaacaa atcagactgg tgaacgcttg 1500
 tatcacattg atgactcgct tggcggttac gaattattgc tggcaaatga cgttgacaat 1560
 tcaaatccac aagttcaggc agaacaattg aattggttgt actacttgat gcattttggg 1620
 gatattacag ctgatgatcc ggatgcaaat tttgatgcca tacggattga tgcggtcgat 1680
 aatgtcgatg ctgatttact tcaactagca gctcagtatt tccgtgatgc ctatggcatg 1740
 gccacgactg acgcgacatc aaataagcat ctttcaatac ttgaggattg gagccataac 1800
 gatccggcgt atatgcaagc acacggcaat gatcaattaa cgatggatga ttatatgcac 1860
 acacagttga tttggtcatt aaccaagcca gaggcacaac gtggcaccat ggcacgcttt 1920
 atggacttct atctcaccaa ccgtgctaag gatgatacag aaaacacggc gcaacctagt 1980
 tactcgtttg tgcgtgccca tgatagcgaa gtgcaaacag tcattgctga aatcgtgacg 2040
 aagctacatc cagaagcagg aaacgggtta atgcctacgg aagaacaaat ggcagaagcg 2100
 tttaagattt acaatgcgga ccaaaagaag gccgttaaaa cttacacgca ctacaatatg 2160
 ccatctgcac acgccatgct gttaacgaac aaggatgtta ttccacgaat ttactatggt 2220
 tactgtatac ctgacgatgg gcaattcatg gcgacaaaat caccctattt tgatgcgatt 2280
 tcggctatgt tacaagcgcg cacgaagtat gtatggttg gacaaacgat ggcggttgac 2340
 cagcacgacg tcttgactag cgttcggttt ggtaagggtg ccatgacggc cagtgattta 2400
 ggaaatgctg agactcggac tgaggggtgt ggattaatta ttagcaacaa cccaaagttg 2460
 caattgggac aacaagataa cgtggtgtta cacatgggac ttgcgcacgc gaatcaagca 2520
 ttccgagcag ttgtactaac gaccgcgacc ggattaacca ttataatga cgatgatgct 2580
 ccaattcgtt ataccgataa taagggtgat ttaattttca ataaccatga cgtatatggc 2640
 gtgttgatc cacaagtgtc aggccttctt gcaatgtggg tgccaaactg tgcaccagcg 2700
 aaccaggatg cgcgatctac tgcgtcaacc aacagttcaa cggatggatc tgcctaccat 2760
 tctaattcgg ctttagatag tcaagtcac tttgaatcat tttcgaattt ccaggctatg 2820
 ccaacaagcc atgacacgta caccaacggt gtgttagcca atcatgctga ccagttacac 2880
 gattggggaa taacttcggt acagtttagc ccacaatacc ggtcttcaac cgacggaacc 2940
 tttttgtagt cgattattca aaatggctat gccttactg accggtatga tttagggttt 3000
 ggtacgccaa ctaagtatgg ggatgatacg gatttgcgga acgtcatcaa agcattgcat 3060
 gcaaatggca tgcaagtaat ggctgatttt gtgccggatc aattgtatac attaccaggt 3120
 aaggaattgg tacaagtcac ccgaacaaac aatatgggtg agccagatac acactctgac 3180
 atccaacata ttttatatgt gacgagcact cggggtggcg gtgagtatca gaaacagtac 3240
 ggtggtgagt tccttagcgc gttacgtgcg ctctaccctg atttatttac gacacgtcaa 3300
 atttcaaccg gacaaacctg tgatgattca gtaaaaatta aagaatggtc agctaagtat 3360
 ttgaatggtg ccgcaattca aggccgtgga gctggctatg tgctacgtga taatggtaca 3420

20151105_CL6294WOPCT_SequenceListing

aatgcttatt	acaaggtgac	ggcaaattgac	ggtaattgtga	acttaccaaa	gcaattactc	3480
ggacaaccag	tgatgaccgg	attctatcac	gaggcagatg	gttatcattt	tgaacatttg	3540
agtggtagct	cggccaaaga	tgcccttcatt	atgggtgacg	atggggcgct	gtattatttt	3600
gatgatcagg	gcgtcatggt	aacgggtaag	caacgtgtgc	accaagacca	gtattttcttc	3660
ctaccaaacg	gtattgtctt	gacggatgcg	tttgtacaaa	gtgcggatgg	tcaacgtcag	3720
tactatgata	aaacagggtcg	cctggtcatt	aatcaatatg	tgactgacca	ccaagcaaat	3780
gcgttccggg	ttgatgcaga	cggtaacggt	gttcgtaacc	aagctttgac	tgttgacggc	3840
catgaacaat	atttcggcac	aaacgggtgc	caagcgaaag	cagtgtctcat	tcgaactgac	3900
gataatcagg	cacggtacta	cgaagccaat	agtggtaatc	tcgtgaagca	acagtttatt	3960
cttgatacag	atggacattg	gttgtagccc	gatgctgcag	gagacttggc	acgcggacaa	4020
attacggttg	gccaaagacac	gttgattttt	gatgataata	atcatcaggt	aaaagatgat	4080
tttgtctatg	atactaacgg	tgtgcattat	tttaatggca	caacaggcgc	tgaatcaaaa	4140
caagattacg	cgtttcatga	tggcaaattgg	tactattttg	atgattttggg	acgaatggta	4200
accggtttgc	agcgtattaa	tggtagatgt	cgctattttg	atgctaattgg	tgtgcaacta	4260
aagggtggta	ccgtgaccga	tccactaacg	caccaaactg	acacttttga	tgcgcaaact	4320
ggtgttggtg	cgttggtgac	gttttaa				4347

<210> 4
 <211> 1448
 <212> PRT
 <213> Weissella cibaria

<400> 4

Met	Tyr	Lys	Ser	Gly	Lys	Phe	Trp	Val	Ala	Ala	Gly	Ala	Leu	Phe	Val
1				5					10					15	
Gly	Leu	Ala	Phe	Ala	Gly	Asn	Thr	Gln	Ala	Asp	Thr	Val	Leu	Pro	Ser
			20					25					30		
Glu	Gln	Arg	Ala	Thr	Glu	Thr	Thr	Gln	Thr	Thr	Gln	Thr	Ser	Glu	Asp
		35					40					45			
Thr	Ser	Ala	Thr	Lys	Thr	Pro	Ala	Ser	Ala	Ser	Thr	Ser	Ser	Ser	Val
	50					55					60				
Asn	Val	Asp	Thr	Ser	Asp	Leu	Pro	Asp	Ser	Ser	Ser	Thr	Val	Val	Asp
65					70				75					80	
Ser	Thr	Ser	Ala	Ser	Ala	Ser	Val	Val	Ser	Asp	Ser	Val	Ala	Val	Pro
			85					90					95		
Asp	Thr	Gly	Ser	Gln	Phe	Thr	Ser	Ser	Ser	Gly	Ser	Met	Ser	Ser	Ser
			100				105						110		
Phe	Val	Lys	Ser	Ser	Leu	Ala	Ala	Thr	Thr	Ser	Asp	Ala	Ser	Gly	Ser
		115					120					125			
Gln	Ser	Ala	Ala	Val	Thr	Ser	Ala	Thr	Val	Ser	Ser	Val	Ala	Thr	Ser
		130				135					140				
Ser	Ser	Ala	Ser	Ser	Val	Thr	Thr	Ala	Thr	Ser	Glu	Ser	Ala	Val	Ile
145					150				155					160	
Ser	Ser	Ala	Val	Ser	Asp	Gly	Tyr	His	Asp	Glu	Gly	Gly	Asp	Trp	Val
			165					170					175		
Tyr	Tyr	Arg	Ala	Gly	Lys	Lys	Leu	Val	Gly	Arg	Gln	Thr	Ile	Asp	Thr
		180					185						190		
Phe	Ala	Val	Tyr	Phe	Asp	Ala	Asp	Gly	Lys	Gln	Val	Lys	Gly	Asp	Trp
		195					200					205			
Arg	Glu	Ser	Asp	Gly	Asn	Arg	Ala	Tyr	Tyr	Asp	Gly	Gln	Glu	Gly	Arg
	210				215					220					
Ala	Leu	Thr	Gln	Thr	Gln	Ala	Val	Asn	Gly	Val	Ile	Tyr	Gly	Phe	Asn
225					230				235					240	
Gln	Ser	Gly	Tyr	Gln	Ile	Lys	Asn	Asp	Phe	Gly	Gln	Thr	Ala	Asn	Arg
			245					250						255	
Asp	Thr	Tyr	Tyr	Phe	Asp	Ala	Gln	Gly	His	Val	Val	Thr	Gly	Ile	Gln
		260					265					270			
Thr	Ile	Ala	Asn	Lys	Val	Tyr	Asp	Phe	Asp	Glu	Gln	Gly	Arg	Met	Leu
	275					280						285			
Lys	Gly	Ile	Ala	Thr	Ser	Val	Asp	Asp	Lys	Met	Met	Tyr	Phe	Asp	Asp
	290				295						300				
Gln	Thr	Gly	Val	Gly	Gln	Pro	Ala	Asp	His	Pro	Glu	Phe	Asn	Pro	Glu
305					310				315					320	
Thr	Glu	Pro	Val	Pro	Asp	Asp	Asn	Ile	Lys	His	Asn	Ala	Ala	His	Gly
			325					330						335	
Thr	Thr	Pro	Ala	Asp	Phe	Asp	Ser	Met	Ala	Gly	Tyr	Leu	Thr	Ala	Asp
		340					345						350		
Thr	Trp	Tyr	Arg	Pro	Thr	Asp	Ile	Leu	Glu	Asn	Gly	Glu	Thr	Trp	Arg

20151105_CL6294WOPCT_SequenceListing

20191103_CLE0234_W01_C1_SequenceListing																		
		355						360						365				
Glu 370	Ser 370	Gln 370	Pro 370	Thr 370	Glu 370	Phe 375	Arg 375	Pro 375	Leu 375	Leu 375	Ala 380	Thr 375	Trp 375	Trp 375	Pro 375			
Thr 385	Lys 385	Gln 385	Thr 385	Gln 385	Ala 390	Asp 390	Tyr 390	Val 390	Asn 395	Tyr 395	Met 395	Asn 395	His 395	Ala 395	Leu 400			
Asp 400	Met 400	Ser 400	Asn 400	Ala 405	Ser 405	Val 405	Ser 405	Ala 410	Ala 410	Asp 410	Ser 410	Glu 410	Ala 410	Thr 415	Leu 415			
Thr 420	Ala 420	Ala 420	Thr 420	Asp 420	Ala 420	Ile 420	Gln 425	Ala 425	Ala 425	Val 425	Glu 425	His 425	Gln 430	Ile 430	Thr 430			
Val 435	Arg 435	Gln 435	Ser 435	Thr 435	Ala 435	Trp 435	Leu 440	Arg 440	Glu 440	Leu 440	Met 445	Ala 445	Ala 445	Phe 445	Val 445			
Val 450	Thr 450	Gln 450	Pro 450	Gln 450	Trp 450	Asn 455	Lys 455	Thr 455	Ser 455	Glu 455	Asp 460	Val 460	Asn 460	Asp 460	Asp 460			
His 465	Leu 465	Gln 465	Gly 465	Gly 465	Ala 470	Leu 470	Thr 470	Phe 470	Glu 470	Asn 475	Asn 475	Gly 475	Asp 475	Thr 475	Asp 480			
Ala 485	Asn 485	Ser 485	Asp 485	Tyr 485	Arg 485	Leu 485	Met 485	Asn 485	Arg 490	Thr 490	Pro 490	Thr 490	Asn 490	Gln 495	Thr 495			
Gly 500	Glu 500	Arg 500	Leu 500	Tyr 500	His 500	Ile 500	Asp 505	Asp 505	Ser 505	Leu 505	Gly 505	Gly 510	Tyr 510	Glu 510	Leu 510			
Leu 515	Leu 515	Ala 515	Asn 515	Asp 515	Val 515	Asp 515	Asn 520	Ser 520	Asn 520	Pro 520	Gln 520	Val 525	Gln 525	Ala 525	Glu 525			
Gln 530	Leu 530	Asn 530	Trp 530	Leu 530	Tyr 530	Tyr 535	Leu 535	Met 535	His 535	Phe 535	Gly 540	Asp 540	Ile 540	Thr 540	Ala 540			
Asp 545	Asp 545	Pro 545	Asp 545	Ala 545	Asn 550	Phe 550	Asp 550	Ala 550	Ile 550	Arg 555	Ile 555	Asp 555	Ala 555	Val 555	Asp 560			
Asn 565	Val 565	Asp 565	Ala 565	Asp 565	Leu 565	Leu 565	Gln 565	Leu 565	Ala 570	Ala 570	Gln 570	Tyr 570	Phe 570	Arg 575	Asp 575			
Ala 580	Tyr 580	Gly 580	Met 580	Ala 580	Thr 580	Thr 580	Asp 585	Ala 585	Thr 585	Ser 585	Asn 585	Lys 585	His 590	Leu 590	Ser 590			
Ile 595	Leu 595	Glu 595	Asp 595	Trp 595	Ser 595	His 595	Asn 600	Asp 600	Pro 600	Ala 600	Tyr 600	Met 605	Gln 605	Ala 605	His 605			
Gly 610	Asn 610	Asp 610	Gln 610	Leu 610	Thr 610	Met 615	Asp 615	Asp 615	Tyr 615	Met 615	His 620	Thr 620	Gln 620	Leu 620	Ile 620			
Trp 625	Ser 625	Leu 625	Thr 625	Lys 625	Pro 630	Glu 630	Ala 630	Gln 630	Arg 630	Gly 635	Thr 635	Met 635	Ala 635	Arg 640	Phe 640			
Met 645	Asp 645	Phe 645	Tyr 645	Leu 645	Thr 645	Asn 645	Arg 645	Ala 645	Asn 650	Asp 650	Asp 650	Thr 650	Glu 650	Asn 655	Thr 655			
Ala 660	Gln 660	Pro 660	Ser 660	Tyr 660	Ser 660	Phe 660	Val 660	Arg 665	Ala 665	His 665	Asp 665	Ser 665	Glu 670	Val 670	Gln 670			
Thr 675	Val 675	Ile 675	Ala 675	Glu 675	Ile 675	Val 675	Thr 680	Lys 680	Leu 680	His 680	Pro 680	Glu 685	Ala 685	Gly 685	Asn 685			
Gly 690	Leu 690	Met 690	Pro 690	Thr 690	Glu 690	Glu 695	Gln 695	Met 695	Ala 695	Glu 695	Ala 700	Phe 695	Lys 695	Ile 695	Tyr 695			
Asn 705	Ala 705	Asp 705	Gln 705	Lys 705	Lys 710	Ala 710	Val 710	Lys 710	Thr 710	Tyr 715	Thr 715	His 715	Tyr 715	Asn 720	Met 720			
Pro 725	Ser 725	Ala 725	Tyr 725	Ala 725	Met 725	Leu 725	Leu 725	Thr 725	Asn 730	Lys 730	Asp 730	Val 730	Ile 730	Pro 735	Arg 735			
Ile 740	Tyr 740	Tyr 740	Gly 740	Asp 740	Leu 740	Tyr 740	Thr 740	Asp										

20151105_CL6294WOPCT_SequenceListing

			900					905					910			
Ser	Thr	Asp 915	Gly	Ser	Ala	Tyr	His 920	Ser	Asn	Ala	Ala	Leu 925	Asp	Ser	Gln	
Val	Ile 930	Phe	Glu	Ser	Phe	Ser 935	Asn	Phe	Gln	Ala	Met 940	Pro	Thr	Ser	His	
Asp 945	Thr	Tyr	Thr	Asn	Val 950	Val	Leu	Ala	Asn	His 955	Ala	Asp	Gln	Leu	His 960	
Asp	Trp	Gly	Ile	Thr 965	Ser	Val	Gln	Leu	Ala 970	Pro	Gln	Tyr	Arg	Ser 975	Ser	
Thr	Asp	Gly	Thr 980	Phe	Leu	Asp	Ala 985	Ile	Gln	Asn	Gly	Tyr 990	Ala	Phe		
Thr	Asp	Arg 995	Tyr	Asp	Leu	Gly	Phe 1000	Gly	Thr	Pro	Thr	Lys 1005	Tyr	Gly	Asp	
Asp	Thr 1010	Asp	Leu	Arg	Asn	Val 1015	Ile	Lys	Ala	Leu	His 1020	Ala	Asn	Gly		
Met	Gln 1025	Val	Met	Ala	Asp	Phe 1030	Val	Pro	Asp	Gln	Leu 1035	Tyr	Thr	Leu		
Pro	Gly 1040	Lys	Glu	Leu	Val 1045	Gln	Val	Thr	Arg	Thr	Asn 1050	Asn	Met	Gly		
Glu	Pro 1055	Asp	Thr	His	Ser	Asp 1060	Ile	Gln	His	Ile	Leu 1065	Tyr	Val	Thr		
Ser	Thr 1070	Arg	Gly	Gly	Gly	Glu 1075	Tyr	Gln	Lys	Gln	Tyr 1080	Gly	Gly	Glu		
Phe	Leu 1085	Glu	Arg	Leu	Arg	Ala 1090	Leu	Tyr	Pro	Asp	Leu 1095	Phe	Thr	Thr		
Arg	Gln 1100	Ile	Ser	Thr	Gly	Gln 1105	Thr	Ile	Asp	Asp	Ser 1110	Val	Lys	Ile		
Lys	Glu 1115	Trp	Ser	Ala	Lys	Tyr 1120	Leu	Asn	Gly	Thr	Ala 1125	Ile	Gln	Gly		
Arg	Gly 1130	Ala	Gly	Tyr	Val 1135	Leu	Arg	Asp	Asn	Gly	Thr 1140	Asn	Ala	Tyr		
Tyr	Lys 1145	Val	Thr	Ala	Asn	Asp 1150	Gly	Asn	Val	Asn	Leu 1155	Pro	Lys	Gln		
Leu	Leu 1160	Gly	Gln	Pro	Val 1165	Met	Thr	Gly	Phe	Tyr	His 1170	Glu	Ala	Asp		
Gly	Tyr 1175	His	Phe	Glu	Thr 1180	Leu	Ser	Gly	Thr	Ser	Ala 1185	Lys	Asp	Ala		
Phe	Ile 1190	Met	Gly	Asp	Asp 1195	Gly	Ala	Leu	Tyr	Tyr	Phe 1200	Asp	Asp	Gln		
Gly	Val 1205	Met	Val	Thr	Gly 1210	Lys	Gln	Arg	Val	His	Gln 1215	Asp	Gln	Tyr		
Phe	Phe 1220	Leu	Pro	Asn	Gly 1225	Ile	Ala	Leu	Thr	Asp	Ala 1230	Phe	Val	Gln		
Ser	Ala 1235	Asp	Gly	Gln	Arg 1240	Gln	Tyr	Tyr	Asp	Lys	Thr 1245	Gly	Arg	Leu		
Val	Ile 1250	Asn	Gln	Tyr	Val 1255	Thr	Asp	His	Gln	Ala	Asn 1260	Ala	Phe	Arg		
Val	Asp 1265	Ala	Asp	Gly	Asn 1270	Val	Val	Arg	Asn	Gln	Ala 1275	Leu	Thr	Val		
Asp	Gly 1280	His	Glu	Gln	Tyr 1285	Phe	Gly	Thr	Asn	Gly	Val 1290	Gln	Ala	Lys		
Ala	Val 1295	Leu	Ile	Arg	Thr 1300	Asp	Asp	Asn	Gln	Ala	Arg 1305	Tyr	Tyr	Glu		
Ala	Asn 1310	Ser	Gly	Asn	Leu 1315	Val	Lys	Gln	Gln	Phe	Ile 1320	Leu	Asp	Thr		
Asp	Gly 1325	His	Trp	Leu	Tyr 1330	Ala	Asp	Ala	Ala	Gly	Asp 1335	Leu	Ala	Arg		
Gly	Gln 1340	Ile	Thr	Val	Gly 1345	Gln	Asp	Thr	Leu	Tyr	Phe 1350	Asp	Asp	Asn		
Asn	His 1355	Gln	Val	Lys	Asp 1360	Asp	Phe	Val	Tyr	Asp	Thr 1365	Asn	Gly	Val		
His	Tyr 1370	Phe	Asn	Gly	Thr 1375	Thr	Gly	Ala	Glu	Ile	Lys 1380	Gln	Asp	Tyr		
Ala	Phe 1385	His	Asp	Gly	Lys 1390	Trp	Tyr	Tyr	Phe	Asp	Asp 1395	Leu	Gly	Arg		
Met	Val 1400	Thr	Gly	Leu	Gln 1405	Arg	Ile	Asn	Gly	Glu	Tyr 1410	Arg	Tyr	Phe		

20151105_CL6294WOPCT_SequenceListing

1415 1420 1425
 Leu Thr His Gln Thr Tyr Thr Phe Asp Ala Gln Thr Gly Val Gly
 1430 1435 1440
 Thr Leu Val Thr Phe
 1445

<210> 5
 <211> 1422
 <212> PRT
 <213> Weissella cibaria

<220>
 <221> MISC_FEATURE
 <222> (1)..(1422)
 <223> mature 2919 gtf

<400> 5
 Asp Thr Val Leu Pro Ser Glu Gln Arg Ala Thr Glu Thr Thr Gln Thr
 1 5 10 15
 Thr Gln Thr Ser Glu Asp Thr Ser Ala Thr Lys Thr Pro Ala Ser Ala
 20 25 30
 Ser Thr Ser Ser Ser Val Asn Val Asp Thr Ser Asp Leu Pro Asp Ser
 35 40 45
 Ser Ser Thr Val Val Asp Ser Thr Ser Ala Ser Ala Ser Val Val Ser
 50 55 60
 Asp Ser Val Ala Val Pro Asp Thr Gly Ser Gln Phe Thr Ser Ser Ser
 65 70 75 80
 Gly Ser Met Ser Ser Ser Phe Val Lys Ser Ser Leu Ala Ala Thr Thr
 85 90 95
 Ser Asp Ala Ser Gly Ser Gln Ser Ala Ala Val Thr Ser Ala Thr Val
 100 105 110
 Ser Ser Val Ala Thr Ser Ser Ser Ala Ser Ser Val Thr Thr Ala Thr
 115 120 125
 Ser Glu Ser Ala Val Ile Ser Ser Ala Val Ser Asp Gly Tyr His Asp
 130 135 140
 Glu Gly Gly Asp Trp Val Tyr Tyr Arg Ala Gly Lys Lys Leu Val Gly
 145 150 155 160
 Arg Gln Thr Ile Asp Thr Phe Ala Val Tyr Phe Asp Ala Asp Gly Lys
 165 170 175
 Gln Val Lys Gly Asp Trp Arg Glu Ser Asp Gly Asn Arg Ala Tyr Tyr
 180 185 190
 Asp Gly Gln Glu Gly Arg Ala Leu Thr Gln Thr Gln Ala Val Asn Gly
 195 200 205
 Val Ile Tyr Gly Phe Asn Gln Ser Gly Tyr Gln Ile Lys Asn Asp Phe
 210 215 220
 Gly Gln Thr Ala Asn Arg Asp Thr Tyr Tyr Phe Asp Ala Gln Gly His
 225 230 235 240
 Val Val Thr Gly Ile Gln Thr Ile Ala Asn Lys Val Tyr Asp Phe Asp
 245 250 255
 Glu Gln Gly Arg Met Leu Lys Gly Ile Ala Thr Ser Val Asp Asp Lys
 260 265 270
 Met Met Tyr Phe Asp Asp Gln Thr Gly Val Gly Gln Pro Ala Asp His
 275 280 285
 Pro Glu Phe Asn Pro Glu Thr Glu Pro Val Pro Asp Asp Asn Ile Lys
 290 295 300
 His Asn Ala Ala His Gly Thr Thr Pro Ala Asp Phe Asp Ser Met Ala
 305 310 315 320
 Gly Tyr Leu Thr Ala Asp Thr Trp Tyr Arg Pro Thr Asp Ile Leu Glu
 325 330 335
 Asn Gly Glu Thr Trp Arg Glu Ser Gln Pro Thr Glu Phe Arg Pro Leu
 340 345 350
 Leu Ala Thr Trp Trp Pro Thr Lys Gln Thr Gln Ala Asp Tyr Val Asn
 355 360 365
 Tyr Met Asn His Ala Leu Asp Met Ser Asn Ala Ser Val Ser Ala Ala
 370 375 380
 Asp Ser Glu Ala Thr Leu Thr Ala Ala Thr Asp Ala Ile Gln Ala Ala
 385 390 395 400
 Val Glu His Gln Ile Thr Val Arg Gln Ser Thr Ala Trp Leu Arg Glu

415

20151105_CL6294WOPCT_SequenceListing

```

945      950      955      960
Gln Asn Gly Tyr Ala Phe Thr Asp Arg Tyr Asp Leu Gly Phe Gly Thr
      965      970      975
Pro Thr Lys Tyr Gly Asp Asp Thr Asp Leu Arg Asn Val Ile Lys Ala
      980      985      990
Leu His Ala Asn Gly Met Gln Val Met Ala Asp Phe Val Pro Asp Gln
      995      1000      1005
Leu Tyr Thr Leu Pro Gly Lys Glu Leu Val Gln Val Thr Arg Thr
1010
Asn Asn Met Gly Glu Pro Asp Thr His Ser Asp Ile Gln His Ile
1025
Leu Tyr Val Thr Ser Thr Arg Gly Gly Gly Glu Tyr Gln Lys Gln
1040
Tyr Gly Gly Glu Phe Leu Glu Arg Leu Arg Ala Leu Tyr Pro Asp
1055
Leu Phe Thr Thr Arg Gln Ile Ser Thr Gly Gln Thr Ile Asp Asp
1070
Ser Val Lys Ile Lys Glu Trp Ser Ala Lys Tyr Leu Asn Gly Thr
1085
Ala Ile Gln Gly Arg Gly Ala Gly Tyr Val Leu Arg Asp Asn Gly
1100
Thr Asn Ala Tyr Tyr Lys Val Thr Ala Asn Asp Gly Asn Val Asn
1115
Leu Pro Lys Gln Leu Leu Gly Gln Pro Val Met Thr Gly Phe Tyr
1130
His Glu Ala Asp Gly Tyr His Phe Glu Thr Leu Ser Gly Thr Ser
1145
Ala Lys Asp Ala Phe Ile Met Gly Asp Asp Gly Ala Leu Tyr Tyr
1160
Phe Asp Asp Gln Gly Val Met Val Thr Gly Lys Gln Arg Val His
1175
Gln Asp Gln Tyr Phe Phe Leu Pro Asn Gly Ile Ala Leu Thr Asp
1190
Ala Phe Val Gln Ser Ala Asp Gly Gln Arg Gln Tyr Tyr Asp Lys
1205
Thr Gly Arg Leu Val Ile Asn Gln Tyr Val Thr Asp His Gln Ala
1220
Asn Ala Phe Arg Val Asp Ala Asp Gly Asn Val Val Arg Asn Gln
1235
Ala Leu Thr Val Asp Gly His Glu Gln Tyr Phe Gly Thr Asn Gly
1250
Val Gln Ala Lys Ala Val Leu Ile Arg Thr Asp Asp Asn Gln Ala
1265
Arg Tyr Tyr Glu Ala Asn Ser Gly Asn Leu Val Lys Gln Gln Phe
1280
Ile Leu Asp Thr Asp Gly His Trp Leu Tyr Ala Asp Ala Ala Gly
1295
Asp Leu Ala Arg Gly Gln Ile Thr Val Gly Gln Asp Thr Leu Tyr
1310
Phe Asp Asp Asn Asn His Gln Val Lys Asp Asp Phe Val Tyr Asp
1325
Thr Asn Gly Val His Tyr Phe Asn Gly Thr Thr Gly Ala Glu Ile
1340
Lys Gln Asp Tyr Ala Phe His Asp Gly Lys Trp Tyr Tyr Phe Asp
1355
Asp Leu Gly Arg Met Val Thr Gly Leu Gln Arg Ile Asn Gly Glu
1370
Tyr Arg Tyr Phe Asp Ala Asn Gly Val Gln Leu Lys Gly Gly Thr
1385
Val Thr Asp Pro Leu Thr His Gln Thr Tyr Thr Phe Asp Ala Gln
1400
Thr Gly Val Gly Thr Leu Val Thr Phe
1415
1420

```

<210> 6
 <211> 4269
 <212> DNA
 <213> Artificial sequence

20151105_CL6294WOPCT_SequenceListing

<220>

<223> 2919 gtf with heterologous signal sequence

<400> 6

gacacagtcc	ttccgtcaga	acaaagagcc	acggagacga	cacagacaac	acaaacaagc	60
gaagacacaa	gcgccacaaa	gacgcctgct	agcgcttcaa	cgagcagctc	agtgaacgtg	120
gacacatcag	atcttccgga	cagctcaagc	acggtggtgg	attcaacgtc	agcctcagca	180
agcgtcgtgt	cagactcagt	cgctgtccct	gatacgggat	cacagttcac	atcatcaagc	240
ggcagcatgt	caagcagctt	tgttaaaagc	tcactggcag	ctacgacgtc	agatgcttca	300
ggctcacaaa	gcgccgctgt	gacatcagca	acagtttcaa	gcgtggcgac	gagctcatca	360
gcgtcatcag	ttacaacagc	cacgagcgaa	tcagcggtta	ttagctcagc	agtttagcgat	420
ggctatcacg	atgaaggagg	cgattggggt	tactacagag	ctggcaaaaa	actggttggc	480
agacaaaagc	ttgatacatt	tgccgtttac	ttcgatgcag	atggaaaaca	ggttaaagga	540
gactggagag	agtcatagcg	aaacagagcg	tactatgatg	gccaaagaag	cagagccctt	600
acgcaaacac	aggcagttaa	cggagtcatt	tatggattta	atcaatcagg	atatcagatt	660
aagaacgatt	tcggccagac	ggctaacaga	gacacgtatt	actttgatgc	tcaaggacat	720
gtggttacgg	gcattccagac	aattgcaaat	aaagtttatg	atttcgatga	acaaggaaga	780
atgctgaaag	gaattgccac	gtcagtcgac	gataaaatga	tgtattttcga	cgaccaaacg	840
ggcgtggggc	aacctgccga	ccaccctgag	tttaatccgg	aaacggagcc	ggtcccggat	900
gacaaacatta	aacataacgc	tgccgacgga	acgacacctg	ctgattttga	tagcatggcc	960
ggatacctta	cggcgggatac	atggtataga	cctacagaca	ttctggagaa	tggcgaaaca	1020
tggagagaaa	gccagcctac	ggagttcaga	ccgcttcttg	ccacatggtg	gcctacgaaa	1080
caaacgcaag	cagattatgt	taattacatg	aaccatgctc	tggatatgtc	aaatgcgagc	1140
gtgagcgtg	ccgatagcga	ggcaaacctt	acagccgcga	cggatgccat	ccaagctgca	1200
gtcgaacatc	aaattacagt	gagacagtca	acggcatggc	ttagagaact	tatggcggca	1260
tttgtcgtga	cgcaaccgca	gtggaataaa	acatcagagg	atgtcaacga	cgatcacctg	1320
caaggaggag	cgcttacatt	cgaaaataac	ggcgatacgg	acgcaaatag	cgattacaga	1380
cttatgaata	gaacgcctac	aaaccaaaca	ggagaaagac	tttaccacat	tgacgactca	1440
cttggaggat	acgaactgct	tctggccaac	gatgttgata	acagcaatcc	tcaagtgcag	1500
gctgagcaac	ttaattggct	ttattacctg	atgcattttg	gcgatattac	agctgacgac	1560
cctgacgcca	acttcgacgc	gattagaatc	gatgcggtcg	ataatgtcga	cgcagacctt	1620
cttcaactgg	ctgctcaata	tttcagagac	gcatacggaa	tggcaacaac	agacgctaca	1680
agcaataaac	atctgtcaat	tcttgaagac	tggtcacata	atgatccggc	gtacatgcaa	1740
gctcatggaa	acgatcaact	tacgatggat	gactatatgc	acacacaact	tatttgggtca	1800
ctgacaaaac	cggagggtca	aagaggaaca	atggctagat	ttatggactt	ttatcttaca	1860
aatagagcga	acgatgatac	agaaaatacg	gctcaacctt	catattcatt	cgtttagagca	1920
catgatttcag	aagttcaaac	agtgattgca	gaaattgtta	caaaactgca	tcctgaggcg	1980
ggcaatggac	tgatgccgac	agaagagcaa	atggcagaag	cctttaagat	ctataatgcc	2040
gatcagaaaa	aagcagtga	aacatataca	cactacaata	tgccttcagc	ttatgcaatg	2100
ctgcttacga	ataaagacgt	cattccctaga	atcttactatg	gagatcttta	tacagatgat	2160
ggacaattca	tggctacaaa	gtcaccttat	tttgacgcta	tcagcgcgat	gctgcaagcg	2220
agaacgaagt	atgtcgcagg	cggccagacg	atggcagtg	atcagcacga	cgtgcttaca	2280
agcgtgagat	ttggcaaagg	cgcaatgaca	gcatacgacc	tgggcaatgc	agagacaga	2340
acggagggag	ttggccttat	catttcaaat	aatccgaaac	tgcaactggg	ccagcaggat	2400
aacgtcgttc	ttcatatggg	cctggcgcac	gcaaaccagg	ccttttagagc	agttgttctt	2460
acaacagcga	cgggcctgac	aatctacaat	gacgatgatg	caccgattag	atatacagac	2520
aataaaggcg	acctgatttt	caacaacctt	gatgtctacg	gcgtcctgaa	cccgcagggt	2580
tcaggcttcc	tggccatgtg	ggttcctaca	ggcgcacctg	ctaaccaaga	tgctagatca	2640
acagcaagca	caaactcatc	aacggatggc	tcagcatatc	attcaaattgc	tgcgtgggat	2700
tcacaagtta	ttttcgaatc	attctcaaat	ttccaagcaa	tgccgacgtc	acatgacaca	2760
tacacgaatg	tggttctggc	caaccacgcc	gaccagcttc	acgattgggg	cattacatca	2820
gtgcagctgg	caccgcagta	tagaagctca	acagacggca	cgttcctgga	tgcaattatc	2880
cagaatggct	atgccttcac	agatagatac	gatcttggct	ttggcacacc	tacaaaatac	2940
ggcgacgaca	cggatctgag	aaatgtgatt	aaggcgcttc	atgccaacgg	catgcagggt	3000
atggccgact	tcgtcccgga	ccaactttat	acacttccgg	gaaaagagct	ggtgcaagtc	3060
acgagaacga	ataacatggg	cgaacctgat	acacactcag	acattcaaca	tattctgtac	3120
gttacgtcaa	cgagaggcgg	aggagaatat	caaaaacagt	atggcggcga	gtttcttgaa	3180
agactgagag	cactgtaccc	tgaccttttt	acgacaagac	aaattagcac	aggccaaaca	3240
attgacgatt	cagtgaagat	caaagagtgg	tcagctaagt	acctgaacgg	cacagctatc	3300
caaggaaag	gcgcaggcta	tgttctgaga	gataatggca	caaatgccta	ctacaaagtt	3360
acagcgaatg	atggaaatgt	caatcttcct	aaacaacttc	ttggacagcc	ggttatgacg	3420
ggcttctacc	acgaggccga	tggatatcac	ttcgagacac	tgtcagggaac	atcagccaag	3480
gatgcgttta	tcattgggaga	tgacggagcg	ctttattact	ttgatgacca	aggcgttatg	3540
gtgacaggaa	aacagagagt	tcataagac	cagtacttct	ttctgcctaa	cggaaattgct	3600
ctgacagacg	cgttcgttca	atcagcagac	ggacaaagac	agtatttatga	caaaacggga	3660
agacttgtaa	tcaaacagta	tgtgacagat	caccaagcta	atgcttttag	agtcgatgct	3720
gatggcaacg	tggttagaaa	ccaagcactt	acagttgatg	gacacgaaca	atatttcgga	3780

20151105_CL6294WOPCT_SequenceListing

acaaatggag	tccaggctaa	agcggttctg	attagaacag	atgataatca	agcgagatat	3840
tacgaagcta	actcaggcaa	tctggttaag	caacaattca	ttcttgacac	agatggccac	3900
tggctgtacg	ccgatgcagc	cggagatctt	gctagaggac	agattacagt	gggacaggat	3960
acactgtatt	tcgacgataa	taaccaccaa	gttaaggatg	attttgtcta	tgatacaaac	4020
ggcgttcatt	atttcaatgg	aacgacagga	gctgagatta	aacaagatta	cgcatttcac	4080
gacggcaaatt	ggtactactt	cgatgatctg	ggaagaatgg	ttacaggact	gcaaagaatt	4140
aacggcgaat	atagatatatt	tgacgctaatt	ggcgtccaac	ttaagggagg	aacagtcacg	4200
gacctctta	cacatcaaac	atatacattt	gatgctcaaa	caggcgttgg	aacgctggtc	4260
acgttttga						4269

<210> 7

<211> 4392

<212> DNA

<213> Lactobacillus fermentum

<400> 7

ttgcaagacg	agtcacagaa	gtttagaaaa	aagatgtata	agtccggaaa	gttttgggta	60
gctgccggtg	ctttgtttgt	tgggctggca	ttcgttggtg	acgcgcaggc	agatactgta	120
ttaccaagtg	aacaacgtgc	aacacagacg	acacagacga	cacagaccag	tgaagacacg	180
tccgccacta	agacgcggcg	atcggcgctcg	acttcaagct	cagacaatgt	tgacacagat	240
gacctgcctg	acagtgcgaag	tgcggtggtt	gatagtgcag	ttacaagtac	aagtacaagt	300
gcaagtgtag	tgagtgatag	cgtcgccgtg	ccagatactg	gatcacaatt	tatgagttcg	360
tcagcgccag	cgatcatcagc	gtttgtttaa	ccgtcactaa	cgtaacaac	tagtggtgct	420
tccggcagtc	agtcacacgc	ggtgactagc	gcaaacgata	gttcgggtggc	aactagtagt	480
tcagcatctt	cagtgcacaac	agccacaagt	gaatcggctg	tggtgaagcag	cgccgtgtca	540
gatggttacc	atgatgaagg	tggtgattgg	gtctattatc	gagctgggaa	aaagttactc	600
ggtcgacaaa	cgattgatac	gtttgcggtt	tactttgacg	ccgatggcaa	acaagtcaag	660
ggtgattggc	gtgaaagtga	tggtaaacgt	gcgtattatg	atgggcaaga	aggacgagca	720
ttaacgcaaa	cgcaagcagt	caatggcggt	atctacgggt	ttaatcaaag	cggctatcaa	780
atcaagaatg	atttcggcca	aacagcgaat	cgagatacgt	attattttcga	cgcacaaggt	840
catggtgtca	cgggaatcca	aacaattgca	aacaaggttt	atgatttttga	tgagcaaggt	900
cgaatgctga	aaggcattgc	cacgtcagtt	gatgacaaga	tgatgtattt	tgatgatcaa	960
acaggtgttg	gacaaccggc	tgatcatcct	gaattcaacc	ctgaaacgga	accggttcct	1020
gacgacaata	tcaaacataa	tgacgcacat	ggtacgacac	cagaagattt	tgattcgatg	1080
gctgactacc	tgacggctga	tacttggtat	cgcccaaccg	atatttttga	aaatggtgag	1140
acgtggcgcg	aatcgcaacc	aactgaattt	cgaccactgt	tagcaacttg	gtggccaaca	1200
aaacaaaccc	aggccgatta	cgtgaactac	atgaatcagc	cattagatat	ggcaaatgca	1260
ggtgtgtcag	ctgctgattc	agaagccacg	ttaaactcgg	caaccgatgc	tattcaagcg	1320
gttgttgagc	accaaatac	ggtgcgtcaa	tcaacggctt	ggttacgtga	attaatggcc	1380
gcatttgttg	tgacacagcc	acagtggaat	aaaacaagtg	aagatgtgaa	tgatgatcat	1440
ttgcaagggtg	gggcattaac	atttgaaaat	aacggcgaca	cagacgctaa	ttcggattat	1500
cgctcatga	accgcacgcc	aacaaatcag	actggcgaac	gcttgtacca	cattgatgac	1560
tcacttgggt	gttacgaatt	attgctggca	aatgacgttg	acaattcaaa	tccacaagtt	1620
caggcgaaac	aattgtaattg	gttgactac	ttaatgcatt	ttggggatat	tacagctgat	1680
gatccggacg	caaattttga	tgccatacgg	attgatgcgg	tcgataatgt	cgatgctgat	1740
ttacttcaac	tagcagccca	gtatttccgg	gatgcctatg	gcatggctac	aactgacgca	1800
acatcaaata	agcatctttc	aattccttgag	gattggagcc	ataacgatcc	ggcgtatatg	1860
caagcacacg	gcaatgatca	attaacgatg	gatgattata	tgacacacac	gttgatttgc	1920
tcattaacca	agcccagagg	acaacgcggg	accatggcac	gctttatgga	cttctatctc	1980
accaaccgtg	ctaattgatga	tacagaaaac	acggcgcaac	ctagttactc	gtttgtgcgt	2040
gcccattgata	gcgaagtaca	aacagtcatt	gctgagatcg	tgacgaagct	gcatccagaa	2100
gcaggaaatg	ggttaatgcc	tacggaagaa	caaatggcag	aagcgtttaa	gattttacaat	2160
gcggaccaaaa	agaaggccgt	taagacttac	acacattaca	atatgccatc	tgcatacgcc	2220
atgctgttaa	cgaacaagga	tgttattcca	cgaatttact	atggtgactt	gtacactgat	2280
gatgggcaat	tcattggcgac	aaaatcacct	tattttgatg	cgatttcgac	catgttacaa	2340
gcacgcacga	agtatgtagc	tggtggacag	acgatggcgg	ttgaccagca	cgacgtcttg	2400
actagcgttc	ggtttggtaa	gggggccatg	acggccaatg	atttagggga	tgctgagacc	2460
cggactgagg	gtgtgggatt	aattatttagc	aacaacccaa	agttgcaatt	gggacaacaa	2520
gacaacgtgg	tgttacacat	gggacttgcg	cacgcgaatc	aggcattccg	cgcagtcgta	2580
ctaacgaccg	cgaccggatt	aaccatttat	aatgacgatg	atgctccgat	tcgtttatacc	2640
gataataaag	gtgatttaatt	tttactaac	catgacgtat	atggcgtggt	gaatccacaa	2700
gtgtcaggct	tcttggcaat	gtgggtgcca	actggtgcac	cagcgaacca	ggatgcgcga	2760
tctactgcgt	caaccaacat	gtcaacggat	ggatctgcct	accatttctaa	tgcggttttg	2820
gatagtcaag	taatctttga	atcattttcg	aatttccagg	ctatgccaac	aagtcatgac	2880
acatacacca	acgttgtggt	agccaatcat	gctgaccagt	tgacagattg	gggaataact	2940
tcggtacagt	tagcaccaca	ataccggtct	tcaaccgacg	gtaccttttt	agacgcgatt	3000
attcaaaatg	gctatgcctt	cactgaccgt	tatgatttag	ggtttggtag	gccaactaaa	3060
tacggggatg	atacggattt	gcggaacgtc	atcaaagcat	tgcatgcaaa	tggcatgcaa	3120

20151105_CL6294WOPCT_SequenceListing

gtaatggctg	attttgtgcc	ggatcaattg	tatacattac	caggtaagga	attggtacaa	3180
gtcaccgaa	caaacaatat	gggtgagcca	gatacgcat	ctgacatcca	acatatttta	3240
tatgtgacga	gcactcgtgg	tgggtggtgac	tatcagaaac	agtacggtgg	tgagttcctt	3300
gcacgattgc	gtgaacgata	cccagattta	tttacgacac	gtcaaatttc	gaccggacaa	3360
acaattgatg	attcagtaaa	aattaaagaa	tggtcagcta	agtatttgaa	tggtaccgca	3420
attcaaggac	gtggagctgg	ctatgtgctg	cgtgataatg	gtacaaatgc	ttattacaag	3480
gtgacagcaa	atgacggtaa	tgtgaactta	ccaaagcaat	tactcggcca	accggtgatg	3540
accggattct	atcacgaggc	agatggttat	cattttgaaa	cattgagtgg	tacgtcggcc	3600
aaagatgcct	ttattatggg	cgacgatggg	gcactgtatt	attttgatga	tcagggtggt	3660
atggtaacgg	gtaagcaacg	tgtgcaccaa	gatcagtatt	tcttcctgcc	aaatggtatt	3720
gctttgacag	atgctttcgt	acaaactgct	gatgggtcaac	gtcagtacta	tgataaaaaca	3780
ggtcgtctgg	tcattaatca	atatgtgact	gaccaccaag	cgaatgcggt	ccgggttgat	3840
gcagacggta	acgttgtccg	caatcaagct	ttgactgttg	acggccatga	acaatatattc	3900
ggcacaaacg	gtgtccaagc	gaaagcagtg	ctcattcgaa	ctgacgataa	tcaggcgcgc	3960
tactacgaag	ccaatagttg	taatctcgtg	aagcaacagt	ttattcttga	tacagatgga	4020
cattggttgt	acgcggatgc	tgcaggtgac	ttggcacgcg	gacaaattac	aattggccaa	4080
gacacgttgt	attttgatga	taataatcac	caggtaaaag	atgatttcgt	ctatgatact	4140
aacggtgtgc	attattttaa	tggcacaaca	ggcgtgaaa	tcaaacaaga	ttacgcgttt	4200
catgatggca	aatgggtacta	ttttgatgat	ttgggacgaa	tggtaacggg	cttgcagcgt	4260
attaatggtg	agtatcgcta	ttttgatgct	aatggtgtgc	aactaaaggg	cggtagcgtg	4320
accgatccac	taacgcacca	aacgtacact	tttgatgcga	aaactggtgc	tggtacgttg	4380
gtgacgattt	aa					4392

<210> 8

<211> 1463

<212> PRT

<213> Lactobacillus fermentum

<400> 8

Met	Gln	Asp	Glu	Ser	Gln	Lys	Phe	Arg	Lys	Lys	Met	Tyr	Lys	Ser	Gly
1			5					10						15	
Lys	Phe	Trp	Val	Ala	Ala	Gly	Ala	Leu	Phe	Val	Gly	Leu	Ala	Phe	Ala
			20					25					30		
Gly	Asn	Ala	Gln	Ala	Asp	Thr	Val	Leu	Pro	Ser	Glu	Gln	Arg	Ala	Thr
			35				40						45		
Gln	Thr	Thr	Gln	Thr	Thr	Gln	Thr	Ser	Glu	Asp	Thr	Ser	Ala	Thr	Lys
			50			55					60				
Thr	Pro	Ala	Ser	Ala	Ser	Thr	Ser	Ser	Ser	Asp	Asn	Val	Asp	Thr	Ser
65					70					75					80
Asp	Leu	Pro	Asp	Ser	Ala	Ser	Ala	Val	Val	Asp	Ser	Ala	Val	Thr	Ser
				85					90					95	
Thr	Ser	Thr	Ser	Ala	Ser	Val	Val	Ser	Asp	Ser	Val	Ala	Val	Pro	Asp
				100				105						110	
Thr	Gly	Ser	Gln	Phe	Met	Ser	Ser	Ser	Ala	Pro	Ala	Ser	Ser	Ala	Phe
							120						125		
Val	Lys	Pro	Ser	Leu	Thr	Ser	Thr	Thr	Ser	Gly	Ala	Ser	Gly	Ser	Gln
							135				140				
Ser	Ser	Ala	Val	Thr	Ser	Ala	Asn	Asp	Ser	Ser	Val	Ala	Thr	Ser	Ser
145					150					155					160
Ser	Ala	Ser	Ser	Val	Thr	Thr	Ala	Thr	Ser	Glu	Ser	Ala	Val	Val	Ser
				165						170					175
Ser	Ala	Val	Ser	Asp	Gly	Tyr	His	Asp	Glu	Gly	Gly	Asp	Trp	Val	Tyr
				180				185						190	
Tyr	Arg	Ala	Gly	Lys	Lys	Leu	Leu	Gly	Arg	Gln	Thr	Ile	Asp	Thr	Phe
							200						205		
Ala	Val	Tyr	Phe	Asp	Ala	Asp	Gly	Lys	Gln	Val	Lys	Gly	Asp	Trp	Arg
						215					220				
Glu	Ser	Asp	Gly	Lys	Arg	Ala	Tyr	Tyr	Asp	Gly	Gln	Glu	Gly	Arg	Ala
225					230					235					240
Leu	Thr	Gln	Thr	Gln	Ala	Val	Asn	Gly	Val	Ile	Tyr	Gly	Phe	Asn	Gln
										250				255	
Ser	Gly	Tyr	Gln	Ile	Lys	Asn	Asp	Phe	Gly	Gln	Thr	Ala	Asn	Arg	Asp
				260				265						270	
Thr	Tyr	Tyr	Phe	Asp	Ala	Gln	Gly	His	Val	Val	Thr	Gly	Ile	Gln	Thr
				275			280							285	
Ile	Ala	Asn	Lys	Val	Tyr	Asp	Phe	Asp	Glu	Gln	Gly	Arg	Met	Leu	Lys
						295					300				
Gly	Ile	Ala	Thr	Ser	Val	Asp	Asp	Lys	Met	Met	Tyr	Phe	Asp	Asp	Gln

20151105_CL6294WOPCT_SequenceListing

305	Thr	Gly	Val	Gly	Gln	310	Pro	Ala	Asp	His	Pro	315	Glu	Phe	Asn	Pro	Glu	320	Thr
				325	Asp	Asp	Asn	Ile	Lys	His	330	Asn	Ala	Ala	His	Gly	335	Thr	
			340						345								350		
	Thr	Pro	Glu	Asp	Phe	Asp	Ser	Met	Ala	Asp	Tyr	Leu	Thr	Ala	Asp	Thr			
			355					360									365		
	Trp	Tyr	Arg	Pro	Thr	Asp	Ile	Leu	Glu	Asn	Gly	Glu	Thr	Trp	Arg	Glu			
			370				375												
	Ser	Gln	Pro	Thr	Glu	Phe	Arg	Pro	Leu	Leu	Ala	Thr	Trp	Trp	Pro	Thr			
385					390						395						400		
	Lys	Gln	Thr	Gln	Ala	Asp	Tyr	Val	Asn	Tyr	Met	Asn	His	Ala	Leu	Asp			
				405						410						415			
	Met	Ala	Asn	Ala	Gly	Val	Ser	Ala	Ala	Asp	Ser	Glu	Ala	Thr	Leu	Thr			
				420					425										
	Ala	Ala	Thr	Asp	Ala	Ile	Gln	Ala	Val	Val	Glu	His	Gln	Ile	Thr	Val			
			435					440											
	Arg	Gln	Ser	Thr	Ala	Trp	Leu	Arg	Glu	Leu	Met	Ala	Ala	Phe	Val	Val			
			450				455					460							
	Thr	Gln	Pro	Gln	Trp	Asn	Lys	Thr	Ser	Glu	Asp	Val	Asn	Asp	Asp	His			
465					470						475						480		
	Leu	Gln	Gly	Gly	Ala	Leu	Thr	Phe	Glu	Asn	Asn	Gly	Asp	Thr	Asp	Ala			
				485						490						495			
	Asn	Ser	Asp	Tyr	Arg	Leu	Met	Asn	Arg	Thr	Pro	Thr	Asn	Gln	Thr	Gly			
			500						505										
	Glu	Arg	Leu	Tyr	His	Ile	Asp	Asp	Ser	Leu	Gly	Gly	Tyr	Glu	Leu	Leu			
			515					520					525						
	Leu	Ala	Asn	Asp	Val	Asp	Asn	Ser	Asn	Pro	Gln	Val	Gln	Ala	Glu	Gln			
			530				535					540							
	Leu	Asn	Trp	Leu	Tyr	Tyr	Leu	Met	His	Phe	Gly	Asp	Ile	Thr	Ala	Asp			
545					550						555						560		
	Asp	Pro	Asp	Ala	Asn	Phe	Asp	Ala	Ile	Arg	Ile	Asp	Ala	Val	Asp	Asn			
				565						570						575			
	Val	Asp	Ala	Asp	Leu	Leu	Gln	Leu	Ala	Ala	Gln	Tyr	Phe	Arg	Asp	Ala			
			580						585						590				
	Tyr	Gly	Met	Ala	Thr	Thr	Asp	Ala	Thr	Ser	Asn	Lys	His	Leu	Ser	Ile			
			595					600					605						
	Leu	Glu	Asp	Trp	Ser	His	Asn	Asp	Pro	Ala	Tyr	Met	Gln	Ala	His	Gly			
			610				615					620							
	Asn	Asp	Gln	Leu	Thr	Met	Asp	Asp	Tyr	Met	His	Thr	Gln	Leu	Ile	Trp			
625					630						635						640		
	Ser	Leu	Thr	Lys	Pro	Glu	Ala	Gln	Arg	Gly	Thr	Met	Ala	Arg	Phe	Met			
				645						650						655			
	Asp	Phe	Tyr	Leu	Thr	Asn	Arg	Ala	Asn	Asp	Asp	Thr	Glu	Asn	Thr	Ala			
			660						665										
	Gln	Pro	Ser	Tyr	Ser	Phe	Val	Arg	Ala	His	Asp	Ser	Glu	Val	Gln	Thr			
			675					680					685						
	Val	Ile	Ala	Glu	Ile	Val	Thr	Lys	Leu	His	Pro	Glu	Ala	Gly	Asn	Gly			
			690				695					700							
	Leu	Met	Pro	Thr	Glu	Glu	Gln	Met	Ala	Glu	Ala	Phe	Lys	Ile	Tyr	Asn			
705					710						715						720		
	Ala	Asp	Gln	Lys	Lys	Ala	Val	Lys	Thr	Tyr	Thr	His	Tyr	Asn	Met	Pro			
				725						730						735			
	Ser	Ala	Tyr	Ala	Met	Leu	Leu	Thr	Asn	Lys	Asp	Val	Ile	Pro	Arg	Ile			
			740						745										
	Tyr	Tyr	Gly	Asp	Leu	Tyr	Thr	Asp	Asp	Gly	Gln	Phe	Met	Ala	Thr	Lys			
			755					760					765						
	Ser	Pro	Tyr	Phe	Asp	Ala	Ile	Ser	Thr	Met	Leu	Gln	Ala	Arg	Thr	Lys			
			770				775					780							
	Tyr	Val	Ala	Gly	Gly	Gln	Thr	Met	Ala	Val	Asp	Gln	His	Asp	Val	Leu			
785					790						795						800		
	Thr	Ser	Val	Arg	Phe	Gly	Lys	Gly	Ala	Met	Thr	Ala	Asn	Asp	Leu	Gly			
				805						810						815			
	Asp	Ala	Glu	Thr	Arg	Thr	Glu	Gly	Val	Gly	Leu	Ile	Ile	Ser	Asn	Asn			
			820						825										
	Pro	Lys	Leu	Gln	Leu	Gly	Gln	Gln	Asp	Asn	Val	Val	Leu	His	Met	Gly			
			835					840					845						
	Leu	Ala	His	Ala	Asn	Gln	Ala	Phe	Arg	Ala	Val	Val	Leu	Thr	Thr	Ala			

20151105_CL6294WOPCT_SequenceListing

850	855	860
Thr Gly Leu Thr Ile Tyr	Asn Asp Asp Asp Ala	Pro Ile Arg Tyr Thr
865	870	875
Asp Asn Lys Gly Asp	Leu Ile Phe Thr Asn His	Asp Val Tyr Gly Val
	885	890
Leu Asn Pro Gln Val	Ser Gly Phe Leu Ala	Met Trp Val Pro Thr Gly
	900	905
Ala Pro Ala Asn Gln Asp	Ala Arg Ser Thr Ala	Ser Thr Asn Met Ser
	915	920
Thr Asp Gly Ser Ala Tyr	His Ser Asn Ala Ala	Leu Asp Ser Gln Val
	930	935
Ile Phe Glu Ser Phe Ser	Asn Phe Gln Ala Met	Pro Thr Ser His Asp
945	950	955
Thr Tyr Thr Asn Val	Val Leu Ala Asn His	Ala Asp Gln Leu His Asp
	965	970
Trp Gly Ile Thr Ser Val	Gln Leu Ala Pro Gln	Tyr Arg Ser Ser Thr
	980	985
Asp Gly Thr Phe Leu Asp	Ala Ile Gln Asn Gly	Tyr Ala Phe Thr
	995	1000
Asp Arg Tyr Asp Leu Gly	Phe Gly Thr Pro Thr	Lys Tyr Gly Asp
	1010	1015
Asp Thr Asp Leu Arg Asn	Val Ile Lys Ala Leu	His Ala Asn Gly
	1025	1030
Met Gln Val Met Ala Asp	Phe Val Pro Asp Gln	Leu Tyr Thr Leu
	1040	1045
Pro Gly Lys Glu Leu Val	Gln Val Thr Arg Thr	Asn Asn Met Gly
	1055	1060
Glu Pro Asp Thr His Ser	Asp Ile Gln His Ile	Leu Tyr Val Thr
	1070	1075
Ser Thr Arg Gly Gly Gly	Asp Tyr Gln Lys Gln	Tyr Gly Gly Glu
	1085	1090
Phe Leu Ala Arg Leu Arg	Glu Arg Tyr Pro Asp	Leu Phe Thr Thr
	1100	1105
Arg Gln Ile Ser Thr Gly	Gln Thr Ile Asp Asp	Ser Val Lys Ile
	1115	1120
Lys Glu Trp Ser Ala Lys	Tyr Leu Asn Gly Thr	Ala Ile Gln Gly
	1130	1135
Arg Gly Ala Gly Tyr Val	Leu Arg Asp Asn Gly	Thr Asn Ala Tyr
	1145	1150
Tyr Lys Val Thr Ala Asn	Asp Gly Asn Val Asn	Leu Pro Lys Gln
	1160	1165
Leu Leu Gly Gln Pro Val	Met Thr Gly Phe Tyr	His Glu Ala Asp
	1175	1180
Gly Tyr His Phe Glu Thr	Leu Ser Gly Thr Ser	Ala Lys Asp Ala
	1190	1195
Phe Ile Met Gly Asp Asp	Gly Ala Leu Tyr Tyr	Phe Asp Asp Gln
	1205	1210
Gly Val Met Val Thr Gly	Lys Gln Arg Val His	Gln Asp Gln Tyr
	1220	1225
Phe Phe Leu Pro Asn Gly	Ile Ala Leu Thr Asp	Ala Phe Val Gln
	1235	1240
Thr Ala Asp Gly Gln Arg	Gln Tyr Tyr Asp Lys	Thr Gly Arg Leu
	1250	1255
Val Ile Asn Gln Tyr Val	Thr Asp His Gln Ala	Asn Ala Phe Arg
	1265	1270
Val Asp Ala Asp Gly Asn	Val Val Arg Asn Gln	Ala Leu Thr Val
	1280	1285
Asp Gly His Glu Gln Tyr	Phe Gly Thr Asn Gly	Val Gln Ala Lys
	1295	1300
Ala Val Leu Ile Arg Thr	Asp Asp Asn Gln Ala	Arg Tyr Tyr Glu
	1310	1315
Ala Asn Ser Gly Asn Leu	Val Lys Gln Gln Phe	Ile Leu Asp Thr
	1325	1330
Asp Gly His Trp Leu Tyr	Ala Asp Ala Ala Gly	Asp Leu Ala Arg
	1340	1345
Gly Gln Ile Thr Ile Gly	Gln Asp Thr Leu Tyr	Phe Asp Asp Asn
	1355	1360
Asn His Gln Val Lys Asp	Asp Phe Val Tyr Asp	Thr Asn Gly Val

20151105_CL6294WOPCT_SequenceListing

1370	1375	1380
His Tyr Phe Asn Gly Thr	Thr Gly Ala Glu Ile	Lys Gln Asp Tyr
1385	1390	1395
Ala Phe His Asp Gly Lys	Trp Tyr Tyr Phe Asp	Asp Leu Gly Arg
1400	1405	1410
Met Val Thr Gly Leu Gln	Arg Ile Asn Gly Glu	Tyr Arg Tyr Phe
1415	1420	1425
Asp Ala Asn Gly Val Gln	Leu Lys Gly Gly Thr	Val Thr Asp Pro
1430	1435	1440
Leu Thr His Gln Thr Tyr	Thr Phe Asp Ala Lys	Thr Gly Ala Gly
1445	1450	1455
Thr Leu Val Thr Ile		
1460		

<210> 9
 <211> 1426
 <212> PRT
 <213> Lactobacillus fermentum

<220>
 <221> MISC_FEATURE
 <222> (1)..(1426)
 <223> mature 2918 gtf

<400> 9

Asp Thr Val Leu Pro Ser Glu Gln Arg Ala Thr Gln Thr Thr Gln Thr	1	5	10	15
Thr Gln Thr Ser Glu Asp Thr Ser Ala Thr Lys Thr Pro Ala Ser Ala	20	25	30	
Ser Thr Ser Ser Ser Asp Asn Val Asp Thr Ser Asp Leu Pro Asp Ser	35	40	45	
Ala Ser Ala Val Val Asp Ser Ala Val Thr Ser Thr Ser Thr Ser Ala	50	55	60	
ser Val Val Ser Asp Ser Val Ala Val Pro Asp Thr Gly Ser Gln Phe	65	70	75	80
Met Ser Ser Ser Ala Pro Ala Ser Ser Ala Phe Val Lys Pro Ser Leu	85	90	95	
Thr Ser Thr Thr Ser Gly Ala Ser Gly Ser Gln Ser Ser Ala Val Thr	100	105	110	
Ser Ala Asn Asp Ser Ser Val Ala Thr Ser Ser Ser Ala Ser Ser Val	115	120	125	
Thr Thr Ala Thr Ser Glu Ser Ala Val Val Ser Ser Ala Val Ser Asp	130	135	140	
Gly Tyr His Asp Glu Gly Gly Asp Trp Val Tyr Tyr Arg Ala Gly Lys	145	150	155	160
Lys Leu Leu Gly Arg Gln Thr Ile Asp Thr Phe Ala Val Tyr Phe Asp	165	170	175	
Ala Asp Gly Lys Gln Val Lys Gly Asp Trp Arg Glu Ser Asp Gly Lys	180	185	190	
Arg Ala Tyr Thr Asp Gly Gln Glu Gly Arg Ala Leu Thr Gln Thr Gln	195	200	205	
Ala Val Asn Gly Val Ile Tyr Gly Phe Asn Gln Ser Gly Tyr Gln Ile	210	215	220	
Lys Asn Asp Phe Gly Gln Thr Ala Asn Arg Asp Thr Tyr Tyr Phe Asp	225	230	235	240
Ala Gln Gly His Val Val Thr Gly Ile Gln Thr Ile Ala Asn Lys Val	245	250	255	
Tyr Asp Phe Asp Glu Gln Gly Arg Met Leu Lys Gly Ile Ala Thr Ser	260	265	270	
Val Asp Asp Lys Met Met Tyr Phe Asp Asp Gln Thr Gly Val Gly Gln	275	280	285	
Pro Ala Asp His Pro Glu Phe Asn Pro Glu Thr Glu Pro Val Pro Asp	290	295	300	
Asp Asn Ile Lys His Asn Ala Ala His Gly Thr Thr Pro Glu Asp Phe	305	310	315	320
Asp Ser Met Ala Asp Tyr Leu Thr Ala Asp Thr Trp Tyr Arg Pro Thr	325	330	335	
Asp Ile Leu Glu Asn Gly Glu Thr Trp Arg Glu Ser Gln Pro Thr Glu				

20151105_CL6294WO PCT_SequenceListing

			340					345					350		
Phe	Arg	Pro	Leu	Leu	Ala	Thr	Trp	Trp	Pro	Thr	Lys	Gln	Thr	Gln	Ala
		355					360					365			
Asp	Tyr	Val	Asn	Tyr	Met	Asn	His	Ala	Leu	Asp	Met	Ala	Asn	Ala	Gly
	370					375					380				
Val	Ser	Ala	Ala	Asp	Ser	Glu	Ala	Thr	Leu	Thr	Ala	Ala	Thr	Asp	Ala
385					390					395					400
Ile	Gln	Ala	Val	Val	Glu	His	Gln	Ile	Thr	Val	Arg	Gln	Ser	Thr	Ala
			405						410					415	
Trp	Leu	Arg	Glu	Leu	Met	Ala	Ala	Phe	Val	Val	Thr	Gln	Pro	Gln	Trp
			420					425					430		
Asn	Lys	Thr	Ser	Glu	Asp	Val	Asn	Asp	Asp	His	Leu	Gln	Gly	Gly	Ala
		435					440					445			
Leu	Thr	Phe	Glu	Asn	Asn	Gly	Asp	Thr	Asp	Ala	Asn	Ser	Asp	Tyr	Arg
	450					455					460				
Leu	Met	Asn	Arg	Thr	Pro	Thr	Asn	Gln	Thr	Gly	Glu	Arg	Leu	Tyr	His
465					470					475					480
Ile	Asp	Asp	Ser	Leu	Gly	Gly	Tyr	Glu	Leu	Leu	Leu	Ala	Asn	Asp	Val
			485						490					495	
Asp	Asn	Ser	Asn	Pro	Gln	Val	Gln	Ala	Glu	Gln	Leu	Asn	Trp	Leu	Tyr
			500					505					510		
Tyr	Leu	Met	His	Phe	Gly	Asp	Ile	Thr	Ala	Asp	Asp	Pro	Asp	Ala	Asn
		515					520					525			
Phe	Asp	Ala	Ile	Arg	Ile	Asp	Ala	Val	Asp	Asn	Val	Asp	Ala	Asp	Leu
	530					535					540				
Leu	Gln	Leu	Ala	Ala	Gln	Tyr	Phe	Arg	Asp	Ala	Tyr	Gly	Met	Ala	Thr
545					550					555					560
Thr	Asp	Ala	Thr	Ser	Asn	Lys	His	Leu	Ser	Ile	Leu	Glu	Asp	Trp	Ser
			565						570					575	
His	Asn	Asp	Pro	Ala	Tyr	Met	Gln	Ala	His	Gly	Asn	Asp	Gln	Leu	Thr
			580					585					590		
Met	Asp	Asp	Tyr	Met	His	Thr	Gln	Leu	Ile	Trp	Ser	Leu	Thr	Lys	Pro
		595					600					605			
Glu	Ala	Gln	Arg	Gly	Thr	Met	Ala	Arg	Phe	Met	Asp	Phe	Tyr	Leu	Thr
	610					615					620				
Asn	Arg	Ala	Asn	Asp	Asp	Thr	Glu	Asn	Thr	Ala	Gln	Pro	Ser	Tyr	Ser
625					630					635					640
Phe	Val	Arg	Ala	His	Asp	Ser	Glu	Val	Gln	Thr	Val	Ile	Ala	Glu	Ile
				645					650					655	
Val	Thr	Lys	Leu	His	Pro	Glu	Ala	Gly	Asn	Gly	Leu	Met	Pro	Thr	Glu
			660					665					670		
Glu	Gln	Met	Ala	Glu	Ala	Phe	Lys	Ile	Tyr	Asn	Ala	Asp	Gln	Lys	Lys
		675					680					685			
Ala	Val	Lys	Thr	Tyr	Thr	His	Tyr	Asn	Met	Pro	Ser	Ala			

20151105_CL6294WOPCT_SequenceListing

				885					890					895		
Tyr	His	Ser	Asn 900	Ala	Ala	Leu	Asp	Ser 905	Gln	Val	Ile	Phe	Glu 910	Ser	Phe	
Ser	Asn	Phe 915	Gln	Ala	Met	Pro	Thr 920	Ser	His	Asp	Thr	Tyr 925	Thr	Asn	Val	
Val	Leu 930	Ala	Asn	His	Ala	Asp 935	Gln	Leu	His	Asp	Trp 940	Gly	Ile	Thr	Ser	
Val 945	Gln	Leu	Ala	Pro	Gln 950	Tyr	Arg	Ser	Ser	Thr 955	Asp	Gly	Thr	Phe	Leu 960	
Asp	Ala	Ile	Ile	Gln 965	Asn	Gly	Tyr	Ala	Phe 970	Thr	Asp	Arg	Tyr	Asp 975	Leu	
Gly	Phe	Gly	Thr 980	Pro	Thr	Lys	Tyr	Gly 985	Asp	Asp	Thr	Asp	Leu 990	Arg	Asn	
Val	Ile	Lys 995	Ala	Leu	His	Ala	Asn 1000	Gly	Met	Gln	Val	Met 1005	Ala	Asp	Phe	
Val	Pro 1010	Asp	Gln	Leu	Tyr	Thr 1015	Leu	Pro	Gly	Lys	Glu 1020	Leu	Val	Gln		
Val	Thr 1025	Arg	Thr	Asn	Asn	Met 1030	Gly	Glu	Pro	Asp	Thr 1035	His	Ser	Asp		
Ile	Gln 1040	His	Ile	Leu	Tyr	Val 1045	Thr	Ser	Thr	Arg	Gly 1050	Gly	Gly	Asp		
Tyr	Gln 1055	Lys	Gln	Tyr	Gly	Gly 1060	Glu	Phe	Leu	Ala	Arg 1065	Leu	Arg	Glu		
Arg	Tyr 1070	Pro	Asp	Leu	Phe	Thr 1075	Thr	Arg	Gln	Ile	Ser 1080	Thr	Gly	Gln		
Thr	Ile 1085	Asp	Asp	Ser	Val	Lys 1090	Ile	Lys	Glu	Trp	Ser 1095	Ala	Lys	Tyr		
Leu	Asn 1100	Gly	Thr	Ala	Ile	Gln 1105	Gly	Arg	Gly	Ala	Gly 1110	Tyr	Val	Leu		
Arg	Asp 1115	Asn	Gly	Thr	Asn	Ala 1120	Tyr	Tyr	Lys	Val	Thr 1125	Ala	Asn	Asp		
Gly	Asn 1130	Val	Asn	Leu	Pro	Lys 1135	Gln	Leu	Leu	Gly	Gln 1140	Pro	Val	Met		
Thr	Gly 1145	Phe	Tyr	His	Glu	Ala 1150	Asp	Gly	Tyr	His	Phe 1155	Glu	Thr	Leu		
Ser	Gly 1160	Thr	Ser	Ala	Lys	Asp 1165	Ala	Phe	Ile	Met	Gly 1170	Asp	Asp	Gly		
Ala	Leu 1175	Tyr	Tyr	Phe	Asp	Asp 1180	Gln	Gly	Val	Met	Val 1185	Thr	Gly	Lys		
Gln	Arg 1190	Val	His	Gln	Asp	Gln 1195	Tyr	Phe	Phe	Leu	Pro 1200	Asn	Gly	Ile		
Ala	Leu 1205	Thr	Asp	Ala	Phe	Val 1210	Gln	Thr	Ala	Asp	Gly 1215	Gln	Arg	Gln		
Tyr	Tyr 1220	Asp	Lys	Thr	Gly	Arg 1225	Leu	Val	Ile	Asn	Gln 1230	Tyr	Val	Thr		
Asp	His 1235	Gln	Ala	Asn	Ala	Phe 1240	Arg	Val	Asp	Ala	Asp 1245	Gly	Asn	Val		
Val	Arg 1250	Asn	Gln	Ala	Leu	Thr 1255	Val	Asp	Gly	His	Glu 1260	Gln	Tyr	Phe		
Gly	Thr 1265	Asn	Gly	Val	Gln	Ala 1270	Lys	Ala	Val	Leu	Ile 1275	Arg	Thr	Asp		
Asp	Asn 1280	Gln	Ala	Arg	Tyr	Tyr 1285	Glu	Ala	Asn	Ser	Gly 1290	Asn	Leu	Val		
Lys	Gln 1295	Gln	Phe	Ile	Leu	Asp 1300	Thr	Asp	Gly	His	Trp 1305	Leu	Tyr	Ala		
Asp	Ala 1310	Ala	Gly	Asp	Leu	Ala 1315	Arg	Gly	Gln	Ile	Thr 1320	Ile	Gly	Gln		
Asp	Thr 1325	Leu	Tyr	Phe	Asp	Asp 1330	Asn	Asn	His	Gln	Val 1335	Lys	Asp	Asp		
Phe	Val 1340	Tyr	Asp	Thr	Asn	Gly 1345	Val	His	Tyr	Phe	Asn 1350	Gly	Thr	Thr		
Gly	Ala 1355	Glu	Ile	Lys	Gln	Asp 1360	Tyr	Ala	Phe	His	Asp 1365	Gly	Lys	Trp		
Tyr	Tyr 1370	Phe	Asp	Asp	Leu	Gly 1375	Arg	Met	Val	Thr	Gly 1380	Leu	Gln	Arg		
Ile	Asn 1															

20151105_CL6294WOPCT_SequenceListing

1400 1405 1410
Phe Asp Ala Lys Thr Gly Ala Gly Thr Leu Val Thr Ile
1415 1420 1425

<210> 10
<211> 4281
<212> DNA
<213> Artificial sequence

<220>
<223> 2918 gtf with heterologous signal sequence

<400> 10
gatacagtg tgcctagcga gcaaagagca acacagacga cacaaacaac gcagacatca 60
gaggatacga gcgcgacgaa gacaccggca agcgcatcaa cgtcaagcag cgataacgtg 120
gatacgtcag atcttccgga tagcgccagc gcagttgtcg attcagcggg tacatcaaca 180
agcacgtcag cctcagtggt gagcgatagc gttgcagtcg cggatacggg atcacaatTT 240
atgtcatcat cagctcctgc gagcagcgcg tttgttaaac ctacgcttac gtcaacgacg 300
tcaggagcga gcggctcaca gagctcagca gtgacaagcg ccaatgattc aagcgctcgt 360
acaagctcat cagcttcac agttacgaca gcaacaagcg agtcagccgt tgtctcaagc 420
gcggtctcag acggctatca tgacgaagga ggagattggg tttactacag agcaggaaaa 480
aaactgcttg gaagacagac aattgatacg tttgctgttt actttgatgc tgacggaaaa 540
caagtgaag gcgactggag agaatcagat ggaaagagag cgtattatga tggacaagaa 600
ggaagagccc ttacgcaaac gcaagccgtt aatggagtga tctatggatt caatcaatca 660
ggataccaga tcaaaaacga ttttgccag acagcgaaca gagatacata ctacttcgac 720
gcacaaggcc atgtggttac aggcattcaa acaatcgca ataaagtta tgacttcgat 780
gaacaaggca gaatgcttaa aggaattgcc acatcagtcg atgacaagat gatgtatttt 840
gacgatcaaa caggcgtggg acaacctgca gatcacctcg agtttaacc ggaaacagaa 900
ccggtgcctg acgataacat caagcataat gcagcccacg gcacaacacc tgaagatttt 960
gatagcatgg cggactatct gacagctgat acatggtata gacctacaga tattctggag 1020
aatggagaaa catggagaga gagccaaccg acggaattta gaccgctgct ggcaacgtgg 1080
tggcctacaa aacagacaca agcagattat gtgaactata tgaaccacgc acttgacatg 1140
gctaattgctg gcgttagcgc tgcggtattca gaggcaacac ttacagcggc tacggatgcc 1200
attcaggctg ttgttagca ccaaattacg gttagacaaa gcacggcctg gcttagagaa 1260
cttatggcgg cttttgttgt tacacaacct caatggaata agacgagcga agatgtcaat 1320
gatgatcacc ttcaaggagg cgcactgaca tttgagaata acggagacac agatgcaaat 1380
agcgattata gacttatgaa tagaacaccg acaaatcaaa cgggcgagag actttatcat 1440
attgatgact cactgggagg ctacgagctg cttcttgcaa acgatgtgga caactcaaac 1500
ccgcaggttc aggcggaaca acttaactgg ctttactatc ttatgcattt cggagatatt 1560
acagccgatg acccgatgc taactttgac gcgatcagaa ttgacgccgt tgataatgtc 1620
gacgtgacc tgcttcagct tgctgccccaa tacttttagag atgcatatgg aatggccaca 1680
acagacgcca cgagcaataa acacctttca atccttgagg attggagcca taacgatcct 1740
gcttatatgc aggcacatgg aaatgaccag cttacaatgg atgactacat gcacacacaa 1800
ctgatttggc cactgacgaa accggaagca caaagaggaa cgatggcaag atttatggac 1860
ttttatctta caaatagagc taacgatgat acagaaaaca cagcgcaacc ttcatattca 1920
tttgtagag cacacgactc agaagtgcag acagttattg cagaaattgt tacgaaactt 1980
caccggagg caggcaacgg ccttatgcct acggaggaac agatggcaga ggcgtttaag 2040
atctacaatg cagacaaaaa gaaagcggtg aaaacatata cacactataa catgccttca 2100
gcctacgcta tgctgtgac aaataaggat gtgattctta gaattctacta cggcgatcct 2160
tacacggacg acggccagtt catggcaaca aagtcaccgt atttcgatgc aatttcaaca 2220
atgctgcaag caagaacaaa atatgttgca ggcggacaaa cgatggcggg tgaccaacat 2280
gatgtcctga cgagcgtgag atttggcaaa ggcgcgatga cagcaaatga ccttgagac 2340
gcggaaacga gaacagaggg cgtgggactg atcatcagca acaaccctaa gctgcaactg 2400
ggacagcagg ataacgtggt ccttcatatg ggcctggcac acgcaaatca ggctttcaga 2460
gcagtctgct ttacaacagc cacaggactg acgatctaca acgacgatga cgctcctatt 2520
agatatcgg acaataaggg cgacctgatc tttacgaatc acgatgttta cggcgcttctg 2580
aaccgcagg ttagcggctt ccttgctatg tgggttccga cgggcgcacc tgccaatcaa 2640
gacgcaagaa gcacggcttc aacgaatatg tcaacggatg gatcagctta tcattcaaac 2700
gcagctctgg attcacaagt tatctttgag tcatttagca actttcaagc aatgccgaca 2760
tcacacgata catacacgaa tgttgctcct gcaaaccatg cagaccaact tcacgattgg 2820
ggaattacgt cagtgcact tgaccgcgaa tatagatcaa gcacagacgg aacgtttctg 2880
gatgcaatta ttcaaatgg atatgctttt acagatagat atgatcttgg ctttggaaaca 2940
cctacgaagt acggcgacga cacggacctg agaaatgtga tcaaagccct tcatgcaaac 3000
ggcatgcaag tcatggcaga ttttgttcct gatcaactgt acacacttcc gggcaagaa 3060
ctggttcaag tgacaagaac aaataacatg ggcgaaccgg atacacacag cgatattcaa 3120
cacatcctgt atgttacatg aacaagagga ggcggagact atcagaaaca atatggcggc 3180
gaatttctgg cttagcttag agaaagatac ccggaccttt ttacgacgag acaaatatgc 3240
acaggccaaa caattgacga cagcgttaag attaaggagt ggtcagcgaa atatctgaac 3300

20151105_CL6294WOPCT_SequenceListing

ggcacagcaa	ttcaaggcag	aggcgctggc	tatgttctga	gagataatgg	aacgaatgca	3360
tactataaag	ttacggccaa	tgatggaaac	gtcaatcttc	ctaagcaact	gctggggccag	3420
ccggttatga	caggcttcta	tcacgaagca	gacggctacc	acttcgagac	actgtcaggc	3480
acatcagcca	aggacgcatt	tatcatggga	gatgatggcg	caactgtacta	tttcgatgac	3540
caaggcgtga	tggttacagg	aaaacaaaga	gttcatcagg	atcaatactt	ttttctgccg	3600
aatggcatcg	ctctgacgga	cgctttcggt	caaacagctg	atggacagag	acagtactac	3660
gataaaacag	gcagactggg	tattaaccaa	tatgtgacag	accatcaggc	gaatgccttc	3720
agagttgatg	cggacggaaa	tgctggtaga	aaccaagcac	ttacagtgga	cggacatgaa	3780
cagtatttcg	gcacgaacgg	agtgcaggca	aaagcagttc	tgattagaac	ggacgataat	3840
caagcgagat	attatgaggc	aaattcaggc	aatctggtga	aacaacaatt	tatccttgac	3900
acagatggcc	actggctgta	cgcagacgca	gcaggcgatc	ttgctagagg	ccagattaca	3960
atcgccagg	atacgctgta	ttttgatgat	aacaatcacc	aagttaaaga	tgacttcggt	4020
tatgatacga	atggagtcca	ttactttaat	ggcacaacag	gagcagagat	taaacaagat	4080
tacgcattcc	atgacggcaa	atggtactac	ttcgacgacc	tggaagaat	ggtcacggga	4140
cttcaagaaa	ttaatggaga	gtatagatac	tttgacgcga	acggcggtcca	actgaaagga	4200
ggcacagtga	cggatcctct	gacacatcaa	acatatacat	ttgatgcaaa	aacgggagcc	4260
ggcacgcttg	ttacaatttg	a				4281

<210> 11
 <211> 4521
 <212> DNA
 <213> Streptococcus sobrinus

<400> 11						
atggaaagaa	aattgcatta	caaattacac	aaggtaaaaa	aacagtgggt	aacgattgcc	60
gttgccctctg	ctgggttggc	tagcattggt	ggtgctgggt	cattaagcca	aactgtttct	120
gccgatgact	tagccaagga	acaagctgcg	gctagtcaac	aaaaggcagc	agccaatcag	180
aatgaggacg	aagtggcttc	tgatgcagct	gatactgcta	gtgcaaaagc	gacttccgaa	240
aaagaagttg	tccaatcttc	tgatacaaat	tcagaaacta	accaagttga	aactaaagat	300
caagctagcg	ctaaggaaag	tgctgacgca	gtagccaagc	aagcaccaca	agctggccct	360
gcaaccacta	gccaggttgc	aagctcagaa	agcagctctg	tagcgcctag	caaggaagct	420
gataaggcag	ctgctggatc	agttagccaa	aatgaagaag	aagcagccct	atcgcttgcc	480
aatattaaaa	agattgatgg	taagtattac	tatgttatgg	cagacggttc	ttataagaag	540
aactttgcc	ttacagttga	tgggtcaaat	ctttactttg	atgccaaaac	aggtgccctg	600
tcttcaacct	ctacctattc	tttcagtcaa	ggtttgacac	caattgtttc	tgattttcta	660
gtcaacaaca	aggctttcga	ttcttctgaa	aagagttttg	aattgggtga	tggtattttg	720
acagctgaaa	gctgggtaccg	tcctgctaag	attcttgaaa	atggttaaac	ttgggttgat	780
tctaaagaaa	ctgacctacg	cccagttctg	atgagctggg	ggccaaacaa	ggatacgcga	840
gttgccctacc	ttaactacat	gagcaaggca	cttgggtggc	aggaagaatt	cacaactgaa	900
acctcccaat	tgaccttgaa	tacagccgct	gagttgattc	aagctaaaat	tgaagctcgc	960
gtttctaaag	aacaagggaac	aaagtgggtg	cgtgaagcta	tggcagcctt	cgttgctacc	1020
caatctcggt	ggaataagga	cagcgaacaa	tacgataaag	ctgaccacct	gcaaggcgga	1080
gccctgctct	ataccaataa	caacttgaca	gagtgggcaa	attcaaaactg	gcgcctgctt	1140
aacctgtacc	caactcgta	agatggtaaa	accattact	ctaaggctga	caaatacggg	1200
ggttatgaat	tcctcttggc	caacgacgtg	gataactcta	acccagtcgt	tcaagcggaa	1260
atgctcaacc	aaatccacta	cctcatgaac	tggggtgaaa	ttgtgatggg	tgataagaat	1320
gccaaactttg	atggtattcg	tgctgatgcc	gtggataacg	tcaatgcaga	tactctgcaa	1380
ctctacacca	actactttaa	ttctgtttat	ggtgtcaaca	agtctgaagc	ccaagccctg	1440
gctcacactc	cagtccttga	agcatggtct	tacaatgata	atgactataa	ccaagacacc	1500
aacggggctg	ccctggctat	ggacaatggg	ctacgctttt	ccctgcttta	taccttgacc	1560
cgctccgatca	atgaacggac	acctgggtatg	tcaaccctga	ttaaatcaga	atatgggttg	1620
actgaccgga	ctaagaatga	taagtatgga	gatacccaac	catcttatgt	ttttgttcgg	1680
gcgcgatgact	cagaagtgc	aaccgttatt	gcacaaatca	tcaaggaaaa	aattgatcca	1740
acaaccgatg	gtttcacctt	caccttgga	caattgaaac	aggcctttga	aatctacaac	1800
aaggatatga	atagtgttaa	caagcactat	acccactata	atatcccagc	agcctacgct	1860
gtcatgttgt	ctaatatgga	atccgtaacc	cgggtttact	atggtgacct	cttcaccgat	1920
gatggtcaat	acatggcatc	taaatctcca	tattatgatg	ccatcaacac	tctcttgccg	1980
gctcgcatc	gttacgcagc	cggtgggtcaa	attatggaac	acaattccta	caaaccatca	2040
gcagccatga	aggcagctca	tccagatgct	ggtaatgtcc	ttggtaacag	cgaagtcttg	2100
gtatcggttc	gtttcgggtca	agatgtcatg	tctgccgatg	atatgactgg	tggtgaagctg	2160
gctaagacct	ctggatgtgt	caccctgatt	tctaacaacc	ctgaattgga	attggatgtc	2220
aatgaagaaa	tcaagggttaa	cgttgggtaaa	atccatgctg	gccaagccta	ccgtcccttg	2280
cttttgacaa	ctgataaggg	tctgcaaaaag	tatctcaatg	attctgatac	caagttgacc	2340
aagattgctg	acaaggatgg	tttcattacc	ttcaagggtg	gcgaaatcaa	gggttacaaa	2400
caagtcgaag	tcaatggtta	cctctcagtt	tgggtaccag	ttggtgctaa	ggctgaccaa	2460
gacattcggt	tggccccctt	aacagcggct	aagggtgaaa	aggccaagac	ttacacagct	2520
agccaagctt	tggaatcgca	attaatctac	gaaggcttct	caaacttcca	agattttgtt	2580
caaaaagatt	ccaatacac	caacaagaag	attgctgaaa	atactgacct	cttcaaggct	2640

20151105_CL6294WOPCT_SequenceListing

tgggggtgtta	cctcatttga	aatggcacca	caatacgttt	cagcaaccga	tggaaccttc	2700
ctggatttcta	tcattgaaaa	cggttatgcc	ttcacccgacc	gttatgacct	tgccatgagc	2760
aagaacaata	aatacgggtc	taaggaagat	ttggccaacg	ccctcaaggc	ccttcacgca	2820
gctgggtattc	aagccattgc	tgactgggta	ccagaccaaa	tttaccact	gcctggtaag	2880
gaagttgtta	ccgctagccg	ggttgacaac	tacggtcgtg	tgaaagttga	ccaaccacta	2940
gttgaaaaaac	tttatctggc	caacaccaag	agctcaggaa	aagattttcca	agctaaatac	3000
ggtgggtgaat	tcttagcaga	actgcaaaaag	aaatatcctg	aaatgttcac	gactaagatg	3060
atttcaactg	gtaaaaccat	tgatccatct	gtcaaattga	aagaatgggtc	tgctaagtac	3120
ttcaacggaa	ccaacgtcct	tgatcggtgt	acggactata	tcctcagtga	tgaagggtact	3180
ggtaaaatact	ttaccgtcaa	tgaaaaaggt	gacttcttac	ctgcctcatt	gactggtaat	3240
aaggatgcc	agactggttt	ctacaacgat	ggtaagggca	ttgtttacta	cacaaccgcc	3300
ggtaacaagg	ctagatcagc	cttcgtaaca	gaagcaggt	atacctatta	cttcgactac	3360
accggccata	tggtaacagg	ccctaacgtt	attaacacta	aattctatta	cttcttgcca	3420
aatgggtatca	tgcttaagga	tgctattaag	caggatgaaa	aaggtcgttc	cgtatactac	3480
ggtaagactg	gtgttatgta	caaggggtggc	cgcgataatg	aatgggttcgc	catgacagac	3540
tctaaggggtc	aaatgcgttt	ccgtcacctt	gacaggtacg	gcttcatgtc	tatcggtttg	3600
gtaaccatca	acaaaaatgt	tcagtattat	gatgaaaatg	gtttccaagt	taaaggtgaa	3660
tttgtaaccg	atcaggatgg	acaaacccgt	tacttcgacc	aagggttcagg	taacttggtt	3720
aagggacaat	tcctcaacaa	ggatggcaac	tggtactacc	ttgatgacca	agggctagtt	3780
gctaaaggag	ctcagacaat	taaagggtcaa	aagctttact	ttgacacaaa	aaccggtgtc	3840
caagttaaag	gggattttgt	aacggataaa	gatggcaata	ccttctttta	cagtggagat	3900
actggcgatt	taatccttgg	tcagttcttc	tcaactggaa	ataacgcttg	gttctatgct	3960
gatgaaaatg	gtcatgtcgc	taagggagct	aagactatca	gaggtcagaa	gctctacttt	4020
gatacaaaaa	caggtcagca	agctaaggga	cgctttatcc	gtgatgacaa	gggggttcgt	4080
tactatgatg	ctgacacagg	taccttggt	accaacgctt	tccttgaaac	taaggctggt	4140
tctaaccaat	gctattacat	gggagcagat	ggttatgctg	tcaaggggaa	ccagaccata	4200
aaaaatcagc	acatgtat	tgatgctgaa	actggccaac	aagctaaggg	aattatagtg	4260
acagatgcc	atggtcgcaa	gtatttctat	gatactttta	ctggcagtcg	tggtgtaaac	4320
caatttggtt	tggttaatgg	aaattggtat	ttctttggtt	atgatggagc	tgtagtaaca	4380
ggtttccatg	atatcaaggg	acaacacctt	tacttcaatt	ccgatggaac	acaggccaaa	4440
gggactacgg	taaaaattgg	caatcgcagc	tatacctttg	atgctcacac	tggtgagctg	4500
acatctgttc	attatggctg	a				4521

<210> 12
 <211> 1506
 <212> PRT
 <213> Streptococcus sobrinus

<400> 12
 Met Glu Arg Lys Leu His Tyr Lys Leu His Lys Val Lys Lys Gln Trp
 1 5 10 15
 Val Thr Ile Ala Val Ala Ser Ala Gly Leu Ala Ser Ile Val Gly Ala
 20 25 30
 Gly Ser Leu Ser Gln Thr Val Ser Ala Asp Asp Leu Ala Lys Glu Gln
 35 40 45
 Ala Ala Ala Ser Gln Gln Lys Ala Ala Ala Asn Gln Asn Glu Asp Glu
 50 55 60
 Val Ala Ser Asp Ala Ala Asp Thr Ala Ser Ala Lys Ala Thr Ser Glu
 65 70 75 80
 Lys Glu Val Val Gln Ser Ser Asp Thr Asn Ser Glu Thr Asn Gln Val
 85 90 95
 Glu Thr Lys Asp Gln Ala Ser Ala Lys Glu Ser Ala Asp Ala Val Ala
 100 105 110
 Lys Gln Ala Pro Gln Ala Gly Pro Ala Thr Thr Ser Gln Val Ala Ser
 115 120 125
 Ser Glu Ser Ser Ser Val Ala Pro Ser Lys Glu Ala Asp Lys Ala Ala
 130 135 140
 Ala Gly Ser Val Ser Gln Asn Glu Glu Glu Ala Ala Leu Ser Leu Ala
 145 150 155 160
 Asn Ile Lys Lys Ile Asp Gly Lys Tyr Tyr Val Met Ala Asp Gly
 165 170 175
 Ser Tyr Lys Lys Asn Phe Ala Ile Thr Val Asp Gly Gln Met Leu Tyr
 180 185 190
 Phe Asp Ala Lys Thr Gly Ala Leu Ser Ser Thr Ser Thr Tyr Ser Phe
 195 200 205
 Ser Gln Gly Leu Thr Pro Ile Val Ser Asp Phe Ser Val Asn Asn Lys
 210 215 220
 Ala Phe Asp Ser Ser Glu Lys Ser Phe Glu Leu Val Asp Gly Tyr Leu

20151105_CL6294WOPCT_SequenceListing

225	Thr	Ala	Glu	Ser	Trp	230	Tyr	Arg	Pro	Ala	Lys	235	Ile	Leu	Glu	Asn	Gly	240	Lys
				245	Ser	Lys	Glu	Thr	Asp	Leu	Arg	250	Pro	Val	Leu	Met	255	Ser	
			260	Asn	Lys	Asp	Thr	Gln	Val	Ala	Tyr	265	Leu	Asn	Tyr	Met	270	Ser	
			275	Gly	Gly	Lys	Glu	280	Phe	Thr	Thr	285	Glu	Thr	Ser	Gln	Leu		
			290	Leu	Ala	Ala	Glu	295	Leu	Ile	Gln	300	Ala	Lys	Ile	Glu	Ala	Arg	
305	Thr	Leu	Asn	Thr	Ala	310	Gly	Thr	Lys	Trp	Leu	315	Arg	Glu	Ala	Met	320	Ala	
	Val	Ser	Lys	Glu	Gln	325	Gly	Thr	Lys	Trp	Leu	330	Arg	Glu	Ala	Met	335	Ala	
	Phe	Val	Ala	Thr	Gln	340	Ser	Arg	Trp	Asn	Lys	345	Asp	Ser	Glu	Gln	350	Tyr	
	Lys	Ala	Asp	His	Leu	Gln	Gly	Gly	Ala	Leu	Leu	355	Tyr	Thr	Asn	Asn	360	Asn	
	Leu	Thr	Glu	Trp	Ala	Asn	Ser	365	Asn	Trp	Arg	370	Leu	Leu	Asn	Arg	375	Thr	
	Thr	Arg	Gln	Asp	Gly	Lys	380	Thr	His	Tyr	Ser	385	Lys	Ala	Asp	Lys	390	Tyr	
	Gly	Tyr	Glu	Phe	Leu	Leu	Ala	395	Asn	Asp	Val	400	Asp	Asn	Ser	Asn	405	Pro	
	Val	Gln	Ala	Glu	Met	Leu	Asn	410	Gln	Ile	His	415	Tyr	Leu	Met	Asn	420	Trp	
	Glu	Ile	Val	Met	Gly	Asp	Lys	425	Asn	Ala	Asn	430	Phe	Asp	Gly	Ile	435	Arg	
	Asp	Ala	Val	Asp	Asn	Val	Asn	440	Ala	Asp	Thr	445	Leu	Gln	Leu	Tyr	450	Thr	
	Tyr	Phe	Asn	Ser	Val	Tyr	Gly	455	Val	Asn	Lys	460	Glu	Ala	Gln	Ala	465	Leu	
	Ala	His	Ile	Ser	Val	Leu	Glu	470	Ala	Trp	Ser	475	Tyr	Asn	Asp	Asn	480	Tyr	
	Asn	Gln	Asp	Thr	Asn	Gly	Ala	485	Ala	Leu	Ala	490	Met	Asp	Asn	Gly	495	Leu	
	Phe	Ser	Leu	Leu	Tyr	Thr	Leu	500	Arg	Pro	Ile	505	Asn	Glu	Arg	Thr	510	Pro	
	Gly	Met	Ser	Thr	Leu	Ile	Lys	515	Ser	Glu	Tyr	520	Gly	Leu	Thr	Asp	525	Thr	
	Lys	Asn	Asp	Lys	Tyr	Gly	Asp	530	Thr	Gln	Pro	535	Ser	Tyr	Val	Phe	540	Arg	
545	Ala	His	Asp	Ser	Glu	Val	Gln	545	Thr	Val	Ile	550	Ala	Gln	Ile	Ile	555	Glu	
	Lys	Ile	Asp	Pro	Thr	Thr	Asp	560	Gly	Phe	Thr	565	Thr	Phe	Thr	Leu	570	Lys	
	Lys	Gln	Ala	Phe	Glu	Ile	Tyr	575	Asn	Lys	Asp	580	Met	Asn	Ser	Val	585	Asn	
	His	Tyr	Thr	His	Tyr	Asn	Ile	590	Pro	Ala	Ala	595	Tyr	Ala	Val	Met	600	Leu	
	Asn	Met	Glu	Ser	Val	Thr	Arg	605	Val	Tyr	Tyr	610	Gly	Asp	Leu	Phe	615	Thr	
625	Asp	Gly	Gln	Tyr	Met	Ala	Ser	620	Lys	Ser	Pro	625	Tyr	Tyr	Asp	Ala	630	Asn	
	Thr	Leu	Leu	Arg	Ala	Arg	Ile	635	Arg	Tyr	Ala	640	Ala	Gly	Gly	Gln	645	Met	
	Glu	His	Asn	Ser	Tyr	Lys	Pro	650	Ser	Ala	Ala	655	Met	Lys	Ala	Ala	660	Pro	
	Asp	Ala	Gly	Asn	Val	Leu	Gly	665	Asn	Ser	Glu	670	Val	Leu	Val	Ser	675	Arg	
	Phe	Gly	Gln	Asp	Val	Met	Ser	680	Ala	Asp	Asp	685	Met	Thr	Gly	Gly	690	Lys	
705	Ala	Lys	Thr	Ser	Gly	Met	Phe	695	Thr	Leu	Ile	700	Ser	Asn	Asn	Pro	705	Leu	
	Glu	Leu	Asp	Val	Asn	Glu	Glu	710	Ile	Lys	Val	715	Asn	Val	Gly	Lys	720	His	
	Ala	Gly	Gln	Ala	Tyr	Arg	Pro	725	Leu	Leu	Thr	730	Thr	Thr	Asp	Lys	735	Leu	
	Gln	Lys	Tyr	Leu	Asn	Asp	Ser	740	Thr	Lys	Leu	745	Thr	Lys	Ile	Ala	750	Asp	

20151105_CL6294WOPCT_SequenceListing

```

770          775          780
Lys Asp Gly Phe Ile Thr Phe Lys Gly Ser Glu Ile Lys Gly Tyr Lys
785 Gln Val Glu Val Asn Gly Tyr Leu Ser Val Trp Val Pro Val Gly Ala
805          810          815
Lys Ala Asp Gln Asp Ile Arg Val Ala Pro Ser Thr Ala Ala Lys Gly
820          825          830
Glu Lys Ala Lys Thr Tyr Thr Ala Ser Gln Ala Leu Glu Ser Gln Leu
835          840          845
Ile Tyr Glu Gly Phe Ser Asn Phe Gln Asp Phe Val Gln Lys Asp Ser
850          855          860
Gln Tyr Thr Asn Lys Lys Ile Ala Glu Asn Thr Asp Leu Phe Lys Ala
865          870          875
Trp Gly Val Thr Ser Phe Glu Met Ala Pro Gln Tyr Val Ser Ala Thr
885          890          895
Asp Gly Thr Phe Leu Asp Ser Ile Ile Glu Asn Gly Tyr Ala Phe Thr
900          905          910
Asp Arg Tyr Asp Leu Ala Met Ser Lys Asn Asn Lys Tyr Gly Ser Lys
915          920          925
Glu Asp Leu Ala Asn Ala Leu Lys Ala Leu His Ala Ala Gly Ile Gln
930          935          940
Ala Ile Ala Asp Trp Val Pro Asp Gln Ile Tyr Gln Leu Pro Gly Lys
945          950          955
Glu Val Val Thr Ala Ser Arg Val Asp Asn Tyr Gly Arg Val Lys Val
965          970          975
Asp Gln Pro Leu Val Glu Lys Leu Tyr Leu Ala Asn Thr Lys Ser Ser
980          985          990
Gly Lys Asp Phe Gln Ala Lys Tyr Gly Gly Glu Phe Leu Ala Glu Leu
995          1000          1005
Gln Lys Lys Tyr Pro Glu Met Phe Thr Thr Lys Met Ile Ser Thr
1010          1015          1020
Gly Lys Thr Ile Asp Pro Ser Val Lys Leu Lys Glu Trp Ser Ala
1025          1030          1035
Lys Tyr Phe Asn Gly Thr Asn Val Leu Asp Arg Gly Thr Asp Tyr
1040          1045          1050
Ile Leu Ser Asp Glu Gly Thr Gly Lys Tyr Phe Thr Val Asn Glu
1055          1060          1065
Lys Gly Asp Phe Leu Pro Ala Ser Leu Thr Gly Asn Lys Asp Ala
1070          1075          1080
Lys Thr Gly Phe Tyr Asn Asp Gly Lys Gly Ile Val Tyr Tyr Thr
1085          1090          1095
Thr Ala Gly Asn Lys Ala Arg Ser Ala Phe Val Thr Glu Ala Gly
1100          1105          1110
Asn Thr Tyr Tyr Phe Asp Tyr Thr Gly His Met Val Thr Gly Pro
1115          1120          1125
Asn Val Ile Asn Thr Lys Phe Tyr Tyr Phe Leu Pro Asn Gly Ile
1130          1135          1140
Met Leu Lys Asp Ala Ile Lys Gln Asp Glu Lys Gly Arg Ser Val
1145          1150          1155
Tyr Tyr Gly Lys Thr Gly Val Met Tyr Lys Gly Gly Arg Asp Asn
1160          1165          1170
Glu Trp Phe Ala Met Thr Asp Ser Lys Gly Gln Met Arg Phe Arg
1175          1180          1185
His Phe Asp Arg Tyr Gly Phe Met Ser Ile Gly Leu Val Thr Ile
1190          1195          1200
Asn Gln Asn Val Gln Tyr Tyr Asp Glu Asn Gly Phe Gln Val Lys
1205          1210          1215
Gly Glu Phe Val Thr Asp Gln Asp Gly Gln Thr Arg Tyr Phe Asp
1220          1225          1230
Gln Gly Ser Gly Asn Leu Val Lys Gly Gln Phe Leu Asn Lys Asp
1235          1240          1245
Gly Asn Trp Tyr Tyr Leu Asp Asp Gln Gly Leu Val Ala Lys Gly
1250          1255          1260
Ala Gln Thr Ile Lys Gly Gln Lys Leu Tyr Phe Asp Thr Lys Thr
1265          1270          1275
Gly Val Gln Val Lys Gly Asp Phe Val Thr Asp Lys Asp Gly Asn
1280          1285          1290
Thr Phe Phe Tyr Ser Gly Asp Thr Gly Asp Leu Ile Leu Gly Gln

```

20151105_CL6294WOPCT_SequenceListing

```

1295      1300      1305
Phe Phe Ser Thr Gly Asn Asn Ala Trp Phe Tyr Ala Asp Glu Asn
1310      1315      1320
Gly His Val Ala Lys Gly Ala Lys Thr Ile Arg Gly Gln Lys Leu
1325      1330      1335
Tyr Phe Asp Thr Lys Thr Gly Gln Gln Ala Lys Gly Arg Phe Ile
1340      1345      1350
Arg Asp Asp Lys Gly Val Arg Tyr Tyr Asp Ala Asp Thr Gly Thr
1355      1360      1365
Leu Val Thr Asn Ala Phe Leu Glu Thr Lys Ala Gly Ser Asn Gln
1370      1375      1380
Trp Tyr Tyr Met Gly Ala Asp Gly Tyr Ala Val Lys Gly Asn Gln
1385      1390      1395
Thr Ile Lys Asn Gln His Met Tyr Phe Asp Ala Glu Thr Gly Gln
1400      1405      1410
Gln Ala Lys Gly Ile Ile Val Thr Asp Ala Asn Gly Arg Lys Tyr
1415      1420      1425
Phe Tyr Asp Thr Phe Thr Gly Ser Arg Val Val Asn Gln Phe Val
1430      1435      1440
Leu Val Asn Gly Asn Trp Tyr Phe Phe Gly Tyr Asp Gly Ala Ala
1445      1450      1455
Val Thr Gly Phe His Asp Ile Lys Gly Gln His Leu Tyr Phe Asn
1460      1465      1470
Ser Asp Gly Thr Gln Ala Lys Gly Thr Thr Val Lys Ile Gly Asn
1475      1480      1485
Arg Ser Tyr Thr Phe Asp Ala His Thr Gly Glu Leu Thr Ser Val
1490      1495      1500
His Tyr Gly
1505

```

```

<210> 13
<211> 1465
<212> PRT
<213> Streptococcus sobrinus

```

```

<220>
<221> MISC_FEATURE
<222> (1)..(1465)
<223> mature 2920 gtf

```

```

<400> 13
Asp Asp Leu Ala Lys Glu Gln Ala Ala Ala Ser Gln Gln Lys Ala Ala
1      5      10      15
Ala Asn Gln Asn Glu Asp Glu Val Ala Ser Asp Ala Ala Asp Thr Ala
      20      25      30
Ser Ala Lys Ala Thr Ser Glu Lys Glu Val Val Gln Ser Ser Asp Thr
      35      40      45
Asn Ser Glu Thr Asn Gln Val Glu Thr Lys Asp Gln Ala Ser Ala Lys
      50      55      60
Glu Ser Ala Asp Ala Val Ala Lys Gln Ala Pro Gln Ala Gly Pro Ala
65      70      75      80
Thr Thr Ser Gln Val Ala Ser Ser Glu Ser Ser Ser Val Ala Pro Ser
      85      90      95
Lys Glu Ala Asp Lys Ala Ala Ala Gly Ser Val Ser Gln Asn Glu Glu
      100      105      110
Glu Ala Ala Leu Ser Leu Ala Asn Ile Lys Lys Ile Asp Gly Lys Tyr
      115      120      125
Tyr Tyr Val Met Ala Asp Gly Ser Tyr Lys Lys Asn Phe Ala Ile Thr
      130      135      140
Val Asp Gly Gln Met Leu Tyr Phe Asp Ala Lys Thr Gly Ala Leu Ser
145      150      155      160
Ser Thr Ser Thr Tyr Ser Phe Ser Gln Gly Leu Thr Pro Ile Val Ser
      165      170      175
Asp Phe Ser Val Asn Asn Lys Ala Phe Asp Ser Ser Glu Lys Ser Phe
      180      185      190
Glu Leu Val Asp Gly Tyr Leu Thr Ala Glu Ser Trp Tyr Arg Pro Ala
195      200      205
Lys Ile Leu Glu Asn Gly Lys Thr Trp Val Asp Ser Lys Glu Thr Asp

```

20151105_CL6294WOPCT_SequenceListing

210	Leu	Arg	Pro	Val	Leu	Met	215	Ser	Trp	Trp	Pro	Asn	220	Lys	Asp	Thr	Gln	Val
225	Ala	Tyr	Leu	Asn	Tyr	Met	230	Ser	Lys	Ala	Leu	Gly	235	Gly	Lys	Glu	Glu	Phe
					245						250						255	
	Thr	Thr	Glu	Thr	Ser	Gln	Leu	Thr	Leu	Asn	Thr	Ala	Ala	Glu	Leu	Ile		
				260					265							270		
	Gln	Ala	Lys	Ile	Glu	Ala	Arg	Val	Ser	Lys	Glu	Gln	Gly	Thr	Lys	Trp		
			275					280										
	Leu	Arg	Glu	Ala	Met	Ala	Ala	Phe	Val	Ala	Thr	Gln	Ser	Arg	Trp	Asn		
		290				295												
	Lys	Asp	Ser	Glu	Gln	Tyr	Asp	Lys	Ala	Asp	His	Leu	Gln	Gly	Gly	Ala		
305					310						315					320		
	Leu	Leu	Tyr	Thr	Asn	Asn	Leu	Thr	Glu	Trp	Ala	Asn	Ser	Asn	Trp			
				325					330							335		
	Arg	Leu	Leu	Asn	Arg	Thr	Pro	Thr	Arg	Gln	Asp	Gly	Lys	Thr	His	Tyr		
				340					345							350		
	Ser	Lys	Ala	Asp	Lys	Tyr	Gly	Gly	Tyr	Glu	Phe	Leu	Leu	Ala	Asn	Asp		
			355					360								365		
	Val	Asp	Asn	Ser	Asn	Pro	Val	Val	Gln	Ala	Glu	Met	Leu	Asn	Gln	Ile		
		370					375											
	His	Tyr	Leu	Met	Asn	Trp	Gly	Glu	Ile	Val	Met	Gly	Asp	Lys	Asn	Ala		
385					390						395					400		
	Asn	Phe	Asp	Gly	Ile	Arg	Val	Asp	Ala	Val	Asp	Asn	Val	Asn	Ala	Asp		
				405												415		
	Thr	Leu	Gln	Leu	Tyr	Thr	Asn	Tyr	Phe	Asn	Ser	Val	Tyr	Gly	Val	Asn		
				420					425							430		
	Lys	Ser	Glu	Ala	Gln	Ala	Leu	Ala	His	Ile	Ser	Val	Leu	Glu	Ala	Trp		
			435					440								445		
	Ser	Tyr	Asn	Asp	Asn	Asp	Tyr	Asn	Gln	Asp	Thr	Asn	Gly	Ala	Ala	Leu		
		450				455						460						
	Ala	Met	Asp	Asn	Gly	Leu	Arg	Phe	Ser	Leu	Leu	Tyr	Thr	Leu	Thr	Arg		
465					470						475					480		
	Pro	Ile	Asn	Glu	Arg	Thr	Pro	Gly	Met	Ser	Thr	Leu	Ile	Lys	Ser	Glu		
				485						490						495		
	Tyr	Gly	Leu	Thr	Asp	Arg	Thr	Lys	Asn	Asp	Lys	Tyr	Gly	Asp	Thr	Gln		
				500					505							510		
	Pro	Ser	Tyr	Val	Phe	Val	Arg	Ala	His	Asp	Ser	Glu	Val	Gln	Thr	Val		
			515					520								525		
	Ile	Ala	Gln	Ile	Ile	Lys	Glu	Lys	Ile	Asp	Pro	Thr	Thr	Asp	Gly	Phe		
		530				535										540		
	Thr	Phe	Thr	Leu	Asp	Gln	Leu	Lys	Gln	Ala	Phe	Glu	Ile	Tyr	Asn	Lys		
545					550						555					560		
	Asp	Met	Asn	Ser	Val	Asn	Lys	His	Tyr	Thr	His	Tyr	Asn	Ile	Pro	Ala		
				565						570						575		
	Ala	Tyr	Ala	Val	Met	Leu	Ser	Asn	Met	Glu	Ser	Val	Thr	Arg	Val	Tyr		
				580					585							590		
	Tyr	Gly	Asp	Leu	Phe	Thr	Asp	Asp	Gly	Gln	Tyr	Met	Ala	Ser	Lys	Ser		
			595					600					605					
	Pro	Tyr	Tyr	Asp	Ala	Ile	Asn	Thr	Leu	Leu	Arg	Ala	Arg	Ile	Arg	Tyr		
		610				615						620						
	Ala	Ala	Gly	Gly	Gln	Ile	Met	Glu	His	Asn	Ser	Tyr	Lys	Pro	Ser	Ala		
625					630						635					640		
	Ala	Met	Lys	Ala	Ala	His	Pro	Asp	Ala	Gly	Asn	Val	Leu	Gly	Asn	Ser		
				645						650						655		
	Glu	Val	Leu	Val	Ser	Val	Arg	Phe	Gly	Gln	Asp	Val	Met	Ser	Ala	Asp		
				660					665							670		
	Asp	Met	Thr	Gly	Gly	Lys	Leu	Ala	Lys	Thr	Ser	Gly	Met	Phe	Thr	Leu		
			675					680								685		
	Ile	Ser	Asn	Asn	Pro	Glu	Leu	Glu	Leu	Asp	Val	Asn	Glu	Glu	Ile	Lys		
		690				695												
	Val	Asn	Val	Gly	Lys	Ile	His	Ala	Gly	Gln	Ala	Tyr	Arg	Pro	Leu	Leu		
705					710						715					720		
	Leu	Thr	Thr	Asp	Lys	Gly	Leu	Gln	Lys	Tyr	Leu	Asn	Asp	Ser	Asp	Thr		
				725						730						735		
	Lys	Leu	Thr	Lys	Ile	Ala	Asp	Lys	Asp	Gly	Phe	Ile	Thr	Phe	Lys	Gly		
			740						745							750		
	Ser	Glu	Ile	Lys	Gly	Tyr	Lys	Gln	Val	Glu	Val	Asn	Gly	Tyr	Leu	Ser		

20151105_CL6294WO PCT_SequenceListing

Val	Trp	Val	Pro	Val	Gly	Ala	Lys	Ala	Asp	Gln	Asp	Ile	Arg	Val	Ala
Pro	770	Thr	Ala	Ala	Lys	775	Glu	Lys	Ala	Lys	780	Thr	Tyr	Thr	Ala
785	Ser	Ala	Leu	Glu	Ser	790	Leu	Ile	Tyr	Glu	795	Phe	Ser	Asn	800
Gln	Ala	Leu	Glu	805	Gln	Leu	Ile	Tyr	810	Gly	Phe	Ser	Asn	815	Gln
Asp	Phe	Val	Gln	Lys	Asp	Ser	Gln	Tyr	825	Thr	Asn	Lys	Lys	Ile	Ala
Asn	Thr	Asp	Leu	Phe	Lys	Ala	Trp	Gly	Val	Thr	Ser	Phe	Glu	Met	Ala
Pro	Gln	Tyr	Val	Ser	Ala	Thr	840	Asp	Gly	Thr	Phe	Leu	Asp	Ser	Ile
Glu	850	Asn	Gly	Tyr	Ala	Phe	855	Thr	Asp	Arg	Tyr	Asp	Leu	Ala	Met
865	Asn	Asn	Lys	Tyr	Gly	Ser	Lys	Glu	Asp	Leu	875	Ala	Asn	Ala	Leu
Asn	Asn	Lys	Tyr	Gly	885	Ser	Lys	Glu	Asp	Leu	890	Ala	Asn	Ala	Lys
Leu	His	Ala	Ala	Gly	Ile	Gln	Ala	Ile	Ala	Asp	Trp	Val	Pro	Asp	Gln
Ile	Tyr	Gln	Leu	Pro	Gly	Lys	Glu	Val	Val	Thr	Ala	Ser	Arg	Val	Asp
Asn	Tyr	Gly	Arg	Val	Lys	Val	920	Asp	Gln	Pro	Leu	Val	Glu	Lys	Leu
Leu	930	Ala	Asn	Thr	Lys	Ser	935	Gly	Lys	Asp	Phe	Gln	Ala	Lys	Tyr
945	Gly	Glu	Phe	Leu	Ala	Glu	Leu	Gln	Lys	Lys	Tyr	Pro	Glu	Met	Phe
Gly	Glu	Phe	Leu	Ala	965	Glu	Leu	Gln	Lys	Lys	970	Tyr	Pro	Glu	Met
Thr	Lys	Met	Ile	Ser	Thr	Gly	Lys	Thr	Ile	Asp	Pro	Ser	Val	Lys	Leu
Lys	Glu	Trp	Ser	Ala	Lys	Tyr	Phe	Asn	Gly	Thr	Asn	Val	Leu	Asp	Arg
Gly	Thr	Asp	Tyr	Ile	Leu	Ser	1000	Asp	Glu	Gly	Thr	Gly	Lys	Tyr	Phe
Thr	Val	Asn	Glu	Lys	Gly	Asp	1015	Phe	Leu	Pro	Ala	Ser	Leu	Thr	Gly
Asn	Lys	Asp	Ala	Lys	Thr	Gly	1030	Phe	Tyr	Asn	Asp	Gly	Lys	Gly	Ile
Val	Tyr	Tyr	Thr	Thr	Ala	Gly	1045	Asn	Lys	Ala	Arg	Ser	Ala	Phe	Val
Thr	Glu	Ala	Gly	Asn	Thr	Tyr	1060	Tyr	Phe	Asp	Tyr	Thr	Gly	His	Met
Val	Thr	Gly	Pro	Asn	Val	Ile	1075	Asn	Thr	Lys	Phe	Tyr	Tyr	Phe	Leu
Pro	Asn	Gly	Ile	Met	Leu	Lys	1090	Asp	Ala	Ile	Lys	Gln	Asp	Glu	Lys
Gly	Arg	Ser	Val	Tyr	Tyr	Gly	1105	Lys	Thr	Gly	Val	Met	Tyr	Lys	Gly
Gly	Arg	Asp	Asn	Glu	Trp	Phe	1120	Ala	Met	Thr	Asp	Ser	Lys	Gly	Gln
Met	Arg	Phe	Arg	His	Phe	Asp	1135	Arg	Tyr	Gly	Phe	Met	Ser	Ile	Gly
Leu	Val	Thr	Ile	Asn	Gln	Asn	1150	Val	Gln	Tyr	Tyr	Asp	Glu	Asn	Gly
Phe	Gln	Val	Lys	Gly	Glu	Phe	1165	Val	Thr	Asp	Gln	Asp	Gly	Gln	Thr
Arg	Tyr	Phe	Asp	Gln	Gly	Ser	1180	Gly	Asn	Leu	Val	Lys	Gly	Gln	Phe
Leu	Asn	Lys	Asp	Gly	Asn	Trp	1195	Tyr	Tyr	Leu	Asp	Asp	Gln	Gly	Leu
Val	Ala	Lys	Gly	Ala	Gln	Thr	1210	Ile	Lys	Gly	Gln	Lys	Leu	Tyr	Phe
Asp	Thr	Lys	Thr	Gly	Val	Gln	1225	Val	Lys	Gly	Asp	Phe	Val	Thr	Asp
Lys	Asp	Gly	Asn	Thr	Phe	Phe	1240	Tyr	Ser	Gly	Asp	Thr	Gly	Asp	Leu
Ile	Leu	Gly	Gln	Phe	Phe	Ser	1255	Thr	Gly	Asn	Asn	Ala	Trp	Phe	Tyr
Ala	Asp	Glu	Asn	Gly	His	Val	1270	Ala	Lys	Gly	Ala	Lys	Thr	Ile	Arg

20151105_CL6294WOPCT_SequenceListing

1280	Gly Gln Lys Leu Tyr Phe	1285	Asp Thr Lys Thr Gly	1290	Gln Ala Lys
1295	Gly Arg Phe Ile Arg Asp	1300	Asp Lys Gly Val Arg	1305	Tyr Asp Ala
1310	Asp Thr Gly Thr Leu Val	1315	Thr Asn Ala Phe Leu	1320	Glu Thr Lys Ala
1325	Gly Ser Asn Gln Trp Tyr	1330	Tyr Met Gly Ala Asp	1335	Gly Tyr Ala Val
1340	Lys Gly Asn Gln Thr Ile	1345	Lys Asn Gln His Met	1350	Tyr Phe Asp Ala
1355	Glu Thr Gly Gln Gln Ala	1360	Lys Gly Ile Ile Val	1365	Thr Asp Ala Asn
1370	Gly Arg Lys Tyr Phe Tyr	1375	Asp Thr Phe Thr Gly	1380	Ser Arg Val Val
1385	Asn Gln Phe Val Leu Val	1390	Asn Gly Asn Trp Tyr	1395	Phe Phe Gly Tyr
1400	Asp Gly Ala Ala Val Thr	1405	Gly Phe His Asp Ile	1410	Lys Gly Gln His
1415	Leu Tyr Phe Asn Ser Asp	1420	Gly Thr Gln Ala Lys	1425	Gly Thr Thr Val
1430	Lys Ile Gly Asn Arg Ser	1435	Tyr Thr Phe Asp Ala	1440	His Thr Gly Glu
1445	Leu Thr Ser Val His Tyr	1450	Gly	1455	
1460		1465			

<210> 14
 <211> 4398
 <212> DNA
 <213> Artificial sequence

<220>
 <223> 2920 gtf with heterologous signal sequence

<400> 14						
gatgacctgg	cgaaggaaca	agcagccgcc	tcacagcaaa	aagcagcggc	taaccagaat	60
gaagacgaag	ttgcatcaga	tgcagccgat	acagctagcg	ccaaagccac	gtcagagaaa	120
gaagtggttc	agtcaagcga	tacaaactca	gaaacaaatc	aggttgagac	gaaagaccaa	180
gcatcagcta	aggagagcgc	agacgcagtc	gcgaaacaag	ctcctcaagc	aggaccggca	240
acaacgtcac	aggtcgccag	ctcagagagc	agcagcgtgg	caccgagcaa	ggaggctgac	300
aaggctgccg	caggctcagt	ctcacagaac	gaggaggagg	cagccctttc	acttgccaac	360
atcaagaaga	ttgacggaaa	atactattac	gttatggccg	atggaagcta	caagaaaaac	420
tttgcgatta	cggttgatgg	acagatgctt	tacttttgac	caaaaacagg	cgcactttca	480
tcaacgagca	cgtatagctt	ttcacaaggc	ctgacgccga	ttgtctcaga	ctttagcgtg	540
aacaataagg	ctttcgattc	atcagaaaag	tcatttgaac	ttgtggacgg	ctacctgaca	600
gccgaaagct	ggtacagacc	ggccaaaatc	ctggaaaacg	gaaagacgtg	ggtcgactca	660
aaagaaacag	atcttagacc	tgtcctgatg	tcattggtgg	cgaacaaaga	cacacaagtc	720
gcatatctga	attacatgtc	aaaagctctg	ggaggcgaag	aagagtttac	gacagagaca	780
tcacaactga	cactgaatac	agcggcagaa	cttatccagg	cgaagatcga	agctagagtg	840
agcaaaagag	agggcacaaa	atggctgaga	gaagcaatgg	cagcatttgt	ggcgacgcaa	900
tcaagatgga	ataaagattc	agagcaatat	gataaagcag	atcatcttca	aggcggagct	960
ctgctgtaca	caaacaacaa	ccttacagaa	tgggctaatt	caaattggag	actgcttaat	1020
agaacaccga	cgagacagga	tggaaaaaca	cattactcaa	aggcagataa	gtatggcgga	1080
tatgagtttc	tgctggctaa	tgatgtcgat	aactcaaatc	cggttgtcca	agctgaaatg	1140
cttaaccgaa	ttcattatct	tatgaattgg	ggcgaatttg	ttatgggcga	taagaatgct	1200
aatttcagag	gaatcagagt	tgatgcagtt	gacaacgtta	atgcagatac	actgcagctt	1260
tatacaaatt	actttaatag	cgtttatgga	gtcaacaagt	cagaagcaca	ggcccttgca	1320
catatttcag	tccttgaggc	atggtcatat	aatgataacg	actataatca	ggatacgaat	1380
ggcgcagcac	ttgcgatgga	taatggcctg	agattctcac	ttctgtatac	gcttacaaga	1440
ccgattaatg	aaagaacgcc	tggcatgagc	acactgatta	agagcgaata	cggactgacg	1500
gatagaacga	aaaacgacaa	gtacggcgac	acgcaacctc	gctatgtctt	cgttagagca	1560
catgatagcg	aggttcaaac	ggttattggc	caaattatca	aggagaaaat	cgatcctaca	1620
acagatggct	ttacattttac	gctggatcaa	ctgaagcaag	ccttcgaaat	ctataacaag	1680
gacatgaact	cagtgaataa	gcactacacg	cattacaata	ttcctgctgc	atacgctggt	1740
atgctgagca	acatggaaag	cgtgacaaga	gtgtactacg	gcgacctttt	tacggatgac	1800
ggccagtata	tggcaagcaa	gtcaccttat	tatgatgcta	tcaatacact	tcttagagcg	1860
agaattagat	acggcgctgg	aggacaaatc	atggaacata	attcatataa	gccgagcgcc	1920
gcaatgaaag	ctgcacaccc	ggacgccggc	aacgtcctgg	gcaattcaga	ggctcctggtc	1980

20151105_CL6294WOPCT_SequenceListing

tcagt	gagat	tcggccaaga	cgtgatgtca	gcagatgata	tgacaggcgg	aaaacttgcg	2040
aaaacat	cag	gcatgtttac	gcttattatgc	aataaccggg	aactggaact	tgacgttaat	2100
gggagat	ca	aagtgaatgt	gggcaaaatc	catgctggac	aagcttatag	accgcttctg	2160
cttacaac	ag	ataagggact	tcagaagtac	cttaatgatt	cagacacaaa	actgacgaag	2220
atcgctg	aca	aagacggatt	cattacattc	aaaggatcag	aaattaaggg	ctataaaca	2280
gttgagg	tta	atggctacct	ttcagtttgg	gtcccggttg	gcgctaaagc	agaccaagat	2340
attagagt	tg	ccccgagcac	agccgcaaaa	ggagaaaagg	ctaaaacgta	tacagcatca	2400
caggctct	gg	aatcacagct	tatctatgaa	ggcttctcaa	actttcaaga	ctttgttcaa	2460
aaagata	g	aatatacgaa	taagaaaatt	gcagagaaca	cagacctggt	taaagcatgg	2520
ggagtta	cgt	cattcgagat	ggctcctcaa	tatgttagcg	caacggatgg	cacatttctg	2580
gattcaat	ca	ttgaaaacgg	ctatgcattc	acagacagat	acgaccttgc	tatgagcaag	2640
aataacaa	aat	atggatcaaa	agaggatctg	gctaacgcac	ttaaggcact	tcacgcagct	2700
ggcattca	ag	ctattgcgga	ttgggtgcct	gaccaaactc	accaactgcc	gggcaaagag	2760
gttgtgac	ag	ccagcagagt	ggataactat	ggcagagtta	aggtggacca	gccgcttgct	2820
gagaagct	gt	atctggcgaa	tacgaaatca	tcaggaaaag	atttccaggc	taagtacggc	2880
ggagagt	tcc	ttgcgagct	gcagaagaaa	tacccggaga	tgttcacgac	aaaaatgatc	2940
agcacagg	aa	agacaatcga	cccgtcagtg	aaagctgaaa	agtggtcagc	caagtacttc	3000
aatggaac	ga	acgtgctgga	tagaggcaca	gactatattc	ttagcgatga	gggaacggga	3060
aagtatttc	ca	cagtcaacga	gaagggcgat	ttcctgcctg	cgagccttac	aggcaacaag	3120
gatgcca	aaa	caggctttta	caatgacgga	aaaggaattg	tttactacac	aacagctgga	3180
aacaagg	cta	gaagcgcgtt	cgtgacagag	gctggcaaca	catactatct	cgactatacg	3240
ggccacat	gg	tgacaggacc	gaatgttatc	aacacgaagt	tctattactt	tcttcctaac	3300
ggcatcat	gc	tgaaggacgc	aattaagcaa	gatgaaaagg	gaagaagcgt	ttattacggc	3360
aagacagg	ag	ttatgtacaa	gggcggcaga	gataacgaat	ggtttgcaat	gacagactca	3420
aagggac	aga	tgagatttag	acatttcgat	agatatggct	tcatgtcaat	tggaacttgt	3480
acaatca	acc	agaatgttca	atactatgat	gagaatggct	ttcaggtgaa	aggcgaattt	3540
gtcacag	atc	aggatggaca	aacgagatac	ttcgaccaag	gctcaggcaa	tcttgttaaa	3600
ggacagt	ttc	ttaacaaaga	tggaaattgg	tattatctgg	atgatcaagg	actggttgct	3660
aaaggag	ctc	aaacgattaa	aggccaaaaa	ctgtattttg	atacgaagac	gggcgtgcag	3720
gttaagg	ggag	atthttgtgac	ggacaaggac	ggcaatacat	tcttctatag	cggagatacg	3780
ggagatc	tga	ttctgggaca	attcttttca	acgggcaata	atgcatgggt	ttatgctggc	3840
gagaacg	gag	acgtcgccaa	aggcgcaaaa	acaatcagag	gacagaagct	ttacttcgat	3900
acaaaaa	cgg	gacaacaagc	caagggcaga	ttcatcagag	acgacaaggg	agtcagatac	3960
tacgatg	cag	acacgggcac	actggttaca	aacgcatttc	tggagacgaa	ggcgggaagc	4020
aatcagt	gg	actacatggg	cgctgatgga	tatgccgtga	agggaaacca	gacgatcaag	4080
aaccagc	ata	tgtactttga	cgctgaaaca	ggacagcaag	ctaagggaat	catcgttacg	4140
gacgcga	acg	gcagaaaata	cttctatgac	acgtttacgg	gctcaagagt	tgttaatcaa	4200
ttcgttct	tg	tgaacggaaa	ctggtaactt	tttggtatag	atggagcagc	agttacagga	4260
ttccacg	ata	tcaagggcca	acatctttat	ttcaactcag	acggaacgca	agcgaaaggc	4320
acgacag	tta	agatcgga	tagaagctac	acattcgacg	cacacacagg	cgagcttaca	4380
tcagtcc	att	acggatga					4398

<210> 15
 <211> 4360
 <212> DNA
 <213> Streptococcus downei

<400>	15						
atgattttc	tggaagaaa	attacattac	aaattacaca	aggtcaagaa	gcagtgggtg		60
accatcgctg	tcgcctctgc	tggtttggcc	agcgtagtcg	gtgctggctc	cttgagccaa		120
accgtttctg	ctgacgatct	tgctaaggac	caagcggcag	cgactgagca	aaaggcatca		180
gccaatcagg	aaaaagaaga	agtagtttct	gatcaggttg	acacgaccag	tgccaaagca		240
acctctgaga	aggaagtgtc	tcaagcttcg	gacactagtt	cagaagccaa	ccaagttcca		300
gccaagaag	aaaagaaggc	tgaaaaggca	gctgctcctg	cgacagcgac	accagctcca		360
cagactgggtg	caaaaaacag	ccaaacagct	agttcagaag	caccagcgac	aagcaatcaa		420
gcaagtggga	cagctgaaac	tggtgcctta	agccaaaaag	aagaagcagc	agttctttcg		480
cttgataata	tcaagaagat	tgatggaaag	tattactatg	ttatggcaga	cggctcttat		540
aagaagaact	ttgccattac	tggtgatggg	caaatgcttt	actttgatgc	caaaacagggt		600
gccctgtctt	caacctctac	ctattctttc	agtcaagggt	tgacaccaat	tgtttctgat		660
ttctcagtca	acaataaggc	tttcgatttc	tctgaaaaga	gttttgaaat	ggtagatggg		720
tacttgacag	ctgaaagctg	gtaccgtcct	gctaagattc	ttgaaaatgg	caagacctgg		780
gtggactcca	aagaaactga	cttctgcca	gttctcatga	gctgggtggc	aaacaaggat		840
acccaagttg	cctacctcaa	ctatatgtcc	aaggcgcttg	gtggcaagga	agagtttaca		900
acagaaacct	ctcaaacaac	cttgaataca	gctgctgagt	tgattcaaac	caagattgaa		960
gctcgtat	ttt	ctaagggaaca	agggaccaaa	tggtctcgtg	aagctatggc	tgcttttcta	1020
gcgactcag	t	ctcgtttgag	ttacgctagt	gagcaatttg	ataaaaaacga	ccacttgcaa	1080
ggtggtgctc	t	tcctttatag	taataataaa	ttgacccaat	gggcagattc	taactatcgt	1140
ttgcttaacc	gcacccctac	ccgacaggat	ggcaagcctc	attattctaa	agctgacgaa		1200

20151105_CL6294WOPCT_SequenceListing

tacggtgggt	acgaattcct	cttggcta	gacgtggata	actccaaccc	agtcgttcaa	1260
gcggaaatgc	tcaaccaa	ccactacctg	atgaactggg	gctctattgt	catgaatgac	1320
aaggatgcc	actttgatgg	tatccgtgtg	gatgcgggtg	ataatgtcaa	tgcggtatacc	1380
ctgcaactct	acactaacta	ttttaattcg	gtttatgggtg	tcaacaagtc	agaagcccaa	1440
gccctagctc	acatttcagt	attagaagct	tggtcttata	atgataatga	ctataaccaa	1500
gataccaatg	gtgcggcctt	ggctatggac	aatgggtctac	gcttctccct	gctttataacc	1560
ctgacacgtc	cacttaatga	gcggactcct	ggtatgtcaa	ccttgattaa	gtcacaatat	1620
ggtttgactg	accggacca	ggatgacaag	tatggcgata	ctcagccatc	ctatgtcttt	1680
gttcgggctc	atgactcaga	agtgc aaacc	gttattgcgc	aaatcatcaa	gaaaaaatt	1740
gatccaacga	ctgatggctt	taccttcacc	ttggaccaat	tgaacaggc	ctttgacatc	1800
tacaataagg	atatgaatag	tggtgataag	cactataccc	actacaatat	tccagcagcc	1860
tacgctgtta	tggtgtccaa	catggaatca	gtaactcggg	tttactatgg	agacctcttt	1920
accgatgatg	gtcaatacat	ggaaaccaag	tctccttact	acgatgctat	caataccctc	1980
cttagggccc	ggattcgtta	cgccgctggg	ggtaaacaca	tggaacacaa	ttcctataag	2040
ccatcagcag	ctatgaaagc	taaaaatcct	gatagtggtg	gtgtgcttgg	caacagcgaa	2100
gttcttgtct	ctgttcgttt	tggtcaagat	gtgatgtctg	ctgacgatat	gactgggtgg	2160
aagctggcta	aaacctctgg	tatgttcagc	ctgatttcca	acaaccctga	attagaattg	2220
gatgccaatg	aagaaatcag	ggtcaatggt	ggtaagattc	atgctgggtc	aacctaccgt	2280
ccattgcttt	tgacaaccga	taagggtctg	caaaagtacc	tcaatgattc	tgataactaag	2340
ctgaccaagg	ttgccgataa	ggatgggtat	atcaccttca	agggcagtg	aatcaagggc	2400
tacaagcagg	ttgaagtcaa	tggttacctt	tctgtttggg	taccagtcgg	cgcaaaggca	2460
gatcaagata	ttcgtgtggc	agcttcaact	aaggttaatg	gtaaggatga	caagacttat	2520
acagctagtc	aagccttaga	atcacaaat	atctacgaag	gtttctcaaa	cttccaagat	2580
ttcgttaaga	aggactccca	atataccaat	aagaagattg	ctgaaaatac	cgacctcttt	2640
aaggcctggg	gcgtgacctc	atttgaaatg	gcgccacaat	acgtttccgc	aactgatggt	2700
accttccctg	attctattat	tgaaaatggg	tatgccttca	ccgaccgtta	tgaccttgcc	2760
atgagcaaga	acaacaagta	cggttctaa	gaagacttgg	ccaatgctct	taaggccctc	2820
cacgctgctg	gtatccaagc	tatcgagac	tggttccag	accaaattta	ccaactccca	2880
ggtaaggaag	tggttaactgc	aagtcgtgtt	gataactatg	gccgtgttaa	gattgaccaa	2940
ccattgggtg	aaaaacttta	cttgccaat	accaagagct	caggaaaaga	cttccaggct	3000
aaatatgggt	gtgaattctt	agaagacctg	caaaagcaat	accctgaaat	gtttaccgct	3060
aagatgattt	caaccgttaa	aaccattgat	ccatctgtca	aattgaagga	atggctagct	3120
aagtacttga	acggaacaaa	tggtctgggt	cgtggtagac	actatgtcct	cagcgatgaa	3180
ggaactggca	aatacttcac	tggttaatgaa	aagggtgact	tcctaccagc	agccctgaca	3240
ggtgataggg	aagccaagac	tggtttctac	aatgatggta	agggaaatgac	ctactataca	3300
acggctggta	acaaggctaa	atctgccttt	gtaaccgtag	ctggaaatac	ctattacttt	3360
gactatactg	gttatatggt	aacaggacca	aacacgatta	acagcaaatt	ctattacttc	3420
ctgccaaatg	gggtaatgct	caaggatgct	atgaagcaag	atgagttggg	ccgttcgggt	3480
tactatggta	aaactggtac	catgtacaag	gcgacagata	aatctcaatg	gtttgccatg	3540
accgactcta	agggtcaaca	acgcttccgt	cactttgacc	gcttcggtat	catgtctgta	3600
ggactgggtta	ccatcaatgg	tagtggtcaa	tattacgatg	aagaaggctt	ccaagttaag	3660
ggcgaatttg	tcactgataa	ggatgggtcaa	acccgttact	ttgacgaagg	ttctggtaat	3720
ctgggttaagg	accgcttctc	caataaggat	ggcaagtggg	actatcttga	tgataaaaggc	3780
ttgctgggtca	agggggctca	aaccatttaag	ggtaaaaaac	tctactttga	caccaagacc	3840
ggtgcccgaag	tcaagggtga	ctttgttgcc	gacaaggatg	gcaacctgac	cttctatagt	3900
ggtgatagtg	gtcaaatggt	tcaaagtgat	ttcttctcaa	caggaaataa	tgcttggttc	3960
tatgccgatg	aaaatggtca	tgctcgtaag	ggagctaaga	ctatcagagg	tcagaagctc	4020
tactttgata	caaaaacagg	tcagcaagct	aagggaagct	ttatccgtga	tgacaagggg	4080
gttcgttact	atgatgctga	cacaggtgcc	ttggttaacca	acgctttcct	tgaaactaag	4140
gctggttcta	accaatggta	ttacatggga	gcagatgggt	atgctgtcaa	ggggaaccag	4200
accataaaaa	atcagcacat	gtattttgat	gctgaaactg	gccaacaagc	taagggaatt	4260
atagtgacag	atgccaatgg	tcgcaagtat	ttctatgata	cttttactgg	cagtcgtggt	4320
gtaaaccaat	ttgttttgg	taatggaaat	tggtatttct			4360

<210> 16
 <211> 1453
 <212> PRT
 <213> Streptococcus downei

<400> 16
 Met Ile Phe Met Glu Arg Lys Leu His Tyr Lys Leu His Lys Val Lys
 1 5 10 15
 Lys Gln Trp Val Thr Ile Ala Val Ala Ser Ala Gly Leu Ala Ser Val
 20 25 30
 Val Gly Ala Gly Ser Leu Ser Gln Thr Val Ser Ala Asp Asp Leu Ala
 35 40 45
 Lys Asp Gln Ala Ala Ala Thr Glu Gln Lys Ala Ser Ala Asn Gln Glu
 50 55 60

20151105_CL6294WOPCT_SequenceListing

Lys 65	Glu	Glu	Val	Val	Ser 70	Asp	Gln	Val	Asp 75	Thr	Ser	Ala	Lys 80	Ala
Thr	Ser	Glu	Lys	Glu 85	Val	Ala	Gln	Ala	Ser 90	Asp	Thr	Ser	Ser	Glu 95
Asn	Gln	Val	Pro 100	Ala	Gln	Glu	Glu	Lys 105	Lys	Ala	Glu	Lys	Ala 110	Ala
Pro	Ala	Thr	Ala	Thr	Pro	Ala	Pro	Gln	Thr	Gly	Ala	Lys	Asn	Ser
Thr	Ala 115	Ser	Ser	Glu	Ala	Pro	Ala	Thr	Ser	Asn	Gln	Ala	Ser	Glu
Ala 130	Glu	Thr	Gly	Ala	Leu	Ser	Gln	Lys	Glu	Glu	Ala	Ala	Val	Leu
Ala 145	Leu	Asp	Asn	Ile	Lys 150	Lys	Ile	Asp	Gly	Lys 155	Tyr	Tyr	Tyr	Val
Leu	Asp	Asn	Ile	Lys 165	Lys	Asn	Phe	Ala	Ile	Thr	Val	Asp	Gly	Gln
Asp	Gly	Ser	Tyr 180	Lys	Lys	Asn	Phe	Ala 185	Ile	Thr	Val	Asp	Gly 190	Met
Leu	Tyr	Phe 195	Asp	Ala	Lys	Thr	Gly	Ala	Leu	Ser	Ser	Thr	Ser	Thr
Ser	Phe 210	Ser	Gln	Gly	Leu	Thr	Pro	Ile	Val	Ser	Asp	Phe	Ser	Val
Asn 225	Lys	Ala	Phe	Asp	Ser 230	Ser	Glu	Lys	Ser	Phe	Glu	Leu	Val	Asp
Tyr	Leu	Thr	Ala	Glu 245	Ser	Trp	Tyr	Arg	Pro	Ala	Lys	Ile	Leu	Glu
Gly	Lys	Thr	Trp 260	Val	Asp	Ser	Lys	Glu	Thr	Asp	Leu	Arg	Pro	Val
Met	Ser	Trp 275	Trp	Pro	Asn	Lys	Asp	Thr	Gln	Val	Ala	Tyr	Leu	Asn
Met	Ser 290	Lys	Ala	Leu	Gly	Gly 295	Lys	Glu	Glu	Phe	Thr	Thr	Glu	Thr
Gln 305	Thr	Thr	Leu	Asn	Thr	Ala	Ala	Glu	Leu	Ile	Gln	Thr	Lys	Ile
Ala	Arg	Ile	Ser	Lys 325	Glu	Gln	Gly	Thr	Lys	Trp	Leu	Arg	Glu	Ala
Ala	Ala	Phe	Val	Ala	Thr	Gln	Ser	Arg	Trp	Ser	Tyr	Ala	Ser	Glu
Phe	Asp	Lys 355	Asn	Asp	His	Leu	Gln	Gly	Gly	Ala	Leu	Leu	Tyr	Thr
Asn	Lys 370	Leu	Thr	Gln	Trp	Ala	Asp	Ser	Asn	Tyr	Arg	Leu	Leu	Asn
Thr	Pro	Thr	Arg	Gln	Asp 390	Gly	Lys	Pro	His	Tyr	Ser	Lys	Ala	Asp
Tyr	Gly	Gly	Tyr	Glu 405	Phe	Leu	Leu	Ala	Asn	Asp	Val	Asp	Asn	Ser
Pro	Val	Val	Gln	Ala	Glu	Met	Leu	Asn	Gln	Ile	His	Tyr	Leu	Met
Trp	Gly	Ser 435	Ile	Val	Met	Asn	Asp	Lys	Asp	Ala	Asn	Phe	Asp	Gly
Arg	Val	Asp	Ala	Val	Asp	Asn	Val	Asn	Ala	Asp	Thr	Leu	Gln	Leu
Thr	Asn	Tyr	Phe	Asn	Ser	Val	Tyr	Gly	Val	Asn	Lys	Ser	Glu	Ala
Ala	Leu	Ala	His	Ile 485	Ser	Val	Leu	Glu	Ala	Trp	Ser	Tyr	Asn	Asp
Asp	Tyr	Asn	Gln	Asp	Thr	Asn	Gly	Ala	Ala	Leu	Ala	Met	Asp	Gly
Leu	Arg	Phe 515	Ser	Leu	Leu	Tyr	Thr	Leu	Thr	Arg	Pro	Leu	Asn	Glu
Thr	Pro	Gly	Met	Ser	Thr	Leu	Ile	Lys	Ser	Gln	Tyr	Gly	Leu	Thr
Arg	Thr	Lys	Asp	Asp	Lys 550	Tyr	Gly	Asp	Thr	Gln	Pro	Ser	Tyr	Val
Val	Arg	Ala	His	Asp 565	Ser	Glu	Val	Gln	Thr	Val	Ile	Ala	Gln	Ile
Lys	Lys	Lys	Ile	Asp	Pro	Thr	Thr	Asp	Gly	Phe	Thr	Phe	Thr	Leu
Gln	Leu	Lys 595	Gln	Ala	Phe	Asp	Ile	Tyr	Asn	Lys	Asp	Met	Asn	Ser

20151105_CL6294WOPCT_SequenceListing

Asp	Lys	His	Tyr	Thr	His	Tyr	Asn	Ile	Pro	Ala	Ala	Tyr	Ala	Val	Met
610	610					615				620					
Leu	Ser	Asn	Met	Glu	Ser	Val	Thr	Arg	Val	Tyr	Tyr	Gly	Asp	Leu	Phe
625					630					635					640
Thr	Asp	Asp	Gly	Gln	Tyr	Met	Glu	Thr	Lys	Ser	Pro	Tyr	Tyr	Asp	Ala
				645					650					655	
Ile	Asn	Thr	Leu	Leu	Arg	Ala	Arg	Ile	Arg	Tyr	Ala	Ala	Gly	Gly	Gln
			660					665					670		
Thr	Met	Glu	His	Asn	Ser	Tyr	Lys	Ala	Ser	Ala	Ala	Met	Lys	Ala	Lys
		675					680					685			
Asn	Pro	Asp	Ser	Gly	Ser	Val	Leu	Gly	Asn	Ser	Glu	Val	Leu	Val	Ser
	690					695					700				
Val	Arg	Phe	Gly	Gln	Asp	Val	Met	Ser	Ala	Asp	Asp	Met	Thr	Gly	Gly
705					710					715					720
Lys	Leu	Ala	Lys	Thr	Ser	Gly	Met	Phe	Ser	Leu	Ile	Ser	Asn	Asn	Pro
				725					730					735	
Glu	Leu	Glu	Leu	Asp	Ala	Asn	Glu	Glu	Ile	Arg	Val	Asn	Val	Gly	Lys
			740					745					750		
Ile	His	Ala	Gly	Gln	Thr	Tyr	Arg	Pro	Leu	Leu	Leu	Thr	Thr	Asp	Lys
		755					760					765			
Gly	Leu	Gln	Lys	Tyr	Leu	Asn	Asp	Ser	Asp	Thr	Lys	Leu	Thr	Lys	Val
	770					775					780				
Ala	Asp	Lys	Asp	Gly	Tyr	Ile	Thr	Phe	Lys	Gly	Ser	Glu	Ile	Lys	Gly
785					790					795					800
Tyr	Lys	Gln	Val	Glu	Val	Asn	Gly	Tyr	Leu	Ser	Val	Trp	Val	Pro	Val
				805					810					815	
Gly	Ala	Lys	Ala	Asp	Gln	Asp	Ile	Arg	Val	Ala	Ala	Ser	Thr	Lys	Val
			820					825					830		
Asn	Gly	Lys	Asp	Asp	Lys	Thr	Tyr	Thr	Ala	Ser	Gln	Ala	Leu	Glu	Ser
		835					840					845			
Gln	Leu	Ile	Tyr	Glu	Gly	Phe	Ser	Asn	Phe	Gln	Asp	Phe	Val	Lys	Lys
	850					855					860				
Asp	Ser	Gln	Tyr	Thr	Asn	Lys	Lys	Ile	Ala	Glu	Asn	Thr	Asp	Leu	Phe
865					870					875					880
Lys	Ala	Trp	Gly	Val	Thr	Ser	Phe	Glu	Met	Ala	Pro	Gln	Tyr	Val	Ser
				885					890					895	
Ala	Thr	Asp	Gly	Thr	Phe	Leu	Asp	Ser	Ile	Ile	Glu	Asn	Gly	Tyr	Ala
			900					905					910		
Phe	Thr	Asp	Arg	Tyr	Asp	Leu	Ala	Met	Ser	Lys	Asn	Asn	Lys	Tyr	Gly
		915					920					925			
Ser	Lys	Glu	Asp	Leu	Ala	Asn	Ala	Leu	Lys	Ala	Leu	His	Ala	Ala	Gly
	930					935					940				
Ile	Gln	Ala	Ile	Ala	Asp	Trp	Val	Pro	Asp	Gln	Ile	Tyr	Gln	Leu	Pro
945					950					955					960
Gly	Lys	Glu	Val	Val	Thr	Ala	Ser	Arg	Val	Asp	Asn	Tyr	Gly	Arg	Val
				965					970					975	
Lys	Ile	Asp	Gln	Pro	Leu	Val	Glu	Lys	Leu	Tyr	Leu	Ala	Asn	Thr	Lys
			980					985					990		
Ser	Ser	Gly	Lys	Asp	Phe	Gln	Ala	Lys	Tyr	Gly	Gly	Glu	Phe	Leu	Glu
		995					1000					1005			
Asp	Leu	Gln	Lys	Gln	Tyr	Pro	Glu	Met	Phe	Thr	Ala	Lys	Met	Ile	
1010						1015					1020				
Ser	Thr	Gly	Lys	Thr	Ile	Asp	Pro	Ser	Val	Lys	Leu	Lys	Glu	Trp	
1025						1030									
Ser	Ala	Lys	Tyr	Leu	Asn	Gly	Thr	Asn	Val	Leu	Gly	Arg	Gly	Thr	
1040						1045					1050				
Asp	Tyr	Val	Leu	Ser	Asp	Glu	Gly	Thr	Gly	Lys	Tyr	Phe	Thr	Val	
1055						1060					1065				
Asn	Glu	Lys	Gly	Asp	Phe	Leu	Pro	Ala	Ala	Leu	Thr	Gly	Asp	Arg	
1070						1075					1080				
Glu	Ala	Lys	Thr	Gly	Phe	Tyr	Asn	Asp	Gly	Lys	Gly	Met	Thr	Tyr	
	1085					1090					1095				
Tyr	Thr	Thr	Ala	Gly	Asn	Lys	Ala	Lys	Ser	Ala	Phe	Val	Thr	Val	
	1100					1105					1110				
Ala	Gly	Asn	Thr	Tyr	Tyr	Phe	Asp	Tyr	Thr	Gly	Tyr	Met	Val	Thr	
	1115					1120					1125				
Gly	Pro	Asn	Thr	Ile	Asn	Ser	Lys	Phe	Tyr	Tyr	Phe	Leu	Pro	Asn	
	1130					1135					1140				

20151105_CL6294WOPCT_SequenceListing

Gly	Val	Met	Leu	Lys	Asp	Ala	Ile	Lys	Gln	Asp	Glu	Leu	Gly	Arg
1145						1150					1155			
Ser	Val	Tyr	Tyr	Gly	Lys	Thr	Gly	Thr	Met	Tyr	Lys	Ala	Thr	Asp
1160						1165					1170			
Lys	Ser	Gln	Trp	Phe	Ala	Met	Thr	Asp	Ser	Lys	Gly	Gln	Gln	Arg
1175						1180					1185			
Phe	Arg	His	Phe	Asp	Arg	Phe	Gly	Ile	Met	Ser	Val	Gly	Leu	Val
1190						1195					1200			
Thr	Ile	Asn	Gly	Ser	Val	Gln	Tyr	Tyr	Asp	Glu	Glu	Gly	Phe	Gln
1205						1210					1215			
Val	Lys	Gly	Glu	Phe	Val	Thr	Asp	Lys	Asp	Gly	Gln	Thr	Arg	Tyr
1220						1225					1230			
Phe	Asp	Glu	Gly	Ser	Gly	Asn	Leu	Val	Lys	Asp	Arg	Phe	Leu	Asn
1235						1240					1245			
Lys	Asp	Gly	Lys	Trp	Tyr	Tyr	Leu	Asp	Asp	Lys	Gly	Leu	Leu	Val
1250						1255					1260			
Lys	Gly	Ala	Gln	Thr	Ile	Lys	Gly	Gln	Lys	Leu	Tyr	Phe	Asp	Thr
1265						1270					1275			
Lys	Thr	Gly	Ala	Gln	Val	Lys	Gly	Asp	Phe	Val	Ala	Asp	Lys	Asp
1280						1285					1290			
Gly	Asn	Leu	Thr	Phe	Tyr	Ser	Gly	Asp	Ser	Gly	Gln	Met	Val	Gln
1295						1300					1305			
Ser	Asp	Phe	Phe	Ser	Thr	Gly	Asn	Asn	Ala	Trp	Phe	Tyr	Ala	Asp
1310						1315					1320			
Glu	Asn	Gly	His	Val	Ala	Lys	Gly	Ala	Lys	Thr	Ile	Arg	Gly	Gln
1325						1330					1335			
Lys	Leu	Tyr	Phe	Asp	Thr	Lys	Thr	Gly	Gln	Gln	Ala	Lys	Gly	Arg
1340						1345					1350			
Phe	Ile	Arg	Asp	Asp	Lys	Gly	Val	Arg	Tyr	Tyr	Asp	Ala	Asp	Thr
1355						1360					1365			
Gly	Ala	Leu	Val	Thr	Asn	Ala	Phe	Leu	Glu	Thr	Lys	Ala	Gly	Ser
1370						1375					1380			
Asn	Gln	Trp	Tyr	Tyr	Met	Gly	Ala	Asp	Gly	Tyr	Ala	Val	Lys	Gly
1385						1390					1395			
Asn	Gln	Thr	Ile	Lys	Asn	Gln	His	Met	Tyr	Phe	Asp	Ala	Glu	Thr
1400						1405					1410			
Gly	Gln	Gln	Ala	Lys	Gly	Ile	Ile	Val	Thr	Asp	Ala	Asn	Gly	Arg
1415						1420					1425			
Lys	Tyr	Phe	Tyr	Asp	Thr	Phe	Thr	Gly	Ser	Arg	Val	Val	Asn	Gln
1430						1435					1440			
Phe	Val	Leu	Val	Asn	Gly	Asn	Trp	Tyr	Phe					
1445						1450								

<210> 17
 <211> 1409
 <212> PRT
 <213> Streptococcus downei

<220>
 <221> MISC_FEATURE
 <222> (1)..(1409)
 <223> mature 2921 gtf

<400> 17
 Asp Asp Leu Ala Lys Asp Gln Ala Ala Ala Thr Glu Gln Lys Ala Ser
 1 5 10 15
 Ala Asn Gln Glu Lys Glu Glu Val Val Ser Asp Gln Val Asp Thr Thr
 20 25 30
 Ser Ala Lys Ala Thr Ser Glu Lys Glu Val Ala Gln Ala Ser Asp Thr
 35 40 45
 Ser Ser Glu Ala Asn Gln Val Pro Ala Gln Glu Glu Lys Lys Ala Glu
 50 55 60
 Lys Ala Ala Ala Pro Ala Thr Ala Thr Pro Ala Pro Gln Thr Gly Ala
 65 70 75 80
 Lys Asn Ser Gln Thr Ala Ser Ser Glu Ala Pro Ala Thr Ser Asn Gln
 85 90 95
 Ala Ser Glu Thr Ala Glu Thr Gly Ala Leu Ser Gln Lys Glu Glu Ala
 100 105 110

20151105_CL6294WOPCT_SequenceListing

Ala	Val	Leu	Ser	Leu	Asp	Asn	Ile	Lys	Lys	Ile	Asp	Gly	Lys	Tyr	Tyr
		115					120					125			
Tyr	Val	Met	Ala	Asp	Gly	Ser	Tyr	Lys	Lys	Asn	Phe	Ala	Ile	Thr	Val
	130					135					140				
Asp	Gly	Gln	Met	Leu	Tyr	Phe	Asp	Ala	Lys	Thr	Gly	Ala	Leu	Ser	Ser
145					150					155					160
Thr	Ser	Thr	Tyr	Ser	Phe	Ser	Gln	Gly	Leu	Thr	Pro	Ile	Val	Ser	Asp
				165					170					175	
Phe	Ser	Val	Asn	Asn	Lys	Ala	Phe	Asp	Ser	Ser	Glu	Lys	Ser	Phe	Glu
			180					185					190		
Leu	Val	Asp	Gly	Tyr	Leu	Thr	Ala	Glu	Ser	Trp	Tyr	Arg	Pro	Ala	Lys
		195					200					205			
Ile	Leu	Glu	Asn	Gly	Lys	Thr	Trp	Val	Asp	Ser	Lys	Glu	Thr	Asp	Leu
	210					215					220				
Arg	Pro	Val	Leu	Met	Ser	Trp	Trp	Pro	Asn	Lys	Asp	Thr	Gln	Val	Ala
225					230					235					240
Tyr	Leu	Asn	Tyr	Met	Ser	Lys	Ala	Leu	Gly	Gly	Lys	Glu	Glu	Phe	Thr
				245					250					255	
Thr	Glu	Thr	Ser	Gln	Thr	Thr	Leu	Asn	Thr	Ala	Ala	Glu	Leu	Ile	Gln
			260					265					270		
Thr	Lys	Ile	Glu	Ala	Arg	Ile	Ser	Lys	Glu	Gln	Gly	Thr	Lys	Trp	Leu
		275					280					285			
Arg	Glu	Ala	Met	Ala	Ala	Phe	Val	Ala	Thr	Gln	Ser	Arg	Trp	Ser	Tyr
	290					295					300				
Ala	Ser	Glu	Gln	Phe	Asp	Lys	Asn	Asp	His	Leu	Gln	Gly	Gly	Ala	Leu
305					310					315					320
Leu	Tyr	Thr	Asn	Asn	Lys	Leu	Thr	Gln	Trp	Ala	Asp	Ser	Asn	Tyr	Arg
				325					330					335	
Leu	Leu	Asn	Arg	Thr	Pro	Thr	Arg	Gln	Asp	Gly	Lys	Pro	His	Tyr	Ser
			340					345					350		
Lys	Ala	Asp	Glu	Tyr	Gly	Gly	Tyr	Glu	Phe	Leu	Leu	Ala	Asn	Asp	Val
		355					360					365			
Asp	Asn	Ser	Asn	Pro	Val	Val	Gln	Ala	Glu	Met	Leu	Asn	Gln	Ile	His
	370					375					380				
Tyr	Leu	Met	Asn	Trp	Gly	Ser	Ile	Val	Met	Asn	Asp	Lys	Asp	Ala	Asn
385					390					395					400
Phe	Asp	Gly	Ile	Arg	Val	Asp	Ala	Val	Asp	Asn	Val	Asn	Ala	Asp	Thr
				405					410					415	
Leu	Gln	Leu	Tyr	Thr	Asn	Tyr	Phe	Asn	Ser	Val	Tyr	Gly	Val	Asn	Lys
			420					425					430		
Ser	Glu	Ala	Gln	Ala	Leu	Ala	His	Ile	Ser	Val	Leu	Glu	Ala	Trp	Ser
		435					440					445			
Tyr	Asn	Asp	Asn	Asp	Tyr	Asn	Gln	Asp	Thr	Asn	Gly	Ala	Ala	Leu	Ala
	450					455					460				
Met	Asp	Asn	Gly	Leu	Arg	Phe	Ser	Leu	Leu	Tyr	Thr	Leu	Thr	Arg	Pro
465					470					475					480
Leu	Asn	Glu	Arg	Thr	Pro	Gly	Met	Ser	Thr	Leu	Ile	Lys	Ser	Gln	Tyr
				485					490					495	
Gly	Leu	Thr	Asp	Arg	Thr	Lys	Asp	Asp	Lys	Tyr	Gly	Asp	Thr	Gln	Pro
			500					505					510		
Ser	Tyr	Val	Phe	Val	Arg	Ala	His	Asp	Ser	Glu	Val	Gln	Thr	Val	Ile
		515					520					525			
Ala	Gln	Ile	Ile	Lys	Lys	Lys	Ile	Asp	Pro	Thr	Thr	Asp	Gly	Phe	Thr
	530					535					540				
Phe	Thr	Leu	Asp	Gln	Leu	Lys	Gln	Ala	Phe	Asp	Ile	Tyr	Asn	Lys	Asp
545					550					555					560
Met	Asn	Ser	Val	Asp	Lys	His	Tyr	Thr	His	Tyr	Asn	Ile	Pro	Ala	Ala
				565					570					575	
Tyr	Ala	Val	Met	Leu	Ser	Asn	Met	Glu	Ser	Val	Thr	Arg	Val	Tyr	Tyr
			580					585					590		
Gly	Asp	Leu	Phe	Thr	Asp	Asp	Gly	Gln	Tyr	Met	Glu	Thr	Lys	Ser	Pro
		595					600					605			
Tyr	Tyr	Asp	Ala	Ile	Asn	Thr	Leu	Leu	Arg	Ala	Arg	Ile	Arg	Tyr	Ala
	610					615					620				
Ala	Gly	Gly	Gln	Thr	Met	Glu	His	Asn	Ser	Tyr	Lys	Ala	Ser	Ala	Ala
625					630					635					640
Met	Lys	Ala	Lys	Asn	Pro	Asp	Ser	Gly	Ser	Val	Leu	Gly	Asn	Ser	Glu
				645					650					655	

20151105_CL6294WOPCT_SequenceListing

Val	Leu	Val	Ser	Val	Arg	Phe	Gly	Gln	Asp	Val	Met	Ser	Ala	Asp	Asp
			660												
Met	Thr	Gly	Gly	Lys	Leu	Ala	Lys	Thr	Ser	Gly	Met	Phe	Ser	Leu	Ile
		675					680					685			
Ser	Asn	Asn	Pro	Glu	Leu	Glu	Leu	Asp	Ala	Asn	Glu	Glu	Ile	Arg	Val
	690					695				700					
Asn	Val	Gly	Lys	Ile	His	Ala	Gly	Gln	Thr	Tyr	Arg	Pro	Leu	Leu	Leu
	705				710					715					720
Thr	Thr	Asp	Lys	Gly	Leu	Gln	Lys	Tyr	Leu	Asn	Asp	Ser	Asp	Thr	Lys
				725					730					735	
Leu	Thr	Lys	Val	Ala	Asp	Lys	Asp	Gly	Tyr	Ile	Thr	Phe	Lys	Gly	Ser
			740					745					750		
Glu	Ile	Lys	Gly	Tyr	Lys	Gln	Val	Glu	Val	Asn	Gly	Tyr	Leu	Ser	Val
		755					760					765			
Trp	Val	Pro	Val	Gly	Ala	Lys	Ala	Asp	Gln	Asp	Ile	Arg	Val	Ala	Ala
	770					775					780				
Ser	Thr	Lys	Val	Asn	Gly	Lys	Asp	Asp	Lys	Thr	Tyr	Thr	Ala	Ser	Gln
	785				790					795					800
Ala	Leu	Glu	Ser	Gln	Leu	Ile	Tyr	Glu	Gly	Phe	Ser	Asn	Phe	Gln	Asp
				805					810					815	
Phe	Val	Lys	Lys	Asp	Ser	Gln	Tyr	Thr	Asn	Lys	Lys	Ile	Ala	Glu	Asn
			820					825					830		
Thr	Asp	Leu	Phe	Lys	Ala	Trp	Gly	Val	Thr	Ser	Phe	Glu	Met	Ala	Pro
		835					840					845			
Gln	Tyr	Val	Ser	Ala	Thr	Asp	Gly	Thr	Phe	Leu	Asp	Ser	Ile	Ile	Glu
	850					855					860				
Asn	Gly	Tyr	Ala	Phe	Thr	Asp	Arg	Tyr	Asp	Leu	Ala	Met	Ser	Lys	Asn
	865				870					875					880
Asn	Lys	Tyr	Gly	Ser	Lys	Glu	Asp	Leu	Ala	Asn	Ala	Leu	Lys	Ala	Leu
				885					890					895	
His	Ala	Ala	Gly	Ile	Gln	Ala	Ile	Ala	Asp	Trp	Val	Pro	Asp	Gln	Ile
			900					905					910		
Tyr	Gln	Leu	Pro	Gly	Lys	Glu	Val	Val	Thr	Ala	Ser	Arg	Val	Asp	Asn
		915					920					925			
Tyr	Gly	Arg	Val	Lys	Ile	Asp	Gln	Pro	Leu	Val	Glu	Lys	Leu	Tyr	Leu
	930					935					940				
Ala	Asn	Thr	Lys	Ser	Ser	Gly	Lys	Asp	Phe	Gln	Ala	Lys	Tyr	Gly	Gly
	945				950					955					960
Glu	Phe	Leu	Glu	Asp	Leu	Gln	Lys	Gln	Tyr	Pro	Glu	Met	Phe	Thr	Ala
				965					970					975	
Lys	Met	Ile	Ser	Thr	Gly	Lys	Thr	Ile	Asp	Pro	Ser	Val	Lys	Leu	Lys
			980					985					990		
Glu	Trp	Ser	Ala	Lys	Tyr	Leu	Asn	Gly	Thr	Asn	Val	Leu	Gly	Arg	Gly
		995					1000					1005			
Thr	Asp	Tyr	Val	Leu	Ser	Asp	Glu	Gly	Thr	Gly	Lys	Tyr	Phe	Thr	
	1010					1015					1020				
Val	Asn	Glu	Lys	Gly	Asp	Phe	Leu	Pro	Ala	Ala	Leu	Thr	Gly	Asp	
	1025					1030					1035				
Arg	Glu	Ala	Lys	Thr	Gly	Phe	Tyr	Asn	Asp	Gly	Lys	Gly	Met	Thr	
	1040					1045					1050				
Tyr	Tyr	Thr	Thr	Ala	Gly	Asn	Lys	Ala	Lys	Ser	Ala	Phe	Val	Thr	
	1055					1060					1065				
Val	Ala	Gly	Asn	Thr	Tyr	Tyr	Phe	Asp	Tyr	Thr	Gly	Tyr	Met	Val	
	1070					1075					1080				
Thr	Gly	Pro	Asn	Thr	Ile	Asn	Ser	Lys	Phe	Tyr	Tyr	Phe	Leu	Pro	
	1085					1090					1095				
Asn	Gly	Val	Met	Leu	Lys	Asp	Ala	Ile	Lys	Gln	Asp	Glu	Leu	Gly	
	1100					1105					1110				
Arg	Ser	Val	Tyr	Tyr	Gly	Lys	Thr	Gly	Thr	Met	Tyr	Lys	Ala	Thr	
	1115					1120					1125				
Asp	Lys	Ser	Gln	Trp	Phe	Ala	Met	Thr	Asp	Ser	Lys	Gly	Gln	Gln	
	1130					1135					1140				
Arg	Phe	Arg	His	Phe	Asp	Arg	Phe	Gly	Ile	Met	Ser	Val	Gly	Leu	
	1145					1150					1155				
Val	Thr	Ile	Asn	Gly	Ser	Val	Gln	Tyr	Tyr	Asp	Glu	Glu	Gly	Phe	
	1160					1165					1170				
Gln	Val	Lys	Gly	Glu	Phe	Val	Thr	Asp	Lys	Asp	Gly	Gln	Thr	Arg	
	1175					1180					1185				

20151105_CL6294WOPCT_SequenceListing

Tyr	Phe	Asp	Glu	Gly	Ser	Gly	Asn	Leu	Val	Lys	Asp	Arg	Phe	Leu
1190						1195					1200			
Asn	Lys	Asp	Gly	Lys	Trp	Tyr	Tyr	Leu	Asp	Asp	Lys	Gly	Leu	Leu
1205						1210					1215			
Val	Lys	Gly	Ala	Gln	Thr	Ile	Lys	Gly	Gln	Lys	Leu	Tyr	Phe	Asp
1220						1225					1230			
Thr	Lys	Thr	Gly	Ala	Gln	Val	Lys	Gly	Asp	Phe	Val	Ala	Asp	Lys
1235						1240					1245			
Asp	Gly	Asn	Leu	Thr	Phe	Tyr	Ser	Gly	Asp	Ser	Gly	Gln	Met	Val
1250						1255					1260			
Gln	Ser	Asp	Phe	Phe	Ser	Thr	Gly	Asn	Asn	Ala	Trp	Phe	Tyr	Ala
1265						1270					1275			
Asp	Glu	Asn	Gly	His	Val	Ala	Lys	Gly	Ala	Lys	Thr	Ile	Arg	Gly
1280						1285					1290			
Gln	Lys	Leu	Tyr	Phe	Asp	Thr	Lys	Thr	Gly	Gln	Gln	Ala	Lys	Gly
1295						1300					1305			
Arg	Phe	Ile	Arg	Asp	Asp	Lys	Gly	Val	Arg	Tyr	Tyr	Asp	Ala	Asp
1310						1315					1320			
Thr	Gly	Ala	Leu	Val	Thr	Asn	Ala	Phe	Leu	Glu	Thr	Lys	Ala	Gly
1325						1330					1335			
Ser	Asn	Gln	Trp	Tyr	Tyr	Met	Gly	Ala	Asp	Gly	Tyr	Ala	Val	Lys
1340						1345					1350			
Gly	Asn	Gln	Thr	Ile	Lys	Asn	Gln	His	Met	Tyr	Phe	Asp	Ala	Glu
1355						1360					1365			
Thr	Gly	Gln	Gln	Ala	Lys	Gly	Ile	Ile	Val	Thr	Asp	Ala	Asn	Gly
1370						1375					1380			
Arg	Lys	Tyr	Phe	Tyr	Asp	Thr	Phe	Thr	Gly	Ser	Arg	Val	Val	Asn
1385						1390					1395			
Gln	Phe	Val	Leu	Val	Asn	Gly	Asn	Trp	Tyr	Phe				
1400						1405								

<210> 18

<211> 4230

<212> DNA

<213> Artificial sequence

<220>

<223> 2921 gtf with heterologous signal sequence

<400> 18

gatgatctgg	caaaggacca	agcggctgcc	acggaacaga	aggcatcagc	gaatcaagaa	60
aaggaggaag	ttgtttcaga	tcaagttgat	acgacaagcg	ccaaagcaac	gtcagaaaaa	120
gaggtggcac	aggctagcga	tacatcatca	gaggccaacc	aggttccggc	ccaagaggaa	180
aagaaagccg	agaaggccgc	agcacctgcg	acagctacgc	cggcaccgca	aacgggagcc	240
aaaaatagcc	aaacagcctc	aagcgaggca	ccggctacat	caaatcaagc	atcagaaacg	300
gcggaaacag	gcgcactgtc	acaaaaggaa	gaagcagctg	tcctttcact	tgataatatc	360
aaaaagattg	acggaaaata	ctactatggt	atggctgatg	gatcatataa	gaaaaacttt	420
gcgattacag	tcgatggcca	aatgctgtat	tttgatgcaa	aaacaggagc	tctttcaagc	480
acatcaacat	attcattttc	acaaggcctg	acaccgattg	ttagcgactt	ctcagtcagt	540
aacaaggcat	ttgatagcag	cgagaaatca	ttcgaacttg	tgatggata	tcttacggcc	600
gagagctggg	acagaccggc	aaaaattctg	gagaatggaa	agacgtgggt	tgattcaaaa	660
gagacggacc	ttagaccggg	gctgatgtca	tggtggccga	ataaggatac	gcaggttgcc	720
tacctgaact	atatgtcaaa	agcacttggc	ggcaaagagg	agttttacaac	ggagacatca	780
caaacgacac	ttaacacggc	tgctgaactt	atccagacga	agatcgaggc	aagaattagc	840
aaagaacacg	gaacgaagtg	gcttagagaa	gctatggccg	catttggtgc	tacgcagtca	900
agatgggtcat	atgcgtcaga	gcagttcgat	aaaaacgata	accttcaagg	cggagcactt	960
ctgtacacaa	ataataagct	gacacaatgg	gctgactcaa	actatagact	gcttaacaga	1020
acgcctacga	gacaggatgg	aaaacctcat	tacagcaaag	cagacgagta	tgagggttat	1080
gagttcctgc	ttgcaaatga	cgctcgataac	tcaaattccg	tggttcaggc	agagatgctt	1140
aatcaaattc	actatcttat	gaactggggc	tcaattgtta	tgaatgataa	ggacgcgaat	1200
ttcgatggaa	ttagagtggg	tgcggttgac	aatgttaatg	cggacacact	tcaactgtat	1260
acgaattact	ttaaactagt	ttacggcggt	aacaaatcag	aagctcaggc	acttgctcat	1320
atcagcggtc	ttgaagcatg	gagctacaac	gacaatgatt	acaatcagga	tacaaatggc	1380
gctgcactgg	ccatggataa	tggaacttaga	ttcagccttc	tttacacact	gacaagaccg	1440
cttaacgaga	gaacacctgg	catgtcaaca	cttattaagt	cacaatatgg	ccttacagac	1500
agaacaaaag	acgataagta	cggcgacacg	caaccgtcat	acgtgtttgt	tagagctcac	1560
gacagcgaag	ttcaaacagt	tattgctcag	attattaaga	agaaaattga	tccgacaaca	1620
gacggattca	catttacact	ggaccaactt	aaacaagcct	tcgatatcta	taacaaagat	1680

20151105_CL6294WOPCT_SequenceListing

atgaatagcg	ttgataaaca	ttacacgcac	tacaatatcc	ctgcagcata	cgctgtcatg	1740
ctgtcaaaca	tggaatcagt	tacaagagtc	tattatggcg	acctgtttac	agatgacggc	1800
caatatatgg	aaacaaaatc	accgtactat	gacgccatta	atacactgct	gagagccaga	1860
atcagatatg	cagctggcgg	acaaacaatg	gaacacaaca	gctataaggc	gtcagctgcg	1920
atgaaggcga	aaaaccctga	tagcggctca	gtccttggca	attcagaagt	tctggttagc	1980
gttagatttg	gacaagatgt	gatgagcgct	gacgatatga	caggaggcaa	acttgctaag	2040
acgtcaggaa	tgttctcact	gatttcaaatt	aatccggaac	tggaaacttga	cgctaataaa	2100
gagatcagag	tgaatgttgg	aaaaatccat	gccggccaaa	cgtacagacc	tcttctgctt	2160
acgacagata	agggcctgca	aaagtatctt	aatgactcag	acacgaaact	tacgaagggt	2220
gcagataaag	atggctatat	tacattttaag	ggctcagaga	ttaaaggcta	taaacagggt	2280
gaagttaatg	gctacctgag	cgtctgggtg	ccggttggcg	ctaaagcaga	ccaagacatc	2340
agagtgcgag	cttcaacaaa	agtcaatgga	aaggatgata	agacgtacac	ggcaagccaa	2400
gcacttgagt	cacagcttat	ttacgagggc	ttctcaaatt	tccaagattt	cgtaaagaaa	2460
gattcacaat	atacaaataa	gaaaatcccg	gaaaatacag	atcttttcaa	agcatggggc	2520
gttacatcat	ttgaaatggc	gcctcagtat	gttagcgcaa	cagatggcac	atttctggat	2580
agcattatcg	agaatggata	tgcattttacg	gatagatatg	acctggccat	gtcaaaaaaac	2640
aacaaatacg	gatcaaaaaga	ggatctttgct	aatgcgctta	aagctctgca	cgcagctggc	2700
attcaagcca	ttgcggattg	ggttcctgat	caaatctacc	aacttcctgg	caaggagggt	2760
gttacagcat	caagagtcga	caattacggc	agagtgaaga	tcgaccaacc	tctggtggaa	2820
aagctgtatc	tggctaacac	aaagagctca	ggcaaagatt	ttcaggcgaa	atatggcgga	2880
gaatttcttg	aagacctgca	gaaacagtat	cctgaaatgt	ttacagcgaa	aatgatttca	2940
acaggaaaaa	cgattgatcc	tagcgttaaa	cttaaggagt	ggtcagccaa	atacctgaat	3000
ggaacaaacg	tgctgggaag	aggcacagat	tatgttcttt	cagatgaggg	aacgggcaaa	3060
tactttacgg	tcaatgagaa	aggcgatttc	ctgccggctg	cacttacagg	cgatagagaa	3120
gcaaagacag	gattctataa	tgacggcaaa	ggcatgacgt	attacacaac	ggccggaaat	3180
aaggcgaaga	gcgcgttcgt	tacagtggcg	ggcaacacat	actactttga	ttatacggga	3240
tatatggtta	caggacctaa	tacaattaac	agcaagtttt	actatttcct	tcctaattggc	3300
gttatgctga	aggatgcaat	taagcaggat	gaacttggaa	gatcagtcta	ctatggcaaa	3360
acgggaacaa	tgtataaggc	aacggataaa	tcacagtggg	tcgccatgac	agatagcaag	3420
ggacaacaga	gattcagaca	ttttgataga	ttcggaatca	tgagcgttgg	acttgtcacg	3480
attaatggaa	gcgtccagta	ttacgacgaa	gaaggctttc	aagttaaggg	agagttcgtg	3540
acggacaaaag	atggacagac	gagatatattt	gacgagggaa	gcggcaacct	ggttaaggac	3600
agattcctga	acaaggacgg	aaagtgggat	taccttgacg	ataagggact	gcttgtcaag	3660
ggagctcaaa	caatcaaggg	ccagaaactt	tatttcgata	caaaaacagg	agcgcaagtc	3720
aaagggagact	ttgtggctga	taaggatgga	aacctgacgt	tttatagcgg	cgattcagga	3780
caaatggtgc	agtcagactt	ctttagcaca	ggcaacaatg	catggtttta	tgcagatgaa	3840
aacggacatg	ttgcaaaaag	cgcgaagaca	atcagaggcc	aaaaactgta	cttcgacacg	3900
aagacgggac	agcaggccaa	gggcagattc	attagagatg	acaaaggcgt	gagatactat	3960
gatgcagaca	caggcgcact	ggtcacaaat	gctttcctgg	aaacgaaggc	tggctcaaat	4020
cagtgggtact	acatgggagc	cgatggatac	gcggtgaagg	gcaaccagac	gatcaagaat	4080
cagcacatgt	actttgacgc	ggagacgggc	caacaagcta	agggcatcat	cgtcacagat	4140
gcaaatggca	gaaagtactt	ctatgacacg	ttcacgggca	gcagagttgt	taaccaattt	4200
gttctggtga	acggcaattg	gtacttttga				4230